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Foreword
For more than a half century, the Committee on Problems of Drug
Dependence has played a distinguished part in research on drugs
that affect the central nervous system. It has served as a
catalyst and bonding agent for the work of academic researchers,
governmental and international organizations, and the pharmaceu-
tical industry while also conducting its own programs to eval-
uate the efficacy and dependence liability of new compounds.
The broad range of CPDD interests is reflected in the diversity
of its membership: chemists and biochemists, pharmacologists,
physicians, psychologists, sociologists, and others share in its
endeavors.
The 43rd Annual Scientific Meeting of the Committee on Problems
of Drug Dependence was held in San Francisco on July 12-15, 1981.
Characteristically, a broad and stimulating program of informa-
tion and ideas was presented. Probably no other single meeting
covers current research in drug abuse so comprehensively. For
the third year, the National Institute on Drug Abuse is pleased
to present the CPDD proceedings in its, Research Monograph series.
William Pollin, M.D.
Director
National Institute on Drug Abuse
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Abraham Wikler, M.D.
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In Memoriam:
Abraham Wikler, M.D.
Abraham Wikler died on March 7, 1981, in Lexington, Kentucky where
he had lived and worked for more than forty years. He was 70 years
old. His wife, Ada, as always, was at his side.
Abe Wikler's scientific work has had a direct and profound influence
on our current understanding of drug dependence and on the lives and
careers of many of us in this room. My own entry into the field of
psychiatry and psychopharmacology was directly attributable to the
reading of Abe's 1957 review article and monograph, The Relation of
Psychiatry to Pharmacology.
Abe's career in psychiatry began with a residency training at the
Hospital at Lexington. Following this he was asked by Clifton
Himmelsbach, in 1942, to set up an experimental neuropsychiatry
laboratory in the Research Department. Calling on the neurophysi-
ological techniques that he had acquired from Fulton at Yale, Lloyd
at the Rockefeller Institute, and the familiarity with Pavlovian
thought that he acquired while studying with Wasserman at North-
western, Abe began to focus on the nature of physical dependence,
drug seeking behavior, and the basis of relapse. In the process,
he was able to demonstrate that physical dependence was not merely
a "psychic" phenomenon and that there were physiological changes
at all levels of the CNS accompanying it. Further, by using nalor-
phine, he demonstrated that such changes could develop early in the
course of drug use. In fact, Abe, Harris Isbell and Nathan Eddy
were the first to demonstrate nalorphine-precipitated withdrawal in
opiate dependent humans.
Abe recognized that these changes could not explain relapse many
months after withdrawal of drugs. Abe's clinical acumen led him
to postulate that the recurrence of abstinence phenomena when addicts
talked about drugs or returned to environments associated with drug
taking was due to conditioning, in which the stimuli associated with
withdrawal symptoms and with positive drug effects came to elicit
these effects as conditioned responses long after the drug had been
withdrawn. He also postulated that the withdrawal phenomena which
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develop early in the course of use provide a regularly recurring
motive that permits the addict to work, or "hustle," for an
immediate reward - the alleviation of withdrawal distress. Thus,
"hustling" to obtain drugs, with its repeated immediate reinforce-
ment, strengthened the drug taking behavior even as it served to
alleviate the addict's boredom and even the hustling could become
a conditioned response. Then, in a long series of experiments
involving rats, Abe was able to demonstrate that a conditioning
process which develops during opiate use increases the likelihood
of opiate self-administration for months after withdrawal.
This view of addiction as a process involving learning and con-
ditioning, which Abe was one of the first to champion, has now
been accepted as a fundamental aspect of our understanding of drug
dependencies and relapse and led, in Abe's lifetime, to a number
of distinct approaches to both opiate and alcohol dependence based
on these ideas.
For these and other contributions, Abe Wikler was given the Nathan
B. Eddy Memorial Award in 1976 for excellence in Drug Abuse Research.
The Abe Wikler I have just described is world famous and belongs to
all of science.
Abe Wikler, the man - friend, colleague, teacher and collaborator -
was known to a small circle. Those of us who came to the scientific
meetings of the Committee on Problems of Drug Dependence were part
of that more privileged circle, for Abe rarely missed these meetings.
Each of us who knew Abe would probably have our own unique way of
describing this complex man, but all would agree that Abe was a man
of vast breadth of scientific and general interests. They ranged
from the philosophy of science to pharmacology and included experi-
mental psychology, electroencephalography, neurology, neurophysiology
and all of general psychiatry. All this was in addition to a thor-
ough knowledge of drug dependence in all of its manifestations.
To those of us whose first relationship with Abe was student to
teacher, Abe was both stimulating and overwhelming.
While Abe had a lively sense of humor and enjoyed a good story, he
found nothing humorous in sloppy thinking. Woe to the colleague,
no matter how deep the friendship, who got the facts wrong, changed
definitions in the middle of an argument, or simply used terms that
were not defined operationally. For Abe usually knew the facts, had
conscientiously mastered the literature, thought precisely, and
defined all terms operationally.
Although he had an encyclopaedic knowledge of drug abuse, Abe seldom
became involved in public debates about drug abuse. He did not often
participate in high level policy making. He had little patience for
the circumlocutions or self-serving behaviors that are the daily
bread of politicians and administrators. As Ada put it - Abe didn't
like flim-flam. He restricted his influence to his fellow scientists
and physicians. These were manifestation of his immutable honesty
and deep compassion. He believed that there was a natural order and
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was committed to understanding it.
Abe had extraordinary powers of concentration. His preoccupations
were from time to time taken as absent-mindedness. His absent-
mindedness together with his humorous but sardonic characterizations
created a rich store of Wikleriana.
He was a wonderful colleague and friend who was unfailingly kind
and considerate. He took time to write detailed critiques of papers,
letters of recommendation, and to drop delightfully descriptive hand-
written notes from his sabbaticals. He was also a dedicated teacher
who took great pride in his pupils and disciples.
Abe retired from the Public Health Service in 1963 to become Pro-
fessor of Psychiatry and Pharmacology at the University of Kentucky.
He continued to work a seven day week. Fifteen years later, he
became Professor Emeritus. The second retirement finally changed
his work habits - he no longer came into the office on Sunday.
Abe's last book Opioid Dependence, was published in 1980, just a
few months- before he died. The preface was typically Wiklerian.
It pointed out the tautological and untestable-nature of the
pleasure-pain principle and other "unconscious intervening vari-
ables." It described drug dependence and the complex conditioning
processes- that cause relapse as a "disease, sui generis." The term
sui generis,
favorites.
meaning not like any other - unique - was one of Abe's
Abe Wikler was many things - researcher, teacher, col-
league, friend, father, husband. But above all, Abe Wikler was a
scholar - sui generis.
Jerome Jaffe. M.D.
Department of Psychiatry
University of Connecticut
School of Medicine
Farmington, Connecticut
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Annual CPDD Meeting
Introduction of Nathan B. Eddy
Memorial Award Recipient
Louis S. Harris
It is a great pleasure and honor for me to introduce the recipient
of this year’s Nathan B. Eddy Memorial Award.
Everette Lee May was born on August 1, 1914, in a small town in
Virginia. He received his baccalaureate degree from Bridgewater
College and his Doctorate in Chemistry from the University of
Virginia. After two years as a Research Chemist at National Oil
Products, he joined the staff at the NIH in 1941, where he remained
until he retired from the Public Health Service Officer’s Corps in
1976 to join us as Professor of Pharmacology at the Medical College
of Virginia, where he is continuing his distinguished career.
In his early years at the NIH, Dr. May made important contributions
to our efforts to control malaria. His synthetic program with
Erich Mosettig led to many new chemotherapeutic agents. In the
early 195Os, Dr. May began his long collaboration with Nathan B.
Eddy in the search for a non-addicting analgesic, a search which
has continued to this day. It was during this period he first
synthesized LAAM, and created the new benzomorphan series which
has proved so fruitful.
Dr. May has contributed to the field of drug abuse, not only as
a scientist, but through his service on numerous national and
international committees and commissions. He served as Editor of
the Journal of Medicinal Chemistry at a crucial period of its
development. He is most proud of the host of young chemists who
came to his laboratory for training and who are now having fine
careers on their own.
Dr. May has been the recipient of many awards, the most noteworthy
being:
1. The Hillebrand Award in Chemistry in 1968
2. The HEW Distinguished Scientist Award in 1974
1
3. The APA Research Award in Medicinal Chemistry in 1976
4. The ACS Smissman Award in Medicinal Chemistry in 1978
His career is summed up by the following citation:
"Everette Lee May - humble, gentle man,
brilliant, yet unassuming chemist, tire-
lessly searching for the non-dependence-
producing analgesic. The Committee on
Problems of Drug Dependence honors one of
its most dedicated members."
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The Committee on Problems of
Drug Dependence—Past, Present,
and Future
The Nathan B. Eddy Memorial
Lecture
E. L. May
I am thrilled and highly honored to be the eighth recipient of
The Nathan B. Eddy Memorial Award. It is especially gratifying
to be joining such stalwarts as Seevers, Isbell, Wikler, Martin,
Kosterlitz, Way and Goldstein. At the same time I stand here in
deep humility, fully aware of the inestimable help and contribu-
tions of others, far too many to name in full. So, may I simply
express heartfelt thanks to a few - those who nominated me; the
Awards Committee who selected me; my former colleagues at the
National Institutes of Health, especially Arthur Jacobson, Joe
Ager and Kenner Rice; Louis Harris, William Dewey, Mario Aceto,
Bob Balster, Billy Martin and their colleagues at The Medical
College of Virginia; and finally my family, all of whom have
always been supportive and understanding.
Concerning the man we honor today, a few anecdotes may be of
interest. I knew him for nearly 40 years and was indeed priv-
ileged to be closely associated with him professionally and
socially from 1941 until his death in 1973. He was a sensi-
tive and proficient teacher, a wise counselor and a warm friend.
Dr. Seevers, in his address in 1974, spoke of Dr. Eddy's dedica-
tion, vitality and intellectual vigor, qualities maintained even
after a severe illness (bacterial endocarditis) at age 64 left him
with a nagging cardiac ,arrhythmia. Indeed, just four months before
his death, on landing at Dulles Airport following a 10-day World
Health Organization meeting in Geneva, he proceeded directly to
Warrenton, Virginia to help "wrap up" The First International
Conference on Narcotic Antagonists..
His horrendously bad eyesight was common knowledge and Dr. Isbell,
in his 1975 lecture mused that it was surprising that he (Dr. Eddy)
could see well enough to play expert bridge. I can tell you
authoritatively that he not only knew his own hand well but also
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the essential content of his partner's and opponents' holdings after
a round or two of bidding. And, as his partner, it could at times
be uncomfortable, even embarrassing. It was reliably recounted
to me that on the Saturday before he died peacefully in his sleep
the following Tuesday night, he and his partner twice bid and
made a "grand slam" at the Cosmos Club in Washington, D.C., his
favorite "hangout."
In pondering a topic and contents for my lecture, I was truly
puzzled. If I talked about chemistry, only a few of you would
be interested. And, needless to say, I cannot speak intelli-
gently on pharmacology, biochemistry, psychology, medicine,
socioloav and other disciplines represented in the audience.
Thus, Ihave taken the easy way out of my dilemma and will try
to tell YOU about the Committee on Problems of Drua Dependence -
its genesis, a little of what it has been doing, and its possi-
ble future role. Perhaps in these reminiscences some of my
own research and participation can be mentioned.
The Committee on Problems of Drug Dependence as we now know
it was spawned as the Committee on Drug Addiction early in
1929 by The National Research Council (NRC), National Academy
of Sciences (NAS). Its first meeting was January 12, 1929.
This committee, unchanged except for the addition of two
members, served until 1939. In May of 1929, the committee
decided to develop a chemical-pharmacological-clinical
research plan.
About this time, Lyndon Small, with Ph.D. training from
Harvard, a brilliant alkaloid chemist and Assistant Pro-
fessor of Research Chemistry at the University of Virginia,
had just returned from two years of postdoctoral study with
Dr. Heinrich Wieland of Munich, Germany. He accepted the
directorship of the chemical effort (called the Drug Addiction
Laboratory), and space was supplied by the Cobb Chemical Labo-
ratory at the University of Virginia. Funds, at first not to
exceed $5O,OOO.OO per year, were from a 10-year Rockefeller grant
to be administered by the NAS. Dr. Small and a few graduate
students were to be concerned with chemical modification of the
main ohenanthrene alkaloids occurring in opium-morphine. codeine
and thebaine. A program involving total synthesis of partial or
simulated structures of morphine was to be directed by Dr. Erich
Mosettig, recruited by Dr. Small from Vienna.
Nearly a year later (June, 1930) when the need for pharmacol-
ogical examination became pressing, a physician turned
pharmacologist, Nathan Eddy, who had been teaching physiology
and pharmacology at The University of Alberta, Edmonton, was
appointed to head such a pharmacology program at The University
of Michigan. It is not quite clear from Dr. Eddy's account
just why Michigan was chosen as the site for his investigations,
but it was probably because during part of the preceding two
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years he had worked in the laboratory of Dr. Robert Gesell at
The University of Michigan. In any event, Dr. Eddy came to
Ann Arbor, June 1, 1930 and was given the title of Research
Professor of Pharmacology with the rank of Associate Professor.
Dr. Eddy, in addition to initiating base-line studies for
morphine and codeine, served in a liaison role by visits to the
University of Virginia and other centers of activity in the
Committee's interest,including human evaluation at the Addiction
Research Center (ARC) in Lexington, Kentucky. I had the good
fortune to become a minuscule part of this program about 1935
when I enrolled in the Graduate School of Chemistry at Virginia
and was accepted into Dr. Small's Laboratory with Dr. Mosettig
as my research advisor.
From 1929-1939, at least 200 new compounds were prepared and
evaluated. And although this effort was not productive of
practical results, a fair amount of good basic chemistry
evolved along with solid pharmacology and structure-activity
In addition to many journal publications, Supplement
No. 138 to The Public Health Reports entitled "Studies on Drug
Addiction", appeared in 1930 - authors: Small, Eddy, Mosettig
and Himmelsbach.
The last full meeting of the Committee on Drug Addiction was
held January 28, 1939, but it was agreed that (as a Division
of Medical Sciences Committee of the NRC) it would continue
in an advisory capacity. In June of the same year, Drs. Eddy
and Small were recipients of the first Scientific Award of
the American Pharmaceutical Manufacturers Association,
presented by the Honorable Harry J. Anslinger, Commissioner
of the Bureau of Narcotics, progenitor of the Drug Enforcement
Administration (DEA). Dr. Eddy, in his acceptance remarks,
noted that the award was an important recognition of the
coordinated research sponsored by the Committee.
It was in June of 1938 that plans for transfer of the Virginia
program to the National Institute (later to become Institutes) of
Health (to continue the research of the Committee on Drug Addic-
tion in continuing close association with the PHS Hospital at
Lexington) began to take shape. This was mainly through the
interest and efforts of PHS Surgeon General Thomas Parran, and
Dr. Ross Harrison, Chairman of the NRC. So, at the close of
business at Virginia about mid-1939, Small, Eddy and Mosettig
moved to Washington, D.C. to resume their studies under govern-
mental auspices with, as stated before, the Committee on Drug
Addiction, serving in an advisory capacity.
With the outbreak of World War II and deep involvement of the
United States late in 1941, malaria became a defense problem, so
that efforts during the next five years were almost entirely
devoted to this (malaria) project. Nevertheless, Dr. Eddy, with
collaborators Sumwalt and Krueger, was able to complete (1941)
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another PHS supplement on the "Pharmacology of the Opium
Alkaloids." In addition, with Dr. Small and representatives from
the pharmaceutical industry, the Bureau of Narcotics, the Public
Health Services and the NAS Narcotics Advisory Committee, Dr. Eddy
made arrangements for the manufacture, distribution and further
clinical testing of metopon, a morphine relative which had been
synthesized by Small and associates at Virginia.
In the meantime, some exciting reports were emanating from Germany
relating the discovery of new, totally synthetic analgesics,
pethidine and methadone and congeners. Methadone received especial
attention because of its close pharmacologic similarity to morphine
and because of a feared opium shortage. Consequently, the NRC-NAS
at that time formed a (new) "Committee on Drug Addiction and
Narcotics" (about 1947), "to deal with present and future problems
relating to synthetic narcotics and drug addiction." The member-
ship of the Committee included Dr. Isaac Starr of the University
of Pennsylvania Medical School as Chairman; Dr. Eddy as Secretary,
Mr. Anslinger and Drs. Raymond Bieter, Dale Cameron, Walter Palmer,
Maurice Seevers and Lyndon Small as members. The first meeting of
this committee was held October 2, 1947, at the NAS Building,
Washington, D.C., and was attended by liaison representatives from
the office of the Surgeon General of the Army, the Bureau of
Medicine of the Navy, the Naval Medical Research Institute, the
Food and Drug Administration (FDA), the American Medical Associ-
ation (AMA) and the American Drug Manufacturers Association.
This liaison relationship continued for many years.
With cessation of the malaria project, Dr. Eddy began a "mass"
testing program for analgesics, refined the Wolfe-MacDonald,
hot-plate method of testing for antinociception, and, I believe,
began rather informally the coordination part of the then
NAS-sponsored drug dependence program that has persisted to
this day. Dr. Mosettig and I resumed our research in this area
with operations on the methadone and isomethadone molecules and
at length prepared all of the possible a and ß-methadols and
isomethadols and their O-acetyl derivatives, some 24 compounds
in all. These were tested subcutaneously and orally in the
hot-plate method and for acute toxicity. One has become popular
as LAAM, levoalphaacetylmethadol, as many of you know.
About 1952, we began our research at The National Institutes of
Health (NIH) on the phenylmorphans and benzomorphans, which
ultimately led to phenazocine, metazocine and indirectly to SKF
10,047, pentazocine and cyclazocine. The demonstration of vast
differences in biological behavior of optical pairs and their
corresponding racemates in these two basic series principally by
Julian Villarreal of the University of Michigan, has proved inter-
esting and is still being explored.
Time will not permit me to give the genesis of the research fund,
the grants program, and the establishment of Dr. Seevers' depend-
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ence studies in monkeys at Michigan about 1950. This is all well
detailed in Dr. Eddy's book which he finished just before he died
in 1973, "The National Research Council Involvement in the Opiate
Problem, 1928-1971.” Suffice it to say that the (world-wide)
pharmaceutical industry has supplied until fairly recently most
of the (fluid) funds for the committee with, however, substantial
supplemental help by various government agencies, particularly
The National Institute on Drug Abuse (NIDA). Eventually,
Dr. Seevers' facility included a Beagle-dog colony for assessing
barbiturate dependence. The program has grown steadily and there
has been good coordination of effort among the NIH, The University
of Michigan, The Addiction Research Center, The Veterans Adminis-
tration and other various grantees, all under the NRC, NAS
umbrella. Dr. Eddy retired from NIH in August, 1960 but continued
as coordinator of the evaluation program. He also succeeded Dr.
Isaac Starr as Chairman of the Committee in 1961 and was in turn,
succeeded by Dr. Dale Cameron in 1962 at which time Dr. Eddy again
became Executive Secretary. About the same time, I became a member
of the Committee and succeeded Dr. Eddy as coordinator at NIH in
1965. Dr. Cameron, then Superintendent of St. Elizabeths Hospital
in Washington, D.C., served as Chairman until 1967 and was suc-
ceeded by Dr. Henry Brill of New York State who served for three
years. On July 1, 1965, the name of the Committee was officially
changed to Committee on Problems of Drug Dependence (CPDD) to
indicate an awareness of and interest in the increasing abuse of
other types of drugs. According to Dr. Eddy's account the initial
suggestion for such a change came from a paper written by Harris
Isbell in which he used such terms as morphinism, cocainism,
pharmacopsychosis, etc.
Dr. Eddy resigned as Executive Secretary in 1967, continued as
a member until 1970 and became Chairman for a second term
1970-1971. He remained as a consultant until his death in 1973.
Dr. Frank Fraser who, as many of you know, performed expertly at
ARC for many years, was Chairman from 1971-1972 and was followed
by Dr. Leo Hollister, our present Executive Secretary.
It was about this time that an evaluation program complementary
to that at the University of Michigan was considered. Because
of a gradually increasing influx of new compounds and the greater
sophistication and time required to study the compounds being
submitted, particularly the agonist-antagonists, Michigan facil-
ities had become overloaded. Consequently, Drs. Harris and Aceto;
at The Medical College of Virginia, established such a complemen-
tary program which has been in full operation since 1974. The
coordination of effort and agreement of results in cases of delib-
erate overlap have been remarkable and gratifying. In retrospect,
it was a timely move for another reason, coinciding with the slow-
down and ultimate cessation of human testing for abuse potential
at the ARC.
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The Committee had the services of a salaried (by NRC-NAS)
Executive Secretary, Mr. Duke Trexler, from 1969-1975 when
NAS decided to relinquish sponsorship. Although such an
action should not have been unexpected (as the average life
of NAS committees is about three years), there was at least
temporary distress and confusion within the Committee.
Nevertheless, due principally to the tireless efforts of
Chairman Hollister, interim Executive Secretary Theresa
Harwood, committee members and no doubt the still pervasive
spirit of Nathan Eddy, the Committee became independent and
incorporated with backing by a consortium of nine prestigious
scientific societies. Each society furnishes from its member-
ship one person to serve on The Board of Directors. Otherwise,
the Committee functions almost as before and has actually broad-
ened its scope of operations to include in vitro binding and
self-administration studies as well as a rodent-Infusion test
for physical dependence liability.
In his award address in 1976, Dr. William Martin recited some of
the accomplishments of the committee - studies and interpreta-
tions that helped pave the way for maintenance therapy and, for
the development of new and improved antitussive and pain-
relieving agents with reduced abuse liability. I should like
to add a few to his here-abbreviated and paraphrased list: its
considerable role in the classification of controlled substances,
including pethidine and methadone which were uncontrolled until
tested at Lexington; the stimulation and the promotion of basic
research on drugs that affect the central nervous system (CNS),
the discovery and characterization of the mixed agonists-antag-
onists, for example; and the sponsoring of clinical efficacy
studies in which not only potentially useful compounds were
fairly evaluated but new and improved protocols were developed.
And when speaking of clinical trials, one can't help being
reminded of Ray Houde who, with his colleagues Stanley Wallenstein
and Ada Rogers, has performed admirably for the committee in his
quiet and unassuming manner for at least 30 years. Other names
that come to mind in the clinical area are Beecher, Keats, Lasagna,
DeKornfeld, Lee, Belleville, Forrest and Brown; the last four
associated with Veterans Administration grants from the Committee.
I should say, too, that the "big five" at Lexington, Himmelsbach,
Isbell, Fraser, Wikler and Martin, have had worthy successors in
Don Jasinski and Chuck Gorodetzky, as have the "big three" at
Michigan, Seevers, Deneau and Villarreal, in Hank Swain, Jim Woods
and Tad Smith. Lou Harris, Mario Aceto, Bill Dewey and Bob Balster
are competently handling operations at the Medical College of
Virginia associated with CPPD activities; while Lou has served
effectively as program chairman for 7-8 years, a considerable
and, at times, delicate task. And finally, Arthur Jacobson as
the biologic coordinator at NIH, sees to it that submitted
compounds reach their proper destination, and then disseminates
the test results as rapidly and tactfully as possible.
8
As implied before, the Committee served capably,I think, in an
advisory capacity to the FDA, the DEA and The World Health
Organization for many years. And while this function has been
diminished during the last several years, because these bodies
now have their own "standing" advisory groups, CPDD - generated
data and opinions are still sought in difficult decisions.
The CPDD is fortunate to have superb liason representation from
FDA, DEA and NIDA in Ed Tocus, Howard McLain and Heinz Sorer,
respectively.
The CPDD published an article, "Testing for Dependence Liability
in Animals and Man." in 1966 which was revised in 1971 and will
undergo a second revision soon. It co-authored, with the AMA,
several position papers on such important subjects as "Methadone
Maintenance," "The use of Opiates in Clinical Practice," and others.
So, here we are today and the burning question is'whither The
Committee tomorrow?" Can it continue to be effective in assessing,
for efficacy and abuse potential, agents that act on the central
nervous system? Can it continue to stimulate research toward
Dr. Eddy's goal of discovering the near-ideal pain-relieving
agent? Can it help restore through advice and research the lost
facility of testing for abuse potential in man? Can it continue,
through its annual meetings, to serve as a proper forum for new
research and ideas on CNS type drugs? And finally, can it continue
to serve as a buffer between the pharmaceutical industry and
government - in effect be the honest broker in developing new and
improved medicines? We believe it can do all this and more.
Often, when I think of Dr. Eddy's scientific zeal and the
dedication of the committee he "sparked" for so many years,
I am reminded of a line from one of the poems of the great
Alfred Lord Tennyson:
not to yield."
"To strive, to seek, to find and
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Precursors of Addiction
David N. Nurco, D.S.W.
INTRODUCTION
Our topic, “Precursors of Addiction,” is one about which much has
been written, sometimes by-authors who did not even regard it as
their major theme. Actually, the term ‘precursors” is used
cautiously in this context. The term “causes” would be obviously
too presumptuous for a scientist to employ, although a number of
popular scientific writers seem to suggest that they have identi-
fied the root causes, such as poverty and the insensitivity of
society to the needy. Certainly, such sociodemographic factors
play a role in the phenomenon, but we should never lose sight of
the fact that the vast majority of persons in rather dire socio-
economic circumstances do not pursue careers in addiction. It is
clear that certain other factors, still unknown or rather specula-
tive at this time, must also be present before the phenomenon of
addiction can manifest itself. Moreover, it is by no means certain
that any given factor-, either known or unknown, is absolutely
essential to the addictive process. Rather, it may be that differ-
ent factors operate in different people, so that no universal
requirements or sine qua nons for addiction exist.
Although available methodology does not permit as much rigor as we
would like, we are prepared to lay a foundation in the search for
the causes of addiction. Therefore, at this time we will settle
for a softer term, “precursors.” Note that a precursor merely
suggests the presence of an association between an earlier and a
later event, and that even this association might not be invari-
able in every case. In this sense, our use of the word “precursors”
connotes an association perhaps even more tentative than that
implied by the word “predictors.”
Theoretical Background
Actually, comparatively little is known about the precursors of
addiction in the sense of factors capable of distinguishing between
subsequent addicts and nonaddicts in populations at high risk.
Still, there is quite a sizable literature on closely related
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topics, and we shall attempt to review this literature briefly
here under the appropriate topical headings.
Social and Demographic Formulations. Much of the sociological
literature has emphasized the relationship of “known narcotic addic-
tion” to social conditions that may, in part, lead to deprivations
of various sorts (Chein et al. 1964; Shaw 1942). Several such condi-
tions are associated with the “urban crisis,” including poor housing;
crowding; low socioeconomic status and lack of social mobility;
family disorganization, typically manifested in broken families and
low levels of cohesion; and minority group membership. The latter
point has clearly been demonstrated by the disproportionate repre-
sentation of Negroes, Puerto Ricans, and immigrants in the addict
population (Chein et al. 1964). According to several writers, it is
for the above reasons that we find concentration of drug addicts in
urban centers.
Unfortunately, the current literature leaves unanswered many
important and relevant questions related to, or flowing from, the
above relationships. For example, granted that addicts are concen-
trated in the deprived and disorganized strata of the populations
of large cities, the question remains as to whether or not they
originated in these same strata. Were they born and reared there,
is there a “drift” so that addicts, or persons in a pre-addict
stage who subsequently became addicts, moved into these levels
from elsewhere? Kleinman (1978), in a searching attempt to predict
onset of addiction, has reported that social class has a marked
effect on (young) age of addiction among inner-city (ghetto)
natives, but virtually no effect among migrants to the city. Thus,
it appear that a form of acculturation is a necessary precon-
dition for the effects of social class to operate.
Even where social class precursors appear strong, why is it that
some children born into lower strata become addicts while others
do not? Was there something different in the socialization process
among those who subsequently became addicts as compared to those
who did not? And did this “something different” manifest itself
in differential patterns of overt behavior which can be identified
by the usual techniques of social-research? 
It may be that differences in the impact of the socialization
process are a function of the perceptions of the individuals
involved, Thus, individuals can be subject to similar life exper-
iences, and yet each may define these experiences differently. For
example, an addict and a nonaddict may both have been brought up
under similar socio-economic circumstances, yet it is entirely
possible that each will have defined these circumstances differently.
Chein et al. investigated this question, but their findings were
inconsistent, i.e., they found that while black users of drugs
were more deprived in a material sense than were nonusers, this
relationship did not hold for whites and Puerto Ricans in their
study. (Controls were selected from the same types of neighbor-
hoods as users of drugs.) However, it is possible that the
important variable may be the perception of socio-economic status
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rather than its reality. The crucial point may be whether addicts,
prior to entering on a “career” of addiction, defined themselves
as deprived rather than whether they were, in fact, deprived. Also,
the perceived deprivation may extend to matters other than socio-
economic status, including various aspects of family functioning
such as maternal &privation and chronic absence of father; health;
physique; ability to “fight” or perform other activities socially
valued by peers and others in the reference groups; sexual adequacy;
etc.
Interpersonal Relationship Theories. Let us next consider a set
of variables usually termed interpersonal (as distinguished from
intrapersonal) and some theories relevant to drug abuse that might
be classified according to this rubric.
In (Dollard et al. 1939), he and his associates postulated a rela-
tionship between frustration and aggression, on the one hand, and
criminality, on the other. They wrote:
All factors which have been found to be causally related
to criminality derive this connection because of imply-
ing, directly or indirectly, on the part of the offending
individual either higher-than-average frustration or
lower-than-average anticipation of punishment.
More recently, Berkowitz (1965) has suggested that a person does
not have to be frustrated to engage in aggressive acts. One might
also add that frustration may lead to reactions other than agres-
sion. Haner and Brown (1955), for example, reported a study in
which children frustrated in the playing of a game responded by
increased goal-directed activity. With respect to theories of drug
abuse etiology, it may be that frustrating experiences are responded
to more frequently in a more aggressive-destructive or passive-with-
drawing way by certain deviant groups than by “normal” individuals.
The second part of Dollard et al’s, statement is frequently
supported by observations and other research data obtained from drug
addicts. Information concerning, early memories reflects, in many
instances, the experience of “getting away with” infractions
(Laskowitz 1965). There is also said to exist, for a large segment
of the known, young, narcotic-using population, a background of
unstable, pampering attitudes on the part of the mother, possibly
linked to a compensatory need to make allowance for the son not
having a stable, significant role in the home. Moreover, researchers
have noted the reports of parents of addicts that as preaddicts
they did not participate in performing household chores (Chein et al.
1964).
It may be that narcotic use has appeal both for those individuals
whose life style includes avoidance of frontal displays of anger
toward the frustrating object as well as for those who are unable
to tolerate feelings of anger and tend to explode with little
provocation. The first group would seem to be one described as
“retreatist” by Merton (1957), since such persons behave as though
they have relinquished institutionally-prescribed ways for pursuing
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goals as well as the goals themselves. This is the group which
Cloward (1959) described as turning to drugs as a “coping” defense,
and such persons appear to be the ones most likely to report feel-
ings of enhanced competence when they are “high.”
In an effort to study adolescents’ preferred response to frustra-
tions, Gold (1960) used the Rosenzweig Picture Frustration Test
(a projective technique composed of 25 cartoon-like pictures, each
depicting two persons involved in a mildly frustrating situation)
and compared the verbal responses of adolescent addicts with those
of delinquent and nondelinquent controls. His results, which
corroborated an earlier study by Diamond, suggested that addicts
typically tend to avoid blame and try to gloss over frustrating
situations.
Intrapersonal Psychological Traits. While the group of theories
lmmediately preceding may be viewed primarily as interpersonal,
in the sense that an interaction between the individual and signif-
icant others is assumed as the principle underlying their operation
as well as their genesis, a second class of theories may be viewed
as primarily intrapersonal or trait theories, in the sense that the
individual is viewed as the  “carrier" of certain psychological traits 
or predispositions that may operate or exist independently of the
presence or actions of others. This is not to deny the role of
social interaction in either the genesis or expression of such
traits; it is merely a question of emphasis in that the focus of
interest is on the individual as an individual, rather than as an
element in a larger functioning system.
There can be no doubt that the vast majority of theories having
relevance to the etiology of drug abuse are primarily intrapersonal,
or psychological trait theories. (Essentially synonymous terms
preferred by some theorists are personalogical or characterological
theories.) Such theories vary greatly in level of complexity,
scope, and sophistication. A very few may be regarded as general
theoretical systems, such as those of Freud (1920), Murray (1938),
Cattell (1957), and Eysenck (1967); however, the overwhelming
majority have reference to a single dimension, trait, or character-
istic that is purported to have considerable salience for some
domain of human behavior.
It is perhaps most convenient to begin by considering a sizable
body of literature concerning the personality characteristics of
drug abusers. Although helpful in many ways, these studies are
largely irrelevant from the point of view of drug abuse etiology.
We refer, of course, to the many studies of the personality charac-
teristics of adult and jwenile drug abusers as revealed by a
variety of questionnaires and other devices. This literature has
recently been reviewed in detail by Haertzen (1978). The reason
for the substantial irrelevancy of this research to issues of
etiology is the fact that, with few-exceptions, subjects have been
studied and groups compared after the fact, i.e., after the syndrome
of drug abuse has, by definition, been firmly established.
13
Consequently, as Fox (1978) has pointed out in another context, it
is impossible to know for a certainty whether trait differences
observed between drug-abusing and nondrug-abusing groups are causes,
effects, or concomitants of the behaviors in question. Fortunately,
a few studies of a prospective (Robins and Wish 1977) and retro-
spective (Robins et al. 1970) nature provide evidence consistent
with the view that certain personality characteristics antedate the
appearance of the behavior subsequently defined as deviant; there-
fore, there would seem to be considerable circumstantial evidence
that the distinguishing personality characteristics of at least some
drug abusers existed prior to the abuse of drugs per se.
Perhaps the most widely used instrument in the drug abuse field to
measure personality traits has been the Minnesota Multiphasic
Personality inventory (MMPI) (Hathaway and McKinley 1967). More-
over, a number of additional inventories may be viewed as "spin-
offs” of the MMPI, such as the California Psychological Inventory
(CPI)(Gough 1957) and the Addiction Research Center Inventory
(ARCI) (Haertzen and Hill 1963). To a lesser extent, several studies
have employed the Sixteen Personality Factor Questionnaire (16PF)
(Cattell and Eber 1961) and the Eysenck Personality Inventory (EPI)
(Eysenck and Eysenck 1964). With respect to the MMPI, the typical
addictive personality pattern that emerges is usually interpreted
as one of psychopathic or antisocial personality, as indicated by
primary peaks on the Pd (Psychopathic Deviate-Scale 4) and Ma
(Hypomania-Scale 9) scales. Secondary peaks on scales Sc (Schizo-
phrenia-Scale 8) and D (Depression-Scale 2) are sometimes noted as
well, but elevations on the latter are frequently a function of
current circumstances, e.g., economic conditions , incarceration,
treatment status, etc. On the other hand, scales 4 and 9 are
thought to tap more enduring, characterological traits, and for this
reason they are frequently regarded as revealing the essence of any
trait commonalities among addicts in general. Interestingly enough,
this description appears applicable to alcohol addicts as well,
although the relationships may not be quite so pronounced (Hill
et al. 1962). With respect to the CPI, addicts are said to score
low on measures of responsibility and socialization (Haertzen 1978).
On the 16PF, there is evidence that addicts as a group significantly
exceed the standardization norms on Scale C (emotionally unstable),
Scale L (suspecting and jealous), Scale M (eccentric and unconcerned),
and Scale O (insecure and anxious) . These characterizations are both
internally-consistent and in keeping with clinical formulations and
observations made over the years by numerous workers in the drug
abuse field (Nurco 1979). It must be emphasized once again, however,
that nearly all such research has been conducted with already con-
finned drug abusers, and hence it is of dubious value as a basis for
prognostic indicators of later outcome, i.e., as the basis for
assembling “risk factors” in the prospective study sense.
Single Principle Theories. We next consider a variety of “limited”
Theories or hypothetical mechanisms thought to be characteristics of
at least some narcotic users and possibly causative of their
addictive conditions. Each of these theoretical constructs is uni-
dimentional, i.e., involves a single explanatory principle, and can
therefore hardly be viewed as a comprehensive theory of behavior
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even in the addictive realm. Nonetheless, it seems possible that
one or more of these constructs may possess some validity as both
an explanation for addictive behavior and as a specification of a
necessary pre-condition for such behavior to occur.
i. The Immediate Gratification Hypothesis. It has become common-
place to observe that an important factor in deviant behavior
appears to be the very great difficulty certain persons experience
in deferring gratification. This factor seems to be of particular
importance in the life styles of addicts. Sullivan (1953) suggests
a conceptual basis for the emergence of this trait: “Delays in
satisfaction constitute dangers to early infantile survival and as
such are sources of augmented tension to which we refer as fear.”
Addicts appear to behave as if the tensions of unfulfilled wants
create an unbearable situation. Waiting becomes unbearable because
future gratification cannot be guaranteed. Moreover, addicts and
other deviant groups appear to have an inability to trust persons
in authority, e.g., they do not appear confident that others will
operate in their best interests. Mischel (1961) has suggested that
preference for delayed rather than immediate reward may be associ-
ated with significant differences in maturity, social responsibility,
long-term goal direction, autonomy, and father’s presence during the
formative years.
ii. The Disturbance in Sexual Identification and Functioning
Hypothesis. Following Chein et al. (1964), it has been hypothe-
sized that addicts, even prior to their entering upon a “career”
of addiction, are-likely to experience problems in the establish-
ment of personal identity, and that these problems will manifest
themselves in an inability to establish an adequate sexual identi-
fication. This inadequate sexual identification is said to be
evident in a confusion as to gender and an ineptness in carrying
out sex-related roles.
With regard to the latter, addicts are said to display poor
performance in major life roles, e.g., occupational, educational,
and familial. Moreover, male addicts may not share concepts of the
self which are associated with male self-images in American culture,
e.g., power, strength, competence, effective and appropriate asser-
tiveness, and responsibility as provider, father, and head of house-
hold. Even in the preaddict phase, males may show signs of being
passive and dependent, Also, they show disturbances in mutual
interpersonal relationships related to reciprocity, i.e., giving and
taking. They may also tend to feel that they are being manipulated,
but that they rarely manipulate others.
Addicts may be likely, early in their lives, to show real confusion
as to gender. This may be particularly evident during adolescence,
but it may also appear at an earlier stage of development. The
symptoms of this confusion may be evident in a concern over the
adequacy of their sexual performance and a profession of disinterest
in sexuality, or at least an indication that it is unimportant in
their system of values.
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Chein et al. (1964) offer case materials to support these hypoth-
eses. However, most of their material pertains to addicts after
they become addicts: It would therefore be important to elucidate
symptoms of disturbance, as characterized by differences in sexual
behavior, both before and after addiction.
iii. The Risk-Curiosity Hypothesis. Curiosity is typically regarded
as a natural and healthy attribute in nearly every culture. How-
ever, the potential addict is said to be driven by insecurity and
inadequacy of a sexual nature, such as described by Chein et al.
(1964) and others, in that sexual identification with a member of
the same sex for the addict is incomplete. Thus, the addict may
be more likely to take chances (risks) when it is inappropriate
to do so. Our own research in this area suggests that addicts,
when talking about their preaddiction behavior, often emphasize
the chances they have taken and the fights they have engaged in,
all of which gives-the impression that they are trying to prove
themselves. Thus it may be that the preaddict is more likely than
his peers to take the risk involved in opiate experimentation,
perhaps the biggest risk of all.
iv. The Boredom-Relief Hypothesis.
invokes the concept of boredom. Many individuals experience
This explanatory principle
extreme boredom, which can lead to both depression and an inability
to function. One mechanism for fighting off such boredom is the
frantic pursuit of almost any activity. Applied to narcotic
addiction, such a mechanism provides. a “double reinforcement”
rationale: In seeking narcotics, the addict runs about filling up
his day with “taking care of business” and thus alleviates boredom
with these activities. After the individual has taken the narcotic,
the drug experience itself removes the boredom and the cycle is
further strengthened and repeated.
The foregoing proposed explanatory principles are, quite obviously,
seriously limited insofar as their being comprehensive theories of
human behavior is concerned. Nonetheless, they may, in a limited
capacity, serve as indicators or “markers” for a more general,
integrated theory of behavior that has yet to emerge. In this
context, it might be well to point out that the disturbed sexual
identification hypothesis, and to some extent the withdrawal-
retreatism hypothesis before it, are descendants of a quasi-psycho-
analytic tradition that seeks causality in certain theories of
psychopathology (Freud 1920). To a lesser extent, this is also
true of the frustration-aggression hypothesis of Dollard et al.
(1939). On the other hand, the immediate gratification, risk:
curiosity, and boredom-relief hypotheses may all be subsumed under
a more general personality trait conception which emphasizes a
deficiency of impulse control. Such a conception has been common
among European theorists since before the time of Jung (1924),
although his notion of introversion-extraversion is perhaps the
best known variant.
Economic and Political Formulations. Although the operation of
economic and sociopolitical factors are implicit in the social and
demographic formulations previously discussed, no discussion of
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these matters would be complete without reference to the radical,
sociopolitical analysis of the addiction street-crime syndrome
provided by Karmen (1974). Kannen characterizes both the heroin
addict and the victim of his criminal activities as the joint
victims provided by the illicit drug industry complex. Karmen’s
paper can be read with profit even by those who do not subscribe
to his political views, primarily for the insights it provides into
the complex symbiotic relationships among the various legal and
illegal components present in any society.
Genetic Predispositions. Even the most casual reader of scientific
journals concerned with the understanding and treatment of deviant
behavior could hardly fail to be impressed by the increasing number
of articles in which genetic explanations and formulations of the
behavior in question are advanced. In addition to the exemplary
work of Rosenthal (1971 and 1970), Rosenthal and Kety (1968), and
Kety (1959) with respect to the major psychoses, Guze and his
colleagues (1973) with respect to hysteria, and Eysenck (1967)
and Miner (1973) with respect to. neurosis, there is also the promi-
nent work of Gottesman (1962, 1963) and Gottesman and Shields (1971),
among many others. Loehlin and Nichols (1976) have also explored
the heritability of various traits within what might be considered
the normal range, as had Gottesman (1963) earlier. Almost needless
to say, substantial genetic contributions to the traits, syndromes,
or behaviors in question have almost invariably been found.
With regard to the area of drug and alcohol abuse, somewhat less
work along these lines has thus far been accomplished, although the
work of Goodwin et al. (1973) with alcoholics is a notable excep-
tion. Moreover, Dole (1978) has stated his belief that a specific
biochemical abnormality will eventually be discovered among addicts.
It is interesting to note in this connection that (partial) genetic
explanations of addictive behavior flow naturally from intrapersonal
trait theorizing, especially since various traits have been shown
to have substantial genetic loadings (Crowe 1972; Cancro 1971).
Perhaps this demonstration has been most striking with respect to
extraversion (Gottesman 1963), the very trait most frequently
implicated in addictive behavior and the one most closely tied to a
physiological basis in Lester’s (1974) formulation.
It is well known that narcotic addiction is a far rarer phenomenon
in most white subcultures than in black ones. In addition, there
iS evidence that white narcotic addicts were involved in more
deviant behavior than were blacks prior to the onset of-addiction.
Therefore, as we investigate the theories presented in this paper,
we expect to find that those theories relating to psychopathology
are more appropriately applied to whites, while those relating to
sociological factors are more appropriately applied to blacks,
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DEVELOPMENTAL EPIDEMIOLOGICAL STUDIES
OF SUBSTANCE USE IN WOODKLAWN
IMPLICATIONS FOR PREVENTION RESEARCH STRATEGY
by S.G. Kellam, C.H. Brown, and J. Flemming
Effective prevention program directed at substance use
require that specific antecedents in the life course be
identified and their functions in the paths leading to use or
nonuse determined. Aimed at reducing these risk factors,
specific interventions can then be tested  experimentally.
Scientists have looked askance at the possibilities of
preventing substance abuse in the specific sense jUst described,
believing that our knowledge is far too insufficient to warrant
such an undertaking. It may be time, however, to examine the
status of our information regarding the early and evolving paths
leading to substance use and other important outcomes.
We examine in this paper the data from other laboratories
regarding antecedents of teenage substance use, as well as data
from the Woodlawn studies. The Woodlewn data l re longitudinal
and prospective and concern antecedents in first grade of teenage
substance use 10 years later when the study population was 16 or
17 years old. These data were gathered in l black, urban, poor
community on the South Side of Chicago. We will focus our
discussion section on a research strategy leading to validated
programs for the prevention of substance use.
A life-span developmental orientation provides an important
framework for longitudinal research About such remote origins.
Baltes, Reese, and Lipsitt (1980) describe three perspective
which comprise this orientation. The first is that of individuals'
socialization and development. The second is concerned with
cohort effects and refers to evolving societal patterns of
behavior and values as these influence the behavior of
individuals. The third perspective concerns those idiosyncratic
events which influence an individual’s behavior without
necessarily affecting the broad population of which the
individual is a member.
Longitudinal research about substance use involves each of
these perspectives. Some studies involve combinations of the
three; others focus mainly upon one or another perspective. The
early and evolving psychological and biological characteristics
of the individual will be important in longitudinal research on
use. The social structural context in which the person develops
and is socialized over time must also be part of our purview.
An important perspective, one that has been central in the
Woodlawn project from its beginning, is that of the Social
adaptation of individuals. By this term we mean the adequacy of
role performance of the individual in a particular social field
at a particular stage of life. Social adaptation refers to the
interaction between the natural raters who define the social
tasks in particular social fields and the individual’s responses
to these social task demands. It is here that many of the
currently known antecedents can be found, as the reader wi11 see.
We summarize our work and that of others on the antecedents
of teenage use of alcohol, marijuana, and cigarettes. Our own
data were gathered prospectively in Woodlawn on total populations
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of first-grade children in this poor, black, Chicago ghetto
community in consecutive cohorts in the 1960s. We will focus on
the 1966-67 first-grade children regarding their psychological
well-being and social adaptational status in first grade. These
children and their families were followed up 10 years later when
they were age 16 or 17. These data are community epidemiological
in that they were gathered on total populations within a
particular urban neighborhood and include a set of outcomes as
well as hypothetically important causes and mediators. Since the
data are prospective, the risk of distortions from after-the-fact
reporting is eliminated.
The Woodlawn Study Population
Between 1964 and 1969 we made assessments of the mental
health of all the first-graders in Woodlawn at several points in
each school year. Further assessments were made on samples of
these children in third grade. We also conducted interviews in
spring of 1965 and spring of 1967 with the mothers (or mother
surrogates) of the children who were in first grade in those two
years. These assessments were coupled with service and
evaluation programs (Kellam, Branch, Agrawal, 6 Ensminger, 1975)
and were supported by a community board composed of leaders from
the community's larger citizen organizations in all of these
service and research ventures (Kellam & Branch, 1971; Kellam,
Branch, Agrawal, & Crabill, 1972).
For 'the long-term follow-up study, the target population has
been the entire first-grade population of 1966-67, the 1,242
students who remained in the Woodlawn first-grade classrooms that
school year, together with their families.
In 1975-76, we located and reinterviewed 939 (75%) of the
mothers or mother surrogates of the 1,242 families from the
1966-67 study. The mothers’ refusal rate was 5.9%. An
additional 18.5% of mothers were not reinterviewed because we
could not find them, because the families had moved from Chicago,
or because their children from the study population were
deceased. After the mother was interviewed and had given
permission, the teenager was approached for reassessment. Of the
939 teenaged children of the reinterviewed mothers, 75% (n=705)
participated in the reassessments. The study population for this
paper consists of the 705 teenagers whom we reassessed (Agrawal,
Kellam, Klein, and Turner, 1978).
In order to assess possible bias resulting from sample.
attrition, we compared the mothers whom we reinterviewed with
those we did not, using the early information. we had on both. We
found little or no difference in the social adaptational status
or psychological well-being (the variables of interest here)
between children reinterviewed and those not reinterviewed. (See
Kellam, Ensminger, and Simon, 1980.)
A Two-Dimensional View of Mental Health
In the Woodlawn studies, we have distinguished between two
broad classes of outcomes: social adaptational status (or role
performance) and psychological status. While the two may be
empirically related (and in the Woodlawn research we found this
to be the case), they are nevertheless conceptually quite
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distinct, and their correlates and consequences are by no means
identical. Many more first-grade children were thought by their
teachers to be maladapting than were symptomatic in the view of
observing clinicians. The short- and long-term courses of social
adaptational status and psychological well-being were strikingly
different. Other investigators (Loney, 1980; Robins, 1966; Watt,
1978) have reported similar findings.
Social Adaptational Status
In considering social role performance we have developed the
Life Course-Social Field Concept (Kellam et al., 1975) based on
the theoretical writings of Havighurst (1952), Erikson (1959,
1963), and Neugarten (1968). Every individual in society passes
through stages of life, some of which are more clearly defined
than others (Neugarten, 1979). Each stage involves that
individual in specific social fields in which there are persons
who define social tasks and judge the adequacy of the
individual’s performance in that field. Such persons, whom we
have termed “natural raters,” are similar to Lippitt’s
“socialization agents” (1968). The parents at home, the teacher
in the classroom, and the foreman at work are examples of such
natural raters in specific social fields. The process involved
is highly interactional, and we have named it social adaptation.
The natural raters rate the adequacy of each individual’s
performance, sometimes formally as teachers do with grades and
sometimes informally as parents judge how well their child is
behaving. Social adaptational status (SA)--the adequacy of
performance as rated by the natural rater in a specific social
field--is a societal judgment of the individual’s performance.
This approach is an elaboration of Parsons’s (1964) concept of
role performance as the adequacy with which an individual meets
the expectations of social roles. We conceive of this
interactional process as the basic interface between the
individual and society.
Psychological Well-Being
In contradistinction to SAS, there is the question of how
the individual is feeling inside: his or her psychological
well-being (PWB). By PWB we mean the thought processes,
affective status, self-esteem, and other aspects of the
psychological status of the individual. These two
components--SAS and PWB--represent the two major dimensions of
mental health. One represents mental health from the viewpoint
of society; the other represents mental health from the viewpoint
of the. individual.
Past findings have suggested that first-grade SAS has very
important long-term predictive and possibly developmental
significance for adolescents (Kellam et al., 1975; Kellam, Brown,
& Fleming, in press-a; Kellam, Ensminger, Branch, Brown, &
Fleming, in press-b; Kellam, Ensminger, & Simon, 1980; Kellam et
al., in press-c). These findings are consistent with those
reported by Robins (1966) in her studies of the long-term
importance of early acting-out behavior to adult pathology and
criminality. Watt (1978) has reported that aggressiveness in
young males appears to be an early antecedent of adult
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schizophrenia. Similarly, Loney (1980) has shown evidence that
early aggressiveness is the component of the hyperactivity
syndrome which is most prognostic of later outcome. It should be
clear from the earlier discussion that aggressiveness as defined
by fighting and breaking rules would fall within the social
meladaptational area rather than psychological.
Other Longitudinal Studies of Drug Use
The present review is focused on studies which have employed
longitudinal research designs, but does not include the Woodlawn
studies, since these will be treated specifically in a later
section.
Psychological Predictors
Psychological distress has been found important by a number
of researchers (Smith and Fogg, 1978) ; Paton, Kessler, and
Kandel, 1977; Kaplan, 1975). The perceived use by others is an
important psychological-predictor (Jessor and Jessor, 1978;
Robins, Davis, and Wish, 1977; Kandel et al., 1978). In a series
of related findings Kandel et al. (1978), Sadava (1973), and
Smith and Fogg (1978) have all established that favorable
attitudes toward substance use are predictive of the initiation
of use. Attachment to or alienation from this society’s social
values and institutions generally show a consistent relationship
to substance use (Jessor and Jessor, 1978; Sodava, 1973; Smith
and Fogg, 1978; Kandel et al., 1978).
Social Adaptational Predictors
The second major grouping of predictive variables is social
adaptational status. A number of investigators have reported
that poor high school performance is a common antecedent of
substance use (Jessor and Jessor, 1978; Kandel et al., 1978; and
Smith and Fogg 1978). In contrast, a study by Mellinger, Somers,
Bazell, and Manheimer (1978) indicated that marijuana use by
college students was associated with higher grade point averages.
Finally, Johnston (1973) reported that although the high school
students who used marijuana and hallucinogens tended to have
lower grade point averages, they had higher general intelligence.
Smith and Fogg (1978) have found that self-report and peer
ratings of obedience were predictive of future marijuana use and
were among the best predictors in a discriminant analysis of
nonusers, early users, and late users. Looking at a very
different form of social behavior, these investigators also
report that peer ratings of tenderness show a negative relation
to the initiation of marijuana use.
We find consistency across studies in regard to anti-social
or aggressive behavior which is possibly one of the strongest
predictors of substance use (Johnston, 1973; Johnston, O’Malley,
& Eveland, 1978; Kandel et al., 1978). Robins (1978) summarizes
her and her colleagues’ consistent findings from three
independent investigations of the relation between childhood and
adolescent antisocial behavior and adult outcomes (Robins, 1966;
Robins & Murphy, 1967; Robins et al., 1977). Across all study
populations there was a reliable association between early
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fighting, truancy, arrests, and drinking and adult alcoholism and
later drug abuse. Antisocial behavior was a better predictor of
adult outcomes than any family variable.
Sample Populations and Community Epidemiology
The prospective longitudinal study of so-called normal
populations is a major methodological advance over the early
studies which examined only clinical populations of addicts,
either at a single point in time or through retrospective reports
(e.g., Ball & Chambers, 1970; Stephens & Cottrell, 1972;
Vaillant, 1966). As Kandel (1980) has pointed out, clinical
populations of addicted individuals found in hospitals or even
outpatient clinics represent very special subgroups of the
population of drug users.
Although these newer studies of general population samples
have facilitated our understanding of substance use, they too
have limitations. One is that almost all these studies have
investigated students in junior or senior high school or in
college. Those who have dropped out of school are systematically
excluded. As the results of the Woodlawn study will demonstrate,
important antecedents to future substance use can be found most
effectively in total rather than school populations. In
addition, important predictors predate the adolescent
developmental period and may only be found by using long-term
prospective data. An important problem in past research has been
the scarcity of such longitudinal studies of well-defined ethnic
and social class groups.
In community-specific epidemiological studies such as the
Woodlawn project , we can hold the broad characteristics of the
community constant, while we focus on the effects of variation in
families, in classrooms and schools, and in the other local
social contexts. Rates of use and relationships to important
determinants may vary from one kind of community to the next.
Replication in similar and different kinds of communities must be
part of research strategy.
Description of Measures
First-Grade Social Adaptational Status (SAS)
Our primary instrument to measure SAS was the Teacher’s
Observation of Classroom Adaptation (TOCA). The instrument
contains rating scales measuring the different social tasks the
teacher expects the child to perform. During a standardized
interview, each teacher -rated her students on each social task.
Teachers made TOCA ratings early in the 1966-67 school year, at
midyear, at year end, and again in third grade. Reliability and
validity data for these scales are reported in Kellam et al.
(1975). The instrument as used in this paper measured three
maladaptive patterns of responding, each with three categorical
levels (not at all, mild, and moderate or severe). The three
patterns are: shyness (e.g., not speaking up, having few
friends, sitting alone); aggressiveness (e.g., breaking rules,
fighting, lying); and learning problems, where the score
consisted of the most severe rating given by the teacher in
either cognitive achievement (does the child learn up to ability
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as the teacher perceives it), maturation (acting with sufficient
independence to accomplish first-grade tasks), or concentration
(paying attention for a sufficient span of time to allow for
teaching and learning). This approach to learning problems is
similar to Kohn and Rosman’s (1972) concept of task orientation
and to a learning problems category developed by Lambert and
Nicoll (1977).
In addition to the teacher ratings of shyness,
aggressiveness, and learning problems, we will also summarize how
drug use in the teenage years was related to the first-grade
children’s performance on the Metropolitan Readiness-For-School
Test and the Kuhlmann-Anderson IQ test both administered in first
grade by the Chicago Board of Education. We consider these
somewhat arbitrarily as SAS measures, since they actually measure
children’s performance, not their intrinsic ability.
First-Grade Psychological Well-Being
Data on psychological well-being were collected from
structured clinical observations, from the mothers, and from the
children in third grade. We will discuss only the mother’s
reports in this chapter. The Mother Symptom Inventory (MSI) was
completed by the mothers in a home interview in 1966-67 about
their first grade child. The instrument is a 38-item inventory
adapted from previous investigations of the epidemiology of
symptoms among children (Kellam et al., 1975). The mothers were
asked to rate their children on each symptom on a 4-point scale
from “not at all” to “very much.” These 38 items as used here
are combined into a single construct.
Collection of Teenage Substance Use Data
The information on teenage drug use that we use in this
paper comes from responses to items in the What’s Happening?, a
questionnaire administered to the teenagers who participated in
the follow-up sessions. The questions concerned the frequency of
use of 12 categories of substance use. For the analyses in this
paper, we use responses to the question “how often have you ever
used?” Drugs are reduced to 5 categories: (1) beer or wine, (2)
hard liquor, (3) cigarettes, (4) marijuana or hashish, and (5)
other drugs. Drugs in the “other” category were used much less
frequently and include psychedelics, uppers, downers,
tranquilizers, cocaine, inhalants, heroin, and codeine.
For all categories except cigarettes, rate of use was broken
into three categories: (1) never used; (2) used 1 to 19 times;
(3) used 20 times or more. Cigarette use was broken into the
following three categories: (1) never used; (2) used 1 or 2
times or occasionally; (3) used regularly.
The questionnaires were administered by two black college
students to adolescents in groups of five to eight. The college
students rotated partners and the leadership role. The
assessment questions were presented visually on slides and orally
on audiotape to control for reading ability differences and to
standardize the pace and the general administration of the
questions (Petersen & Kellam, 1977). The group process in which
the data were gathered focused on the trust issue, allowing the
adolescents to express their fears and questions. During the
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administration, the assessors stopped the slides and tape
whenever a teenager had questions about either the purpose or the
meaning of the items. Confidentiality of responses was
emphasized.
The pattern of drug use in the Woodlawn teenagers was
heavily centered on beer or wine, hard liquor, marijuana, and
cigarettes (Kellam et al., 1980).
beer or wine, hard liquor,
Males used significantly more
and marijuana than did females. There
were no significant sex differences in the rates of cigarette use
and the use of illicit drugs other than marijuana.
Overall, both males and females reported frequent substance
use. More than one-third of the males and about one-sixth of the
females reported using marijuana and beer or wine 20 times or
more. Fewer used hard liquor frequently, but 47% of males and
38% of females had used it at least once. Rates of use of
illicit drugs other than marijuana were low. Only 1% of these 16
or 17 year old teenagers had tried heroin. About 8% reported
using cocaine at least 1 time, while 12% reported using
unprescribed codeine. We will not include these drugs in the
analyses described in this chapter because of the small numbers
and the nature of the analyses we wish to describe.
Prediction of Substance Use
Shyness, Aggressiveness, and Learning Problems
The three teacher-rated variables of shyness,
aggressiveness, and learning problems were examined as three
distinct traits with three levels of “not at all,” “mild,” and
“moderate or severe." Four-variable log-linear analyses,
involving first-grade shyness, aggressiveness, learning problems,
and a single teenage substance variable, were done separately for
males and females (Goodman, 1971, 1973). Similar analyses of
these three first-grade measures and teenage symptoms were also
done to identify and contrast important antecedent traits of
substance use and symptoms; these will be reported elsewhere
(Kellam et al., 1980).
The results clearly demonstrated that first-grade learning
problems did not predict teenage substance use. Once learning
problems was confirmed as not predicting substance use, it was
omitted from the drug analyses. First grade learning problems in
males (and to a lesser extent females) strongly predicted teenage
psychiatric symptoms, however. Table 1 contains the distribution
for males’ drug use by aggressiveness and shyness. Substance use
by teenage males was positively predicted by first-grade teacher
ratings of aggressiveness 10 years later. Comparing aggressive
versus not-aggressive categories for each category of substance
use in Table 1, we see that aggressive males used these
substances more frequently and were less likely to be nonusers
than were non-aggressives. In contrast teenage marijuana and
cigarette use (with similar trends for beer or wine and hard
liquor) were inversely related to first-grade teacher ratings of
shyness. However, the combination of shyness and aggressiveness
(as shown in the last column of Table 1) generally produced
enhanced use.
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In strong contrast to the results for males, first-grade
ratings of shyness and aggressiveness were not related to drug
use among female teenagers. To emphasize further the sex
contrast, first-grade ratings of psychiatric symptoms were
unrelated to male substance use ten years later but did predict
teenage cigarette use among females. In an earlier paper we
reported that of the high symptomatic females, 17% were frequent
users of cigarettes compared to 32% of those females who were
rated as nonsymptomatic by their mothers in first grade (Kellam
et al., 1980).
The complete log-linear statistics in the form of likelihood
ratio chi-square tests for teenage drug use are available in the
full length manuscript. We have drawn threeinferences from the
log-linear analyses of shyness, aggressiveness, learning
problems, and substance use.
(1) Aggressiveness in males in first grade leads to 1-1/2
times more use by teen agers of beer or wine, hard liquor,
marijuana, and cigarettes compared to not-aggressive males.
(2) Shyness without aggression in first grade leads to an
inhibition of both cigarette and marijuana use by teenagers.
Trends in this direction are evident for hard liquor and beer or
wine.
(3) While shyness without aggression appears to decrease use,
shyness in the presence of aggression seems to enhance use. In
fact the moderate/severe shy in combination with the moderate/
severe aggressive males in first grade show the highest substance
use in three of the four substance categories ten years later.
This effect is most clear for cigarettes and marijuana.
First-Grade Readiness and IQ Test Scores
The rates of drug use as a function of female first-grade
performance on the Metropolitan Readiness Test are presented in
Table 2. The same relationships hold for males. These data
confirm that for beer or wine, hard liquor, and marijuana, the
level of heavy use by teenagers was positively predicted by test
performance in first grade. Similarly, students performing less
well on the test were more likely to have never used these drugs.
Also predictive of the heavy use of beer or wine was higher first-
grade IQ as measured by the Kuhlmann-Anderson instrument. It
should be noted that both of these first-grade test measures were
predictive for both males and females, in contrast to the shyness
and aggressiveness results. These results are statistically
independent of those in the shy/aggressive analyses. These
therefore represent two different paths leading to later use or
non-use.
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Table 1
First-Grade Shyness and Aggressiveness
and Teenage Substance Use by Males
Not Shy Shya
Not
Teenage
substance useb
Aggressive
(n=l60)
Aggressive
(n=32)
Not
Agressive Aggressive
a
(n=20) (n=22)
Cigarettes
Never Used 29.2% 9.4% 35.0% 9.1%
Regular use 30.4 40.6 5.0 59.1
Marijuana
Never Used 26.2 12.9 65.0 31.8
Heavy Use 35.6 35.5 10.0 45.4
Hard Liquor
Never Used 58.4 40.6 75.0 31.8
Heavy Use 10.6 18.8 0.0 18.2
Beer or Wine
Never Used 13.8 6.2 25.0 9.1.
Heavy Use 28.8 37.5 20.0 50.0
aIncludes only moderate and severe levels. Mild levels are
included in the log linear analyses. See full manuscript
available from first author;
bPercentages for level of use within each substance category
do not add to 100% because the category "moderate use" is
not included.
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Table 2
First-Grade Readiness Test Scoresa
and Teenage Substance Use by Females
First-Grade Readiness
Low
Teenage
substance useb
Immature Normal Average Average
(n=53) (n=115) (n=114) (n=41)
Cigarettes
Never Used
Regular Use
29% 18% 22% 27%
21 30 25 26
Marijuana
Never Used
Heavy Use
64 57 40 39
11 15 18 24
Hard Liquor
Never Used
Heavy Use
75 67 54 49
2 4 5 10
Beer or Wine
Never Used 40 30 20 22
Heavy Use 8 14 25 27
aMetropolitan Readiness Test
bpercentages for level of use, within each substance category
do not add to 100%, because the category "moderate use" is
not included.
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Discussion
Research by an impressive number of laboratories has pointed
to social maladaptive and psychological behaviors as important
predictors of substance use.
salience of social maladaptive
The Woodlawn studies point to the
ratings as early as the latter
part of first grade. Aggressiveness and shyness have shown
particularly striking relationships to substance use in this
population. Many of the other studies have shown that ratings of
aggressive behavior have predictive relations with substance use,
while others point to psychological predictors which appear to be
closely related to aggressive and antisocial behavior.
Major sex differences in patterns and antecedents of use
remain unexplained and must have dramatic importance in
understanding the origins and evolving paths leading to substance
use or nonuse.
Learning problems in Woodlawn first-graders were almost
invariably a concomitant of aggressivenees. However, the fact
that learning problems frequently occurred without aggressiveness
allowed us to differentiate the predictive power of
aggressiveness in contrast to that of learning problems.
Learning problems alone in first grade did not predict drug use
but rather teenage psychological distress in Woodlawn;
aggressiveness appears to be the real antecedent of later drug
use in males.
Shyness in first grade--the tendency to sit alone, not to
speak up in class, not to be with other children--appears to
function as an inhibitor of teenage male drug use. It seems to
inhibit strongly the regular use of cigarettes and considerably
decreases the likelihood of ever using marijuana. The
combination of moderate to severe shyness and moderate to severe
aggressiveness tended to enhance the aggressive effect in males.
The most striking aspect in observing these results was that
these predictors spanned 10 years, from first grade to age 16 or
17. These factors must be studied in other communities similar
and dissimilar to Woodlawn before we can be clear as to their
generalizability or the specific conditions in which they hold
true. In the meantime we are left to conjecture as to their
meaning. Based on Woodlawn data, shyness alone inhibits drug
use, but with aggression tends to enhance it, thus suggesting
that these two "traits" are not opposite ends of the same scale,
but are two different phenomena., They are social q aladaptive
responses to social demands to interact with others and to obey
rules. These social maladaptive patterns may derive from
biological predispositions, and/or socilization processes in the
family and in the school prior to or during first grade.
A strong beginning has been made by a number of research
groups in clarifying the remote and evolving courses leading to
substance use among adolescents. We are now in a position to
develop an overall research strategy directed at specific
programs of prevention of substance use among teenagers. Such
a statement deliberately focuses upon the need for research
strategies, while recognizing the need to continue the rinds of
nonspecific, often educational preventive programs now in place.
A research strategy directed at the ultimate goal of
prevention programming will require collaborative design and
highly coordinated analyses. This is not the first time that
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such integration across investigative groups has been required.
Collaborative studies involving several research laboratories
have often been successful. The multi-hospital studies of the
phenothiazine treatment of schizophrenia in the early sixties are
but one example (NIMH, 1964).
Our recommendation for a collaborative preventive research
strategy includes the following stages:
1.
2.
3.
4.
5.
Collaborative examination of existing longitudinal data
bases and planning of analyses where each laboratory
would attempt to replicate specifically chosen findings
from other laboratories.
The collaborative design of new studies with
specification of the population samples from whom the
data is to be collected. Such planning should include
the possibility of extending existing longitudinal data
bases to include additional cohort follow-up. Such
extension would inform us if predictors of the
initiation of use are also predictive of the level of
use and abuse later in the life course.
Collaborative design at the appropriate stage should
include. experimental interventions directed at specific
antecedents found to be strong predictors of substance
use among teenagers. The purpose of these experimental
interventions will be to understand the function of the
specific predictors in the causal paths leading to
substance abuse.
Broad-based evaluation studies of highly
specified preventive intervention programs in specific
populations is the final stage of preventive
intervention research.
Following the preventive intervention evaluation
studies, we will be in a position to recommend national
policy and help to design the implementation of
prevention interventions aimed at specific antecedents.
Most of this research must be epidemiological, and much of
it will have to be directed at specific community populations.
Some research could be done using experimental animal analogs.
Aggressive behavior in first-graders can be studied using animal
analogs as well as children. Animals can be socialized to be shy
and aggressive, and they can also be bred to be shy and
aggressive. Such animal studies-allow the examination of the
difficulty or ease with which drug-seeking behavior can be
initiated and maintained. Experiments like these can help us
understand whether the shyness and aggressiveness observed to
predict substance use is more likely to derive from
socialization , genetic background, or both. Experimental
intervention with animals can proceed side by side with
experimental intervention with humans, thus augmenting our
understanding and saving time and resources in our prevention
research strategies.
Substance use is one of a group of adolescent outcomes of
great interest to the public and scientist alike. The research
strategy described above will be most useful if delinquency,
school achievement, psychological well-being, sexuality and other
relevant teenage outcomes are studied along with substance abuse.
Such studies can help specify which antecedents are generally
predictive of a variety of teenage outcomes, and which
antecedents are specific to substance use alone (Kohn, 1976).
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Susceptibility to Substance Abuse
Among American Indians: Variation
Across Sociocultural Settings
Philip A. May
According to the 1980 Census there are 1,418,195 American Indians
in the U.S., which represents 0.6 percent of the total U.S. popula-
tion. The Indian population is currently growing rapidly and as a
result is very young (median age=19.4; U.S.=29). Most Indians have
been characterized as being quite poor, and median education on most
reservations is also quite low. Recent trends indicate that an in-
creasingly large number of Indians now reside in and depend on urban
area, which is producing many changes in both individual Indians
and in many tribal groups.
Many Americans think of Indians as one, homogeneous group, but the
opposite is true. Cultural variation was and still is extreme from
one tribe and cultural group to the next. Not only is the culture
of a group like the Seminole of Florida greatly different from the
Sioux of South Dakota, but the personalities and behaviors produced
by each of these cultures are also quite different. In addition
there is also a variation of behavior within most tribes. This var-
iation of behavior is a vital consideration for anyone studying a
particular behavior among Indians. Drug use and related phenomena
are certainly no exceptions.
Difficulty of Indian Research
Undertaking research among Indians on reservations, and even in urban
areas, is very difficult. Patterns of secrecy, aloofness and a dis-
trust of researchers have been developed by Indians over the years.
Access to social gatherings, schools, individuals and data is there-
fore very difficult for researchers, particularly non-Indians. Sui-
cide and alcohol research among Indians reflect this difficulty.The
earliest studies on suicide and alcohol use among Indians were sub-
ject to a number of problems. In general, they were overly simplis-
tic and did little more than reinforce the old stereotype of the
“drunken Indian” and create a new one of “suicidal Indian” (May
1977; Shore 1975). Neither of these concepts was truly accurate,
and recent research has shown wide variation in both behaviors. In-
deed, certain tribes and sub-groups among tribes have problems with
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these behaviors but most individual Indians and some large tribes
have no major problem with either (May and Dizmang 1974).
The following discussion of drug abuse among Indians is subject to
the same pitfalls. The study of most types of drug usage among
Indians has just begun, and any conclusions and generalizations
should be approached with caution. Just as the complexity and var-
iation of Indian self-destruction and alcohol behavior were obscured
for many years, the same may hold true in substance-abuse research.
The information in this paper, therefore, should be approached with
caution.
ALCOHOL
In spite of the considerable attention paid to Indian drinking, in-
sights into prevalence, incidence, variation of patterns, and sus-
ceptibility to alcohol intoxication and dependence were slow in de-
veloping. Prevalence and incidence are explored here and a few very
selective works on Indian drinking are used to illustrate topics
vital to the understanding of susceptibility to all types of sub-
stance abuse.
Biological Considerations
For many years it was believed that Indians may have deficient abi-
lity to metabolize or process alcohol, By 1976 good Research in this
area began to emerge. Bennion and Li (1976) reported on a study in
which controls were instituted on the important variables of body
weight and drinking experience prior to the study. Their results
showed no difference in alcohol metabolism between Indians and
whites. More recent studies have consistently shown that individual
Indiana have an equal or oven greater ability to metabolize ethanol
(see Schaefer 1981) than people of other ethnic groups. Some ques-
tions still remain about high acetaldehyde levels of Indians and
several brain-bared enzymes but there is no proof today of any
metabolic deficit among Indians.
Extent of Drinking - Adults
The prevelance and incidence of Indian alcohol use are popularly be-
lieved to be high, but this is not validated by research. In the
four detailed studios on adult prevalence, the range from one reser-
vation to the next is striking. In the U.S. as a whole 67 to 68 per
cent of all adults drink at least once a year or more (Akers 1977).
Similar statistics for Indians indicate that 30 percent of the Na-
vajo of the Southwest (some Navajo communities are as high as 42
percent), 69 percent of the Standing Rock Sioux (SD) , 80 percent of
the Ute of Igacio (CC) and 84 percent of the Ojibwa of the Broken-
head Reserve in Canada drink (Levy and Kunitz, 1974; Whittacker
1962; Jessor et al. 1968; Longclaws et al. 1980). Therefore, two
of the groups surveyed are higher than the U.S. average, one is
about the same and one is considerably lower. All of the above tribes
are ones with reputations as ‘hard drinking” groups, and the low
incidence of reported use in some of them surprises many.
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Surveys on a number of other Indian groups, particularly those with
less notorious drinking reputations, would probably yield an inci-
dence similar to or lower than the rest of the nation.
Extent of Drinking - Youth
The extent of drinking reported by Indian youth is different from
that of adults. Recent national surveys have shown that between 53
and 73 percent of all youth in grades 7-12 drink to some extent
(Abelson et al. 1977; N.I.A.A.A. 1981). Surveys of Indian youth
show a slightly higher experience with alcohol: 56 to 89 percent
with three of four studies above the 71 percent most often reported
for U.S. youth. As with other youth in the U.S., factors such as
peer pressure, recreation, experimentation, anxiety and depression
have been documented as motivations for teenage Indian drinking
(Forslund 1978; Cocker-ham 1977; Western Behavioral Studies 1979).
Nevertheless, the incidence is higher among the youth of most Indian
groups. Variation from one group to the next is present, however.
Frequency of use, heavy use, and abuse are difficult to compare.
N.I.A.A.A. (1981) cites statistics that indicate that 11 percent of
all U.S. youth use alcohol heavily. Self-report data from various
tribes report that 17 to 46 percent are heavy users. There is some
problem however, with the comparability of alcohol abuse criteria
used in these studies due to quantity and frequency of differences
in Indian drinking styles.
Drinking Styles
The variety of drinking styles practiced by Indians has been well
researched and described in only a few studies. Various drinking
styles are practiced by Indians: abstinence, moderate drinking,
flamboyant extended binges, etc. Unfortunately, dozens of articles
have focused only on binge drinking, for it is perceived as the
unique “Indian” style and is the most easily observed and exotic
(May 1977).
In one article Ferguson (1968) describes two major types of drinkers
among the Navajo that are also present in a number of tribes. The
recreational drinker is typically a younger Navajo male who will
drink with a group of friends (mostly male), on various weekends,
at special and social events (i.e., dances), for it serves an im-
portant social cohesion and recreational function. The drinking in
these groups is generally forced, done in large amounts, consumed
quickly and for an extended period of time (i.e., all night). In-
toxication as a positive trait is often encouraged. Recreational
drinking is most common for ages 15-35. Recreational drinking is
sporadic, and long periods of abstinence (i.e., a week to several
months) occur between each instance. The other type of drinker, the
anxiety drinker, however, is much different and the behavior consi-
dered less acceptable by most tribes. Anxiety drinkers drink alone,
constantly, and are physically and psychologically addicted to alco-
hol. They fit the pattern of the “wino,” have suffered downward
social mobility and tend to concentrate in border towns off the
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reservation, central
ble. In most Indian
cities! or areas where supply is most accessi-
communities these people are labeled with an
ethnic term similar to “alcoholic” and are stigmatized and/or ostra-
cized. Anxiety drinkers are few in most Indian groups, and recrea-
tional drinkers predominate. Standard alcoholism indices work fairly
well in accurately classifying anxiety drinkers, but are not useful
in evaluating the alcohol abuse of recreational drinkers.
As in the rest of the U.S., fewer Indian women drink than Indian men.
In some tribes in the southwestern U.S. (Navajo and pueblo) it is
rare and quite unacceptable for any woman to drink, particularly
after some experimentation. In other tribes such as the Plains and
Basin tribes, more women drink and drinking is somewhat more accept-
able. Nevertheless, Indian women overall are less likely than Indian
men to be drinkers.
A final note on style concerns acculturation. Indians who are ac-
culturated are particularly likely to follow the modal pattern of
drinking that is popular in the segment of modem society with which
they identify. Indian professionals and bureaucrats generally drink
as other professionals do. Indian laborers will drink as their
fellow laborers, etc.
Alcohol-Related Problems
Alcohol-related problems are prevalent among Indians and have re-
ceived a great deal of attention. Alcohol-related mortality, for
example, is consistently higher among most tribes than in the gen-
eral U.S. population. For all U.S. Indians, the age-adjusted rate
of motor-vehicle-accident death is 4.4 times more common; cirrhosis
of the liver mortality is 4.4 times more frequent; and death from
other accidents is 3 times the national average (U.S. Public Health
Service 1978). Some tribes such as the Navajo have had low rates of
cirrhosis in the past, but recent statistics indicate an increase
(May and Broudy 1980). Deaths from exposure and drowning have also
been frequently linked to alcohol, while alcohol-related injury and
illness have also been documented as problems among many groups of
Indians.
Alcohol-related arrests have also been a problem for Indians. Off-
reservation arrests have been extremely high for intoxication,
driving while intoxicated, and other alcohol-related crimes. Alco-
hol-specific arrests on most reservations have been high, but not
significantly higher than in most U.S. communities (May 1976).
Alcohol Summary
From the above facts Indians have been shown to have no biological
susceptibility to intoxication, not an unusually large percentage
of adult drinkers, a slightly higher percentage of youthful drink-
ers, a variety of drinking styles and problems with alcohol-related
mortality and arrest. Most of the problems can be related to the
recreational drinking style. Drinking rapidly in a forced, group
situation produces high blood-alcohol levels and intoxication in a
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person who may not drink regularly. High blood-alcohol levels are
related to most of the health and arrest problems mentioned above.
Acutely high blood-alcohol levels coupled with other environmental
and legal factors produce high rates of alcohol-related arrest,
death and illness. Ihus,the binge pattern of drinking can be related
to most of the alcohol-related problems mentioned above. The major
exception is cirrhosis of the liver. Chronic, steady, escape drink-
ing , as practiced by the anxiety drinker, is related to cirrhosis.
Therefore, the style of drinking among some Indian drinkers results
in alcohol-relate problems; It should again be pointed out that
these statistics are produced by a minority of Indians and that many
Indians abstain. Also, many Indians who do drink, do so without
major problems.
Turning now to other drugs, the use of marijuana by Indians will be
examined. As with much of the marijuana research in the U.S., most
of the data have been collected from students. National surveys have
shown that approximately 10 to 48 percent of all U.S. youth in
grades 7-12 have ever used marijuana. Approximately 4 to 16 percent
of youth are current and/or recent users (Akers 1977). Four studies
on Indian youth in the same grades indicate a range from 22 to 62
percent. Three of the four surveys found over 40 percent users a-
mong Indian students. The highest percentage of users, 62 percent,
was found among southwestern tribes who are close to the major sup-
ply routes from Mexico; the lowest percent, 22 percent, was found
in central Canada. Indian students are also reported being current
users as often or more often than other youth (17-41 percent). There-
fore, use of marijuana appears to be higher among Indians in grades
7-12 (Western Behavioral Studies 1979; Oetting et al. 1980; Cocker-
ham 1977; Longclaws et al. 1980).
Among post-high-school youth, there is also a difference between
narijuana reporting in U.S. averages and Indian reports. National
college polls have consistently shown 50-55 percent of students use
marijuana,with 35-40 percent reporting regular or frequent use
(Akers 1977). The two surveys done on Indians of this age group were
ione in post-high-school, technical schools which may not be direct-
ly comparable. Between 70-78 percent of Indians in these schools
were found to have used marijuana, while 50 to 63 percent were regu-
lar users (Goldstein et al. 1979; Briggs 1980). Therefore, at the
post-high-school level Indian youth report a higher use of marijuana.
Only one survey reports any marijuana data for Indian adults. In
Canada, Longclaws et al. (1980) found that 36 percent of the Broken-
head Ojibwa Indians have ever used marijuana and 7 percent used it
more than once a week. This is slightly higher than national adult
statistics, but comparable to California data. In summary, Indian
youths generally report more use of marijuana at all ages. Some
variability is evident, based on tribal and/or geographical differ-
ences , but much more information is needed.
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The use of inhalants (i.e., glue, gas, solvents, spray paints) has
been reported as being quite popular among Indian youth. Samples
of U.S. youth from 12-19 years find that 9 and 11 percent have used
inhalants, but less than 1 percent do so regularly (Abelson et al.
1977). Of the two studies reporting on Indian youth of the same
ages, between 17 and 22 percent have used inhalants (Oetting et al.
1980; Western Behavioral Studies 1979). In a national Indian survey
16 percent reported recent use. In general, almost twice as many
Indian youth have used inhalants (Oetting and Goldstein 1979). One
study in an Indian boarding school in Oklahoma reported that 13
percent of the students in grades 6-8 were judged to be heavy users
(Schottstaedt and Bjork 1977) but boarding schools are frequently
populated by high risk or problem youth. Among Indian post-high-
school students, studies have indicated 20 and 31 percent of the 
students have used inhalants. Recent ‘use among these students was
reported by only 1 and 4 percent of the students (Goldstein et al.
1979; Briggs 1980). Therefore, actual use of inhalants is highest
in the early and middle teens and then declines in later years.
Inhalant abuse has received a lot of popular attention on many In-
dian reservations, for it seems to be an abusive behavior which is
notably too popular among Indians. In addition, it is recognized
that some physiological damage results from inhalation of particular
solvents. An optimistic note is the low recent use reported by the
post-high-school Indians. Most Indian youth may only experiment
with inhalants at an early age and never use them extensively.
OTHER DRUGS
In the most extensive and complete survey-of all types of drug use
among U.S. Indian youth, Oetting, Goldstein, et al. found little
difference in use of most drugs by Indians and others in the U.S.
As stated above, the use of alcohol, marijuana, and inhalants was
found to be greater among Indians,
drug use was equal.
but in most other categories,
One exception was barbituate use. Indians in
grades 7-12 were much less likely to use barbituates than other U.S.
youth (Oetting and Goldstein 1979). Several other studies provided
similar results. Indian youth and Indians adults of many tribes are,
therefore, less likely or no more likely to use drugs such as bar-
bituates, amphetamines, cocaine, and opiates.
Several issues deserve mention here. The use of hallucinogens
(particularly peyote), is reported to be slightly higher among In-
dian youth than other youth -in the U.S. Adult Indian use of peyote
and, therefore, hallucinogens is probably higher than other U.S.
adults. In most cases, however, use by Indians could not be consi-
dered abuse. Most adult use of peyote is strictly controlled by the
Native American Church (NAC) and is only taken in rigidly controlled
highly organized, religious ceremonies. In such situations side
effects are minimal, group functioning and group solidarity are
enhanced and usage and behavior are strictly controlled (Bergman
1971). Usage of peyote under these conditions could be considered
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sacramental and therapeutic. The use of peyote by Indian youth,
however, is sometimes outside these church practices and in these
instances problematic.
Variation in use of barbituates, amphetamines, cocaine, opiates and
various prescription drugs seems to exist from one Indian group to
the next. For example, as a means of suicide and suicide attempts,
drugs are seldom used by Indians in the Southwest, but overdose is
more common among some tribes elsewhere (May and Dizmang 1974). Use
of a variety of prescription and street drugs seems to be slightly
higher among some Plains Indian tribes (Cockerham 1977). Culture,
isolation, and other variables may affect prescription and other
drug use.
A SUSCEPTIBILITY SCHEME
With the above material reviewed, a susceptibility scheme is now
proposed, ‘Ibis scheme is based on the previous literature review,
the author’s experience, and other literature on alcohol, drugs,
crime, suicide, and motor-vehicle accidents among Indians (particu-
larly Levy and Kunitz 1974; Ferguson 1976; Jenson et al. 1977). It
is tentative and awaits further direct testing.
The Traditional Cultural Factor
Particular Indian tribes and cultural groups have been found to be
higher risk for many types of deviance because their traditional
tribal customs tolerate or encourage individualistic, flamboyant
behaviors (Levy and Kunitz 1974). Tribes which are characterized by
loose, small group or band-level organization have been found to
produce more individualistic behavior which can be considered de-
viant. Examples of these are nomadic tribes traditionally based on
a hunting, gathering, and/or raiding complex such as those found in
the Plains and Great Basin regions. On the other hand, tribes which
are organized in larger groups, have a more rigid and fixed social
structure, are much more prone to enforce conformity and less likely
to produce deviance. These tribes were and are more sedentary, agri-
culture or fishery based and organized around strict social systems
and rules of governance. This type is exemplified by tribes east of
the Mississippi, the Pueblo and northwest coast Indians. In this
manner, traditional social organization has been found to be impor-
tant in producing or impeding various kinds of deviance. Drug use
should also follow this pattern.
The Modern Factor
One other theme has also been consistently proposed as influential
in producing deviant behavior. Social disorganization, cultural and
social change, and cultural conflict which result in interpersonal
stress have been frequently cited as causing crime, suicide, and
alcohol problems among Indians. This theme states that the accul-
turation dilemma that many tribes and their members face will raise
deviance rates. Therefore, tribes who are firmly entrenched in their
traditional ways are less likely to produce high levels of deviant
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behavior. On the other hand, tribes which are undergoing rapid
change and whose way of life is being assaulted will produce higher
levels of deviance. Drug use might be highly influenced by this
dynamic.
Combining Modem and Traditional
Combining these two schemes, evaluation and explanation of patterns
of drug abuse might be possible. Tribes with loose social organiza-
tion would be expected to have the highest rates of drug abuse while
those with high levels of organization would have the lowest rates,
particularly under conditions of relative isolation from moderniza-
tion and acculturation stress. However, tribes undergoing forced and
rapid change will also experience higher rates of drug abuse than
similar tribes in relative isolation from these pressures. There-
fore, the order of risk for drug abuse would be expected to be:
highest risk--loosely integrated tribes undergoing rapid change;
lowest risk--tightly integrated tribes undergoing little change in
life style, economy and exposed to few outside influences.
This scheme must be translated from the tribal to the individual
level. Families and individuals make adjustments, decisions, and base
their lives on the definitions and options afforded them in their
social and cultural context. This is vividly reflected in drinking
and drug behavior. Individuals growing up and living in particular
tribal cultures will be more or less likely to use drugs based on
both traditional Indian culture and change factors. The suscepti-
bility of a particular person can be judged based on the adaptation
which the person and also his/her family have made. Their adjustment
to particular Indian traditional values and also modem, mainstream
values will be reflective on their likelihood to use drugs. Figure
1 illustrates at least four types of adaptation which contemporary
Indian individuals can make.
FIGURE 1
COMMMON SOCIAL INTEGRATION ADAPTATIONS OF CONTEMPORARY
AMERICAN INDIANS AND SUSCEPTIBILITY TO DRUG ABUSE
Both
Social Role of Western Traditional Indian
the Individual Modem and Modem Traditional
Level of
Susceptibility*
*The higher the susceptibility, the greater the use of drugs
and extent of drug abuse.
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If an individual and his family of orientation are well integrated
socially and perceptually with both Indian and modem society, they
are the lowest risk for drug abuse. These people would have a steady
meaningful job and also relate to traditional Indian values and prac-
tices. Thus, these people have a dual source of identity. Closely
related to this in terms of susceptibility, are people who are well
integrated to traditional Indian society. If they derive satisfac-
tion, positive self-identity and meaning from traditional Indian
culture, they are less likely to be drug abusers. The same might be
said for Indians who are highly integrated into modem, non-Indian
culture except that their identity and self-esteem come from a dif-
ferent source (i.e. , a profession, sports, etc.) Therefore, those
with a strong integration or attachment to either modem or Indian
society are also low risk, but not as low as those with both. Fin-
ally the high-risk people or most susceptible to drug abuse are
those who are not integrated into either traditional or modem soc-
iety via their family of orientation or their own achievements.
This model of susceptibility is not new, but is a logical extension
of some previous works. Results which support this have appeared in
the alcohol and deviance literature and are now emerging in recent
drug surveys (Western Behavioral Studies 1979). One exception be-
tween the proposed scheme and previous research, though, is that no
previous study has found individuals with “modem only” integration
to be good risks. The same may also prove to be true with drug abuse,
but reservations, the location of virtually all alcohol studies, are
poor places to locate well adjusted Indians with only modem inte-
gration. One should look for these types in urban areas, particular-
ly among 2nd and 3rd generation, city-dwelling Indians.
CONCLUSIONS
From the previous material, some patterns of drug use among Indians
can be described. Slightly higher levels of use of some drugs among
Indian youth are indicators of stress during adolescence when social
integration from the family of orientation has weakened, the peer
group is powerful, and adult adaptations and roles have not yet been
crystalized. Because this period is complicated for Indians bya dual
set of options and prejudice, a higher percentage of Indian youth
may use particular substances as a temporary escape. Many Indian,
adolescent. peer groups define alcohol, inhalants and marijuana as
acceptable. But for most young Indians the usage of drugs other.
than alcohol is an experimental, transitory behavior. Individuals
who are well integrated into and identify with both modem and tradi-
tional Indian customs are the least susceptible to drug abuse. Those
who are not well established in any socially integrated role of
either white or Indian society are the most likely to abuse drugs
and to continue their use. This scheme awaits testing and, if vali-
dated, translation into applied solutions.
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Progress Report of the NIDA
Addiction Research Center
Donald R. Jasinski, Charles A. Haertzen, Jack E.
Henningfield, Rolley E. Johnson, Hassan M. Makhzoumi,
and Katsumasa Miyasato
An administrative decision terminating the participation of
federal prisoners in research ended the Addiction Research
Center clinical research program using volunteer prisoner
addicts. In July 1979, the program was relocated to Baltimore
City Hospitals where it operates on a speciality ward in a
general hospital conducting research in volunteer addicts from
the Baltimore area. The first subject was admitted in February
1980; however, the program did not become fully operational
until July 1980. This progress report covers the one-year
period of July 1980 to July 1981.
The experience to date indicates that non-therapeutic and
therapeutic research can be conducted in volunteer addicts in
such a manner that ethical concerns as well as counseling and
aftercare needs can be met. Several studies of interest to the
committee have been completed and will be summarized in this
report.
STUDY I - EVALUATION OF ORALLY GIVEN BUPRENORPHINE
STUDY II - EVALUATION OF SUBLINGUALLY GIVEN BUPRENORPHINE
Previously, we reported to the Committee that buprenorphine acts
as a partial agonist of morphine with a long duration of action
(Jasinski et al., 1976, Jasinski, Pevnick and Griffith, 1978).
The drug produces morphine-like effects with a low toxicity and
little or no physical dependence. We further proposed that
buprenorphine could be utilized as a short term
detoxification/maintenance agent for narcotic addiction. The
original studies were done with subcutaneously injected
buprenorphine. This report covers two recent studies done to
evaluate the oral and sublingual routes as modes of
administration of buprenorphine.
When given subcutaneously the effects of buprenorphine plateau
at acute doses of 1 to 2 mg. It is assumed that for a partial
agonist, the initial part of the plateau represents the response
to a dose that produces maximum receptor occupation and maximum
agonist effects. This in turn would represent a basis for a
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daily dose for maintenance. For the oral route, the dose
producing maximum agonist effects was estimated to be 20 mg of
buprenorphine and for the sublingual route, 2 mg.
Two studies were done comparing the effects of orally and
Sublingually given buprenorphine to Subcutaneously given
buprenorphine and placebo. The studies were similar, with each
involving 10 non-dependent subjects. Each study was conducted
as a "double blind", "double dummy" placebo-controlled study.
Drug effects were measured with our standard procedures for
acute morphine-like effects (Jasinski, 1977). In the first
study, each subject was given buprenorphine orally in doses of
20mg and 40 mg, subcutaneously in doses of 1 and 2 mg and
placebo administered according to a latin square design at 3-day
intervals. In the second study, each subject was given
buprenorphine sublingually in doses of 2 and 4 mg, buprenorphine
subcutaneously in doses of 1 and 2 mg, and placebo.
The onset, time of peak effect, and duration are similar for
orally and subcutaneously given buprenorphine. The subjective
and physiologic effects of orally and subcutaneously given
buprenorphine were similar, with no dose response. Drug
responses were significantly greater than placebo responses.
Sublingually given buprenorphine has a slower onset of
subjective and objective effects than subcutaneously given;
these responses were greater than those to placebo. The
duration of effects is similar by both routes with no dose
response for either the subcutaneously or Sublingually given
buprenorphine.
These studies indicate that maximum agonist effects are produced
with a 20 mg oral dose or a 2 mg sublingual dose of
buprenorphine and that both doses would be suitable as daily
maintenance doses in treating narcotic addiction.
STUDY III - EVALUATION OF CLONIDINE IN MORPHINE WITHDRAWAL
Clonidine has been reported useful in treating the narcotic
withdrawal syndromes with its mode of action related to its
ability to decrease hyperactivity in the locus ceruleus (Gold et
al., 1980, Washton, Resnick, 1980).
The present studies were designed to test the efficacy of
clonidine under experimental conditions with known levels of
morphine dependence, with negative control (placebo) and
positive controls (partial doses of morphine). In addition, it
was hoped that some’ information could be obtained on the mode of
action of clonidine since its hypothesized mode of action in
treating withdrawal (suppression of autonomic activity) is
inconsistent with previous observations that autonomic changes
of withdrawal occurred during withdrawal of nalorphine and
cyclazocine without drug-seeking behavior or subjective
discomfort (Martin et al., 1965).
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Ten subjects dependent upon maintenance methadone or illicit
heroin were stabilized on 60 mg morphine sulphate per day
administered in 15 mg doses at 6:00 a.m., 10:00 a.m., 4:00 p.m.
and 1O:OO p.m. After staoilization, five 24-hour substitution
tests were conducted at weekly intervals using our standard
procedures (Jasinski, 1977). The procedure for the substitution
tests is that subjects receive their last maintenance dose of
morphine at 4:00 p.m. At 10:00 p.m. (hour 6), 6:00 a.m. (hour
14) and 10:00 a.m. (hour 18), subjects are given an oral
medication and a subcutaneous injection, such that each
medication is administered three (3) times under "double dummy"
conditions to mask the route of administration. The five tests
involved the substitution of placebo (orally and subcutaneous),
morphine 3 mg and 6 mg subcutaneously and clonidine 0.2 mg and
clonidine 0.4 mg orally. Each of these doses was given three
times within a substitution test.
The results of these crossover studies indicated that clonidine
suppressed autonomic signs of withdrawal to a far greater extent
than morphine; in contrast, clonidine was markedly less
effective than morphine in suppressing the subjective discomfort
of withdrawal, producing only slight alleviation of the
withdrawal illness late in the substitution period. Clonidine,
but not morphine, produced marked sedation and orthostatic
hypotension throughout the 11 hours of observation. It is
concluded that clonidine partially alleviates the subjective
discomfort of withdrawal, markedly depresses the autonomic
hyperactivity and produces sedation; however, the alleviation of
subjective discomfort is probably unrelated to the autonomic
depression or the sedation.
STUDY IV - EVALUATIM OF DIAZEPAM FOR PENTOBARBITAL-LIKE EFFECTS
Previously we had reported that addicts discriminated
pentobarbital from morphine, d-amphetamine and placebo.
However, pentobarbital, morphine and d-amphetamine all produce
similar feelings of well-being and elation. Quantitative
measures of the subjective and behavioral effects of
pentobarbital were developed and it was shown that crossover
studies could be done to assay sedatives for.pentobarbital-like
effects. Since pentobarbital represented a prototype for highly
abused sedative hypnotics, such assays could seem to be a means
for assessing sedative hypnotics for abuse potential. Using
these procedures it was shown that secobarbital, phenobarbital
and methaqualone produced pentobarbital-like effects including
euphoria (Jasinski et al., 1977).
The current studies were done to determine if diazepam produces
pentobarbital-like effects and euphoria. Subjects were 12
volunteer alcoholic and sedative abusers who were not physically
dependent at the time of study. Studies were done as double
blind crossover studies utilizing the procedure for sedative
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hypnotics. Each subject was given by the oral route diazepam
10, 20, and 40 mg; pentobarbital 120 and 240 mg; and placebo.
Drugs were administered at 3-day intervals according to a latin
square design.
Diazepam produced typical pentobarbital-like effects including
euphoria. The onset, peak and duration of effects were similar
for both drugs. Relative potencies, meeting the statistical
criteria for validity, were similar across subjective and
behavioral measures, indicating that diazepam is 10 times more
potent than pentobarbital.
STUDY V - EVALUATION OF CHLORDIAZEPOXIDE FOR PENTOBARBITAL-LIKE
EFFECTS
A study, similar in design and procedures to the diazepam study,
was initiated in six subjects where chlordiazepoxide 50, 100 and
200 mg, pentobarbital 120 and 240 mg and placebo were admin-
istered. Chlordiazepoxide produced dose-related pentobarbital-
like effects and euphoria, but the responses to the 200 mg dose
were less than the 240 mg dose of pentobarbital. Valid assays
were not obtained. The study will be extended with larger doses
of chlordiazepoxide.
On the basis of these two studies, it is concluded that the
current procedures and methods can be utilized to assay the
relative abuse potential of benzodiazepines.
STUDY VI - EVALUATION OF ZOMEPIRAC FOR MORPHINE-LIKE
SUBJECTIVE EFFECTS AND EUPHORIA
Zomepirac is a non-steroidal anti-inflammatory drug that when
given orally is l/6 to l/10 as potent as subcutaneously given
morphine in relieving pathologic pain (Wallenstein et al., 1980;
Forrest, 1980). Its mode of action is more closely related to
aspirin than morphine. The drug is felt to have little or no
abuse potential. Some analgesic studies, however, have
indicated that euphoria may occur as a side effect. This
observation led us to consider that zomepirac may be a
psychoactive drug with some abuse potential.
A single dose, crossover study was conducted with zomepirac
using our standard crossover procedures for assaying the abuse
potential of narcotic analgesics (Jasinski, 1977) to learn if
zomepirac produces euphoria in non-tolerant, non-dependent
narcotic addicts. Each of six subjects was given zomepirac 400
and 800 mg orally, morphine 15 and 30 mg subcutaneously and
placebo. Drugs were administered twice weekly under "double
blind", "double dummy" conditions.
Morphine produced typical subjective and behavioral effects
including euphoria and miosis. The 400 mg dose of zomepirac was
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indistinguishable from placebo on all measures. The responses
to 800 mg of zomepirac were not significantly different from
placebo; however, one subject reported a drug effect because of
"stomach pain" and another reported slight relaxation and
"liking". There were no significant changes in the incidence of
positive stool guaiac following zomepirac administration nor
were there any significant Changes in blood pressure, pulse
rate, respiratory rate or rectal temperature.
It is concluded that to doses of 800 mg orally, zomepirac is not
a euphoriant in narcotic addicts.
STUDY VII - STUDIES OF TOBACCO DEPENDENCE
A series of studies of the acute effects of nicotine delivered
by tobacco smoking and intravenously administered nicotine have
been done in cigarette smokers with and witnout a history of
drug abuse. These studies were done to: (1) investigate the
mechanism underlying compulsive tobacco use including
delineating the role of nicotine, (2) determine if the addictive
process with tobacco is similar to that for morphine, (3) adapt
the clinical pharmacological methods used for other substances
of abuse to studies of tobacco and nicotine, (4) to introduce
and validate behavioral pharmacologic methods into clinical
studies and (5) to conduct conjoint human and animal behavioral
pharmacologic studies in order to validate animal models (this
is done in conjunction with Dr. Stephen Goldberg of our
laboratory).
The first studies involved measuring the subjective and
physiologic responses to graded doses of nicotine delivered'by
tobacco smoke and intravenously after 8 hours of deprivation of
cigarettes in 8 subjects.
One set of studies involved the intravenous administration of
placebo and nicotine base in doses of 0.75, 1.5 and 3.0 mg at
l-hour intervals to each subject. Each subject received these
four doses on four separate occasions according to 4 X 4 latin
squares. Thus, there were 32 responses for each dose (8
subjects, 4 replications). Following each dose, physiologic,
behavioral and subjective responses were measured continuously
for 30 minutes.
Nicotine produced a predominantly euphoric response related to
dose. The effects began within 15 seconds of injection and were
gone within 3 minutes. Subjects identified the effects as
cocaine-like. The two lower doses increased heart rate while
the largest (3 mg) lowered heart rate. Subjects accurately
discriminated among the doses of nicotine.
Another set of studies involved the same 8 subjects using the
same procedures except that nicotine doses were delivered by
controlled puffing on cigarettes at 30-second intervals with
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smoking down to a 23 mm butt length. The four dose levels were
puffing on an unlit cigarette, and controlled smoking of
cigarettes delivering 0.4, 1.4 and 2.9 mg of nicotine, again
administered at l-hour intervals on 4 occasions for 32 responses
per dose (8 subjects, 4 replications). Subjects accurately
discriminated among the cigarettes as to strength, again with
onset of positive subjective effects within 15 seconds after
termination of smoking.
To characterize the subjective effects of nicotine in terms of
other drugs of abuse, 10 cigarette smokers with histories of
substance abuse were given placebo intravenously on one day and
nicotine intravenously in doses of 0.75, 1.5 and 3 mg on another
day. The doses of nicotine were given in ascending order at
l-hour intervals. Following completion of the nicotine
injections (Day 1) and the placebo injection (Day 2) subjects
completed the Addiction Research Center Inventory and were asked
to simulate their responses to the intravenous nicotine and to
placebo (Haertzen, 1974). The profile of responses was compared
to 10 criterion groups based on 4000 responses for various drug-
induced subjective states and diagnostic categories (previous
studies have shown that addicts can accurately simulate drug-
induced subjective states). These studies indicated that
nicotine produces a euphoria and a subjective state that most
closely resemble those of morphine and, secondarily, cocaine.
The second major group of studies were behavioral pharmacologic
studies of intravenously given nicotine using a self-
administration paradigm. Subjects were allowed to self-
administer through a catheter in 3-hour sessions on a FR10
schedule with 1-minute time outs and 1 dose per session. Five
subjects have completed the studies of self-administration of
placebo and nicotine in doses of 0.75, 1.5 and 3.0 mg. In these
studies, nicotine served as a positive reinforcer with a pattern
of responding similar to that observed in animal studies.
It is concluded from these studies that valid methods have been
developed for studying the dependence process underlying
compulsive tobacco use and further that nicotine is a euphoriant
and a positive reinforcer in man.
The first years’ experience in the Baltimore clinical research
program indicates that the methods and procedures developed in
prisoner volunteers are adaptable, that ethical and treatment
concerns can be met in such a way as to allow non-therapeutic
and therapeutic research in volunteer addicts and alcoholics,
and that sufficient numbers of subjects will volunteer for
studies.
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Progress Report from the NIDA
Addiction Research Center (Pre-
clinical Laboratory), Lexington, KY
C. W. Gorodetzky, E. J. Cone, J. L. Croughan, S. R. Goldberg,
M. E. Risner, H. E. Shannon, T.-P. Su, and S. Y. Yeh
In January 1981, the ARC underwent a reorganization, in which the
Center was split into two major units, the Clinical Laboratory in
Baltimore and the Preclinical Laboratory in Lexington. In this
progress report from Lexington, I will briefly review three ongoing
studies from several different labs in the unit.
AN OPIUM RATER: A DRUG METABOLIC CASE STUDY
The subject of this study was a 52-yr-old male from Iran admitted
to the hospital at Washington University (St, Louis, MO.) for treat-
ment of cancer of the esophagus. When it was discovered that the
patient had been a, chronic opium eater for many years (and had
brought his drug supply with him), Dr. Croughan was consulted on
the best method for opioid withdrawal, Dr. Croughan contacted us
to assist in determining the amount of intake of dependence-producing
opiates and the probable level of physical dependence, When a liter-
ature search revealed very little drug metabolic data in opium eat-
ers, it was decided to undertake a limited study in this patient.
Clinical Drug History and Samples
The patient had been ingesting for many years approximately 1 g.
per day of smoked opium residue (locally called sukhteh), in three
divided daily doses. Two sets of samples were obtained for analy-
sis. The first was samples of the opium residue itself. We
-received what was described as a typical l-day intake., consisting
of three hand-rolled spherical portions of black gummy material.
The second sample set was seven consecutive 24-hr. urine collections.
Methods
Morphine, codeine, normorphine, and norcodeine were the compounds
of primary quantitative interest from the perspective of opiate
physical dependence. An attempt was also made to identify thebaine,
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oripavine, papaverine, and noscapine. Analytic methods used were
thin-layer chromatography (TLC), gas chromatography (GC), and gas
chromatography/mass fragmentography (GC/MF).
TLC, developed with ethyl acetate:methanol:ammonium hydroxide and
sprayed with iodoplatinate, was performed on a methanol triturate
of the opium residue samples and on urinary extracts with 15 per-
cent isopropanol in dichloroethane at pH 9-10. Urine was extracted
both with and without prior hydrolysis by glusalase or acid. For
GC and GC/MF,urine was extracted at pH 9.5 with methylene chloride:
isopropanol (7:3) after addition of -isocodeine as internal stan-
dard. The dried residue of the organic phase was silylated with
Tri-Sil Z. GC was performed on a 2 mm. x 36 cm. glass column
packed with 3 percent OV-210 on 100/120 mesh Gas Chrom Q; tempera-
ture of the column was programmed at 10°/min. between 170 and
260° C. MF was performed on a Finnigan Model 4021 GC/MS instru-
ment using the chemical ionization mode with methane serving as
both the carrier and reagent gas. The two most prominent ions of
the CI spectrum of each compound were selected for monitoring and
were generally the (M + 29), (M + 1) , or (M - 15) ions.
Results and Discussion
Qualitative results of the analysis of the smoked opium residue
samples indicated the presence of major amounts of morphine and
codeine, minor amounts of nor-morphine and norcodeine, and trace
amounts of noscapine. There were also TLC spots consistent with
trace amounts of oripavine and papaverine. On quantitative analy-
sis, the three opium portions supplied were very close in weight,
ranging only from about 286 to 310 mg., with a total daily intake
of a little over 900 mg. Morphine content averaged 11.7 percent
or 105 mg./day and codeine 5.3 percent or 47 mg./day, giving an
estimated daily morphine plus codeine intake of about 153 mg.
This composition of the smoked opium residue shows both similari-
ties and differences from the reported composition of raw opium.
The nearly 12 percent composition as morphine is consistent with
the 10 percent reported in opium; however, the codeine content of
over 5 percent is tenfold higher than usually reported for raw
opium. Noscapine in raw opium is usually quoted at 6 percent; a
trace amount was found in these samples. Papaverine and thebaine,
reported as constituting 1 and 0.2 percent of raw opium, respec-
tively, were not found in these residue samples. On the other
hand, minor amounts of normorphine and norcodeine were found in
these samples and are not reported as constituents of raw opium.
Roth qualitative and quantitative analyses were also performed on
the urine samples. Using GC/MF, those compounds identified in
the urine were: morphine, codeine, normorphine, norcodeine, and
a trace of noscapine. Those standards which could be detected by
the method but were not found in the urine extracts were thebaine,
papaverine, and oripavine. Urine samples were quantitatively
analyzed for morphine, codeine, nor-morphine, and norcodeine, both
in the free form and after acid hydrolysis. Conjugated morphine
was the major urinary excretion component with total morphine
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excretion, making up about 11 to 14.5 percent of the estimated total
daily morphine plus codeine intake, with an average daily excretion
of about 13 percent. Total codeine accounted for 2.5 to 3.5 per-
cent of the total morphine plus codeine, with a daily average of
3.25 percent; normorphine, about 1 to 1.5 percent, with a daily
average of 1.4 percent; and norcodeine, about 0.25 to 0.5 percent,
with a daily average of 0.3 percent. Day-to-day variability was
greatest for morphine, but not excessive for any of the monitored
compounds. Morphine excretion averaged about 4.5 percent in the
free form and 95.5 percent as conjugated; codeine and nor-morphine
were excreted about 11 percent as free; and norcodeine about 28
percent as free. The proportion of these compounds originating
directly from ingested compounds vs. metabolites of ingested
opiates is not known. Comparing the composition of the ingested
opium residue to the excretion pattern, it seems likely that at
least some of the nor compounds represent metabolites of ingested
morphine and codeine, and some of the ingested morphine may be a
metabolite of codeine. A total of little less than 18 percent of
the morphine plus codeine intake could be accounted for in the
urinary excretion of these four compounds. Much of the remainder
was probably excreted in the feces, and some may have been con-
verted to other metabolites.
In answer to Dr. Croughan’s inquiry concerning potential level of
physical dependence, using potency estimates of approximately 6:l
for oral vs. parenteral morphine and 20:1 for oral codeine vs.
parenteral morphine, we estimated this patient’s habit as approxi-
mately equivalent to 20 mg. of parenteral morphine per day, a
relatively low level of physical dependence. This estimate was
consistent with the subsequent clinical course of the patient,
who was withdrawn on 400 mg./day of propoxyphene napsylate over
10 days with minimal discomfort.
SPECIFIC BINDING SITES FOR SKF-10047
This study was undertaken to investigate the binding character-
istics of SKF-10047 (N-allylnormetazocine), the prototypic sigma
receptor agonist in the three receptor scheme of Martin. Binding
studies were carried out in guinea pig brain synaptic membranes,
and concomitant pharmacologic studies were done in the rat discrimi-
native stimulus model.
Binding Studies
In the binding studies, synaptic membranes were prepared from
homogenates of brain of male Hartley guinea pigs. Incubations of
synaptic membrane preparation were carried out at 22° C., first
with competing ligand in the absence and presence of 0.1 mM
unlabeled SKF for 5 min., followed by addition of 1 mM H3-SKF and
reincubation for 15 min., and then an additional 10 min. on ice.
Free ligand was separated from bound by rapid filtration through
Whatman GF/C filters presoaked in t-amyl alcohol-saturated water,
and radioactivity was evaluated by liquid scintillation spectrome-
try.
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Inhibition of specific H3-SKF binding (i.e., total minus that in
the presence of unlabeled SKF) by several opioids was studied.
Binding was saturable and represented about 90 percent of total
binding. Inhibition of H3-SKF binding by a series of opioid
derivatives gave similar relative potencies as those previously
described for displacing H3-naloxone and probably represent binding
of H3-SKF to mu receptors, where it is a potent antagonist. How-
ever, -etorphine, a potent mu agonist, even at very high concen-
trations could not completely inhibit the binding of H3-SKF.
These “etorphine inaccessible” sites were preliminarily desig-
nated as psi-binding sites. The psi-binding sites were subse-
quently studied in the presence of 100 mM of -etorphine added
to mask the assumed mu receptors. Specific psi-binding was
studied with different concentrations of H3-SKF. Scatchard analy-
sis was consistent with a single class of binding sites with
apparent Kd of 322 nM and estimated Bmax of 792 fmol./mg. protein.
Relative potencies of a series of opioid derivatives to inhibit
H3-SKF binding to psi-binding sites showed a rank order totally
different from inhibition of binding of H3-naloxone to assumed
mu receptors. SKF itself had an IC50 of 254 nM. Traditional
morphine-like drugs (such as morphine and levorphanol) and nal-
trexone were poor inhibitors of SKF psi-binding. However, d,
cyclazocine, dextrorphan, and phencyclidine (PCP) were potent
inhibitors and showed monophasic inhibition curves. Several
potent inhibitors showed biphasic inhibition curves, with plateaus
at about 30 percent binding. These included d, -pentazocine and
haloperidol (the most potent psi-binding inhibitors); ethylketo-
cyclazocine, the prototypic kappa receptor agonist; and propranolol.
Psi-binding appeared to show stereoselectivity in reverse of that
shown for mu receptors. Several d-isomers (such as cyclazocine,
SKF, and dextrorphan) were three- to 20-fold more potent than
their -isomers: A number of other nonopioids, such as imipramine,
chlorpromazine, pimozide, and phenoxybenzamine, showed potent
inhibition of psi-binding.
Discriminative Stimulus Studies
In order to evaluate the possible pharmacologic relevance of psi-
binding, the discriminative stimulus properties of SKF were evalu-
ated in male Fisher rats trained to discriminate between saline and
3 mg./kg. SKF in a two-choice discrete trial avoidance procedure,
in which rats were required to respond on one lever after receiving
saline and on a second lever after receiving SKF. Animals were
trained and maintained at a 90 percent correct response criterion.
There was good concordance between the effectiveness of drugs to
inhibit specific SKF psi-binding and their effectiveness in pro-
ducing SKF-like discriminative stimuli. Those drugs inhibiting
psi-binding with good potency in a monophasic fashion (such as
cyclazocine, phencyclidine, and dextrorphan) also produced greater
than 90 percent SKF-appropriate responding. Those drugs which
inhibited psi-binding in a biphasic fashion (such as pentazocine,
ethylketocyclazocine, and propranolol) produced significant but
less than 90 percent SKF-appropriate responding. Haloperidol,
which also exhibited biphasic binding, gave a small degree of
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SKF-appropriate responding and was able to partially antagonize
the discriminative stimulus properties of the training dose of
SKF, Drugs which were poor inhibitors of psi-binding (such as
levorphanol and naloxone) did not produce SKF-appropriate respond-
ing. Also, naloxone was unable to antagonize the discriminative
stimulus properties of either the racemic mixture or pure d-isomer
of SKF. Preliminary studies with   d-  and -isomers of   SKF were
consistent with the binding studies and showed that d- was the
most potent isomer, was not antagonized by naloxone, and was
partially antagonized by haloperidol.
Discussion and Conclusions
There appears to be a class of binding sites in guinea pig brain
synaptic membranes for SKF: clearly distinguishable from naloxone
binding sites. The characteristics of the binding sites appear to
be somewhat different from those which have been ascribed to the
sigma receptor. Naloxone has been described as an antagonist at the
sigma receptor (although there is some debate and opposing data on
this point); naloxone did not antagonize psi-binding of SKF nor the
discriminative stimulus properties of SKF. Ethylketocyclazocine is
proposed to have little or no effect at the sigma receptor, but did
oroduce inhibition of psi-binding and significant SKF-appropriate
responding. However, the biphasic nature of some of the inhibition
curves and the reactivity of ethylketocyclazocine are also consis-
tent with the hypothesis that psi-binding is a mixture of sigma and
kappa binding, a possibility which cannot be definitely ruled out
at this time. The Scatchard analysis did show one class of binding
sites; however, it is possible that a small difference in the
affinity and number between two receptors (i.e., sigma and kappa)
might be missed in this analysis. The relative effectiveness of a
variety of drugs to inhibit specific SKF psi-binding, including
the activity of nonopiates and the activity of haloperidol and
chlorpromazine, is consistent with the hypothesis that the psi-
binding sites may represent the neuronal substrates mediating
psychotomimetic effects of certain opioids and other drugs.
BEHAVIORAL STUDIES OF NICOTINE
The potential role of nicotine in the maintenance of tobacco smoking
has been questioned in part because of the difficulty in demonstrat-
ing consistent reinforcing effects in controlled laboratory studies.
The present studies show that nicotine will maintain self-adminis-
tration behavior in two species, the beagle dog and the squirrel
monkey, using several different schedules of reinforcement.
Dog Studies
In the dog studies, four animals with surgically implanted intra-
venous catheters were studied under two different reinforcement
schedules. In the first study, dogs were given access to response-
contingent drug infusions during daily sessions consisting of 15
signalled trials, each lasting a maximum of 10 min. During each
trial, the dogs could obtain one drug infusion by making 15
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responses (i.e., an FRl5 schedule). There was a 4 min. timeout
between successive trials. Dogs were initially trained on cocaine,
attaining stable responding at an overall rate of 0.8 responses/
sec. at a 30 ug./kg. dose. Nicotine was tested at four dose levels,
each for 7-10 consecutive daily sessions with randomized treatment
order. All doses of nicotine were self-administered above saline
levels. There was an inverted U-shaped dose response relationship
for both number of infusions and average overall response rate with
the highest rates of responding and number of infusions occurring
at the 30 ug./kg./infusion dose. The local response rate (i.e.,
from the third to the last response of each ratio) declined mono-
tonically from 1.8 resp./sec. at 10 ug./kg. to 0.5 resp./sec. at
300 ug./kg. There was minimal responding by the dogs during the
timeout periods. Vomiting was occasionally seen during or shortly
after the daily sessions, particularly at the two highest dose
levels.
The second dog study is being performed with a progressive ratio
reinforcement schedule. Two dogs have been studied so far, both
with considerable progressive ratio experience. Dogs were given
access to response-contingent drug infusions during three experi-
mental sessions each day; each session lasted a maximum of 1 hr.
with a minimum intersession interval of 3 hr. Only one infusion
could be obtained during each session. The response requirement
was increased daily until the dog failed to complete the necessary
fixed-ratio; that is, until he reached the “break-point.” Dogs
were tested on saline and four doses each of nicotine and cocaine
and treatment order was randomized. All doses of cocaine and
nicotine maintained self-administration behavior at FR values well
above those of saline. For both drugs there appeared to be a bi-
phasic relationship between dose and break-point. Cocaine was a
more effective reinforcer than nicotine under this schedule,
attaining break-points several hundred responses greater than the
maximum obtainable with nicotine.
Monkey Studies
The monkey studies were the result of a joint collaboration between
Drs. Goldberg of the ARC and Roger Spealman of the Harvard Medical
School. In the monkey studies, four animals with chronic venous
catheters were used; three were experienced and one naive. A
second-order schedule of reinforcement was used; experimental
sessions were carried out with the subjects sitting in a chair
equipped with a response lever and two stimulus lights and enclosed
in a sound-attenuated chamber. At the beginning of each experi-
mental session, a green stimulus light was turned on and every
10th lever pressing response during a 1 or 2 min. fixed interval
changed the light from green to amber for 1 sec. The first FR10
unit completed after the FI elapsed turned off the green light and
produced both the 1 sec. amber light and an i.v. injection of
30 ug./kg. of nicotine. A 3 min. timeout period then followed.
Each session ended after the 12th timeout period or 90 min.,
whichever occurred first.
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Stable responding developed in all subjects within 30 sessions and
showed the pattern of responding typical of this reinforcement
schedule. Overall response rates were consistently high, averaging
0.81 to 1.58 resp./sec.; local rates (from the first to the last
response in each FR unit) were even higher, averaging from 1.22 to
4.77 resp./sec. Substitution of saline for nicotine usually resulted
in a rapid decline of response rate, which returned rapidly to high
rates on reinstitution of nicotine infusions. Tn one monkey, when
the rate of responding failed to fall consistently during saline
substitution, the brief light presentations during the interval
were omitted and the rates of responding fell; the response rate
stayed low when the brief amber lights were again presented during
saline substitution and did not return to high rates until nicotine
infusions were resumed. Pretreatment 30 min. prior to the session
with 1 mg./kg. mecamylamine, i.m., caused a decrease in response
rates similar to those seen after saline substitution. Overall
response rates under the present second-order fixed-interval
schedule with brief stimulus presentations were considerably
higher than in a previous study using a simple fixed-interval
schedule with no stimulus presentations during the interval,
although the frequency of nicotine injection was about the same in
the two studies. To further explore the role of the brief visual
stimulus in maintaining high rates of responding, the amber light
presentations were entirely omitted during the interval in two
subjects. The amber light was presented only in conjunction with
the i.v. nicotine infusion at the end of each interval. Omission
of the visual stimulus was followed by a drop in response rates to
about one-half the previous rate; and the hign rate returned when
the brief stimulus presentations were resumed. These results indi-
cate that nicotine can function as an effective reinforcer under
a second-order schedule of drug self-administration and that
environmental stimuli associated with nicotine intake can con-
tribute importantly to the maintenance of drug-seeking behavior
The second-order schedule of nicotine injection in the squirrel
monkey appears to be a sensitive laboratory method for evaluation
of both pharmacologic and environmental factors which may play
a role in the maintenance of tobacco use by man.
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Evidence for the Release of En-
dogenous Opiates by Morphine
William L. Dewey, Tsu-Ching Fu, Agneta Ohlsson, Edward
Bowman, and Billy Ray Martin
Many, many papers have been published on the mechanism of antino-
ciceptive action of morphine and other narcotic analgesics. Yet ,
the extent of our knowledge of the exact mechanisms by which mor-
phine relieves pain is meager. Certainly the information presented
in this report will not clarify the elusive mechanisms involved
in pain relief. Hopefully, the approach taken in our laboratory
along with the other approaches being carried out in other labora-
tories at this time will be useful in expanding our knowledge in
this area, Cur experiments are based on the hypothesis that mor-
phine and other narcotic analgesics release endogenous opiates
which play an intricate and important role in the manifestation
of pain relief. The pharmacology of the endogenous opiates
resembles that of morphine in most aspects. A good correlation
has been shown between the distribution of endogenous opiates and
stereospecific opiate-binding sites in brain. However, little
evidence has appeared in the literature to suggest that opiates
do in fact release endogenous opiates from brain tissue. Puig and
Musacchio and their colleagues (4) have shown that extensive
stimulation of the isolated guinea pig ileum causes the release of
endogenous opiates into the isolated organ bath. We chose to test
our hypothesis by studying the concentration of endogenous opiates
in cerebrospinal fluid following the injection of antinociceptive
doses of morphine.
The mouse was used in the first series of experiments in which we
studied the effects of various types of spinalizations on the
activity of morphine. The results of these studies have been
published in detail (2). Essentially we found that spinal liga-
tion, like cauterized transection, caused a marked reduction in the
efficacy of morphine in increasing tail-flick latency. These
results showed that morphine’s action in this test system emanated
from a supra spinal level. The activity of morphine was not
altered when only the neural component of the spinal cord was
disrupted. These results suggested that the humoral component
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(CSF) was more important than the neural component of the spinal
cord for the transmission of the effect of morphine in the brain
to inhibition of the tail-flick reflex at the lower spinal level.
If in fact this were true, disruption of the flow of CSF down
the spinal cord should cause a decrease in the activity of mor-
phine. This was tested by carefully removing a portion of the
dura mater at the lower thoracic level of the cord which allowed
some of the CSF to leak out rather than be transported to lower
portions of the spinal cord. This surgical procedure reduced
the antinociceptive activity of morphine by more than fifty per-
cent. These results were confirmed in an experiment in which an
opening was made in the cisterna magna and the mice were main-
tained head down-tail up at a 60-70° angle immediately prior to
the injection of morphine and until the post injection tail-flick
latency was determined. Wetness of the fur at the opening in
many mice confirmed that the CSF was “leaking out” rather than
being transported to the lower spinal levels. The activity of
morphine was reduced significantly in this experiment.
Our conclusion at this point was that spinalization by cautery,
ligation or removal of a portion of the spinal cord blocked the
antinociceptive activity of morphine, suggesting that the supra
spinal structures are essential for morphine’s activity. This
conclusion supports the work from many laboratories which shows
that a higher concentration of stereospecific opiate-binding
sites .exists in the mid or hind brain than in the spinal cord. It
has also been shown that although morphine and other narcotic
analgesics produce antinociception when administered directly
into the spinal cord, the threshold for activity is much lower in
a number of sites in the brain stem.
The second conclusion which we drew from these initial experiments
was that the humoral component of the mouse spinal cord (CSF) was
more important than the neural component for transmitting the
effect of morphine in the brain to the actual inhibition of the
tail-flick reflex in the lower spinal cord. The existence of
stereospecific opiate-binding sites in the spinal cord was essen-
tial to our hypothesis that endogenous opiates were released in
the brain, transported in the CSF and acted on spinal neurons to
inhibit the tail-flick reflex.
We tested our hypothesis that endogenous opiates were released
into CSF by morphine by quantitating the opiate-like activity
of rabbit CSF taken prior to and after morphine injection in
two bioassays, the when paraphenylquinone writhing test and the co-
axially stimulated guinea pig ileum. The methods used and the
results of these experiments have been published in more detail
elsewhere (3). CSF taken from rabbits prior to the injection
of morphine caused an inhibition of writhing (26%) indicating that
opiate(s) exist in normal CSF. The inhibition was reproducible
and significant and was antagonized by naloxone, suggesting that
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it was an opiate effect. Much greater inhibition of writhing
(60%) was found when CSF taken 1 hour after morphine was injected
into the lateral cerebroventricle of mice. This effect was also
antagonized by pretreating the mice with naloxone.
CSF taken prior to the administration of morphine to the rabbit
caused an inhibition of the coaxially stimulated guinea pig ileum,
an assay routinely used to quantitate opiate activity. This
modest but reproducible inhibition was antagonized by naloxone.
Considerably more inhibition of the coaxially stimulated guinea
pig-ileum was seen following the addition of CSF taken after the
injection of morphine to the rabbit. Again, this inhibition was
reversed by naloxone.
Pretreating the rabbit with 2 mg/kg naloxone apparently blocked
the release of endogenous opiates since CSF taken 1 hour fol-
lowing morphine in naloxone-pretreated rabbits did not inhibit
writhing or block the twitch induced by coaxial stimulation of
the guinea pig ileum. These results are not surprising, since
naloxone probably antagonized the binding of the morphine to the
opiate-sensitive binding sites on the cells which released the
endogenous opiate.
An obvious alternate hypothesis to explain our data was that mor-
phine itself existed in the CSF in sufficient quantities to
activate opiate-sensitive binding sites in the spinal cord and
block the tail-flick reflex, inhibit paraphenylquinone-induced
writhing and block the coaxially stimulated guinea pig ileum.
This possibility was tested by administering 3H-dihydromorphine
and in another experiment 3H-morphine to rabbits,taking CSF one-
hour after administration and quantitating the radioactivity per
sample of CSF. In this way we quantitated both the parent com-
pound and all metabolites which may have opiate effects. The
results of these experiments are presented in Tables 1 and 2.
The data presented in these tables caused us to conclude that
the opiate-like activity of CSF taken after the administration of
morphine was not due to the presence of morphine and/or its
metabolites in CSF. This conclusion was based on the fact that
the total amount of radioactivity in the 5 ul of CSF, the volume
injected per mouse, was approximately one-fiftieth the minimal
effective dose of morphine in the writhing test and the concen-
tration of radioactivity in 0.4 ml CSF was approximately 75 percent
of the minimally effective dose of morphine in the coaxially
stimulated guinea-pig ileum assay. The existence of opiate-like
material in the CSF of untreated rabbits supported this con-
clusion.
Further support for this position was generated from a study of
the stability of the opiate-like material in CSF. A sample of
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TABLE 1
Relationship Between Morphine Levels in Cerebrospinal
Fluid of Rabbits Injected with 10 mg/kg Radiolabelled
Morphine Sulfate or Dihydromorphine and Effec-
tive Doses of Morphine in the Wriching Test
Radiolabelled
Drug Administered
3H-dihydro-
morphine
Animals #
1
2
Morphine Equivalents Morphine Equivalents in
in CSF (ng/ml) 5 µl CSF (ng)
190 0.95
130 0.65
14C-morphine 3 128 0.64
4 134 0.67
5 134 0.67
x ± S.E.M. 143.8 ± 11 0.71 ± 0.06
Minimal effective dose of morphine given i.v.t. in the writhing test - 10 ng
ED-50 of morphine given i.v.t. in the writhing test - 50 ng
TABLE 2
Relationship Between Morphine Levels in Cerebrospinal
Fluid of Rabbits Injected with 10 mg/kg Radiolabelled
Morphine Sulfate on Dihydromorphine and Effec-
tive Doses of Morphine in the Guinea Pig Ileum Assay
Morphine Equivalents in
in 400 µl CSF
Radiolabelled
Drug Administered
Morphine Equivalents Diluted to 10 ml
Animal # in CSF (ng/ml) (moles/l)
3H-dihydromorphine 1 190 1 x 10
-8
2 130 7 x 10-9
14C-morphine 3 128 7 x 10
-9
4 134 7 x 10
-9
5 134 7 x 10
-9
x ± S.E.M. 143.8 ± 11 7.6 x 10-9
Minimal effective concentration of morphine in guinea pig ileum assay 1 x 10-8
ED-50 of morphine in guinea-pig ileum assay 1 x 10-7
CSF, taken from a rabbit one hour after the injection of morphine,
was injected into the lateral cerebroventricle of mice to test
for its ability to inhibit paraphenylquinone-induced writhing
immediately after it was taken from the rabbit. Another aliquot
of the same sample was placed in a vial at room temperature and
two hours later injected into the lateral cerebroventricle of
other mice and tested for its ability to block writhing. Mor-
phine was added to CSF taken from an untreated rabbit in suffi-
cient amount to inhibit paraphenylquinone-induced writhing to an
extent similar to that seen in the CSF taken from the morphine-
treated rabbit. An aliquot of the CSF to which morphine was
added was also stored at room temperature for 2 hours and
then injected into the lateral ventricle of mice and tested
for its ability to inhibit paraphenylquinone-induced writhing.
The results of this experiment are presented in Table 3.
TABLE 3
Comparison of the Stability of Endogenous Opiate-
Like Material and Morphine in Rabbit CSF
Sample
CSF from a rabbit treated
with 10 mg/kg morphine
Percent Inhibition of PPQ Writhing
No Incubation 2 Hr Incubation at
Period Room Temperature
60 0
Morphine added to CSF
from a drug naive rabbit
89 96
The data presented in Table 3 convinced us that the opiate
material in CSF taken after morphine treatment to the rabbits
was not morphine itself. As a matter of fact, the stability of
morphine in control CSF as quantitated in the writhing bioassay
exceeded 8 hours.
The data presented in this manuscript and data submitted for
publication elsewhere cause us to propose that morphine stimulates
the release of endogenous opiates which are an important step
in the manifestation of the antinociceptive action of morphine.
The endogenous materials diffuse into intercellular fluid (CSF)
and are carried throughout the central nervous system in CSF.
The results of our experiments suggest to us that these endogen-
ous opiates cause the inhibition of the tail-flick reflex in
mice. It is our proposal that the released endogenous opiates
interact with stereospecific opiate-binding sites on neurons in
the brain, and possibly the spinal cord, of many other species
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including man, to produce analgesia. The release of endogenous
opiates by morphine has been reported by other workers (1). On
a more global basis, it is our working hypothesis that all mani-
pulations including drugs, acupuncture, stress and others, that
relieve pain do so by releasing endogenous opiates. The observa-
tion that naloxone blocks the analgesia induced by each of these
modalities supports our hypothesis. The isolation, characteriza-
tion and eventual identification of these endogenous opiates is
the main goal of our current research efforts.
1.
2.
3.
4.
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Comparison of the Effects of Bupre-
norphine and Methadone on Opiate
Self-Administration in Primates
N. K. Mello, M. P. Bree, and J. H. Mendelson
The primate drug self-administration model was used to compare
the relative efficacy of buprenorphine and methadone in suppress-
ing opiate self-administration. Although the value of this model
in predicting drug abuse liability has been repeatedly demon-
strated (cf. Griffiths et al. 1980), it has seldom been used to
evaluate the efficacy of phannacotherapies for the treatment of
heroin addiction.
Buprenorphine is a new mixed opiate agonist-antagonist drug which
significantly suppressed heroin self-administration by heroin
addicts in controlled clinical studies (Mello and Mendelson,1980).
Buprenorphine has 25 to 40 times the analgesic potency of mor-
phine and similar subjective effects, but it does not produce
significant physical dependence after prolonged administration
(Houde, 1979; Jasinski et al. 1978; Lewis et al. 1981). Bupre-
norphine’s antagonistic properties can effectively block the ef-
fects of high doses of morphine for 24 to 36 hours (Jasinski et
al. 1978). The antagonistic component appears to preclude bupre-
norphine overdose (Lewis et al. 1981).
Methadone, an opiate agonist, has been used to treat heroin
addiction for over 15 years. It induces cross-tolerance to the
euphoric effects of other opiates and after abrupt termination,
a protracted morphine-like withdrawal syndrome occurs. Despite
its demonstrated clinical utility, methadone abuse has been
associated with overdose deaths (Kreek, 1978). Clinical studies
have consistently shown that methadone reduces but seldom com-
pletely eliminates opiate use (Martin et al. 1973; Jones and
Prada, 1975) . Moreover, some methadone-maintained patients en-
gage in a diverse pattern of polydrug use.
METHODS
The effects of maintenance on methadone or buprenorphine on
opiate and food self-administration were studied. An ascending
and descending ‘series of doses of methadone (0.179 to 4.73 mg/kg/
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day) and buprenorphine (.014 to .789 mg/kg/day) were compared
with saline control and drug free baseline conditions. Each suc-
cessive dose of buprenorphine or methadone was studied for 20
sessions over 5 consecutive days. Buprenorphine and methadone
doses were extrapolated on a mg/kg basis from doses shown to be
clinically effective in suppressing opiate self-administration in
man (Martin et al. 1973; Mello and Mendelson, 1980). Methadone
doses were comparable to 12.5 to 330 mg/day in man. Buprenor-
phine doses were comparable to 1 to 56 mg/day in man.
This report describes the effects of a single ascending dose ser-
ies of methadone or buprenorphine on opiate and food self-admin-
istration in two groups of monkeys; the descending dose series on
the same maintenance drug is still in progress. Subsequently,
the buprenorphine maintenance group will be studied under metha-
done maintenance conditions and the methadone maintenance group
will be studied under buprenorphine maintenance conditions in a
single cross-over design.
Data are reported on 5 male monkeys that weighed between 5.3 and
8.4 kg. Four monkeys had a long history of opiate agonist and
mixed agonist-antagonist self-administration. One experimentally
naive monkey (A420) was trained to self-administer dilaudid
(.02 mg/kg/inj) for 25 days, then heroin (.01 mg/kg/inj) was sub-
stituted for dilaudid. Three monkeys were rhesus and 2 monkeys
(A389 and A429) were pigtail macaques. Monkeys were maintained
at ad lib weight and were given multiple vitamins, fresh fruit
and vegetables to supplement a banana pellet diet.
Monkeys worked at an operant task for food (1 gm banana pellet)
and for either dilaudid (.02 mg/kg/inj) or heroin (.01 mg/kg/inj).
Food and drug self-administration were maintained under a second-
order schedule of reinforcement (FR 4 (VR 16:S)). An average of
16 responses on a variable ratio schedule (VR 16) produced a
brief colored stimulus light (S+). However, a drug injection or
a food pellet was delivered only after a fixed ratio of 4 (FR 4)
of the VR 16 response requirements had been completed; i.e., each
food pellet or drug injection required an average of 64 responses.
Second-order schedules were used to minimize the possible seda-
tive effects of drug infusions on operant responding.
Four periods of food availability and of drug availability oc-
curred each- day. A l-hour food session was followed by a l-hour
drug session and 2 hours of time-out when responses had no pro-
grammed consequences. The conditions of food and drug availabil-
ity and time-out periods each were associated with a different
colored stimulus light (S+) projected on a translucent response
key on an operant panel. Drug injections were limited to 20 per
session or 80 per day and food pellets were limited to 65 per
session or 260 per day. Experiments continued 24 hours a day, 7
days a week.
Each monkey was surgically implanted with a double lumen catheter
under aseptic conditions. Opiates were self-administered
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through one lumen and maintenance drug solutions were injected
through the second lumen so that there was no confounding of the
two drug administration procedures. Buprenorphine, methadone and
saline control solutions were given intravenously at 9:30 a.m.,
2½ hours before the first daily drug session and 13½ hours before
the last daily drug session. A single daily methadone or bupre-
norphine injection corresponds to the frequency with which these
drugs are used clinically to suppress illicit opiate self-admin-
istration.
Methadone, heroin (3-6 diacetylmorphine), dilaudid and buprenor-
phine hydrochloride solutions were diluted to the appropriate
concentration for individual monkeys and doses are expressed in
terms of salts. All drug solutions were passed through millepore
filters to remove pyrogens.
RESULTS AND DISCUSSION
Buprenorphine and methadone had divergent effects on both opiate
and food self-administration over a dose range shown to be clini-
cally effective in suppressing opiate use in opiate addicts. Bu-
prenorphine significantly suppressed opiate self-administration,
whereas methadone was associated with increased opiate self-ad-
ministration at doses equivalent to 130 to 240 mg/day in man. Bu-
prenorphine maintenance was associated with increased food self-
administration which was often significant at higher dose levels
whereas methadone maintenance was associated with decreased food
self-administration.
Table 1 shows that buprenorphine at doses of .170 mg/kg/day
(equal to 12 mg/day in man) produced a significant suppression of
opiate self-administration in comparison to baseline in 3 monkeys.
However, it was necessary to increase the daily dose of bupre-
norphine to the equivalent of 24-32 mg/day in man to achieve a
71% to 86% suppression of heroin self-administration in a monkey
(A389) taking high baseline levels of opiates. An 83% to 97%
suppression of opiate self-administration was achieved at lower
buprenorphine doses in a monkey (B205) with a lower baseline lev-
el of opiate intake. After a transient suppression of opiate
self-administration at buprenorphine doses of .170 to .226 mg/kg/
day, Monkey A420 self-administered significantly more heroin than
during baseline conditions at buprenorphine doses of .254 to .504
mg/kg/day . Significant sustained suppression of opiate self-ad-
ministration by 79% to 95% required .675 to .789 mg/kg/day of
buprenorphine, equivalent to 48 to 56 mg/day in man. Monkey A420
differed from Monkeys A389 and B205 in two respects: he was ex-
perimentally naive when these studies began, and he worked for
heroin instead of dilaudid.
Considerably higher doses of buprenorphine were required to
suppress opiate self administration in monkey than in man. A
daily buprenorphine dose of 8 mg SC suppressed heroin self-admin-
istration by 95% to 98% in 4 subjects and by 69% to 84% in 2
subjects, whereas placebo maintenance subjects took between 93%
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TABLE I - BUPRENORPHINE EFFECTS ON OPIATE SELF-ADMINISTRATION  [INJECTIONS PER DAY (X ± S.E.)]†
TABLE II - METHADONE EFFECTS ON OPIATE SELF-ADMINISTRATION [INJECTIONS PER DAY (X ± S.E.)]†
and 100% of all the heroin available (Mello and Mendelson, 1980).
These data do not confirm an earlier report that pre-treatment
with buprenorphine over a dose range of .003 to .30 mg/kg had no
significant effect on morphine self-administration in monkey
(Downs and Harrigan, 1978). Downs and Harrigan (1978) observed
significant increases in morphine self-administration during con-
tinuous infusion of buprenorphine at doses of .020 and .040 mg/
kg/hr in monkeys not physiologically dependent on morphine. How-
ever, no comparable increases in opiate self-administration at
relatively low doses of buprenorphine (.014 to .087 mg/kg/day)
were seen in the present study.
In contrast to buprenorphine, which produced dose-related decre-
ments in opiate self-administration, maintenance on methadone was
associated with increased heroin self-administration (Table 2).
At methadone doses equivalent to 120 to 240 mg/day in heroin
self-administration increased by 14% to 87%. At methadone doses
equivalent to 260 to 330 mg/day in man, heroin self-administration
remained higher (A319) or equivalent to baseline levels (A105).
The most parsimonious interpretation of these data appears to be
that methadone over a dose range of .179 to 4.73 mg/kg/day did not
induce sufficient cross tolerance to significantly attenuate the
reinforcing properties of heroin. Analysis of the distribution
of heroin injections across daily drug sessions, 2½ to 13½ hours
after methadone administration, showed no significant differences
in number of drug injections taken during the first two and last
two sessions each day. This suggeststhatpossible differences in
the duration of action of methadone in monkey and man did not sig-
nificantly influence data obtained.
Increased heroin self-administration during methadone maintenance
was associated with suppressed food intake which was significantly
below baseline levels in Monkey A105 (Table 3). However, there
were no significant changes in body weight across the dose-range
studied. Maintenance on increasing doses of buprenorphine was
associated with increased food self-administration (Table 4).
These increases were often significantly above baseline at higher
buprenorphine doses, Buprenorphine appears to antagonize the
usual depressant effects of opiates on food self-administration.
These data confirm our previous observations that chronic bupre-
norphine self-administration at daily dose levels of 1.0 to 3.0
mg/kg was usually associated with significant increases in food
self-administration (Mello et al. 1981).
In conclusion, these data suggest that buprenorphine may be more
effective than methadone in suppressing heroin self-administra-
tion. However, controlled clinical comparisons of these drugs re-
main to be done. These data are consistent with a clinical eval-
uation of buprenorphine in heroin addicts (Mello and Mendelson,
1980). Persistence of heroin self-administration during metha-
done maintenance is consistent with the composite clinical ex-
perience (Martin et al. 1973; Jones and Prada, 1975) as well as
animal studies (Griffiths, 1976; Jones and Prada, 1977).
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TABLE III - METHADONE EFFECTS ON FOOD SELF-ADMINISTRATION [BANANA PELLETS PER DAY (x ± S.E.)]†
TABLE IV - BUPRENORPHINE EFFECTS ON FOOD SELF-ADMINISTRTAION [BANANA PELLETS PER DAY (X ± S.E.)]†
Each data point equals 20 sessions over 5 days except drug free baseline which equals 60 sessions over 15 days.
*Different from baseline (p< .05); **Different from baseline(p < .01); ***Different from baseline (p < .001)
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Oral Self-Administration of
Phencyclidine (PCP) and PCP
Analogs and Tolerance to PCP’s
Behavioral Effects
Marilyn E. Carroll, Ph.D.
Phencyclidine (PCP) has been demonstrated to serve as a potent
reinforcer when self-administered orally by rhesus monkeys
(Carroll and Meisch, 1980). The oral preparation is well-suited
for the study of PCP’s behavioral effects, since it is a common
mode of human PCP abuse. The oral preparation lasts the life of
the animal, allowing for a series of within-subject comparisons
and a model of chronic drug abuse. In addition, with the oral
route, it is possible to offer a choice between two or more
substances.
The present paper summarizes the results of three studies. In
the first study, methods were developed for rapidly establishing
PCP as a reinforcer, without using a food reinforcement schedule
or food ‘deprivation to induce PCP drinking. In previous work
whereby orally-delivered ethanol (Meisch and Henningfield, 1977,
etonitazene (Carroll and Meisch, 1978) and pentobarbital (Meisch
et al., 1981) were established as reinforcers, schedule-induced
polydipsia or food-induced drinking procedures were used. These
procedures require food depriving the animal and presenting the
daily food ration while only the drug is available to drink. In
the second study, two PCP analogs (PCE and TCP) were substituted
for PCP and compared for their reinforcing effects. There have
been previous comparisons of the PCP analogs with respect to
discriminative stimulus properties (Brady and Balster, 1981;
Brady et al., 1980; Shannon, 1980) and effects on schedule-
controlled behavior (Brady and Balster, 1980); however, their
relative reinforcing potential has not yet been determined. In
the third study, the acquisition and loss of tolerance were exa-
mined in monkeys self-administering orally-delivered PCP.
Methods
Fourteen adult male rhesus monkeys served as subjects. Daily
3-hr drug self-administration sessions began at 11:00 a.m. Each
session was preceded and followed by a 1-hr timeout when no
liquids or stimulus conditions were presented. During the 19-hr
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intersession period water was freely available. Each experimen-
tal chamber contained a panel on one wall with two drinking
spouts and a large jeweled stimulus light above each. A green
light signaled water, a blinking green light, PCP and a yellow
light, saccharin. Liquid deliveries (0.5 ml) were contingent
upon lip-contact responses on solenoid-operated drinking spouts
under a fixed-ratio (FR) schedule. The number of lip-contact
responses required for a liquid delivery varied between 1 and 16.
PCE (N-ethyl-1-phencyclohexamine), PCP (1- 1-phencyclohexyl)
pipiridine and TCP (1- 1-(2-thienyl) cyclohexyl pipiridine) HCI
(NIDA: Research Triangle Institute) concentrations are expressed
in terms of the salt. Further details of the procedure and
apparatus have been previously reported (Carroll and Meisch,
1980; Carroll et al., 1981b; Henningfield and Meisch, 1976).
Experiment 1: Rapid Acquisition of PCP-Reinforced Behavior. Two
procedures were tested: food deprivation and food satiation, and
there were four monkeys in each group. All monkeys were experi-
mentally naive except M-A1 and M-G who had previous i.v. drug
self-administration experience in another laboratory. The speci-
fic procedure and results are described in tables 1 and 2.
Experimental conditions were run sequentially as they are listed
from left to right at the top of the table. Each condition was
held constant until five sessions of stable behavior were
obtained.
The first group of monkeys (table 1) was initially food satiated
and water was available from both drinking devices under an FR 1
schedule. A PCP (0.25 mg/ml) solution was then substituted for
water at both drinking devices during the session. When behavior
stabilized, the monkeys were food deprived by allowing them
access to only 75 g of food after the daily 3-hr session. The FR
was then gradually increased from 1 to 8. At FR 8 concurrent
water was introduced, and side positions were reversed daily.
The FR for both PCP and water was then increased to 16. Table 1
shows that food deprivation increased drug self-administration
nearly two-fold. Similar results have been previously reported
(e.g., Carroll et al., 1979, 1981a). When the FR was increased
from 1 to 8, the number of liquid deliveries (vs. water) under
the concurrent FR 8 schedule indicated that the drug was serving
as a reinforcer. An increase in the FR to 16 resulted in a
greater contrast between drug and water. The mean number of
sessions of drug availability before PCP was demonstrated to
serve as a reinforcer was 37.2.
The procedure used in the second group (table 2) was similar to
the first except that the monkeys were food satiated throughout
the acquisition phase. Table 2 shows that baseline drinking
rates were much lower in this group, and when PCP was substituted
for water, liquid deliveries increased. However, liquid deli-
veries decreased only slightly as the FR was increased. After a
mean of 25.9 drug sessions, it was clearly demonstrated PCP was
serving as a reinforcer. Thus, it appeared that food-induced
drinking (e.g., polydipsia) conditions and food deprivation were
not necessary to establish PCP as a reinforcer. The number of
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liquid deliveries in the food satiated group nearly doubled when
the monkeys were food deprived after the acquisition procedure.
Table 1: Mean** Session Liquid Deliveries
Table 2: Mean** Session Liquid Deliveries
Experiment 2: Substitution of PCP Analogs for PCP. A separate
group of three rhesus monkeys (M-B, M-M1 and M-R1) was used in
this experiment. They had been trained according to food-induced
drinking procedures previously described (Carroll and Meisch,
1980). After a stable baseline was obtained under a concurrent
FR 16 schedule with PCP (0.25 mg/ml) and water, a range of con-
centrations was tested according to the following sequence:
0.25, 0.5, 0.25, 0.125, 0.25, 0.0625, 0.025, 0.0312, 0.25,
0.0156, 0.25. Each concentration was held constant until at
least five sessions of stable behavior were obtained. An iden-
tical procedure was used with PCE. A mean of approximately 6
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sessions was necessary to obtain stable behavior; there did not
appear to be any tolerance to self-administration behavior. When
TCP was substituted for PCP at 0.25 mg/ml, two of the monkeys
(M-M1 and M-R1) showed marked muscle rigidity, and signs of
severe ataxia were present for over 24 hr. The monkeys were then
given access to the following TCP concentration series: 0.0625,
0.125, 0.25, 0.5, 0.0625, 0.0312, 0.0156, 0.0625, 0.25 mg/ml.
The results shown in Figure 1 indicate that all compounds were
self-administered in excess of water; thus they served as
effective reinforcers over a range of concentrations. PCE
appeared to be considerably less potent than PCP, and TCP was
the most potent of the three drugs tested. Behavioral obser-
vations revealed that PCE had very little effect, but PCP and TCP
produced severe behavioral disruptions (e.g. ataxia, anesthesia)
at the higher concentrations. These effects lasted 4 to 6 hr
with PCP, but only 10 to 15 minutes with TCP. That TCP was more
potent and shorter acting might suggest that it would serve as a
more effective reinforcer. The comparison of potency of these
three compounds in a self-administration test agrees with a
report of their effects on suppression of operant responding in
squirrel monkeys (Brady et al., 1980). However, the present
results differ from relative potencies found with effects on
fixed-interval performance in rhesus monkeys (Brady et al., 1980)
motor performance in mice (Balster, 1981; Pinchasi et al., 1978)
and tests of the discriminative stimulus properties of the three
compounds (Brady and Balster, 1980; Shannon, 1980).
Figure 1. Mean liquid
deliveries (upper frame)
and mg/kg intake (lower
frame) are presented for
PCE (circles, dotted
lines), PCP (triangles,
dashed lines) and TCP
(squares, solid lines)
over a range of concen-
trations. Open symbols
refer to concurrent water
deliveries. Each point
represents the mean of 15
observations: 3 monkeys
x the last five sessions
of stable behavior at
each concentration.
Vertical bars represent
the mean (N = 3) standard
errors (2) of the mean.
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Tolerance to the Effects of Orally Self-Administered Phencycli-
dine on Saccharin-Maintained Behavior. Three additional monkeys
(M-A, M-R, M-M2) were used. PCP (0.25 mg/ml) or water was
available on the left drinking device and a saccharin solution
(0.05% wt/vol) was available on the right. A five component
schedule was used (see Figure 2). During the first component (20
min), the saccharin solution was available from the right
drinking spout under an FR 8 schedule. This component was used
as a control for nonspecific changes in saccharin-maintained
behavior.  The second component was a 5-min timeout when all
stimulus conditions were off and responses in the drinking spouts
had no consequences. In the third component (30 min), phen-
cyclidine (0.25 mg/ml) was available from the left drinking spout
under an FR 1 schedule. An oral dose of 4, 8 or 16 mg/kg was
determined by limiting the number of liquid deliveries. PCP
doses were tested in descending order. The fourth component was
another 5-min timeout, and the fifth component was identical to
the first, except it lasted 2 hr. After a stable baseline (5
sessions) was reached under these conditions, water was substi-
tuted for PCP during the third component for 4 sessions, and PCP
was subsequently reinstated at the same dose for at least 6
sessions.
Figure 3. Saccharin
deliveries durinq the
last component - (2-hr)
are presented as a func-
tion of PCP dose for the
three monkeys. Filled
circles are the means (+
S.E.) for the last 5
sessions and open
circles represent the
first session PCP was
available after 4 ses-
sions of water substi-
tution.
78
Figure 3 shows that the dose response functions for the three
monkeys were shifted to the right nearly two-fold when PCP was
available daily indicating tolerance had developed. An example
of the patterns of responding for saccharin and PCP is shown in
Figure 4. Saccharin-maintained (FR 8) responding in the first
component showed no systematic changes. PCP-maintained
responding (FR 1) during the second component began immediately
at the onset of the component and continued at a high rate until
the liquid delivery limit was reached. Saccharin-maintained (FR
8) responding in the last component began at high rate, but it
became disrupted at the two higher doses about 30 min after PCP
consumption. At all doses the disruptions were always greater
after the four sessions of water substitution. When saccharin
deliveries during the last component (after PCP access) were com-
pared to saccharin deliveries after water access, they were lower
at 16 mg/kg, the same at 8 mg/kg, and considerably higher than at
4 mg/kg.
Fiqure 4. Two cumulative records are presented for monkey M-A at
the 16 mg/kg PCP dose. The upper record was taken from the last
session when PCP was available daily, and the lower record was
obtained from the first session PCP was reinstated after 4
sessions of water substitution. The event pen (lower line) was
deflected downward during the two time out periods. The stepping
pen marked liquid responses, and it reset at about 500 responses.
After the dose-effect relationship was established, the monkeys
were maintained at a 12 mg/kg dose of PCP (with PCP access under
an FR 1 schedule and saccharin access under an FR 16), and the
number of sessions of water substitution was varied from 1 to 16
to examine the rate of tolerance development and loss of
tolerance. The results (Figure 5) indicate that tolerance is
acquired within 4-5 days and a considerable amount of tolerance
is lost by 8 days. These results are similar to those that have
been previously reported concerning the effects of parenterally
administered PCP on schedule-controlled behavior (Balster and
Chait, 1976; Chait and Balster, 1978; Murray, 1978; Ruffing and
Domino, 1980).
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Fiqure 5. Mean saccharin
deliveries (FR 16) during
the final 2-hr component
are presented for the
last 5 sessions (when PCP
was available daily)
before 1, 4, 8 or 16
sessions of water substi-
tution. Connected points:
saccharin deliveries for
6 consecutive sessions
after PCP (12 mg/kg) was
reinstated.
Summary
The major findings of these studies were that phencyclidine can
be rapidly established as a reinforcer without using food to
induce drinking. Food deprivation is also not necessary to pro-
duce PCP self-administration, but it does increase the rate of
responding by nearly two-fold. The PCP analogs, PCE and TCP were
also self-administered. TCP was slightly more potent and much
shorter acting than PCP, and PCE was considerably less potent
than PCP. Finally, tolerance to the behavioral effects of PCP
was rapidly acquired and lost, and a two-fold shift in the dose
response curve was found.
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WHO Response to International
Treaty Obligations
Dr. lnayat Khan, M.B., B.S., Ph.D.
It is a great pleasure for me to speak to you and to give you
information on the activities of the World Health Organization
during the past year since we met at Cape Cod last June.
I wish to convey that, keeping in view WHO’s programme for
health for all by the year 2000, drugs will continue to play
an important role. WHO’s evolutionary efforts to establish
a list of essential drugs will always contain some drugs which
act on the central nervous system and may have dependence
liabilities; thus it is essential that the limited number of
drugs be thoroughly investigated, and thus the work of the
CPDD has become more important.
1. EVALUATION OF PSYCHOACTIVE DRUGS FOR INTERNATIONAL CONTROL
A WHO group reviewed nine anorectic drugs and concluded that
phendimetrazine, phentermine, benzphetamine and mazindol be
controlled under Schedule IV of the 1971 Convention. This
recommendation of WHO was accepted by the UN Commission on
Narcotic Drugs which met in February of 1981 in Vienna.
2. Under the 1971 Convention, parties can exempt from certain
control measures those combination products containing more
than a controlled psychotropic substance compounded in such a
way that presents no or negligible risk of abuse and that it
cannot be recovered by readily applicable means in a quantity
liable to abuse. During the September 1980 Review Meeting,
the lists provided by the Governments of Mexico and Bulgaria
were examined. Certain products did not deserve exemption
granted by the authorities. The UN Commission reviewed WHO’s
recommendations and approved them. This subject has become
of great practical importance since the 70 countries who
have so far ratified the 1971 Convention have a large number
of such products which require review by WHO. This year
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notifications from these countries are being reviewed.
3. DEVELOPMENT OF GUIDELINES IN THE CONTEXT OF THE
INTERNATIONAL TREATIES FOR THE CONTROL OF NARCOTIC AND
PSYCHOTROPIC DRUGS
You will recall that in 1981 the UN Commission on Narcotic
Drugs, the Economic and Social Council, and the 33rd World
Health Assembly (WHA/33.27) requested that WHO develop such
guidelines for the help of Member States. WHA/33.27 in
Paragraph 7.(3) requested the Director General of WHO,
"to promote the initiation and strengthening of national and
international programmes for the assessing, scheduling, control
and appropriate use of narcotic and psychotropic substances,
including those of plant origin and to support such programmes
by the development of appropriate guidelines." WHO has
initiated a project with funds from the Government of the
Netherlands and UNFDAC, and we have begun undertaking an in
depth study of the situation in six countries who have
obtained a reasonable level of control of psychoactive
substances. This will enable us to formulate guidelines for
presentation to the Executive Board of WHO in January of 1984.
A team has already visited Malaysia in March of this year
and another team will soon begin a visit to Panama the day
this Committee ends its deliberations. The other four
countries to be visited in 1982 are Kuwait, Thailand, Morocco
and Nigeria. WHO's concern is to try to develop guidelines
which are simple and pragmatic.
4. A WHO Expert Committee on the implementation of the
1971 Convention on Psychotropic Substances met in September
of 1980 and reviewed the methodology for assessing the public
health and social problems associated with the use of
psychotropic drugs. This was essential since the 1971
Convention requires this type of data as an essential for the
evaluation of the benefit/risk ratio of a psychotropic drug
(WHO Technical Report Series, No. 656, 1981). This Committee
was headed by Prof. Harold Kalant from Toronto. It
recommended that a mechanism be established for monitoring
the non-medical use of psychotropic substances and for
assessing the associated public health and social problems.
The Committee also noted that many developing countries have
only limited resources and because of other priorities do not
have the finances, personnel, technological capacity or the
training facilities to collect reliable data. On the other
hand, many of the psychotropic drugs are being exported in
large quantities in these countries where national control
measures are inadequate. The Committee recommended a number
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of steps to remedy the situation -- including making
available research findings in a form that can be readily
utilized and also the sponsoring of national and international
workshops and seminars. The Committee also recommended that
WHO should expeditiously begin to review the various groups of
the numerous psychotropic substances which are widely used for
possible control. It also requested WHO to strengthen its
programme for investigating the relationship between alcohol
and psychotropic substances on the one hand and injury,
disability and death from road traffic accidents on the other.
The Committee also recommended that the knowledge and
methodology developed for this purpose be extended to
investigations of industrial and other accidents.
Yet another recommendation was that governments be urged to
require studies of the effects of drugs and drug interactions
in driving ability as a pre-condition for licensing new
psychotropic drugs for use in their countries. WHO and the
National Institute for Drug Abuse of the U.S. have already
reviewed this subject; a meeting entitled “Strategies for the
Control of Drugs as Related to Traffic Safety” took place in
Washington in April of this year under the leadership of
Dr R. Willette. A report of this meeting will soon be
available.
WHO has taken yet another practical step to utilize the
information contained in this Expert Committee Report and
convened a workshop in Finland in June of this year where 12
participants from developing countries and a large number of
experts from within and outside Finland, WHO and UNFDAC took
part. The goal of the workshop was the development of a manual
for use in developing countries in establishing the role of
psychotropic drugs in specific areas in public health where
psychotropic drugs can and have created problems. The group
recommended further study in a general hospital in developing
countries.
5. Continuing WHO’s efforts to encourage Member States to
adhere to the 1971 Convention and to use this Convention as an
instrument to use psychotropic drugs rationally, two national
and two regional workshops were organized. The two national
workshops on the use and misuse of psychotropic drugs were
held in London and Bangkok. The regional workshops were held
in Manila and Buenos Aires. The latter was especially for
Portuguese and Spanish speaking participants. Later this
year a Third Travelling Seminar on the Safe Use of
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Psychotropic and Narcotic Substances will take place in Moscow
and Tashkent in October. English, Russian and French
speaking participants have been invited. One of the goals
of this seminar is the development of guidelines for
registration of psychoactive drugs with dependence liability.
6. This year we have planned two meetings for review of
psychoactive substances -- in September for the opioid agonists
and antagonists and in November for review of a number of
benzodiazepines which are already on the market.
7. I wish to comment on the excellent paper presented by
Professor Everette May while receiving Nathan B. Eddy
Memorial award during the last part of his address referring
to the future role of CPDD. I may add yet another role which
is related to cooperation between CPDD and WHO in developing
base line data from animal studies on certain groups and
representative psychotropic drugs which is lacking today.
I have already taken up this issue with Professor Joe Cochin,
Chairman of CPDD. Yet another area worthy of attention to
this committee is to draw up a paper elucidating further
cooperation between the pharmaceutical industry and the
national and international authorities and in particular
WHO as it relates to the implementation of the
international treaty obligations. I made this point at the
last meeting of the UN Commission on Narcotic Drugs held in
Vienna in February 1981 and was supported by the Executive
Director of the UN Fund for Drug Abuse Control.
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Structure-Activity Relationships of Ox-
ygenated Morphinans. III. An Exploration of the
Effect of the Aromatic Oxygen and 6-Keto
Group on Antinociceptive Activity, Receptor
Affinity, and Narcotic, Antagonism
A. E. Jacobson, H. Schmidhammer, F.-L. HSU,
M. D. Rozwadowska, L. Atwell, A. Brossi, M. D. Aceto,
L. S. Harris, J. L. Katz, J. H. Woods, and F. Medzihradsky
We have, previously, reported on the synthesis of 4-hydroxy-N-
methylmorphinan (1) (Hsu et al. 1979; Rozwadowska et al. 1980;
Hsu, Rice, and Brossi 1980), 4-hydroxy-N-methylmorphinan-6-one (2 )
and 4-methoxy-N-methylmorphinan-6-one (3) (Hsu et al. 1979;
Rozwadowska et al. 1980). Our comparison between the
antinociceptive activities of 2 and 2 with those of
3-deoxydihydromorphine (4) and 3, 6-dideoxydihydromorphine (5 )
(Reden et al. 1979) initiated further work at NIH on a wide
variety of oxygenated morphinans (figure 1) (Jacobson et al. 1981;
Schmidhammer et al. 1981) in an attempt to ascertain the
influence which oxygen atoms, in the morphinan skeleton, have on
binding to the opiate receptor and on in vivo activity.
4-Methoxy-N-methylmorphinan (6) was found to be essentially
equlpotent with morphine as an antinociceptive, emphasizing the
fact that a c-3 hydroxyl function was unnecessary for in vivo
antinociceptive activity in this set of opiate-like molecules. An
oxygen atom in the C-4 position could be, apparently, "recognized"
by the opiate receptor. If an hydroxyl function was returned to
the C-6 position of a 4-oxygenated morphinan, either as the
C-6alpha (7) or C-6beta (8) compound, to make it structurally more
comparable to the morphine molecule, antinociceptive potency was
markedly reduced. However, conversion of the 6-hydroxyl moiety in
7 or 8 to a ketone produced a much more potent compound (2).
Conversion of 2 to its methyl ether produced 3, which had an
ED50=0.9 µmol/kg; 3 was more than three times as potent as
morphine. That discovery, in 1979, pointed to the idea that it
was, generally, best to mask the aromatic hydroxyl group at C-4.
Conversion to compounds without a phenolic or C-6 hydroxyl group
obviates the possibility of involvement of the hydroxyl group in
hydrogen bonding to some macromolecule in vivo. This theoretical
idea that molecules with a C-4 or C-6 hydroxyl group could hinder
macromolecules involved in the process leading to antinociception
led us to the preparation of various morphinans, some of which will
be discussed in this paper; others will be published elsewhere.
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TABLE 1
Antinociceptive Activity of Selected Levo Enantiomers of Morphinans.
Morphinan-6-ones and Reference Drugs in the Hot Plate Assay
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METHODS
Chemistry: All of the prepared compounds had elemental analyses,
mass, infrared and proton nuclear magnetic resonance spectra in
accord with their designated molecular structures.
Assay procedures: The hot plate assay was described in Atwell and
Jacobson (1978). The phenylqulnone writhing, tail flick and tail
flick antagonism vs. morphine procedures were described by Dewey et
al. (1970), and Dewey and Harris (1971).
Binding to Opiate Receptors: This assay was described in Valentino
et al. (1981) and Woods et al. (1979).
Monkey Studies: Single dose suppression and precipitated
withdrawal in rhesus monkeys was carried out as described in Aceto
et al. (1981) and Woods et al. (1981), and references therein.
RESULTS & DISCUSSION
Generally, the most potent compounds in table 1 were those which had
a 4-methoxy group either with, or without, an additional methoxy
group at position 3 on the aromatic ring (compounds 3, 6, 11 and
12). The 6-keto compounds (2, 3, 11 and 13) were either equipotent
with, or perhaps somewhat -more potent than, comparable compounds
with a non-oxygenated C-ring (compounds 1, 6, 12 and 14).
Compounds with 3-methoxyl groups, with or without a 6-keto moiety,
were about as potent as morphine (9 and 10) but were much less
potent than the comparable C-3 phenolic morphinan (levorphanol).
Phenols are almost always more potent than their comparable ethers
in the 3-substituted opiates (e.g. - morphine vs. codeine).
However, the introduction of a second methoxyl group, at C-4 on the 
aromatic ring (11, 12), increases potency three fold. It is
striking to note that the 4-Methoxy-N-methylmorphinan-6-one (3) and
the 3,4-dimethoxy compounds (11, 12) are significantly more potent
than their comparable phenolic relatives. The 4-acetoxyl compounds
(13, 14) are essentially equipotent with the 4-hydroxyl compounds 1
and 2. Presumably, the phenolic esters are cleaved in vivo in a
manner similar to that of the phenolic ester in heroin.
Some of the compounds had good oral (PO) activity in the hot plate.
assay (3, 9, 11, 13). Compounds 3 and 11, orally, are almost as
potent as SC administered morphine, in that assay. The ratio of sc
to oral potency of 2 and 13 appears to be better than that ratio in
morphine, and equivalent to that in codeine. The possible narcotic
antagonists (16, 17, 18, 19, 20) had, as might be expected, little
activity in the hot plate assay, with the exception of compound 20.
Some have been examined for their narcotic antagonist activity in
mice and in monkeys (table 2).
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TABLE 2
Antinociceptive and Narcotic Antagonist Activity of Selected
N-Substituted Compounds
a) Dose (sc) at which half the mice are affected, in µmol/kg.
Parenthesized numbers are 95% confidence limits; b) Single dose
suppression, in morphine-dependent rhesus monkeys: c) Precipitated
withdrawal in morphine-dependent rhesus monkeys: d) Phenylquinone
writhing assay in mice; e) Tail flick assay in mice: f) Tall flick
antagonism vs. morphine in mice; g) Complete substitution at
1-4mg/kg: h) No dose-response relationship; i) No substitution
(exacerbates withdrawal at 1-3mg/kg); j) Precipitates withdrawal at
0.1-3mg/kg, ca. 1/3 to 1/10 the antagonist-potency of nalorphine:
k) Inactive: 1) Precipitates withdrawal at 0.1-3mg/kg, ca. 1/3 the
antagonist potency of nalorphine; m) Complete substitution at 3,
5.6 and 10mg/kg; n) Partial substitution for morphine.
It was apparent from our former data on receptor binding affinity
(Reden et al. 1979) that oxygen atoms on the aromatic ring, or on
the C-ring, were unnecessary for binding to the opiate receptor.
3,6-Dideoxydihydromorphine (5) had ca. one-third the binding
affinity of morphine for the receptor. The affinity the compound
displayed for the receptor was remarkable in that the C-3 phenolic
hydroxyl might have been, a priori, considered to be critical for
the binding. Although the phenolic hydroxyl group can now be said
to aid in the binding of the antinociceptive drug to a receptor, it
is not critical to that event. The 4-methoxy-N-methyl-
morphinan-6-one (3) (table 3) has the same relative affinity to the
presumed µ receptor as does 5, when compared with the binding
affinity of morphine. The greater in vivo relative potency
compared to in vitro relative potency of 3 might be explained
simply by more facile transport to the receptor sites. Metabolism
of 3 to 2 probably need not be invoked to explain the in vivo
antinociceptive potency of 3, in contrast with other phenolic
ethers (e.g. - codeine). It is apparent from the data in table 3
that the 6-keto group in the 4-methoxyl series (2 vs. 1 and 3 vs.
6) enhances interaction with the receptor. Further, al though the
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binding affinity of the 4-methoxy-N-methylmorphinan-6-one (3) is
somewhat lower than that of the comparable 4-hydroxy compound 2,
this is markedly different from the usual binding affinity of
phenols and their ethers in C-3 substituted opiates (e.g. - codeine
vs. morphine). Thus, there are two very unusual characteristics of
some of the 4-methoxy-6-keto morphinans. Their binding affinity to
the opiate receptor in rat brain membranes is extraordinary for
aromatic ethers, and they appear to be considerably more potent in
vivo than their phenolic counterparts.
The N-methyl derivatives appear, in general, to be morphine-like in
their capacity to suppress withdrawal in SDS in morphine-dependent
monkeys, which is in agreement with the +Na/-Na ratios they display
in binding experiments to opiate receptors in rat brain membranes.
Some of the 4-methoxyl compounds were successfully converted to
agonist-antagonists. using N-moieties similar to those which are
known to convert C-3 oxygenated opiates to their antagonists (table
2). The N-allyl (16) and N-cyclopropyl (17) analogs were found, in
non-withdrawn monkeys, to exhibit narcotic antagonist activity.
Compound 17 had ca. one-third the potency of nalorphine. .
TABLE 3
Potency of Selected Morphinans, Morphinan-6-ones and Comparison
Drugs in Displacing Stereospecifically Bound 3H-Etorphine in
Membrane Preparations From Rat Brain
a) From Woods, et al., 1979.
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Bicifadine: Non-Narcotic Analgesic
Activity of 1-Aryl-3-azabicyclo[3.1.0]
hexanes
J. W. Epstein, A. C. Osterberg, B. A. Regan
Bicifadine (USAN 1979) (1) CL 220,075 [1-(4-methylphenyl)-3-azabi-
cyclo[3.1.0]hexane], is undergoing clinical trials as a non-
narcotic analgesic. It has a greater potency than aspirin, and
a greater therapeutic index than codeine, pentazocine, or propoxy-
phene in a variety of tests in rats and mice (Epstein et al. 1981).
It was essentially inactive in the high-intensity rat tail-flick
procedure (Gray et al. 1970) and by the mouse hot plate method
(59° C) (Eddy et al. 1950). It did not show physical dependence
liability when tested by a subcutaneous pellet implant procedure
(Way et al. 1969) or by using an incremental intraperitoneal dos-
ing schedule (with naloxone challenge) (Saelens et al. 1971).
Also, it had no in vitro opiate receptor binding properties using
tritiated dihydromorphine. Single-dose substitution studies in
morphine-dependent rhesus monkeys (Aceto et al. 1979) produced
transitory effects that did not necessarily imply morphine-like
properties. In a private communication, Aceto et al. (1979) re-
ported that primary dependence studies in rhesus monkeys over a
period of 40 days did not produce morphine-like physical depen-
dence . Relatively little tolerance was seen to develop. It does
not show anti-inflammatory activity, nor in vitro prostaglandin
synthetase inhibition.
Bicifadine is being evaluated in its racemic form; however, the
(1R, 5S)- (+) enantiomer has been shown to be the active component.
PHARMACOLOGICAL METHODS
Inflamed Rat-Paw Reversal of Abnormal Gait. A modification of the
procedure of Atkinson and Cowan (1974) was used as the primary
assay. Brewers’ yeast was injected into the plantar surface of
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the left hind paw of each rat, and 3 hours later a pre-drug assess-
ment was determined for each rat (range: 0 = normal gait to 2 =
maximum abnormal walking behavior). Rats with a gait score of 2
were then treated with vehicle or test compound, and post-drug
scores were determined at selected time intervals; A > 50% reduc-
tion of abnormal gait was considered a positive analgesic response;
the dose estimated to reduce the gait score from 2 to 1 in 50% of
the rats was defined as the ED5 0 .
Phenylquinone Mouse Anti-Writhing Method. A modification of the
procedure of Hendershot and Forsaith (1958) was used.
Inflamed Rat-Paw-Pressure Threshold Method. A modification of the
method of Randall and Selitto (1957) was used to measure the pain
threshold of rats whose paws were made sensitive to pressure by
the injection of a 20% aqueous suspension (0.1 mL) of brewers’
yeast into the plantar surface of the left hind paw.
Statistics. ED50's and 95% confidence limits were calculated ac-
cording to the linear arc sine transformation method (Finney 1964).
CHEMICAL SYNTHESIS
The general synthesis of 1-aryl-3-azabicyclo[3.1.0]hexanes is out-
lined in scheme I (Epstein et al. 1981) using the synthesis of
bicifadine (1) as an example. The cyclization of bromoester (2)
and methyl acrylate using sodium hydride in ether gave cis-
cyclopropane dicarboxylate (3) , which was then hydrolyzed to diacid
(4). Cyclization of diacid (4) with urea gave imide (5), which was
subsequently reduced with a hydride to the title amine (1).
SCHEME I
The optical resolution was achieved at the diacid 4 stage using
optically active -methyl-1-naphthalenemethylamine. The absolute
configuration of the (+)-enantiomer 12 was determined by single-
crystal X-ray analysis. Eschweiler-Clark (CH2 O, HCO2 H) reaction
of 1 gave the N-methyl derivative 33, while reaction of 1 with
allyl bromide and bromomethylcyclopropane gave the N-allyl, and
N-cyclopropylmethyl derivatives 34 and 35 respectively.
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The profadol (Bowman 1969) (6) analog 8 was prepared by demethyl-
ating the m-methoxyphenyl compund, 7, using sodium ethyl mercap-
tide in N,N-dimethylformamide. Compounds 26 and 27 were likewise
prepared from 19 and 20 respectively by this general method.
PHARMACOLOGY
The results of analgesic tests are presented in table 1. A
structure-activity relationship was derived by examining the
“abnormal gait” data. For the substituents CH3, Cl, and OCH3 the
para substituted compounds 1, 14 and 19, respectively, were more
potent than the corresponding meta substituted 10, 15 and 20. The
ortho substituted 11 and 16 were inactive. The particular substi-
tuent effect that governs potency in this test is not evident;
however, it can be seen that p-alkyl substituents such as CH3 (1)
and C2H5 (28) impart the greatest degree of activity of the sub-
stituents studied.
Potency diminished for compounds in which the alkyl group was
larger than ethyl, e.g. isopropyl (29) and n-hexyl (31), while
the p-tert-butyl analog 30 was inactive. The effect of optical
isomerism clearly discernible from the greater potencies of the
(1R, 5S)-(+) enantiomers 12 and 17, as compared to the relative
inactivity of the (1S, 5R)-(-) antipodes 13 and 18.
The effects of N-alkylation are not uniform. For the p-C1 analog
14, activity is diminished in going to the N-Me derivative 36,
whereas for the p- C H3 analog 1, conversion to the N-Me derivative
33 is accompanied by no loss in potency. However, when the allyl
and cyclopropylmethyl groups were incorporated into 1 to give 34
and 35 respectively, there was a considerable loss of analgesic
potency, and these compounds were not morphine antagonists. These
groups are generally used as N-substituents for narcotic-antagonist-
type analgesics (Bowman et al. 1973).
A comparison of the analgesic activity of the N-methyl-m -hydroxy-
phenyl congener 8 with profadol 6 shows that the incorporation of
these two structiiral features which are generally found in agonist-
antagonist analgesics, resulted in a compound of minimal activity.
The p-tolyl analog 1 was chosen for further study as an analgesic
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Table 1. Analgesic Activities of 1-Aryl-3-azabicyclo[3.1.0]hexanes
a Highest dose tested, active.
b Highest dose tested, inactive.
c NT = not tested. d 50 mg/kg, 4/5 reversed. e Allyl.
f Cyclopropylmethyl.
based on its uniform potency in all three screening tests. A study
of oral therapeutic indices in rats (table 2) showed that bicifadine
(1) compared favorably with aspirin, while it was significantly
better than codeine, pentazocine and propoxyphene.
In conclusion, bicifadine (1) is an orally active analgesic. It is
structurally distinct from the general class of agonist-antagonist
analgesics and shows little or no physical dependence liability.
Table 2. Oral Therapeutic Indices in Rats
P = paw-pressure method. G = abnormal gait method.
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Synthetic Opium Alkaloids and
Derivatives 2. Efficient Total
Synthesis of (-)-Dihydrocodeinone
and Congeners
Kenner C. Rice
The remarkable pharmacological effects of opium were recognized in
ancient times and for many centuries this substance was the mainstay
of the practicing physician. Even today, natural (-)-morphine (1),
(-)-codeine (2) and other opium derivatives are still an important,
if not indispensable group of drugs for the effective practice of
modern medicine (Schwartz, 1980). The rising U.S. annual production
and use of opium derivatives currently stands near 60,000 kg, with
worldwide consumption at about 200,000 kg/year of which about 90% is
codeine (2) (Schwartz, 1980). In this country, the sole source of
these drugs has been extracts of the opium poppy, Papaver somniferum,
purchased abroad, principally from India. The consequences of total
dependence on foreign sources of a natural product were graphically
illustrated during the opium shortage of 1973-5, when the U.S.
Government was forced to release large portions of the strategic
materials reserves of opium to domestic processors in order that
requirements of this country could be met (Schwartz, 1980). Pract-
ical production of opium derivatives by total synthesis is thus a
desirable capability, which could render this country independent
of foreign sources, and would afford a number of new options, parti-
cularly in the event of armed conflict in the areas of poppy pro-
duction or in the case of national emergency. A number of other
ramifications of such a capability, as in the area of illicit
heroin control, can also be envisioned. Herein is described
straightforward methodology for synthesis of intermediates which
could be utilized for production of medical opiates by total
synthesis.
Since the correct formulation of the gross structure of morphine (1)
and codeine (2) by Gulland and Robinson (1925), which followed the
brilliant degradative work of Pschorr, Knorr and others (Holmes, 1952)
in earlier attempts at structural elucidation, these alkaloids have
been the subject of numerous synthetic studies. The relatively
complex, unsymmetrical structures of morphine and codeine first
yielded to the elegant synthetic efforts of Gates and Tschudi (1952).
Later successes (Barton et al., 1963; Beyerman et al., 1976; Beyer-
man et al., 1978; Elad and Ginsberg, 1954; Grewe and Friedricksen,
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1967; Kametani et al., 1969; Lie et al., 1979; Morrison et al., 1967;
Rice, 1980; Schwartz and Mami, 1975; Szantay, 1980) afforded dihydro-
thebainone (3), which had been converted to morphine and codeine by
Gates and Tschudi (1952), or other intermediates previously con-
verted to these alkaloids.
Most efforts at total synthesis of opium alkaloids have utilized
either a biomimetic route (Barton et al., 1963; Schwartz and Mami,
1975; Szantay et al., 1980) in which a phenolic l-benzyltetrahydro-
isoquinoline is oxidized to a morphinandienone convertible to the-
baine (4) and thence to morphine, or a Grewe-type (Beyerman et al.,
1976; Beyerman et al., 1978; Grewe and Friedrichsen, 1967; Lie et
al., 1979; Rice, 1980) electrophilic reaction of a suitably func-
tionalized 1-benzylhexa or octahydroisoquinoline to form the mor-
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phinan carbon-nitrogen skeleton. In the former approach, control
of the product distribution ratio, and the lability of the desired
morphinandienone to secondary transformations have been major pro-
blems. In the Grewe approach, dihydrothebainone (3) has been a
frequent objective for reasons described below; however, predomin-
ant cyclization to morphinans with an undesired oxygenation pattern,
failure of Grewe cyclization with suitably blocked (to undesired
cyclization) intermediates and lengthy routes employing symmetri-
cal 1-benzyl substituents have rendered these attempts unfeasible
for large scale synthesis.
In contrast to these results, a preliminary disclosure (Rice, 1980)
from this laboratory recently described the successful execution of
a modified Grewe-type synthesis of racemic dihydrothebainone (3),
nordihydrocodeinone (5) and dihydrocodeinone (6) in 37, 30 and 29%
overall yield respectively, from m-methoxyphenethylamine. This
route utilized free phenolic intermediates, obviating the several
additional steps for protecting and deprotecting the hydroxyl which
are usually needed. It required isolation of only six intermediates
(that were obtained sufficiently pure for further transfomation)
and optionally afforded access to either the N-methyl or N-nor series.
The (-)-enantiomer of dihydrothebainone (3) has been converted
(Weller and Rapoport, 1976) to natural codeine in 68% overall yield
without isolation of intermediates, to natural thebaine (4) in some-
what higher yield, and conversion of codeine (2) to morphine (1) in
90% yield has been described (Rice, 1977). Thus, the recent dihydro-
thebainone synthesis appeared to be a particularly promising lead for
total synthesis of all medically valuable opium-derived morphinan
derivatives, since the entire spectrum of this series consists of
morphine (l), codeine (2), their transformation products and the
drugs based on thebaine (4).
I would now like to describe extension of the route I used earlier
in the racemic series to the efficient synthesis of the (-)-enantio-
mers of dihydrothebainone (3), dihydrocodeinone (5) and nordihydro-
codeinone (6). Racemic tetrahydroisoquinoline 7 available from m-
methoxyphenethylamine in 82% overall yield was readily resolved
with (-)-tartaric acid to afford (+)-7 in 89% yield. The optical
purity of (+)-7 was readily demonstrated by selective conversion to
the corresponding urea derivative with optically pure a-methylbenzyl
isocyanate followed by HPLC or NMR analysis. The former method
proved to be at least an order of magnitude more sensitive in this
system. Birch reduction of (+)-7 (30g scale) easily afforded
essentially pure (+)-8 by TLC in 97% yield.
Selective N-formylation of (+)-8 occured essentially quantitatively
by TLC as in the racemic series (Rice, 1980), however solubility
properties of the crystalline N-formyl derivative of (+)-8 did not
permit high recovery, in contrast to the racemic series. Thus, N-
formylation of (+)-8 with chloral in THF, ketalization with ethylene
glycol, regioselective bromination and deketalization without puri-
fication of the intermediates afforded crude octahydroisoquinoline
9. Cyclization of 9 as in the racemic series (Rice, 1980) gave
crystalline (-)-1-bromo-N-formylnordihydrothebainone that was
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identical in every respect with a sample prepared by degradation
of naturally derived (-)-dihydrocodeinone (5). The combined yield
of this N-formyl derivative and the parent base, isolated after
acid hydrolysis of the filtrates was 40 % from (+)-8. The observa-
tion that (+)-7 affords (-)-1-bromo-N-formylnordihydrothebainone
identical with that derived from natural (-)-codeine confirms the
absolute configuration of (+)-7 previously assigned (Rice, 1980)
on the basis of NMR arguments. Transformation of (-)-l-bromo-N-
formylnordihydrothebainone to (-)-dihydrothebainone (3), (-)-
dihydrocodeinone (5) and (-)-nordihydrocodeinone (6) was accomplished
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in high yield as in the racemic series. Further work dealing with
transformation of (+)-8 to (-)-3, (-)-5 and (-)-6 is in progress,
and the results of these investigations will be reported. Based
on data accumulated thus far, and in light of the work of Weller
and Rapoport (1976), it now appears that overall yields of (-)-
morphine (1) and (-)-codeine (2) from m-methoxyphenethylamine will
be in the range of 10-30%.
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14-AIkoxy Dihydrocodeinones,
Dihydromorphinones, and Morphin-
anones—A New Class of Narcotic
Analgesics
Anil C. Ghosh, Rosemary L. Lavoie, Patricia Herlihy, John F.
Howes, and Raj K. Razdan
INTRODUCTION
It is well dccmented that in morphinan-like narcotics, the
region of the electrophilic nitrogen plays an imporatant role
during the interaction of the drug with the opiate receptors
(Blumberg and Dayton 1974; Leow and Berkowitz 1978; Pachter 1974).
It has also been demonstrated that introduction of 14ß-hydroxy
group in close proximity of the N- substituent group leads to
compunds possesing potent pharmacological activity as agonists
or mixed agonist antagonists or pure narcotic antagonists
(Blumberg and Dayton 1974; Pachter 1974; Jasinski et al. 1967;
Kosterlitz and watt 1968).
Thus oxymorphone (1a) is nearly ten times as potent as morphine
as a narcotic analgesic. On the other hand, naloxone (1b) is a
potent antagonist, and the corresponding N-cyclobutyl analog 1c
is a mixed agonist antagonist.
In our search for nonaddictive analgesics, we wished to study
effect of introducing an electrondonating group such as alkoxyl
in the vicinity of the N-substituents in the morphine and
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morphinan skeleton. This has led to a series of potent narcotic 
agonist antagonists having excellent potential as nonaddictive
analgesics. This new class of compounds are represented by the
structures 2-9.
It may be pointed out that these 14-alkoxy derivatives, unlike
the well documented 14-acyloxy analogs, are not likely to be
converted to the corresponding l4-hydroxy derivatives. The
14-cinnamoyloxy derivative (1d) is a potent analgesic but
shows significant physical dependence properties (Buckett 1965;
Buckett 1966).
METHODS
Chemistry
The starting material for compoubds of type 2-9 was the baine
(10) (Scheme I), which was converted (Iijima et al. 1977) into
14-hydroxycodeinone (11) by treatment with m-chloroperbenzoic
acid in CF3 COOH-AcOH-H2 O. Reaction of 11 with methyl iodide in
presence of sodium hydride led to 14-methoxycodeineone (12).
Catalytic hydrogenation led to 14-methoxy dihydrocodeineone,
which was converted into compounds such as 15, 16, 18 and 19
in several steps. In another series of studies 10 was converted
into 13. Structural modifications of 13 led to compounds 14,
17, 18 and 19. Introduction of the 8-alkyl substitution was
accomplished by treatment of 12 and 14 with (CH3 )2 Culi to give
3-methoxy-N-methyl analogs of 16 and 17, respectively.
Pharmacology
a) Mouse Acetic Acid Writhing Test
Male albino CD-1 mice (18-22g) were used for this study. A modi-
fication of the Whittle procedure (Whittle 1964) was used. The
testdrugwas given by subcutaneous injection 15 minutes prior to 
an intraperitoneal injection of 0.5% acetic acid (0.4ml). The
number of writhes per group of five mice were counted for 20 minutes
starting five minutes after the acetic acid injection. Analgesic
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SCHEME I
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potency was calculated from the difference between the test groups
and their controls.
b) Rat Tail-flick Procedure (for Narcotic Antagonist Activity)
Male albino Wistar rats (lOO-15Og). were used for this study. The
method described by Harris and Pierson (1964) was used.
Two control reaction times were determined thirty minutes apart
and prior to intraperitoneal injection of the test drug. Ten
minutes later an ED80 dose of morphine was administered subcut-
aneously and reaction times were then determined twenty minutes
later. The narcotic antaqonist activity was determined from the
difference between the groups and control groups which received
morhpine alone.
RESULTS AND DISCUSSION
The introduction of a substituent
The antinociceptive properties of
series are shown in Table I. The
noteworthy.
various compounds in the morphine
following trends in SAR are
to the 14 position of morphine-
like molecules has resulted in the formation of compounds whose
pharmacological profile differs significantly from the unsubstit-
uted molecule (Blumberg and Dayton 1974; Leow and Berkowitz 1978;
Pachter 1974). Thus, 14-hydroxy hydromorphine (oxymorphone) and
l4-hydroxyhydrocodone (oxycodone) are more potent than hydro-
morphone and hydrocodone respectively. N-cyclopropylmethylnoroxy-
morphone (Naltrexone) is a more potent antagonist than its unsub-
stituted analogs but lacks agonist activity.
In N-cycloalkyl substituted 4,5-epoxymorphinan series, replacement
of 14-H with 14-methoxy resulted in compounds with weaker agonist
and antagonist actions. Additional introduction of an 8 methyl
group led to more active series of compounds, such as TP5162.
This compound caused morphinelike symptomology in rodents
A number of interesting compunds were obtained in the l4-methoxy-
morphinan series (Table II).
In the cyclobutylmethyl series, introduction of l4-methoxy group
led to 5306 having potent agonist activity with no antagonist
activity. A combination of 14-methoxy and N-cyclopropylmethyl
group, however, provided compounds  5305 and 5400 with excellent
agonist-antagonist ratio and good activity. Compund 5400, in view
of its potency, as well as excellent agonist/antagonist ratio, has
been selected as a potential clinical candidate.
When an 8 methyl group was introduced to the 17-cyclobutylmethyl-
14-methoxy morphinan skeleton, compound 5249 with good mixed
agonist-antagonist properties was obtained.This compound sup-
ported morphine-like physical dependence in the rat. On the other
hand, introduction of a 8ß-methyl group in l4-methoxy morphinan led
to pure narcotic antagtists. Thus,compound 5210 is an extremly
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potent narcotic antagonist. In this series, even the N-cyclo-
butylmethyl compound were potent antagonists with little or no
agonist activity. This lack of agonist properties with cyclo-
butyl series is interesting, as it is in contrast to what has
been generally observed in opiods.
TABLE I
Analgesic and Narcotic Antagonist Activities of Dihydrocodeinone
and Dihydromorphinones
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TABLE II
Analgesic and Narcotic Antagonist Activities of Morphinanones
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Structural Requirements for Af-
finity and Intrinsic Activity at the
Opiate Receptor Defined in 4-
Phenylpiperidine and Related
Series
D. M. Zimmeman, S. E. Smits, M. D. Hynes, B. E. Cantrell,
M. Reamer, and R. Nickander
In previous reports (Zimmerman and Nickander, 1977; Zimnerman et al.
1978a; 1978b), the structure-activity relationships of a series of
1,3,4-trialkyl-4-phenylpiperidines, containing potent narcotic
antagonists, were explored. The importance of 3-methyl substitution
for this antagonist activity was demonstrated and the narcotic
agonist and antagonist properties of LY150720 were described. Since
that time the pharmacology of LY150720 has been extensively evalu-
ated and the results of these studies are the subject of an
accompanying report.
LY150720 is a racemic mixture whose resolution results in a highly
unique stereospecific separation of narcotic agonist and antagonist
activity. The partial agonist properties of LY150720 are a conse-
quence of the potent morphine-like agonist activity of the d-isomer
and nalorphine-like antagonist activity of the l-isomer.
Though there have been previous reports of stereospecific separation
of analgesic activity from physical dependence liability for certain
benzomorphan analogs (Ager et al., 1969) and 5-m-hydroxyphenyl-2-
methylphenylmorphan (May and Takeda, 1970), in no case was the
degree of separation of pharmacological activities achieved as seen
with LY150720.
In this paper, a series of SAR studies is described in an attempt
to further characterize this unique class of opiate partial agon-
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ists. The structural requirements for both affinity and intrinsic
activity and the possible importance of conformational binding modes
on the opiate receptor in the 4-phenylpiperidine and 4 -phenyl-2-
pyrindine series are described.
CHEMISTRY
The synthesis of the 1,3,4-trialkyl-4-phenylpiperidines (U.S. Patent
No. 4,081,450), the 1,2,3,4-tetraalkyl-4-phenylpiperidines (U.S.
Patent No. 4,228,288) and the cis- and trans-phenylpyrindines (U.S.
Patent No. 4,236,009; Evans et al., 1980) have been previously
reported. The isomeric configurations were confirmed by 360 MHz
- 1H  NMR and 13C NMR analysis.
METHODS
The method for the acetic acid-induced mouse writhing analgesic test
was similar to that previously described (Nickander et al., 1977).
The ED50 value, defined as the dose required for a 50 percent
reduction in the frequency of writhing, was computed by "The Use of
the Regression Line in Reverse" (Brownlee, 1965).
The method for the rat tail heat analgesic test has been previously
described (Nickander et al., 1977; Robbins, 1955). The ED2sec value
is defined as the dose requied for a 2-sec increase in reaction time
and was computed by "The Use of the Regression Line in Reverse"
(Brownlee, 1965).
The ability of the test compound to reduce or antagonize the anal-
gesic effect of morphine was measured in the rat tail heat test
(Zimmerman and Nickander, 1977). The test antagonist was admin-
istered 20 min before the administration of morphine sulfate (10
mg/kg, s.c.) and the analgesic effect of morphine was measured 10
min later. The AD50 value, computed by "The Use of the Regression
Line in Reverse" (Brownlee, 1965) was that dose required for a 50-
percent reduction in the analgesic response to morphine.
The affinity for opiate receptors of rat brain homogenates was mea-
sured by assaying the displacement of 3H-naloxone from specifically
bound sites as described before (Pasternak et al., 1975).
RESULTS
Narcotic agonist and antagonist measures for LYl50720, its d-isomer
(LY97435) and its l-isomer (LY97436) are shown in table 1, while
opiate receptor biiiding affinities are given in table 2. The ED5 0
values in the mouse writhing test for LY150720 and LY97435 were com-
parable to that of morphine, while LY97436 was 1/10 as potent. In
the rat tail heat test the analgesic potencies of LY150720 and
LY97435 were again similar to that of morphine; however, LY97436
failed to produce a significant analgesic effect in this test. In-
spection of table 2 shows that the potency difference between the
enantiomers, LY97435 vs. LY97436, was not primarily due to differ-
ences in affinity for opiate receptors, as is normally the case.
Both compounds had opiate receptor binding affinities similar to
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that of morphine. In addition, LY97436 had a low sodium ratio com-
pared to that of LY97435 and morphine (3.7, 26.7 and 20.0, respec-
tively), inferring that LY97436 has properties of a partial
agonist. In accord with this, LY97436 antagonized the analgesic
response of morphine with an AD50 value l/4 that of pentazocine,
and 8 times that of nalorphine. These data indicate that LY97436
has low intrinsic activity (i.e., a reduced ability to stimulate
the opiate receptor). Comparison of LYl50720 and its d- and
l-isomers with compound 1, figure 1, revealed that 3-methyl
substitution on either'enantiotropic edge of the piperidine ring had
relatively little effect on opiate receptor affinity, table 2.
These results coupled with their narcotic agonist and antagonist
activities, table 1, indicate that loss of intrinsic activity at
the opiate receptor is associated only with substitution on the
enantiotropic edge leading to the l-isomer.
FIGURE 1.
In an attempt to determine the conformational binding mode (axial-
phenyl or equatorial-phenyl, figure 1) (Portoghese, 1965) respons-
ible for the narcotic antagonist activity seen with the 1,3,4-tri-
alkyl-4-phenylpiperidines, a series of 1,3,4,6-tetramethyl-4-
phenylpiperidines was synthesized.
The energy difference between the two conformations shown in figure
1 is relatively small for the 1,3,4-trialkyl-4-phenylpiperidines,
though the equatorial-phenyl conformation appears to be favored for
compounds 2 and 3. Consequently, a conformational change of the
ligand might be induced during the course of a drug-receptor inter-
action. With the 1,3,4,6-tetraalkyl-4-phenylpiperidines this event
would seem less likely because of the additional energy barriers
involved. For example the axial-phenyl conformer would appear to be
favored in compounds 4 and 5 because of severe 1,3-diaxial interac-
tions in the equatorial-phenyl conformer. Similarly for compounds
6 and 7 the equatorial-phenyl conformation would be favored.
Tables 1 and 2 show that substitution of methyl for hydrogen at R6 b
in compound 2, predicted to cause an equatorial to axial-phenyl con,
formational change, transforms a pure antagonist to a potent,
morphine-like agonist (compound 4). This transformation results in
a 12-fold increase in opiate receptor binding affinity in the
absence of sodium; however, affinity is reduced two-fold in the
presence of sodium. In contrast, the addition of a methyl at R6a, to
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compound 2, giving compound 7, in which the equatorial-phenyl con-
former would be further energetically favored, reduces opiate recep-
tor affinity two-fold with no effect on intrinsic activity (i.e.,
narcotic antagonist activity is retained). These results strongly
indicate that the narcotic antagonist activity in the 1,3,4-trialkyl-
4-phenylpiperidine series is mediated through an equatorial-phenyl
conformer receptor interaction. Similar observations with compounds
3, 5 and 6 are in accord with these conclusions.
The relationships of the cis-phenylpyrindines (compounds 8, 9 and
10), the trans-phenylpyrindines (compounds 11, 12 and 13) and the 5-
phenyl-2-methylmorphans (May et al., 1955; 1970) (compounds 14, 15
and 16) to LY150720 were explored. As shown in figure 2, the trans-
4 -phenyl-2-pyrindines have an axial constrained phenyl group while
the 5-phenyl-2-methylmorphans have the phenyl ring fixed in the
equatorial position. However, with the cis-4 -phenyl-2-pyrindines,
as with LYl50720, both axial and equatorial phenyl conformations
are possible.
TABLE 1
As shown in table 1, compound 11 is a potent morphine-like agonist.
Furthermore, resolution of compound 11 shows the d-isomer (compound
13) to be 10 times as potent as the l-isomer (compound 12) in both
the mouse writhing and rat tail heat-analgesic tests. Inspection of
table 2 shows that the potency difference between these two enantio-
mers can be explained on the basis of opiate receptor affinities.
In addition the high intrinsic activity of both compounds is con-
firmed by their ability to completely suppress withdrawal symptoms
in morphine-dependent monkeys (Woods et al., 1981).
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Similarly, compound 8 appears to be a potent morphine-like agonist;
however, separation of its d- and l-isomers shows compound 8 to be
quite different from compound 11. Its d-isomer (compound 10) is
approximately 5-10 times more potent than the l-isomer (compound 9,
LY150342) as an analgesic. However, receptor binding measures,
table 2, show compound 10 to have only twice the affinity for opiate
receptors and suggest that compound 10 has higher relative intrinsic
activity.
TABLE 2
FIGURE 2
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Although compound 9 fails to block the analgesic effects of mor-
phine, its partial agonist activity has been demonstrated by its
ability to precipitate withdrawal in morphine-dependent monkeys
(Aceto et al., 1980) and rats, its failure to suppress withdrawal
symptoms in morphine-dependent monkeys (Woods et al., 1980; Aceto
et al., 1980), and its relatively small effect on mouse locomotor
activity. In addition, respiratory depression studies in conscious
rats show compound 9 to have a reduced depressant effect.
The agonist and antagonist measures and affinity values for com-
pounds 14, 15 and 16 are given in tables 1 and 2. These data and
published reports on compounds 14, 15 and 16 (Ong et al., 1974)
show the cis-4 -phenyl-2-pyrindines and the 5-phenyl-2-
methylmorphans to have similar pharmacological profiles.
In an attempt to more closely establish the structure-activity rela-
tion of the 3,4-dialkyl-4-phenylpiperidines with the 4 -phenyl-2-
pyrindine series, the synthesis of the cis-9-methyl-4 -phenyl-2-
pyrindine (compound 17) was undertaken.
As shown in table 1, compound 17 was found to be a relatively pure
narcotic antagonist, in striking contrast to the potent agonist ac-
tivity of its des-9-methyl analog, compound 8. Table 2 shows both
compounds 8 and 17 to have comparable opiate receptor affinities,
indicating that g-methyl substitution gives a compound with reduced
intrinsic opiate receptor activity. The effect of 9-methyl substi-
tution on compound 8 is highly comparable to the effect of 3-methyl
substitution on the 4-alkyl-4-phenylpiperidines and infers a strong
similarity of action between the two series at the opiate receptor.
CONCLUSIONS
The effect of 3-methyl substitution in the 4-alkyl-4-phenyl-piperi-
dine series has been shown to be primarily related to a loss of
intrinsic activity rather than affinity at the opiate receptor and,
as seen with LY150720, this effect can be highly stereospecific.
Comparisons of the 1,3,4-trimethyl- with the 1,3,4,6-tetramethyl-4-
phenylpiperidines suggest that this loss of intrinsic activity, and
resulting narcotic antagonist activity, is mediated through an equa-
torial-phenyl conformational binding mode. Furthermore, the pharma-
cological changes arising from 2-methyl substitution in the 1,3,4,6-
tetramethyl-4-phenylpiperidines appear to be the result of a change
induced in the conformational binding mode by steric interactions.
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The cis-phenylpyrindines, like the 1,3,4-trialkyl-4-phenyl-piperi-
dines and the 2-methylphenylmorphans, appear to bind to the opiate
receptor and exert their pharmacological actions in the equatorial-
phenyl binding mode. Consequently, factors affecting receptor
affinity and intrinsic activity in these series are related.
These results further substantiate the existence and importance of
at least two distinct bind ing modes at the opiate receptor
postulated by Portoghese (1965). In the equatorial-phenyl binding
mode the 3 position of the piperidine has been characterized as a
stereospecific site that alters intrinsic activity, producing
antagonist activity.
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Preclinical Pharmacology of Lilly
Compound LY150720, A Unique
4-Phenylpiperidine Analgesic
M. D. Hynes, S. E. Smits, B. E. Cantrell, R. Nickander, and
D. M. Zimmerman
The idea of using a mixture of morphine and nalorphine for the
relief of pain with the hope of minimizing the side effects associ-
ated with morphine was explored more than 25 years ago. Adverse
effects associated with nalorphine precluded clinical utility.
However, the concept that a mixture of a morphine-like agonist and
a nalorphine-like antagonist would be a useful analgesic had
considerable merit which warranted further investigation.
An agent with such properties is Lilly compound LY150720, a racemic
mixture of a d-optical isomer with potent morphine-like agonist
activity and an l-optical isomer exhibiting nalorphine-like activ-
ity. LY150720 is an N-methyl-4-phenylpiperidine derivative, a
unique structure for a narcotic with agonist-antagonist properties
It is a member of a series of 1,3,4-trialkyl-4-phenylpiperidines,
the discovery of which led to the definition of a new class of
narcotic antagonists (Zimmerman and Nickander 1977; Zimmerman et
al. 1978a, 1978b). This paper reports the results of the
preclinical studies with LY150720 and its stereoisomers.
MATERIALS AND METHODS
Mouse Writhing Analgesic Test. The writhing response was deter-
mined for each of 5 mice observed simultaneously beginning 5 min
after the injection of a 0.6 percent solution of acetic acid as
previously described (Nickander et al. 1977).
Rat Tail Jerk Analgesic Test. The tail of the rat was held near a
nichrome resistance wire which was heated by the passage of a 6.5
amp current (AC). Radiant heat from the wire becomes aversive to a
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normal rat within 6 to 7 sec, at which time the rat attempts to jerk
away from the heat source (Nickander et al. 1977; Robbins, 1955).
Narcotic Antagonist Measurement in Mice. The ability of a test
compound to reduce morphine-induced (46 mg/kg) Straub tail reaction
and increase in motor activity was determined. The presence or
absence of these behaviors was scored. When both signs were present
a score of 2 was assigned, whereas mice showing one or the other
were scored 1, and those showing neither sign received a score of 0.
Narcotic Antagonist Measurement in Rats. The ability of the test
compound to antagonize the analgesic effect of morphine was measured
in the rat tail heat analgesic test as described above. The stimu-
lus intensity was increased to 7 amp, which enhances the likelihood
of detecting morphine antagonism (Zimmerman and Nickander 1977).
Mouse Locomotor Activity. Mouse locomotor activity was measured in
circular wire mesh cages 2 inches high and 11 inches in diameter.
Two mice were placed in each cage and allowed to acclimatize for one
hour before being injected subcutaneously. One count was registered
each time the light beam passing through the center of the cage was
interrupted. The total number of counts was recorded for a 4-hour
period following injection.
Single Dose Suppression of Spontaneous Withdrawal in Morphine-
Dependent Rats. Rats were made dependent by administration of
increasing doses of morphine. Withdrawal signs including diarrhea
ptosis, jumping and body shakes, were observed 16 to 20 hours after'
the last morphine injection.
Respiratory Depressant Measures in Conscious Rats. Experiments were
conducted on rats fitted with permanently-indwelling arterial cathe-
ters. On the day of the test blood was drawn anaerobically from
this catheter and blood gas values determined. Rat arterial blood
samples were analyzed on an Instrumentation Laboratory 513 pH/Blood
Gas Analyzer that measured pH, pCO2 and pO2 directly (Smits et
al. 1981).
Affinity for Opiate Receptors in Rat Brain Homogenates. Interaction
of test compounds with ooiate receptors of freshlv prepared rat
brain homogenate was measured by assaying the. displacement of 0.25
µM 3H-naloxone (50 Ci/mmole. New England Nuclear) or 0.75 µM 3H -
D-Ala-D-Leu-enkephalin (31 Ci/µmole, Amersham). Following incuba-
tion, the samples were filtered through Whatman glass fiber filters
(GF/C) and washed twice with buffer. Filters were subsequently
placed in vials and, after adding 10 ml of Phase Combining System
(Amersham), counted by liquid scintillation spectrophotometry.
RESULTS
Mouse Writhing Analgesic Test. Compound LY150720 inhibited acetic
acid-induced writhinq in mice following both oral and subcutaneous
administration. The-ED50 values are presented in reference to
standard narcotic analgesics in Table I. Following-subcutaneous
administration, compound LY150720 was twice as active as meperidine,
equivalent to pentazocine and about 1/4 as potent as morphine.
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Comparison of writhing inhibition following oral administration
showed that compound LY150720 was more active than pentazocine,
equivalent to meperidine and less active than morphine. The anal-
gesic effects of LY150720 in the writhing test were blocked by the
narcotic antagonist naloxone.
TABLE 1
Analgesic Activity of LY150720 in the Mouse Writhing Test
Inhibition of Mouse Writhinga
ED50 (95 Percent Confidence Limits)
Treatment Subcutaneous Oral
LY150720 2.4 (1.8 - 3.2) 18.0 (15.0 - 23.0)
Morphine 4.4 ( 3.6 - 5.3)
Meperidine
0.5 (0.3-0.8)
4.9 (4.2-5.9) 15.8 (11.5 - 21.7)
Pentazocine 2.0 (1.4-2.9) 46.0 (38.0 - 56.0)
a. The mouse writhing ED50 values are expressed in mg/kg.
The two optical isomers of compound LY150720 were examined for their
analgesic activity in the mouse writhing assay. Following subcutan-
eous administration, the d-isomer, compound LY97435, dose dependent-
ly inhibited writhing and-was calculated to have an ED50 value of
0.76 (0.56-1.0) mg/kg. The l-isomer, compound LY97436, also inhibited
writhing, but had an ED50 value of 8.1 (5.1-13) mg/kg, which is 10
times that observed for the d-isomer.
Rat Tail Jerk Analgesic Test.
Dose response data for com
pound LY150720 in the rat
tail jerk test following sub-
cutaneous administration are
shown in Figure 1. Compound
LY150720 produced a dose-
related analgesia in rats as
evidenced by a prolongation
of rat tail jerk reaction
times. A comparison of the
dose-response curves for
morphine, meperidine and
LY150720 indicated some dif-
ferences. For example, the
dose response for morphine
had a steep slope which
reached the cut-off time of
15 seconds at a 10 mg/kg
dose. At the lower end of
the dose response curve,
FIGURE 1.
Analgesic activity of LY150720
in the rat tail jerk analgesic
test
Subcutaneous Dose
(mg/kg)
compound LY150720 was approximately half as potent as morphine and
equipotent with meperidine. However, beginning at about 20 mg/kg,
there was only a slight increase in effect with larger doses of
LY150720. The effect of compound LY150720 was still slightly below
the cut-off value at doses as high as 50 mg/kg.
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The optical isomers of LY150720 were also examined for analgesic
activity after subcutaneous administration in the rat tail jerk
test. The d-isomer was comparable with morphine in potency, shape
of the dose-response curve, and duration, whereas the l-isomer
exhibited little if any effect even at very high doses. These
results suggest that the analgesic activity of the racemate resides
in the d-optical isomer. The l-isomer appears to limit the
analgesia of the d-isomer when the racemate is given, suggesting
that the l-isomer may have some narcotic antagonist properties.
Narcotic Antagonist Measures in Mice. The ability of compound
LY150720 and its l-isomer, compound 97436, to block the morphine-
induced Straub tail reaction and increased locomotor activity in
mice was determined in comparison to nalorphine and pentazocine.
All four agents produced a dose-related antagonism of the above
effects of morphine. The dose of nalorphine that caused a 50
percent antagonism of these effects (AD50) was calculated to be 0.46
mg/kg. Correspondingly, AD50 values for LY97436, pentazocine and
LY150720 were 5.9, 19 and 45 mg/kg, respectively. Thus, the
l-isomer of LY150720 was approximately 1/10 as potent as nalorphine
and slightly greater than 3 times more potent than pentazocine in
blocking the narcotic effects of morphine. Compound LY150720
exhibited weak morphine antagonist activity in this test in that
greater than 70 percent antagonism was not achieved. Morphine
antagonism is much easier to demonstrate for the l-isomer alone
than when the d-isomer is present, as is the case with the racemate.
Narcotic Antagonist Measures in Rats. Dose response data for the
antagonism of morphine by compounds LY150720 and LY97436 in the rat
tail jerk test were then generated. The pretreatment times were 30
min for compound LY97436 and 180 min for compound LY150720, the
time of peak antagonist activity for each compound. Morphine
analgesia was effectively antagonized by both compounds in a
dose-dependent manner. The AD50 (95 percent confidence limits)
values were 4.4 (2.6-7.4) mg/kg for compound LY97436 and 41 (18-91)
mg/kg for compound LY150720.
Mouse Locomotor Activity. Morphine
is well known for its ability to
dose-dependently stimulate locomotor
activity in mice as can be seen from
the data depicted in Figure 2. In
contrast to morphine, LY150720 pro-
duced dose-related increases in
locomotor activity from 4 to 16
mg/kg, while the effects following
doses of 16 and 32 mg/kg were sim-
ilar. Thus, the maximum degree of
stimulation obtainable with
LY150720 appears to be similar to
that seen with a morphine dose of
between 4 and 8 mg/kg. The results
for the two optical isomers are also
given in Figure 2. There was a
dose-related increase in activity
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when the d-isomer, compound LY97435, was administered. As can be
seen from-this figure the effect of a 32 mg/kg dose was only
slightly less than that observed with morphine at the same dose.
Thus, the d-isomer appears to be a morphine-like agonist in this
procedure. In marked contrast to these results, the 32 mg/kg dose
of the l-isomer was without effect on activity levels in mice.
This marked difference in the effect of the two isomers provides an
explanation for the plateau in effect observed with the racemate.
Single Dose Suppression of Spontaneous Withdrawal in Morphine-
Dependent Rats. Morphine, meperidine and LY150720 were investi-
gated for their ability to suppress the signs of spontaneous with-
drawal in morphine-dependent rats. Morphine and meperidine produced
a dose-related suppression of withdrawal and were calculated to have
ED50 values of 4.9 and 17.3 mg/kg, respectively. In marked con-
trast, compound LY150720 did not suppress withdrawal at doses as
high as 64 mg/kg. At the lowest dose tested, 0.5 mg/kg, there was a
significant increase in the severity of withdrawal. These data
clearly distinguish compound LY150720 from the standard narcotic
agonists, such as morphine and meperidine, and suggest a low abuse
potential.
Respiratory Depressant Measures in FIGURE 3.
Conscious Rats. Morphine and Changes in arterial blood
LY150720 were compared for their gases followinq LY150720 or
ability to produce respiratory morphine administration
depression in conscious rats.
The respiratory depressant effects
of LY150720 as measured by arter-
ial blood pCO2, pO2 and pH are
shown in Figure 3 in reference to
those produced by morphine. Sub-
cutaneous administration of
LY150720 or morphine to conscious
rats depressed respiratory func-
tion, as indicated by the decrease
in arterial blood pO2. The
depressant effects of morphine
increased in a dose-dependent
manner from 4 to 64 mg/kg, whereas
administration of compound LY150720
in doses of 4 and 16 mg/kg pro-
duced a dose-related respiratory
depression. However, the adminis-
tration of compound LY150720 at
doses greater than 32 mg/kg only
slightly decreased blood pO2, pro-
ducing a maximum achievable effect
for LY150720 equivalent to that of
approximately 16 mg/kg morphine. Changes in pCO2 and pH were
consistent with those seen for arterial blood pO2. These data
suggest that respiratory depression in man could be less of a
problem with LY150720 than with morphine.
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Affinity of LYl50720 and its Isomers for In Vitro Opiate Receptors
Labeled with [3 H]-Naloxone and [H]-D-Ala-D-Leu-Enkephalin. The3
data summarized in Table 2 show the IC50 values for LYl50720 and its
optical isomers for inhibiting 3H-naloxone and 3H-D-Ala-D-Leu-
enkephalin binding in rat brain homogenates. These IC50 values were
then compared to give a µ/8 ratio. As expected, morphine and fen-
tanyl were found to exhibit a marked preference for the µ receptor.
Conversely, D-Ala-D-Leu-enkephalin was found to have a higher affin-
ity for the delta site as indicated by 3H-D-Ala-D-Leu-enkephalin
displacement. Compound LYl50720 was found to hav good affinity for
both receptors, with a slight preference for the  3H-naloxone site.
The ratio was calculated to be 0.6, which is almost 10-fold
greater than observed for morphine. Compound LY97435 was found to
have equal affinity for the 3H-naloxone and 3H-D-Ala-O-Leu-
enkephalin site. Although its affinity at the site was not as
great as that observed for D-Ala-D-Leu-enkephalin it had a signifi-
cantly higher affinity for this site than either morphine or fen-
tanyl. In fact the activity of the d-isomer was 16 times greater
than that observed for morphine and 40 times that for fentanyl. The
l-isomer also exhibited good affinity for the D-Ala-D-Leu-enkephalin
site, but not as good as that seen for the d-isomer.
TABLE 2
Affinity of LYl50720 and its Isomers for Opioid Receptors
a. The data present the concentration (nM) of each compound
inhibiting the stereospecific binding by half.
DISCUSSION
Good analgesic activity was observed in rodent assays following
administration of the structurally unique partial opiate agonist
LYl50720. Pharmacological evaluation of the two optical isomers of
this racemate revealed that the d-isomer, compound LY97435, was a
potent morphine-like narcotic agonist, whereas the l-isomer, COm
pound LY97436, was a partial opiate agonist. Apparently the antag-
onist activity of the l-isomer limits the extent to which the
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d-isomer can exert its narcotic character when the racemate,
LY150720, is administered. Acute toxicity determinations in rodents
indicated a good margin of safety which was supported by the
limited depression of respiration produced by LYl50720.
The fact that LYl50720 did not suppress morphine withdrawal in
rodents distinguishes it from standard narcotic agonists and sug-
gests a low liability for abuse (Zimmerman et al., 1978b). This
contention is supported by studies in monkeys conducted under the
auspices of the Committee on Problems of Drug Dependence. In
single-dose suppression studies in morphine-dependent rhesus monkeys
undergoing spontaneous withdrawal, LYl50720 caused only mild CNS
depression at doses up to 40 mg/kg and did not suppress or precipi-
tate morphine abstinence. Primary dependence studies in monkeys
revealed an abstinence syndrome of mild to moderate severity
following chronic LYl50720 administration which was not typical of
morphine or related opioids (Aceto et al. 1981; Woods et al. 1981).
from other partial agonists.
The good therapeutic index of LYl50720 in rodents, coupled with its
unique binding properties and low physical dependence liability,
suggests that it mav have a clinical profile distinctly different
REFERENCES
Aceto, M. D., Harris, L. W., Dewey, W. L. and May, E. L. Committee
on Problems of Drug Dependence 1980. In: NIDA Research
Monograph 34, (ed. L. S. Harris), p. 297, 1981.
Nickander, R., Smits, S. and Steinberg, M. J Pharmacol Exp Ther
200:245, 1977.
Robbins, E. B. J Am Pharm Assoc 44:497, 1955.
Smits, S. E., Nickander, R Booher, R. N., Zimmerman, D. M., Wong,
D. T., Hynes. M. D. and pohland, A. Committee on Problems of
Drug Dependence 1980. In: NIDA Research Monograph 34 (ed. L.
S. Harris), p. 75, 1981.
Woods, J. H., Medzihradsky, F., Smith, C. B., Young, A. M. and
Swain, H. H. Committee on Problem; of Drug Dependence 1980.
In: NIOA Research Monograph 34 (ed. L. S. Harris), p. 327, 1981.
Zimnerman, 0. M. and Nickander, R. Proc 39th Ann Mtg, Committee
on Problems of Drug Dependence, 1977.
Zimmerman, D. M. and Nickander, R., Horng. J. S. and Wong, D. T.
Nature 275:332, 1978a.
Zimmerman, 0. M., Smits, S. and Nickander, R. Proc 40th Ann Mtg
Committee on Problems of Drug Dependence, 1978b.
AUTHORS
M. D. Hynes, S. E. Smits, B. E. Cantrell, R. Nickander and D. M.
Zimmerman, Lilly Research Laboratories, Eli Lilly and Company, 307
East McCarty Street, Indianapolis, Indiana 46285
125
A Structure Activity Relationship
Study of the Cyclohexyl and Aro-
matic Rings of Phencyclidine (PCP)
Edward Cone, Harlan Shannon, Bruce Vaupel, Tsung-Ping
Su, and Roy McQuinn
The pharmacology of PCP has been studied extensively; however,
the mechanism of action at the molecular level remains poorly
understood. We have undertaken studies on PCP directed toward
defining the structural requirements for pharmacological activ-
ty. A consideration of the PCP molecule reveals that it is a
semirigid structure consisting of a cyclohexane ring (C) gemi-
nally substituted with an aromatic ring (A, benzene) and a basic
ring (B, piperidine).
symbol,
It can be conveniently represented by the
The unique pharmacology of this compound has
already engendered several structure activity studies (Maddox et
al., 1965; Kalir et al., 1969; Geneste et al., 1979; Kalir et
al., 1978). The focus of these studies has been the substitu-
tion of various functional groups for the A, B and C rings, with
the majority of new compounds representing A or B substitutions:
groups that are believed to be mainly responsible for PCP’s ac-
tivity.
We directed our studies to an examination of the pharmacologic
importance of the C ring of PCP and to alterations of electronic
and spatial relationships of the A and B rings. Since the
steric relationship between the A and B rings is determined by
the size of the cycloalkane ring (C), the systematic alteration
of the size of ring C would result in predictable changes in the
distance between rings A and B (see table 1). Alteration of the
distance between A and B also could be accomplished by “inser-
tion” of methylene linkages [-(CH2 )n-] between rings A and
C. A third structural change considered was the enlargement of
the aromatic ring system of A, thereby extending conjugation and
altering the electronic profile of the A ring and, consequently,
the entire molecule.
This report describes the synthesis and pharmacological activity
of two series of PCP derivatives (see figure 1). In Series 1,
the size of the C ring was varied from C3 (cyclopropyl) to C8
(cyclooctyl). In Series 2, compounds were prepared which repre-
sent methylene “insertions” between the A and C rings. Other
members of the latter series were prepared which represent
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FIGURE 1
Figure 1. Structures of phencyclidine derivatives
simple substitution of the A ring by napthyl groups. Pharmaco-
logical activities of these compounds were measured by the rat
discriminative stimulus and the mouse rotarod assay. In vitro
testing was performed with the 3H-PCP binding assay.
METHODS
Syntheses of Phencyclidine Derivatives
The procedures for the preparation of PCP derivatives by Kalir
et al. (1969) was used with appropriate modifications for the
syntheses of 4-PCP, 5-PCP, 7-PCP, 1-NCP, 2-NCP, PMCP, PECP and
PPCP. BZP was made in good yield by refluxing benzylamine in
the presence of 1,5-dibromopentane and potassium carbonate in
dimethylformamide. 3-PCP was prepared by the method of Kaiser
et al. (1962). 8-PCP was synthesized by a modification of the
method of Geneste et al. (1979) for the preparation of PCP
derivatives. The structure and purity of all compounds were
confirmed by elemental analyses, thin-layer chromatography, mass
spectrometry and nuclear magnetic resonance.
Discriminative Stimulus Assay
Male, Fischer-derived CDF rats were trained to discriminate be-
tween PCP and saline in a two choice, discrete-trial avoidance
task similar to that described in detail elsewhere (Jasinski et
al., 1980). Pupil diameter was measured photographically with a
Polaroid CU5 close-up camera. The pupils were photographed im-
mediately before the rats were injected (control) and again im-
mediately before the start of the test session 30 min later.
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Table  1
Effect of cycloalkyl ring size on the bond angle and interatonic
distance between the nitrogen atom (N13) and the C1 carbon of
the benzene ring in phencyclidine derivatives.
a The angle for compounds where n = 6,7 was assumed to be equal
to that of phencyclidine. For compounds where n = 2,3,4 the angle
was obtained from Coulson and Moffitt, Phil. Mag. 40, 1 (1949).
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3H-PCP Binding Assay
The binding assay was performed as described by Zukin and Zukin
(1979) with the exception that the glass fibre filter was pre-
treated with water saturated with t-amyl alcohol to reduce non-
specific binding.
Mouse Rotarod Test
Relative potencies of PCP-like compounds and their precursors
were determined in male ICR Swiss mice by measuring ataxia using
the rotarod method of Dunham and Miya (1957). Each mouse was
tested sequentially at 6-min intervals for 1 hr after injection
according to the modification of Kalir et al. (1969).
RESULTS
Two series of phencyclidine derivatives were synthesized and
characterized by standard chemical and physical means. The
structures of these compounds are illustrated in figure 1. All
were tested in the rat discriminative stimulus (DS) assay and
the 3H-PCP binding assay. Activities of the Series 1 com-
pounds also were measured in the mouse rotarod (RR) assay. The
results are shown in table 2.
In the rat DS assay, rats were trained in a two-choice discrete-
trial avoidance procedure to discriminate between saline and 3.0
mg/kg of PCP administered intraperitoneally 30 min before the
start of the session. PCP produced dose-related increases in
the percentages of trials completed on the PCP-appropriate
choice lever. 4-PCP, 5-PCP and 7-PCP also were effective in
producing at least 90 percent PCP-appropriate choice responding,
although they were much less potent. The remainder of the com-
pounds of Series 1 and 2 were inactive up to the highest dose
tested (table 2). Pupillary miosis was observed for PCP, but
the remainder of the compounds produced mydriasis or no change.
In the 3H-PCP binding assay, PCP was the most potent of the
Series 1 compounds followed by 8-PCP with a relative potency
(RP) of 0.72 (PCP = 1.0). There were only slight differences in
binding for the other members of this series. In the Series 2
compounds, conversion of the aromatic ring (A) to that of a
napthyl group reduced relative potency by one-fifth (2-NCP) and
by one-half (1-NCP). For the methylene “insertion” compounds,
binding affinity rose dramatically from the weakly binding PMCP’
(RP = 0.24) to PPCP (RP = 1.35) with PECP (RP = 0.52) exhibiting
intermediate activity.
The Series 1 compounds were tested in the mouse rotarod assay
for impairment of gross motor performance. Although all com-
pounds were active (with the exception of 8-PCP which was too
toxic to obtain a dose response curve), valid bioassays using
PCP as the standard were obtained only for 3-PCP, 4-PCP and
BZP. All compounds were less active than PCP.
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TABLE 2
Pharmacological activities of phencyclidine derivatives
a Values represent relative potencies where the number listed
indicates the number of µM of PCP equivalent to 1 µM of the
compound. Numbers in parentheses represent the 95% confidence
limits or, if the compound was inactive (IA), represent the
highest dose tested. NT = not tested.
bThe IC50 of unlabeled PCP was 270 nM.
c A parallel line bioassay was not obtained.
dThis compound was too toxic (seizures) to obtain a
dose-response curve.
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DISCUSSION
The geometric and electronic similarity of PCP to acetylcholine
has been proposed as an explanation of PCP’s in vitro activity
(Kalir et al., 1978). The positive charge on the protonated
nitrogen (B ring) is said to mimic the trimethyl ammonium group
and the region of high electron density (aromatic ring, A)
mimics the ester oxygen of acetylcholine. Overlap of these
groups is readily apparent by inspection of Dreiding models and
it has been emphasized that the distances between the positive
charge (nitrogen) and the region of high electron density (ben-
zene) is a critical factor for overlap (Weinstein et al.,
1973). Deviations from this critical distance should presumably
prevent overlap and binding with the cholinergic receptor.
Clearly, the cyclohexyl ring (C) offers rigidity to the PCP
molecule and also determines the distance between rings A and B
by nature of its SP3 hybrid bonding orbitals. By reducing the
size of the C ring in a stepwise fashion, the distance between
rings A and C should increase from 2.518 A for PCP as measured
between N13 and C7, table 1) to a maximum of 2.623 A for 3-PCP
as a result of the required changes in bonding orbitals for
smaller ring systems. The effect of this stepwise decrease in
the size of ring C was to decrease both in vivo activity (rat DS
assay and mouse RR assay) and in vitro activity (3 H-PCP bind-
ing assay).
Alternate molecular changes were also made to increase the size
of ring C to seven- and eight- membered rings. For these com-
pounds, it is presumed that the bonding orbitals would remain
equivalent to those of PCP with the distances between rings A
and B also being equal. Despite these predictions, their activ-
ities were greatly reduced or completely abolished. Also,
severe toxicity became the limiting factor in testing 8-PCP in
the mouse RR assay. It is obvious from these data that the cy-
cloalkyl ring serves more pharmacological purpose than providing
rigidity and defining the spatial relationship between rings A
and B. It appears likely that the cyclohexyl ring (C) plays an
integral role in the activity of PCP, serving not only as the
main steric determinant in the molecule, but also as a hydro-
phobic attachment site. This view is supported by the lack of
activity of BZP, a compound which lacks the C ring but possesses
both A and B rings needed for overlap with acetylcholine.
The lack of activity of 1-NCP and Z-NCP in the rat DS assay in-
dicates that the potential for overlap with acetylcholine does
not necessitate the appearance of PCP-like activity. These com-
pounds have similar molecular features with PCP, the only change
being in the size and electronic properties of the aromatic ring
(A). It is possible that the napthyl groups would present
changes in the electrostatic potential pattern sufficient to
account for their lack of activity; however, this remains to be
determined. This would also serve to explain the lack of activ-
ity of the methylene “insertion” compounds in the rat DS assay.
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There was good correspondence between the in vivo activity-meas-
ures (rat DS assay and mouse RR assay) and the in vitro 3H-PCP
binding assay within the Series 1 cycloalkyl. compounds. There
was, however, a complete lack of agreement between the results
of the rat DS assay and the 3H-PCP binding assay for the
Series 2 compounds. There are a number of possible explan tions
for the discrepancy between these assays. The original 3H-PCP
binding assay has been criticized for its high binding to the
glass fiber filter (Maayani and Weinstein, 1980). The assay
used in these studies is a modification of the original proce-
dure (Zukin and Zukin, 1979) by pretreatment of the filter with
t-amyl alcohol, a step which reduces binding to the filter but
does not eliminate it. Consequently, the relative potencies of
these compounds could be distorted by high background. Another
possible explanation for these discrepancies would be an antago-
nistic component for the Series 2 compounds, in which case they
would show high binding affinities and low in vivo activities.
This, however, appears not to be the case basis of pre-
liminary experiments in which the impairment of gross motor per-
formance induced by PCP was not reversed by these co ounds. An
alternate and possibly more viable explanation would that the
binding of PCP derivatives encompasses a wider range of poten-
tial pharmacological effects than those elicited by PCP alone.
Some credence is given to this proposal by the obvious overlap
of effects elicited by the Series 1 compounds, 4-, 5- and 7-PCP,
with PCP in the rat DS assay, but with divergent pupillary
effects. A lack of parallelism with PCP in the dose response
curve also was seen with the 5- and 7-PCP compounds in the mouse
RR assay. Other potential explanations of the differences in
the in vivo and in vitro results include possible differences in
rates of metabolism, distribution and excretion.
In summary, the requirements for PCP-like activity a pear to
necessitate the inclusion of a cyclohexyl ring (ring C) in new
derivatives. Although relative potency measures were obtained
for other compounds without this structural feature, a lack of
correspondence in other pharmacological measures was evident.
For compounds in which the phenyl ring (A) was spatially located
further away Erom the cyclohexyl ring by methylene “insertion”
and those compounds in which a napthyl group was substituted for
the A ring, a complete lack of PCP-like activity was found by
the rat DS assay, but moderate to high activity was seen in the
3H-PCP binding assay.
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The Effects of Centrally Acting Pep-
tides on the Chronic Actions of
Buprenorphine in the Rat
Hemendra N. Bhargava, Ph.D.
INTRODUCTION
Buprenorphine is a potent analgesic dry with rapid onset and long
duration of action (Cowan et al., 1977a). This drug belongs to mixed
opiate agonist-antagonist analgesic. It also possesses low physical
dependence liability (Cowan et al., 1977b; Jacob et al., 19791. A recent
report indicated that buprenorphine suppressed the self-administration
of heroin in heroin dependent subjects and it had an advantage over
methadone since its use did not result in opiate abstinence syndrome
following its termination (Mello and Mendelson, 1980).
In spite of its beneficial properties as a potent analgesic and as a
pharmacotherapeutic agent for the treatment of heroin addiction,
buprenorphine suffers from a major disadvantage, which is the develop
nent of tolerance to its analgesic action when administered
chronically (Cowan et al., 1977b). Previous studies from these
laboratories have indicated that certain hypothalamic peptide
hormones, like melanotropin release inhibiting factor (Pro-Leu-Gly-
NH2 MIF) and its analog cyclo (Leu-Gly), block the tolerance to
morphine in mice and rats (Bhargava, 1980; 1981a, b; Bhargava et al.,
1980) and to human ß-endorphin in the rat (Bhargava, 1981c,d).
Because of the importance of buprenorphine as a therapeutic agent, in
this report the effects of MIF and cyclo (Leu-Gly) on tolerance to
buprenorphine in the rat are described.
M E T H O D S
Male Sprague-Dawley rats weighing 150 to 200 g obtained from King
Animal Laboratories, Oregon, Wis., were used. The rats were
acclimated to the laboratory for at least 4 days prior to being used.
Food and water were continuously available.
MIF was obtained as a gift from the Abbott Laboratories, N. Chicago,
Illinois, through the courtesy of Dr. A.O. Geiszler. Cyclo (Leu-Gly)
was synthesized in these laboratories as described previously
(Bhargava, 1981b). Dr. A. Cowan of Temple University, Philadelphia,
kindly furnished a sample of buprenorphine. The peptides and
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buprenorphine were dissolved in distilled water and injected sub-
cutaneously in a volume of 1 ml/kg of body weight.
Induction and assessment of tolerance to buprenorphine
The tolerance to buprenorphine was induced in the rat by twice daily
injections of buprenorphine (0.5 mg/kg SC) for 4 days. The tolerance to
analgesic and hyperthermic effect of buprenorphine was assessed on day
5 by measuring the intensity of the two responses following a challenge
dose (0.5 mg/kg) of buprenorphine. The analgesic response was
measured by using a tail-flick apparatus as described previously
(Bhargava, 1981a). The tail-flick latencies to thermal stimulation were
determined prior to and at various times after buprenorphine injection.
The basal latencies were found to be 1.8 ± 0.1 sec (S.E.). A value of 10
sec. for the tail-flick reaction time was used as the cut-off point to
avoid damage to the tail. The analgesic reponse for each rat was
calculated according to the following formula.
% analgesia =
T-C
X 100,
10-C
were C and T represent the tail flick reaction times in seconds prior to
at a specified time after buprenorphine injection. The data are
expressed as mean % analgesic response  ± S.E.M.
The rectal temperature of each rat was measured prior to and at
various times after buprenorphine injection by using a rectal probe and
a telethermometer (Yellow Spring Instrument Co., Yellow Springs,
Ohio). The change in rectal tmeperature at each time interval was
calculated. The data are expressed as mean increases in rectal
temperature, °C ± S.E.M.
Effect of MIF and cyclo (Leu-Gly) on tolerance to buprenorphine
To study the effect of peptides on tolerance to buprenorphine, rats
were divided into three groups. The groups received injections of water
(vehicle), MIF (2 mg/kg) or CLG (2 mg/kg), respectively. Each
treatment group was further divided into two subgroups. One hour
after the water or peptide injection, rats in one subgroup received the
vehicle for buprenorphine (water) while those in the second subgroup
received buprenorphine (0.5 mg/kg). The injections of buprenorphine
and its vehicle were repeated in their respective groups in p.m. The
various treatments were repeated every day for 4 days. On day 5, all
the rats were injected with buprenorphine (0.5 mg/kg) and the analgesic
and therrnic responses were determined as described above.
Statistics
The differences in the means of various treatment groups were
analyzed by analysis of variance followed by Scheffe’s ‘S’ test. The
difference was considered significant when the p value was less than
0.05.
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RESULTS
Analgesic and thermic responses to buprenorphine
The administration of buprenorphine produced a dose-related analgesia
and hyperthermia in the rat. As shown in Figure 1 A, buprenorphine
0.25 mg/kg, produced 46.7% analgesia at 30 min, and this level of
analgesia was maintained for 90 min. Buprenorphine at 0.5 mg/kg dose
produced 100% analgesia for 90 min and for the next 90 min was
maintained at 45% level.
Figure 1 Effect of buprenorphine on the analgesic and thermic
response in the rat
136
The administration of buprenorphine produced a hyperthermic response
in the rat. As shown in Figure 1 B. The hyperthermia produced by 0.25
and 0.5 mg/kg doses lasted for more than three hours.
Effect of peptides on tolerance to buprenorphine
Based upon the initial studies, a dose of 0.5 mg/kg of buprenorphine was
selected for tolerance studies. Chronic administration of buprenorphine
(0.5 mg/kg SC twice a day for 4 days) resulted in the development of
tolerance to its analgesic effect. This tolerance was inhibited by daily
injections of MIF or cyclo (Leu-Gly). The administration of
buprenorphine (0.5 mg/kg) to rats treated chronically with water
(vehicle) produces 88.8, 77.8 and 34.3% analgesia at 30, 60 and 90,
respectively after its injection. This analgesic response was not
modified by daily injections of either MIF or cyclo (Lew Gly). In
contrast to 88.8% analgesia at 30 min after buprenorphine injection in
water-treated rats, only 14.1% analgesia was observed in rats treated
chronically with buprenorphine. The analgesia was practically absent
(1.5%) at 60 and 90 min after buprenorphine injection in buprenorphine-
tolerant rats. The administration of buprenorphine produced signifi-
cantly higher level of analgesia at each time interval in buprenorphine
tolerant rats which were given daily injections of MIF or cyclo (Leu-
Gly).
Chronic administration of buprenorphine also resulted in the develop-
ment of tolerance to its hyperthermic effect. As shown in Thirty min
after the buprenorphine (0.5 mg/kg) injections, the body temperature of
nontolerant rats rose by 1.76°C, whereas, in buprenorphine tolerant rats,
an increase of only 0.97° C was noted. Daily injections of MIF or cyclo
(Leu-Gly) did not alter the hyperthermic effect in buprenorphine naive
rats. However, the injections of peptides completely blocked the
tolerance to the hyperthermic effect of buprenorphine. The increase in
body temperature after buprenorphine (0.5 mg/kg) in buprenorphine-
naive and buprenorphine-tolerant rats injected with peptides did not
differ.
DISCUSSION
The present studies indicate that buprenorphine produces dose-
dependent analgesia and hyperthermia in the rat. Whereas, morphine
produced its peak analgesic effect at 30 min after administration
(Bhargava, 1980) and had short duration of action, buprenorphine (0.5
mg/kg) produced intense (100%) analgesic response for 90 min and a fair
degree of analgesia was maintained for a 3-hour observation period.
Similarly, the hyperthermic effect lasted for 3 hours. This suggests
that buprenorphine is a potent drug which has a long duration of action.
Chronic administration of buprenorphine resulted in the development of
tolerance to its analgesic and hyperthermic effects in the rat.
Tolerance to the analgesic effect has been reported in the mouse
previously (Cowan et al., 1977a). Although Cox et al., (1976) failed to
observe tolerance to the hyperthermic effect of opiate agonists, like
morphine, others have shown that tolerance does develop to the
hyperthermic effects of both the endogenous and the exogenous opiates
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(Huidobro-Toro and Way, 1980; Bhargava,l981 d,e). The present study
demonstrates that tolerance also develops to buprenorphine-induced
hyperthermia.
Daily administration of MIF or cyclo (Leu-Gly) inhibited the develop
ment of tolerance to both the analgesic and the hyperthermic effects of
buprenorphine.
The precise mechanism by which the peptides inhibit the development
of opiate-induced tolerance is not clear. It is possible that these
peptides are acting as narcotic antagonists since narcotic antagonists,
like naloxone and naltrexone, have been shown to prevent the develop
ment of narcotic tolerance and dependence (Mushlin and Cochin, 1976;
Bhargava, 1978; Huidobro-Toro and Way, 1980). Indeed MIF possesses
naloxone-like activity in some tests. For instance MIF antagonizes
morphine-induced analgesia; however, unlike naloxone, MIF was
inactive in reversing the Straub-tail reflex, or the inhibition of
electrically induced contraction of the vas deferens (Kastin  et al.,
1979).
Chronic administration of opiates induced supersensitivity of brain
dopamine receptors (Lal, 1975; Bhargava, 1980, 1981 a; Ritzmann et al.,
1979). The supersensitivity results from chronic depression of
dopaminergic transmission. The opiate-induced supersensitivity of
dopamine receptors is blocked by MIF and cyclo (Leu-Gly) (Bhargava,
1980, 1981; Ritzmann et al., 1979). The administration of bupre-
norphine elevates the forebrain homovanillic acid concentration which
suggests its interaction with dopaminergic neurons (Cowan et al., 1976).
Since MIF is known to potentiate the behavioral effects of l-dopa
(Huidobro-Toro et al., 1974), it is possible that inhibition of bupre-
norphine tolerance by MIF and cyclo (Leu-Gly) may involve central
dopaminergic systems.
In summary, the present studies indicate that the hypothalamic peptide
MIF and its analog cyclo (Leu-Gly) inhibit buprenorphine-induced
tolerance. Therefore these peptides may find use as adjuncts to the
pharmacotherapy of pain and narcotic addiction when buprenorphine or
other opiates are used.
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Interactions Between Tetrahy
drocannabinol (THC) and Morphine
in Rats
F. Cankat Tulunay, I. H. Ayhan, and S. B. Sparber
INTRODUCTION
Because of the possibility that narcotic analgesics and marijuana
my be used together in various doses and sequences, it is impor-
tant to study their interactions. Tolerance develops to several
of the effects of morphine and (-)trans- 9-tetrahydrocannabinol
(THC), the primary psychoactive constituent of marijuana (McMillan
et al., 1971; Jones et al., 1976; Tulunay et al., 1980, 1981; Uran
et al., 1980), in both man and animals. It has also been shown
that THC can produce tolerance and dependence within a few days
(Ulku et al., 1980; Uran et al., 1980; Tulunay et al., 1980,1981;
Kaymakcalan et al., 1977) and the irreversible long-acting nar-
cotic antagonist, chlornaltrexamine, effectively blocks develop-
ment of tolerance to and dependence upon THC in rats (Tulunay
et al., 1981).
In the present study, we have investigated the interactions
between THC and morphine on locomotor activity and autoshaped
behavior of rats during tolerant and dependent states.
MATERIAL AND METHODS
Male white rats (Ankara University Medical School strain) 150-200
g were used in locomotor activity studies. Male Holtzman rats,
initial body weight 325-345 g, were used in autoshape behavior
studies.
The locomotor activity of rats was counted by Animex activity
meter (Farad, Sweden). The locomotor activity of rats was
counted 2½ hr after THC or solvent, 45 min after morphine and 5
min after naloxone injections for 30 min.
In another series of experiments, mature male rats SD-Holtzman,
(Madison WI) were partially food deprived to 80 percent of their
free-feeding weights and conditioned to an operant autoshape
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response in a manner described in detail elsewhere (Hughes and
Sparber, 1978).
All subjects in this experiment were implanted with either mor-
phine rods (12.5 mg) or placebo rods and injected with either THC
or its solvent for several days prior to being injected with
naloxone to precipitate opiate-type withdrawal abstinence.
Specially prepared 75 mg morphine base pellets (two pellets/rat)
were implanted S.C. without ansthetics for locomotor activity
studies.
Except total latency times, square-root transformations were
applied to all parameters in order to decrease variability of
data to homogeneity of variances (total lever contact, total
lever press, total strip contact and locomotor activity). Total
latency time was evaluated as mean min ± SEM. The other figures
represent mean square root ± SEM. Student's t-test was used for
statistical comparisons and p value set to 0.05 for significance.
RESULTS
Motor Activity. As shown in table 1, acute treatment of animals
either by morphine (20 mg/kg) or THC (40 mg/kg) produced a signi-
ficant decrease in motor activity. When 5 mg/kg of naloxone was
injected 2½ hr after THC and 45 min after morphine, morphine-
induced decreased activity reversed canpletely, but THC-induced
depression reversed partially.
Solvent treatment (group I) did not produce any significant
changes during the experiment. On the second day of THC treat-
ment partial tolerance and on the third day complete tolerance
developed to the locomotor inhibitory action of THC. Naloxone
produced (group II/b) a significant depression in chronic THC-
treated animals and produced typical withdrawal symptoms (for
details, see Tulunay et al., 1980, 198l). On the fourth day of
treatment when animals were challenged with 20 mg/kg of morphine
(group II/a), motor activity was significantly depressed and this
depression was not significantly different than with the test
dose of morphine. In other words, there was no cross-tolerance
to morphine.
The test dose of morphine produced a significant depression in
rats and tolerance to this effect developed within four days.
When morphine-pelleted animals were challenged with naloxone,
motor activity increased significantly when compared to naloxone
(group I/b) controls and THC+naloxone (group II/b) groups. In
morphine-pelleted animals, partial cross-tolerance was observed
to the depressant action of THC (group III/c versus test dose
THC).
Results are summarized in table 2.
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a - p < 0.05 when compared with solvent group; b - p < 0.05 when
compared with THC and morphine groups.
TABLE 2
LOCOMOTOR ACTIVITY CHANGES DURING
TOLERANT AND DEPENDENT STATES
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TABLE 1
THE ACUTE EFFECTS OF THC AND MORPHINE ON LOCOMOTOR ACTIVITY
OF RATS AND THEIR INTERACTIONS WITH NALOXONE
TABLE 3
OPERANT BEHAVIOR RESULTS
Autoshape Behavior. After 3-8 sessions, all animals made maximum
correct lever contacts (20 times in 20 min). The injection of 5
mg/kg THC significantly lowered their lever contact, lever presses
and strip contacts and increased total latency time. On the
fifth day of the experiment (fifth dose of THC), tolerance devel-
oped to these effects. When chronic THC-treated animals were
challenged with naloxone, these parameters were again signifi-
cantly decreased; total latency increased.
when THC was injected into the morphine pelleted (MP) animals,
significant decreases in autoshaped responding and lever presses
were observed. After five injections of THC, partial tolerance
developed to these effects. On the fifth day of the experiment,
animals were challenged with naloxone and an obvious opiate-like
abstinence syndrome was observed. While lever contacts, lever
presses and strip contacts significantly decreased, total latency,
expectedly, increased. Results are summarized in table 3.
DISCUSSION
A number of papers have appeared in recent years describing the
interactions between THC and opiate agonists and/or angatonists.
For example, THC has been shown to potentiate morphine-induced
Straub tail reaction and hyperactivity in mice (Buxbaum et al.,
1972; Ayhan et al., 1979; Ulku et al., 1980) and analgesia in
rats and mice (Buxbaum et al., 1972; Kaymakcalan and Deneau,
1972). Narcotic antagonists have been found to be effective in
blocking some pharmacological actions of THC or other cannabin-
oids such as analgesia, hypothermia, increase in the synthesis of
catecholamines and development of tolerance to the analgesic and
hypothermic effects and dependence on THC. As with morphine,
tolerance also develops to the effects of THC (Uran et al., 1980;
Tulunay et al., 1981). Moreover, THC has been shown to produce
an attenuation of naloxone-precipitated abstinence in morphine-
dependent rats (Hine et al., 1975). In addition, naloxone has
also been found to precipitate an abstinence syndrome in THC
tolerant-dependent rats (Kaymakcalan et al:, 1977; Tulunay et al.,
1980, 1981); Recently, Tulunay et al. (1981) have shown that
chlornaltrexamine, a selective, irreversible opiate antagonist,
inhibits THC-induced analgesia, hypothermia, hypothermic toler-
ance and dependence in rats. These studies suggest there may be
sane common receptor mechanism for THC and opiates for certain
effects of both drugs such as analgesia. On the other hand, some
effects develop in the opposite direction. In the same strain of
rats it has been found that THC always produces hypothermia (0.6-
40 mg/kg) while morphine produces hyperthermia (2.5-160 mg/kg)
(Tulunay, 1980; Uran et al., 1980). Another difference found in
this experiment was that there is increased motor activity during
morphine withdrawal while there is decreased motor activity in
THC withdrawal.
Several aspects of our results deserve special consideration.
First, THC can produce opiate-like physical dependence within a
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short time in rats which is detectable with naloxone. Second,
cross-tolerance develops to the locomotor depressive action of
THC in morphine tolerant rats but not to morphine in THC-tolerant
rats. Third, even very small doses of morphine potentiate the
development of dependence in chronic THC-treated rats. Fourth,
naloxone effectively antagonizes the depressant actions of both
drugs in acute experiments. The possible relationship of these
interactions with the enkephalin/endorphin systems should be
considered.
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Guinea Pig Ileum
Interaction of Ca++ With. Normor-
phine and ß-Endorphin on the
J. Pablo Huidobro-Toro, Ph.D., J. Hu, M.D., and E. Leong
Way, Ph.D.
Considerable evidence indicates that calcium may have an important
biochemical role in the actions of morphine and its surrogates.
In vitro, only a few attempts have been carried out to characterize
the pharmacologic interactions between calcium and the opiates. In
the guinea pig ileum, the classical in vitro preparation for stu-
dies on opiate action (Paton, 1957; Schaumann, 1957), it has been
well documented that the ability of opiates to inhibit the twitch
caused by electrical stimulation of the ileum correlates well with
antinociceptive potency (Kosterlitz and Waterfield, 1975). However,
the effect of Ca++ on this opiate inhibitory response has scarcely
been studied. Our laboratory (Hu et al., 1980) and Opmeer and van
Ree (1979) in a short communication stated that Ca++ produced com-
petitive antagonism of the morphine effects on the guinea pig ileum.
More recently, Opmeer and van Bee (1980) reported that modifica-
tions in the external calcium concentrations altered the sensiti-
vity to the opiate-like inhibitory response produced by high fre-
quency of electrical stimulation. However, these findings are not
consistent with the studies on opiate binding where divalent cations
have been reported to increase the binding of opiate agonists.
Since calcium, magnesium, nickel and especially manganese increased
the binding of opiates to brain membranes (Pasternak et al., 1975)
or to membrane preparations derived from neuroblastoma x glioma
hybrid cells (Blume, 1978) one might infer that these cations
should enhance opiate action. These inconsistencies prompted a
detailed examination of the interaction of normorphine and B-endor-
phin with calcium on the isolated preparation of the guinea pig
ileum.
EXPERIMENTAL PROCEDURES
Chemicals
Nonmorphine sulfamate was generously supplied by Dr. E.L. May from
the National Institutes of Health. Acetylcholine, choline chloride,
noradrenaline and adrenaline bitartrate, adenosine diphosphate so-
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dium salt, were purchased from Sigma Chemical Co. B-Endorphin was
a generous gift of Professor C.H. Li (UCSF).
Bioassay preparation
The longitudinal muscle myenteric plexus preparation of the
guinea pig ilea was dissected according to Puig et al., (1978).
The tissues were maintained on a modified Ringer solution as de-
tailed by Huidobro-Toro et al. (1981). Segments of about one
inch in length wer mounted in a 10-ml organ bath containing Rin-
ger solution at 37°C and bubbled with a mixture of 95% O2 and 5%
CO2 isometric muscular contractions were registered by means
of a force displacement transducer (model FT 03C) coupled to a
Grass polygraph recorder. Intestinal strips were stimulated elec-
trically through two ring platinum electrodes with supramaximal
pulses (80 volts, 5 msec duration) at a frequency of 0.1 Hz.
Quantification of the response to acetylcholine and to opiate
Before electrical stimulation was initiated, each preparation was
challenged with 15 nM acetylcholine (Ach). Most strips responded
immediately with a vigorous contraction of about 1 g. After the
contractions Became uniform, a dose-response curve for Ach was de-
termined. The maximal contraction, considered to be a 100% re-
sponse, was generally achieved with 5.0 uM Ach. A plot (% response
vs. log Ach) was performed for each strip, and the median effective
dose (ED50) was determined by interpolation.
Upon application of electrical pulses to the strips the prepara-
tions reactedwith regular twitchings. Normorphine, or B-endorphin,
were added for a period of two minutes, after which the preparations
were washed three to four times with the Ringer solution and al-
lowed to stand for about 20 minutes prior to the next drug appli-
cation. Activity was expressed as the percentage of inhibition of
the electrically induced muscular twitch as detailed previously
(Huidobro-Toro et al., 1978). The concentration of nomorphine,
B-endorphin or other neurochemicals to inhibit the muscular twitch-
ing by 50% (IC50) was estimated by interpolation from log dose
response curves.
Effect of calcium on inhibitory effects of opiates and other
To study the effect of calcium on the opiate responses, the calcium
concentration in the Ringer was varied between 1.25 mM and 5.0 mM.
All of the other conditions were unchanged. Dose-effect curves to
the inhibitory response of opiates, catecholamines, or adenosine
diphosphate were determined in strips equilibrated in Ringer con-
taining 1.25, 2.5, 3.75, or 5 mM Ca++.
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drugs
Development and assessment of morphine tolerance and cross
opiate tolerance
Guinea pigs were made tolerant-dependent on morphine by the sub-
cutaneous implantation of six pellets containing 75 mg morphine
base each. Four pellets were implanted on the first day and two
were implanted 48 hours later. The animals were sacrificed ap-
proximately 72 hours after the first implant. The intact ileal
strip preparations were mounted as described previously. For the
control experiments, guinea pigs were implanted with placebo pel-
lets, but otherwise were treated identically to the morphine group.
To prevent in vitro opiate withdrawal from the ileum of the to-
lerant-dependent animals, the Ringer solution was supplemented
with lOO nM morphine, as recommended by Schulz and Herz (1976).
Dose-effect curves for Ach and opiates were determined as already
described.
RESULTS
Effect of Ca++ on the opiate responses
Calcium produced a concentration-dependent antagonism of the inhi-
bitory effect of normorphine to electrical stimulation. Increa-
sing the Ca++ concentration in the Ringer caused a marked decrease
in the sensitivity to nonmorphine or to B-endorphin. As shown in
Figure 1, the normorphine IC50 increased linearly more than 100-
fold with changes in Ca++ between 1.25 and 5 mM. In striking con-
trast the relative change in Ach sensitivity was much less, the
ED50 increasing modestly four-fold. Opiates were considerably
more sensitive to the Ca++ blockade than other agents that cause
inhibition of the twitching response of the ileum. A four-fold
increase in Ca++ (from 1.25 to 5 mM) caused only a minor reduc-
tion of the inhibitory potency of norepinephrine (5.21 fold), epi-
nephrine (2.25 fold) or adenosine diphosphate (6.23 fold) as com-,
pared to that of the opiates, which was about 100-fold for normor-
phine or about 60-fold for Bendorphin.
The antiopiate effect of Ca++ was quite selective since other di-
valent metal cations did not mimick the action of calcium. Mg++
or Mn++ for example increased in a dose-dependent fashion the sen-
sitivity of the intact ileum to normorphine. This effect of Mg++
occurred without altering the sensitivity to Ach, but with Mn++
there was considerable decrease in the sensitivity of the prepara-
tions to Ach.
Effect of calcium on the opiate responses of morphine tolerant-
dependent strips
Ileum strips obtained from guinea pigs implanted with morphine
pellets exhibited cross tolerance to the in vitro responses of
normorphine or B-endorphin as compared to tissues obtained from
placebo-treated animals. During the resting period prior to
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the electrical stimulation, segments from tolerant animals show-
ed considerably more spontaneous activity than those from controls.
Figure 1
Effect of Ca++ on the responses of normorphine and acetylcholine
Normorphine inhibition of the twitching response of the ileum to
electrical stimulation and the contractile effect of acetylcho-
line were measured at varying Ca++ concentrations. The ED50
values were interpolated from dose-effect curves and are expressed
in molar concentrations in the ordinate. Symbols refer to the
mean value obtained in eight separate experiments, bars to the
S.E.M.
As can be noted in figure 2, cross-tolerance between morphine and
nomorphine was demonstrated by nearly a twenty-fold increase in
the IC50 for normorphine. Despite the high degree of opiate to-
lerance, the antiopiate action of Ca++ was still very much in
evidence as indicated by a four-to eight-fold displacement of the
normorphine dose-effect curves to the right at all Ca++ concen-
trations. Maximal agonist response was always observed at the
highest opiate concentrations. Similar results were obtained for
Bendorphin. Figure 2 shows about a 10-fold degree of crossed
morphine-B-endorphin tolerance. In addition, raising the concen-
tration of calcium in the media caused a marked reduction in the
potency of Bendorphin to inhibit the electrically induced neuro-
muscular twitching in both the control, non-tolerant strips, and
in the ileum strips derived from animals chronically treated with
morphine.
Tolerance development did not alter the sensitivity to exogenous-
ly applied Ach. The Ach ED50 was not significantly modified in
strips of ileum obtained from guinea pigs implanted with morphine
pellets when compared to that of the placebo-treated animals. Nor
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7.2 + 0.9 nM in the morphine-treated  preparations as compared to
8.3 + 0.4 nM in the preparations obtained from placebo-treated
animals. At 3.7 mM Ca++,the Ach ED50 was 8.3 + 0.4 and 8.1 + 1.1
nM in the morphine-treated and non-treated preparations respectively.
Figure 2
Effect of Ca++ on the inhibitory responses of nomorphine and B-
endorphine in non-tolerant and tolerant guinea pig ileum
Guinea pigs were rendered tolerant on morphine, by the S.C. im-
plantation of six morphine Pellets containing 75 mg morphine base.
Placebo-pellet-treated animals served as controls. Ilea from the
morphine-tolerant guinea pigs were incubated with 100 mM morphine
to prevent opiate withdrawal. The normorphine ID50 values were
determined in preparations containing 1.2, 2.5, 3.75 or 5 mM Ca++.
See panel on the left. The B-endorphin IC50 was calculated at
2.5, 3.75 and 5 mM Ca++ in non-tolerant and morphine-tolerant
tissues (right panel). Columns indicate the mean ID50 value; bars
represent the S.E.M. (n=8) for each condition.
DISCUSSION
The present results demonstrate that Ca++ reduces the inhibitory
effect of nomorphine and Bendorphin in the longitudinal muscle
myenteric plexus preparation of the guinea pig. In general, at
the lower and intermediate calcium concentrations, the normorphine
response curves show parallelism, suggesting a competitive inter-
action between Ca++ and the opiate. At the highest calcium con-
centration the parallelism was lost. Opiates are far more sensi-
tive to the Ca++ antagonism than other types of neurally active
agents such as catecholamines or adenosine derivatives that also
cause inhibition of neuromuscular  twitching. The high degree of
specificity of the blockade by opiates is indicated by the fact
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was the Ach Ed50 of the two groups altered by changing the exter-
nal Ca++ from 2.5 to 3.75 mM. The Ach ED50 at 2.5 mM Catt was
that the contractile response to Ach was reduced only to minor
degree by a very high concentration of Ca++. The specificity of
Ca++ in antagonizing the opiate action was also evidenced by the
fact that other divalent cations failed to elicit a similar ef-
fect. Mn++ and Mg++ both increased the sensitivity of the ileum
to the inhibitory effect of nonmorphine (Huidobro-Toro et al.,
1981). In the case With Mg++ the augmentation in opiate action
was achieved Without any alteration in sensitivity to Ach. This
suggests that the effect with Mg++, my have been achieved by en-
hancement of the inhibitory effects of normorphine on Ca++ uptake.
A similar conclusion may also hold for Mn++ but the fact that Mn++
also reduced sensitivity to Ach clouds the tissue.
The precise site of action of opiates in the guinea pig-ileum has
not yet been determined. Since the work of Schaumann (1957) and
Paton (1957), it has been generally accepted that morphine and
derivatives decrease the release of Ach from the nerve terminals
in the myenteric plexus Which causes the inhibition of the twitch-
ing evoked by electrical stimulation. The present results sug-
gest that the antagonism of Ca++ on the opiate responses is pre-
synaptic in origin. This conclusion is supported by the fact that
the contractile effect of exogenous Ach was modified only to a
minor extent by changes in Ca++ that caused dramatic reductions
in the effects of nonmorphine. Moreover, normorphine decreased
the release of radioactive Ach in isolated intestinal strips, and
this action was significantly reduced by increasing the external
Ca++(Huidobro-Toro et al., 1981).
The development of tolerance to normorphine does not appear to al-
ter the responses to acetylcholine or the antiopiate effect of
Ca++ in a major manner. Implantation of morphine pellets to ren-
der animals tolerant resulted in about a 10-to 20-fold increase
in the nomorphine and B-endorphin IC50 for inhibiting the elec-
trically stimulated contractile response of the ileum but the sen-
sitivity of the preparation to exogenous acetylcholine was essen-
tially unaltered. Also, despite the high degree of tolerance,
Ca++ retained its ability to antagonize the inhibitory response
to these two opiates in a dose-dependnet manner. This would sug-
gest that the site for Ca++-opiate acute effects is not materially
affected by the development of tolerance. Such a conclusion is
compatible With our earlier studies (Loh et al., 1969), where we
noted that an inhibitor of protein synthesis (cycloheximide)could
block the development of tolerance to morphine Without altering
its acute response to morphine. We suggested that the macromole-
cules responsible for tolerance and physical-dependence develop
ment Were different from those concerned With acute opiate effects
and Were turning over a more rapid rate.
lb explain the effects of Ca++ in the present experiments on the
guinea-pig ileum, it appears reasonable to draw upon the results
of in vivo studies showing that Ca++ antagonizes morphine antino-
ciception and that morphine acutely lowers neuronal Ca++ at nerve
endings and elevates it after chronic administration (Kakunaga et
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al., 1966, Harris, et al., 1975, 1976, 1977, Cardenas and Ross 1975,
1976, Yamamoto et al., 1978 and Guerrero-Munoz et al., 1979a,
1979b). Based on these studies and the close correlation noted
between the potency of opiates to produce antinociception and to
depress the electrical twitch of the fleum (Kosterlitz and
Waterfield, 1975), we suggest that opiates act to block the cal-
cium uptake at the terminals of the opiate-sensitive neurones of
the myenteric plexus. As a result of the decreased calcium influx
in the presence of opiates, less neurotransmitter is released from
the nerve terminals, and this effect results in a depression of the
neurotransmission. Increasing the extracellular Ca++ facilitates
an increase in the Ca++ uptake following the electrical depolari-
zation, which in turn causes an increase in the acetylcholine re-
lease to oppose the inhibitory effect of normorphine. Also, du-
ring tolerance, assuming there is an increase in the intrasynapto
somal Ca++ content analogous to that in the brain, one might ex-
pect the increased Ca++ to oppose the opiate effects. Thus, to-
lerance would be evidenced as an increase in the opiates IC50
by the present data as well as by earlier findings (Goldstein and
Schulz, 1973; Ward and Takemori, 1976). In this connection, it
is of importance to cite also the observation of Mattila et al.
(1962) who first reported that ilea from tolerant-dependent guinea
pigs showed an increase in the spontaneous activity of the prepa-
ration. Our present findings confirm this report and suggest
that this effect may be due to an accumulation of Ca++ during the
development of morphine tolerance. Further experiments are in
progress to assess the release of Ach by other opiates and to
extend these observations to other endogenous opioid-like pep-
tides in the guinea-pig ileum bioassay.
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Localization of the Reward-Relevant
Opiate Receptors
Michael A. Bozarth and Roy A. Wise
Recognition of the importance of the rewarding properties of opiates
in establishing compulsive drug use (Eddy, 1973; Jaffe, 1975) has
prompted a search for the identification of brain mechanisms sub-
serving opiate reward. Oneofthe first steps is the neumanatomical
localization of the reward-relevant opiate receptors, but attempts
to identify the brain site of rewarding drug action have been sub-
ject to serious limitations of current paradigm (Bozarth, 1982).
The most powerful method to demonstrate that a drug is acting at a
particular brain site is to show that the drug is self-administered
directly into that site. This can identify the initial target of
rewarding drug action and thus neuroanatomically define the popula-
tion of receptors mediating this effect. Another method for studying
drug reward is the conditioned place preference paradigm (Rossi &
Reid, 1976). In this paradigm, animals are confined to a normally
nonpreferred portion of a test chamber following drug‘injections.
They are subsequently tested in the drug-free condition to determine
if a learned preference or aversion has developed to the place where
the drug was experienced. This technique can potentially reveal the .
affective consequences of the drug experience: increases in the
amount of time spent in the portion of the test chamber associated
with the drug experience suggest that the drug has positive affective
consequences. Thisparadigmhasthe advantage of not making any
response demands on the animal in the drugged condition, so it avoids
the problem of sedative side-effects of some drug treatmnts.
The present paper reports the results of experiments using the
intracranial self-administration and conditioned place preference
paradigms. Rats quickly learned a  lever-pressing response to inject
morphine directly into the ventral tegmental area but did not self-
administer morphine into other brain regions. This rewarding effect
of morphine was confirmed using the conditioned place preference
paradigm. The reward produced by systemically injected heroin, as
assessed by the conditioned place preference paradigm, was blccked
by dopamine receptor blockade. These studies suggest that the
rewarding properties of opiates are dependent on a dopaminergic
mechanism probably activated through opiate receptors in the ventral
tegmental area.
158
INTRACRANIAL SELF-ADMINISTRATION STUDIES
The usefulness of the intracranial self-administration  paradigm rests
on the demonstration of behavioral, pharmacological, and anatomical
specificity of the effect. First, it must be established that the
animals are working for the rewarding properties of the drug injec-
tions, and that responding is not merely the consequence of nonspe-
cific behavioral arousal. Second, it is necessary to demonstrate
that the rewarding effects of central drug injections are dependent
on the same receptor mechanism that mediates systematic drug reward.
Third, it must be determined if the intracranial self-administration
of a drug is localized to restricted brain regions or is an effect
which is demonstrable throughout the brain. It is in the localiza-
tion of the reward-relevant opiate receptors that intracranial self-
administration can make its most important contribution to the under-
standing of the mechanisms of opiate reward and abuse.
Experimentally naive, male Long-Evans rats were unilaterally implant-
ed with 22-gauge guide cannulae stereotaxically aimed at one of sev-
eral brain regions. Obturators were fitted to a depth of 0.5 mm
beyond the guide cannula. The rats were tested in a 27 x 38 x 39 an
box housed in a dimly illuminated, sound-attenuating chamber. An
operant lever was mounted on one wall of the test box. Drug injec-
tions were delivered using an electrolytic microinfusion transducer
(EMIT) system. In these experiments, a 200-µA current applied for
5 seconds was used to deliver 100 nl of drug solution. For method-
ological details of the EMIT system, see Bozarth and Wise (1980).
Experiment I: Reward From Ventral Tegmental Morphine Injections
The first experiment was designed to determine if experimentally
naive rats would learn to press a lever to inject morphine directly
into the ventral tegmental area. To control for accidental lever
contacts, a yoked control procedure was used. Each morphine-reward
rat was paired with a yoked-control animal such that lever-presses
by the experimental rat produced concurrent infusions in both ani-
mals. Lever-presses by the yoked-control rat were recorded but did
not produce infusions. Using this procedure, the influence of in-
creased locomotor activity on response measures could be assessed.
Rats implanted with guide cannulae in tbe ventral tegmental area were
randomly assigned to either a morphine-reward, yoked control, or
Ringer's control group. For the morphine-reward group, each lever-
press produced a l00-nl infusion of morphine sulfate dissolved in
100 nl of Ringer's solution. Yoked-control animals received the same
injections as their experimental partners. The Ringer's-control
group received response-contingent vehicle only. The rats were test-
ed for lever-pressing in three four-hour sessions on alternate days.
Rats in the morphine-reward group were tested in a fourth session in
which naloxone hydrochloride (10 mg/kg, i.p.) was injected one hour
into the session.
The morphine-reward group rapidly learned the lever-pressing response
making significantly more responses than the yoked or Ringer's-con-
trol groups (p<.01). Naloxone, injected one hour into the last test
session, effectively blocked morphine self-administration.
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FIGURE 1: Mean (±standard error) number of response/hour across all
three sessions. Exp. I: all rats were implanted with, cannulae in
the ventral tegmental area (VTA); (a) morphine-reward, (b) yoked
control, (c) Ringer’s control, n=5/group (adapted from Bozarth &
Wise, 1981). Exp. II: all rats received response-contingent mor-
phine; cannulae were implanted in the VTA, periventricular gray sub-
stance (PVG), lateral hypothalamic area (LHA), nucleus accumbens
septi (NAS), or caudate nucleus (CPU), n=6 to B/group.
These data suggest that morphine injected into the ventral tegmental
area can serve as a reward for a lever-pressing response. Since the
response rates of the morphine-reward group were reliably greater
than those of the control group, the lever-pressing was not due to
nonspecific behavioral arousal. The fact that intracranial self-
administration was blocked by naloxone (data not illustrated) sug-
gests that the rewarding action of these microinjections was depen-
dent on an opiate-receptor mechanism and notthe consequence of some
nonspecific changes in local osmolarity, pH, or calcium flux.
Several observations suggest that the dopaminergic cells of the ven-
tral tegmentum mediated the rewarding effects of these microinjec-
tions. First, opiate receptors appear to be located on these dopa-
minergic cells or their afferents (Schwartz, 1979) and microinjec-
tions of morphine into this region cause an increase in the single
unit activity of these cells (Finnerty & Chan, 1980). Second, mor-
phine microinjected into the ventral tegmental area has been reported
to increase locomotor activity (Joyce & Iversen, 1979; Pert et al.,
1979), and this effect was observed in both the morphine-reward and
yoked-control animals of the present study. Stimulation of locomotor
activity seems to be dependent on a dopaminergic substrate with cell
bodies located in the ventral tegmental area (Joyce & Iversen, 1979,
1980). Furthermore, since the rewarding injections were unilateral,
the increased locomotor activity was asymmetrical and resulted in
circling: the direction of circling was contralateral to the side
of injection indicating that dopamine release was enhanced at the
terminal fields of these cells (Ungerstedt, 1971a).
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Experiment II: Lack of Morphine Reward From Other Injection Sites
To determine if other brain sites would support intracranial self-
administration, rats were unilaterally implanted with guide cannulae
in the following brain regions: ventral tegmental area, periventric-
ular gray substance, lateral hypothalamic area, nucleus accumbens,
or caudate nucleus. Experimentally naive animals were tested every
other day for three four-hour sessions. Each lever-press resulted
in a 100-ng infusion of morphine as in the first experiment.
Acquisition of the lever-pressing response was found only in rats
with cannulae in the ventral tegmental area. The lack of self-
administration into the periventricular gray substance is of partic-
ular significance since it eliminates the possibility that morphine
injected into the ventral tegmentum is rewarding because of diffusion
up the guide cannula to the cerebral ventricles (the anterior-poster-
ior and medial-lateral stereotaxic coordinates for these two sites
were the same). The failure to obtain morphine self-administration
into the lateral hypothalamic area is in conflict with previous re-
ports (E. Stein & J. Olds, 1977; M. Olds, 1979). There are two meth-
odological differences that deserve particular attention. First,
intraventricular self-administration of opioids has been demonstrated
(Amit et al., 1976; Belluzzi & L. Stein, 1977). The studies report-
ing morphine self-administration into the lateral hypothalmic area
used guide cannulae that were much larger than used in the
present study. This can facilitate drug spread up the guide shaft
and into the cerebral ventricles (Routtenberg, 1972) resulting in
diffusion to a distal site of action. Second, the reports of later-
al hypothalamic self-administration have involved rats previously
trained to lever-press for brain stimulation reward. Lateral hypo-
thalamic morphine injections might be capable of maintaining an al-
ready learned response but not capable of establishing a new habit;
this might be expected if lateral hypothalamic injections were slowly
diffusing to a distal site of action and serving as a weak reward.
Regardless of the explanation for the lateral hypothalamic self-
administration reported by others, it is apparent that ventral teg-
mental morphine injections are a much more potent reward than are
microinjections into the other brain regions tested in this study.
CONDITIONED PLACE PREFERENCE STUDIES
The conditioned place preference paradigm can make several important
contribution to the study of drug reward. It offers an independent
method of assessing a drug's rewarding properties which is not sus-
ceptible to behavioral debilitating effects of various drugs or
lesions. Also, conditioning variables have been implicated in the
maintenance of drug-seeking behavior (Schuster & Woods, 1968), and
this paradigm allows a direct comparison of these conditioning vari-
ables across different drugs and parameters of conditioning. Final-
ly, this paradigm is extremely quick and easy to use.
Place preference was measured in a shuttle box (25 x 36 x 35 cm) with
a wood floor on one side and a wood floor covered with wire mesh on 
the other. The amount of time rats spent on each side of the box was
automatically recorded in 15-minute sessions for five consecutive
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preconditioning days Next, the animalss received daily drug injec-
tions for four days in which they were restricted to the nonpreferred
side of the box for 30 minutes. Finally, the animals were retested
for place preference during access to the entire shuttle box.
Experiment III: Place Preference From Central Morphine Injections
In intracranial self-administration studies, the animal controls the
number of infusions and thus the total dose and volume of drug injec-
ed. .Since the field of effective drug spread varies as a function
cannula placements to the reward-relevant receptors (Bozarth, 1982).
of response rate, it is difficult to estimate the distance of the
This problem can be overcome by injecting each animal with the same
volume of drug and assessing reward using the conditioned place pref-
erence paradigm. Cannula placements can then neuroanatomically map
the region of the reward-relevant receptor Population.
Rats were injected with 250 ng of morphine sulfate into the ventral
tegmental area immediately before each of the four conditioning tri-
als. The infusions were delivered over 28 seconds in 500 nl of Ring-
er's solution using the EMIT method (Bozarth & Wise, 1980).
Rats with cannulae in the same region as those supporting self-a&in-
istration in the earlier experiments developed a conditioned place
preference for the side of the box associated with morphine injec-
tions. Rats with cannulae placed caudal to this region failed to
acquire such a preference. Preliminary estimates suggest that the
FIGURE 2: Mean (± standard. error) number of seconds on the side of
putative conditioning. Exp. III: (a) cannulae 2.8 to 3.8 mm pos-
terior to bregma, n=11, (b) cannulae 4.2 to 4.8 mm posterior to
bregma, n=8; histological verification was based on Pellegrino et al.
(1979); between group difference, p<.01. Exp. IV: (c) heroin plus
saline, (d) heroin plus naloxone, (e) heroin plus pimozide, (f)
saline plus naloxone, (g) saline plus pimozide, n=ll/group.
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caudal limit of the reward-relevant receptor population corresponds
to the boundary of the ventral tegmental dopamine-cell group.
Experiment IV: Neuroleptic challenge of Heroin Reward
Ihe conditioned place preference paradigm avoids some of the problems
of lever-pressing experiments by assessing drug reward in the drug-
free state. Thus, this paradigm is not sensitive to the response
depressant or excitatory effects of drugs or brain lesions. In the
next experiment, the conditioned place preference produced by system-
ic heroin injections was challenged with the dopmine-receptor block-
er  pimozide and the opiate antagonist naloxone.
Five groups of rats were tested. Three group received heroin (0.5
mg/kg, s.c.) preceded by either saline (1.0 ml/kg, i.p.), naloxone
(3.0 mg/kg, i.p.), or pimozide (0.5 mg/kg, i.p.), One group was
injected with naloxone alone and another with pimozide only. All
drugs were injected immediately before the conditioning trials except
pimozide which was injected four hours prior to conditioning.
Animals injected with heroin plus saline showed a shift in place
preference similar to that seen after intracranial morphine injec-
tions (p<.01). Pretreatment with either naloxone or pimozide blocked
the development of a heroin-induced place preference, while treatment
with either naloxone or pimozide alone had no effect.
These results are concordant with self-administration studies sug-
gesting an attenuation of opiate reward following neuroleptic treat-
ment (Hanson & Cimini-Venema, 1972; Pozuelo & Kerr, 1972). Since
place preference is tested in drug-free animals, pimozide's blockade
of heroin reward cannot be attributed to a general sedative effect
that could confound lever-press measures.
GENERAL DISCUSSION
The use of the intracranial self-administration paradigm in Experi-
ments I and II has provideda direct demonstration of the rewarding
action of morphine delivered into the ventral tegmental area. The
fact that the rats learn to lever-press rapidly suggests that the
rewarding effects of these injections occur soon after the drug in-
fusions. Rats would not be expected to learn this response as rapid-
ly if the rewarding impact of the infusions were delayed, as would
be the case if the rewarding effects were dependent on the diffusion
of drug to a distal site of action.
The rewarding action of morphine injected into the ventral tegmental
area has been confirmed using the conditioned place-preference para-
digm. In a similar study, place preference was established with bi-
lateral morphine injections into the ventral tegmentum but not with
injections dorsal to it (Phillips & LePiane, 1980). Experiment III
extended these results showing that unilateral injections are also
effective and that injections caudal to the ventral tegmental area
are not effective.
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The failure to find intracranial self-administration into the brain
sites tested in Experiment II suggests a neuroanatomical seperation
of the rewarding, analgesic, and sedative properties of opiates. The
periventricular gray substance has been implicated in opiat-induced
analgesia (Jacquet & Lajtha, 1976; Pert & Yaksh, 1974; Sharpe et al.,
1974; Yaksh et al., 1976) and sedation (Pert et al., 1978), while the
rewarding properties of morphine appear to be dependent on an action
in the ventral tegmental area. The site of action for opiate-induced
physical dependance is less clearly defined,but it seems to involve
receptors in the thalamus and periventricular gray region (Wei et
al., 1973; Wei & Loh, 1976; Wei, 1981). These studies suggest that
the ability of an opiate to produce analgesia, sedation, and physical
dependence may be neuroanatomically separable from its rewarding
properties.
The importance of dopamine-containing cells in the regulation of
food, water, and brain stimulation reward is well established
(Ungerstedt, 197lb; Wise, 1978; 1980). An important role for dopa-
minergic cells projecting to the nucleus accumbens has also been
demonstrated in psychomotor stimulant reward(Roberts et al., 1980).
The fact that reward from systemic heroin appears to be dependent on
a dopaminergic mechanism (Experiment IV)suggests that it may share
a common neural substrate with these other sources of reward. The
localization of the reward-relevant opiate receptors in the ventral
tegmental area makes this a likely place for opiate reward to inter-
face with a dopaminergic substrate of reward.
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Endogenous Opioids May Mediate
Ethanol’s Effects on the
Hypothalamic-Pituitary-LH Axis
Theodore J. Cicero, Edward Ft. Meyer, Carol E. Wilcox, Peter
F. Schmoeker, and Steven M. Gabriel
ABSTRACT
There has been a good deal of speculation regarding the possibil-
ity that endogenous opioids participate in the effects of ethanol
on the central nervous system. Thus far, however, this relation-
ship has been very difficult to establish. Ideally, an appropri-
ate model to employ to examine the interaction between the CNS ac-
tions of ethanol and endogenous opioid-containing neuronal elements
would satisfy two criteria: first, that a role for opioid peptides
in the system has been established; and, second, that the actions
of ethanol on the system are also well-defined. The hypothalamic-
pituitary-luteinizing hormone (LH) axis satisfies both of these
criteria and was employed in the present studies. We found that
naloxone substantially attenuated the inhibitory effects of ethanol
on serum LH levels and, similarly, that ethanol effectively antago-
nized naloxone-induced increases in serum LH levels. The results
thus support the hypothesis that ethanol exerts some of its effects
through opioid containing neuronal elements in the CNS.
INTRODUCTION
It has been suggested that ethanol exerts sane of its effects by
interacting with endogenous opioids in the CNS. This hypothesis is
based upon two observations: first, there are a number of similar-
ities between the pharmacological and physiological actions of eth-
anol and the narcotics and, second, naloxone has been shown to an-
tagonize a number of the CNS effects of ethanol (e.g., Blum et al.
1980; Ho and Ho 1979; Jeffcoate et al. 1979; Triana et al. 1980;
Lorens and Sainati 1978; Middaugh et al. 1978).
An inspection of the literature, however, suggests that a defini-
tive relationship between the CNS actions of ethanol and endogenous
opioids has not as yet been established. For example, similarities
between the actions of ethanol and the narcotics need not imply a
common mechanism of action. Moreover, it is difficult to interpret
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many of those studies in which naloxone has been found to antago-
nize ethanol's effects because endogenous opioids have not been
clearly shown to be involved in the complex behaviors that have
been examined. Thus, it is uncertain whether naloxone blocks the
effects of ethanol by a specific antagonism of ethanol-induced al-
terations in endogenous opioids or by sane other action. Ideally,
the best model to employ in examining the CNS actions of ethanol
should satisfy two criteria: that a definitive role for endcgenous
opioids in the function of the system has been clearly established
and, in addition, that the effects of ethanol on the system have
also been well-defined. The hypothalamic-pituitary-LH axis seems
to provide a model preparation that satisfies these two criteria
since it has been clearly established that endogenous opioids play
a prominent role in regulating activity in this axis (see Cicero
198Oa; Meites et al. 1979. for reviews) and that ethanol depresses
serum LH levels in the male of several species in a dose-dependent
fashion, apparently by inhibiting the release of LH-RH (see Cicero
1980b for a review). This system was employed in the present
studies to examine whether ethanol reduced serum LH levels by in-
teracting with opioid-containing systems in brain.
METHODS
Effects of Naloxone on Ethanol-Induced Depressions in Serum LH
Groups of rats were injected with saline or naloxone (0.25 mg/kg),
subcutaneously; half of the animals in each group were simultane-
ously (<15 sec) injected with saline or various doses of ethanol.
The animals were killed 2 hours later, and hypothalamic-LH-RH con-
tent (Nett et al. 1973) and pituitary and serum LH levels (Nis-
wender et al. 1969) were determined.
Effects of Ethanol on Naloxone-Induced Increases in Serum LH
To determine whether ethanol would antagonize the effects of nalox-
one on serum LH, rats were injected with saline or ethanol (1.0
g/kg) 30 min prior to the injection of sufficient doses of naloxone
to construct appropriate dose-response curves with respect to in-
creasesin serum LH. The rats were killed 20 min after the nalox-
one or saline injections (50 min after the ethanol injection).
Brains, pituitaries and bloods were obtained fran the animals in
both studies for the determination of hypothalamic-LH-RH content
and pituitary and serum LH levels.
Opiate Binding Studies
[3H]-naloxone binding assays were performed essentially as de-
scribedpreviously (Smith and Simon 1980). Binding assays were
carried out in the presence or absence of ethanol (1x10-6 to 2x10-1
M, final concentration. In all of the experiments reported in
this paper, specific [3H]-naloxone binding represented 75-80% of
the total binding.
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Effects of Naloxone on Ethanol-Induced Inhibitions of Serum LH
RESULTS
The effects of naloxone on ethanol-induced depressions in serum LH
levels are shown in table 1. It is apparent that naloxone substan-
tially antagonized the effects of ethanol on serum LH. In fact, at
doses of ethanol up to 1.5 g/kg, serum LH levels were significantly
elevated in naloxone-ethanol treated animals when compared to sa-
line-ethanol-treated rats. It is important to note that naloxone
itself, at this dose and time interval, had no effect on serum LH
levels.
TABLE 1
The effects of saline or naloxone (0.25 mg/kg) on ethanol-induced
changes in serum LH levels (ng/ml).
Effects of Ethanol on Naloxone-Induced Increases in Serum LH
The effects of 1.0 g/kg ethanol on the naloxone dose-response
curve, with respect to increases in serum LH, are shown in table
2. As can be seen, ethanol markedly reduced naloxone-induced in-
TABLE 2
All serum LH levels in naloxone-treated animals were sig-
nificantly (p<.01) higher than those found in the respec-
tive control group. *Significantly (p<.01) lower than
saline-treated rats.
167
creases in serum LH levels and appeared to shift the dose-response
curve significantly to the right when compared to controls. Al-
though the data shown in table 2 represent the effects of only one
dose of ethanol, similar results were obtained with other doses as
well. Ethanol itself did not depress serum LH levels at this rela-
tively low dose, and short time interval.
Opiate Binding Studies
As shown in figure 1, ethanol had no effect on specific [3 H]-nalox-
one binding to rat brain membranes at concentrations up to 2x10- 1M.
FIGURE 1
Specific [3H]-naloxone binding (CPM) as a function of the ethanol
concentration in the incubation medium. The determination of spe-
cific binding is given as an inset in this figure. Values are
mans (±SEM) of at least three experiments carried out in tripli-
cate.
DISCUSSION
Previous research has demonstrated that endogenous opioid peptides
are involved in regulating the normal activity of the hypothalamic-
pituitary-LH axis and may mediate the negative feedback control of
this axis by testosterone (see Cicero, l98Oa, for a review). The
present results demonstrated that pretreatment with a low dose of
naloxone substantially blocked ethanol-induced depressions in serum
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LH. In addition, ethanol markedly attenuated naloxone-induced in-
creases in serun LH levels. Thus, these data indicate that nalox-
one and ethanol mutually antagonize each other's effects on serum
LH. Moreover, this antagonisn appears to take place at a suprasel-
lar site, presumably in those areas of brain regulating LH-RH re-
lease, since it has been found that LH-RH readily overcomes etha-
nol's inhibition of naloxone-induced increases in serun LH (unpub-
lished observations) and that naloxone and ethanol do not interfere
with the response of the pituitary to LH-RH under in vivo or in
vitro conditions (Cicero, 198Oa, b; Meites et al. 1979). These re-
sults, therefore, are compatible with the hypothesis that ethanol
depresses serum LH levels by activating endogenous opioid peptide
systems in the hypothalamus that normally inhibit LH-RH.
There are several mechanisms, other than direct mediation by opioid
peptides, that could explain the interaction between ethanol and
naloxone observed in this and other studies. These should be
discussed.
First, it could be that the antagonism between ethanol and naloxone
observed in the present studies is "physiological" as opposed to
"pharmacological." Although it is difficult to completely rule out
"physiological" antagonisn, it can be minimized by employing a
standard dose of the test drug (i.e., ethanol or naloxone), that
is known to elicit a physiologically relevant response and then at-
tempting to antagonize its effects by using dosage and time inter-
vals at which the competing drug has no observable effect of its
own. If antagonism is observed under these conditions, the likeli-
hood that physiological antagonism can fully explain the observed
antagonistic interaction between the two drugs is diminished. In
the present studies, we found that naloxone and ethanol were cap-
able of antagonizing each other's effects on serum LH levels at
doses and time intervals at which neither drug itself affected
LH. Thus, although "physiological" antagonism cannot be ruled
out entirely, and this possibility should be borne in mind, the
present data would seem to argue against this interpretation and
suggest that some other mechanism is involved.
A second mechanism that could be involved in the interaction be-
tween ethanol and naloxone is that ethanol or its highly reactive
metabolite, acetaldehyde, might influence opiate-receptor mecha-
nisms in some way under in vivo conditions. In the presentp sent stud-
ies, the possibility that ethanol directly inhibited [3H]-naloxone
binding under in vitro conditions was excluded, but it is quite
possible that under in vivo conditions ethanol, or some consequence
of its metabolism, including the generation of acetaldehyde, could
influence opiate-receptor processes in sane fashion.
As a final possibility, acetaldehyde could react with endogenously
occurring compounds in brain to form substances that have an affin-
ity for the opiate receptor and thereby exert significant biologi-
cal activity of their own. Support for this conclusion has been
provided by two sets of observations. First, acetaldehyde reacts
with several endogenous opioids to form compounds that compete for
opiate receptors in the brain and the guinea pig ileum (Summers and
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Hayes, 1980). Second, acetaldehydereadily condenses with indole-
amines to form iscquinoline alkaloids, similar in structure to a
number of opium alkaloids (Weiner, 1979). Since these compounds
have been shown by a number of investigators to bind to opiate re-
ceptors and elicit a number of effects after their administration
(Lasala et al. 1980; Nimikitpaisan and Skolnick, 1978; Siggins and
French, 1979), it may not be unreasonable to speculate that acetal-
dehyde condenses with a number of compounds in brain that could in
turn influence opiate binding and/or exert opiate like effects
themselves.
In conclusion, the studies described in this paper strongly rein-
force previous suggestions that ethanol exerts sane of its effects
by interacting with opioid-containing systems in brain. In these
earlier studies, this conclusion was based upon similarities be-
tween the acute and chronic actions of the two drugs and several re-
ports that naloxone can prevent some of the actions of ethanol. In-
ferences can be misleading, however, and unfortunately those studies
showing an antagonism of ethanol's effects by naloxone have been
somewhat difficult to interpret. In the present studies, however,
we have been able to demonstrate an apparent interaction between
opioid-containing systems and ethanol.
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Evidence for a Single Opioid
Receptor Type on the Rat Deferens
Richard J. Freer, Alan R. Day, and Chung Shin Liao
INTRODUCTION
There is no doubt that there exist in nature several distinct
populations of opioid receptor sub-types (Martin et al. 1976,
Chang and Cuatrecasas 1979 and Lord et al. 1977). This fact
is formally stated in the "Multiple Receptor Theory" of opioid
action first espoused by Martin et al. (1976). In fact, opioid
drugs are now invariably categorized based on their selectivity
for the various receptor sub-types. However, as more data has
accumulated it has become necessary, in order to preserve the
classifications defined under the multiple receptor theory, to
postulate the co-existence of more than one type of opioid receptor
within a single target tissue. An alternative explanation, how-
ever, is that there is but a single receptor type in each target
tissue which is capable of multiple modes of binding. This con-
cept, first proposed by Portoghese. (1965), could also explain the
heterogeneous responsiveness of single-target tissues to opioid
drugs. It is, of course, important that the question of multiple
receptors versus multiple modes of binding be resolved since one
must think quite differently when dealing with several binding
complexes rather than a single macromolecular system.
The rat vas deferens (RVD) is an unusual tissue in that it is
quite unresponsive (only producing approximately 20% of the maxi-
mum response) to the archetype opioid alkaloid, morphine (Lemaire
et al. 1978, Schulz et al. 1979, Wuster et al. 1980). This has
been intrepreted to mean that there is in the RVD a low density
of morphine-sensitive mu (µ) receptors. However, the published
data are also consistent with the possibility that morphine is
a partial agonist in this preparation. If that were the case,
the same effect (i.e., decreased maximum response) would be obser-
ved but only a single type of opioid binding site would be ne-
cessary to explain these results. The experiments described be-
low were designed therefore to determine if morphine is a partial
agonist in RVD and, if so, whether the data are consistent with
the presence of a single opioid receptor type in this tissue.
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METHODS
Vas deferens were dissected from Sprague-Dawley rats (250-400 g)
and mounted in 10 ml jacketed organ baths (Metro Scientific) con-
taining Kreb’s solution at 37 C. The Krebs had the following
composition (mM) : NaCl, 118; KCl, 4.7; CaC12, 2.5; KH2 PO4, 0.93;
NaHCO3, 25 and glucose, 11. The solution was continually gassed
with a mixture of 95% O2/5% CO2 The RVD was placed between two
parallel platinum electrodes (separated by 5 mm) and adjusted to
a resting tension of 200 mg. Field stimulation was applied at
100V, 0.1 HZ, with 2-msec duration as described previously (Liao
et al, 1980) and the twitch response recorded isometrically using
a Beckman Dynograph system. The field stimulation was validated
as being due to pre-junctional nerve stimulation since 10 M te-
trodotoxin could block the twitch response but did not affect
post- junctional sensitivity to serotonin. The ID50 concentration
(i.e. the concentration necessary to inhibit the twitch response
by 50%) of the various agonists were obtained from a full dose-
response curve, and antagonists were tested against that concentra-
tion. Antagonists were added to the bath 3 min before challenge
with the agonist.
The synthesis of D-Ala2-N1e5 (des-COOH)-enkephalin has been de-
scribed (Day et al, 1978). Human ß-endorphin was purchased from
Peninsula Laboratories. Morphine sulfate, oxymorphone hydrochlo-
ride, etorphine hydrochloride, naloxone hydrochloride and sufen-
tanil citrate were kindly supplied by Dr. William Dewey, Medical
College of Virginia. Ketobemidone hydrochloride and -(+)-N-allyl-
normetazocine hydrobomide were the generous gift of Dr. Everette
May, Medical College of Virginia.
RESULTS
Our experiments on RVD with ß-endorphin, etorphine and sufentanil
showed these drugs to be full agonists with ID50‘s of 28, 38 and
48 nM respectively. This is consistent with previous data in the
literature (Lemaire et al, 1978, Schulz et al, 1979, Wuster et al,
1980) as was our finding that morphine produced only a slight in-
hibition (20% at 10-5M) of the twitch response. We have extended
these studies to look further at opioids which have been classi-
fied as being selective for µ (oxymorphone and etonitazine, keto-
bemidone) , [D-Ala -Nle (des-COOH) -enkephalin] , ( (+) -N-allyl-
normetazocine) receptors (Figure 1). Of this group the etonita-
zine and enkephalin were full agonists (ID50‘s of 0.15 and 2 µM
respectively) while oxymorphone only reduced the twitch response
by 10% at 10-5M. Ketobemidone and -(+)-allyl-normetazocine were
inactive at concentrations up to 10-5M.
On inspection of our dose-response curves as well as those in the
literature (Lemaire et al, 1978) it seemed possible that the low
responsiveness of RVD to morphine and its congener, oxymorphone,
could be due not to a low concentration of a particular receptor
typebuttothefactthatthesedrugs arepartialagonists. By definition
a partial agonist should competitively antagonize a full agonist
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FIG. 1
Inhibition of field stimulated rat vas deferens by opioids. ß-en-
dorphin etonitazine D-Ala2-Nle-(des-COOH)-Enkephalin
morphine and oxymorphone Each point is the ave-
rage ± SEM of 6-10 determinations.
acting on the same receptor site. Therefore, to investigate the
possibility that ß-endorphin and morphine interacted with the same
receptor site, morphine was tested as an antagonist of ß-endorphin.
As shown in Fig. 2 (right) and Table 1, morphine (10-5M) clearly
antagonized ß-endorphin in a dose-dependent manner. As one would
expect with a true partial agonist, the concentration of morphine
necessary to produce blockade of ß-endorphin was identical to those
which produced its weak agonist activity (compare to Figure 1).
The  morphine  congener oxymorphone behaved in the same way and was,
in fact, a slightly more effective antagonist of ß-endorphin (Fig
2 right, Table 1). For comparison the antagonism produced by 10-7M 
nalo one is also shown in Fig. 2 (left). In addition both morphine
(10-5M) and oxymorphone (10-3M antagonized D-Ala2-Nle5- (des-COOH)-
enkephalin while oxymorphone (10-5M) also antagonized etorphine and
sufentanil. The magnitude of the antagonism of ß-endorphin, enke-
phalin, etorphine and sufentanil was very similar (dose ratio of
174
30-100 fold) in the presence of 10-5 oxymorphone, again sugges-
ting that all the drugs were reacting with the same binding site.
Finally, ketobemidone, -(+)-N-allyl-normetazocine and ketocycla-
zocine were found also to inhibit ß-endorphin. These were, on a
molar basis, equipotent with morphine and oxymorphone in this re-
spect.
FIG. 2
Antagonism of ß-endorphin inhibition of field stimulated rat vas de-
ferens. Left: control and in the presence of 10-7M naloxone
Right: control and in the presence of 10-5M morphine
or oxymorphone Each point is the average ± SEM of 6-20
determinations.
DISCUSSION
In its basic form the multiple-receptor theory of opiate action pre-
dicts that there exists in Nature several distinct kinds of recep-
tors which show differing selectivity for opioids of varying struc-
ture. This is undoubtedly true when one compares different species
or different tissues within a single species, However, this concept
of multiple receptors has been extended to individual tissues and
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cells such that the presence of several different opiate receptors
are postulated to be present within a single tissue. The principal
evidence to support this notion comes from differing rank order po-
tencies of opioid agonists and antagonists on different test sys-
tems . Using this kind of approach it has been suggested that the
RVD contains predominantly and/or receptors within lesser num-
bers of µ receptors and few, if any, or receptors (Lemaire et
al, 1978, Schulz et al, 1979, Wuster et al, 1980).
Table 1.
*Data are the average ± SEM of 6-8 determinations.
There is, however, an alternate explanation to account for differ-
ent pharmacological profiles amongst opioid target tissues. This
was elaborated first in 1965 and again in 1978 by Portoghese. In
its simplest form it says that the diverse responsiveness of opioid
target tissues may be due to multiple modes of binding to a sin-
gle binding site. It is this kind of mechanism which we feel best
explains the data obtained in our study. It seems clear that there
is only one binding site in the RVD, at least as measured pharma-
cologically in the field-stimulated preparation. The evidence for
this is that there is complete interchangability between drugs se-
lective for each of the major receptor classifications. For ex-
ample there are full agonists from the and class [i.e. ß-en-
dorphin and the D-Ala2-Nle-5des-COOH)-enkephalin] and the µ class
(etorphine, etonitazene and sufentanil). Other µ drugs (i.e. mor-
phine and oxymorphone) are partial agonists but will inhibit the
and class [i.e. ß-endorphin and D-Ala2-Nle5(des-COOH)-enkepha-
lin] as well as other µ agonists (i.e. sufentanil, etorphine, and
etonitazene). Finally drugs classified as a (+)-N-allyl-nor-
metazocine) or (ketocyclazocine) ligands will antagonize both the
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and agonists. In short each drug tested was either an agonist,
partial agonist or antagonist. None were inactive. It is inte-
resting that a recent paper (Gillan et al, 1981) also reported
similar data but chose to interpret their data under the multiple-
receptor theory. Furthermore, they observed that a kappa li-
gand (ethylketocyclazocine) also is an antagonist in RVD.
Two additional points should be made to strengthen our contention
that only a single binding site exists in this tissue. First is
the fact that the partial agonists morphine and oxymorphone anta-
gonize ß-endorphin in a concentration-dependent manner. This con-
centration range is virtually identical to that at which these
drugs exhibit their weak agonist activity, suggesting that each
effect is mediated via interaction with the same receptor site.
The second point is that the oxymorphone antagonism is the same
regardless of the nature of the agonist used. It will, for ex-
ample, antagonize and drugs (ß-endorphin and enkephalin) to
the same degree as it blocks µ drugs (etorphine and sufentanil).
There is no discrimination based on drug classification, again
suggesting a single binding site.
In conclusion, we believe that our data is consistent with the
suggestion that the opiate receptor in the rat vas deferens is
homogeneous. Our results have been interpreted within the frame-
work of Portoghese’s original concept of different binding moda-
lities to a single receptor.
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Autoradiographic Localization of
the Phencyclidine/Sigma “Opiate”
Receptor in Rat Brain
R. Quirion, R. P. Hammer, Jr., M. Herkenham, and C. B. Pert
In the past few years, phencyclidine ("Angel Dust", PCP) has become
a major drug of abuse in the United States. The "psychosis" in-
duced by PCP resembles schizophrenia and makes the question of its
molecular mechanism of action one of considerable interest. Re-
cently, classical ligand binding to brain homogenates with rapid
filtration to reduce nonspecific binding has been used to demon-
strate PCP receptors in rat brain (Vincent et al., 1979; Zukin and
zukin, 1979). Using the new brain-slice technique (Herkenham and
Pert, 1980), we now report specific [3H]PCP binding to slide-
mounted sections of fresh-frozen rat brain. Subsequently, using
tritium-sensitive LKB film analyzed by computerized densitometry
(Goochee et al., 1980), we visualized the distribution patterns of
[3H]PCP binding in rat brain and found a unique distribution
which predominates in cortex and hippocampus. Furthermore,
although morphine and opiate peptides fail to displace [3H]PCP
binding, opiates that produce psychotomimetic effects, classified
as sigma (Martin et al., 1976), potently displace [3H]PCP bind-
ing, suggesting that the sigma effects of opiates are mediated
through the PCP binding site.
MATERIALS AND METHODS
Male Sprague-Dawley rats were decapitated and their brains ware
rapidly immersed in isopentane at -40°C, mounted on cryostat
chucks, and cut into 25 µm-thick coronal sections at -14°C. Sec-
tions were thaw-mounted near the edge of precleaned gelatin-coated
slides, air-dried on ice about 2 h and then stored at -14°C for at
least 48 h before use.
Frozen slide-mounted sections (one section per slide) were incubat-
ed for 45 min in 30 ml ml beakers in a volume of 10 ml consisting of
5.0 mM Tris-HCl buffer plus 50 mM sucrose, pH 7.4 at 0°C with 8.2
nM [3H]PCP (400,000 cpn/ml; 48 Ci/mmol; New England Nuclear) or
in the presence of nonradioactive PCP or other indicated drugs. At
the end of the incubation, the slides were placed in racks holding
30 slides and transferred sequentially through six rinses (30 sec
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in each) of 5.0 mM Tris-HCl buffer plus 50 mM sucrose, pH 7.4 at
0°C plus 1 percent bovine serum albumin. Binding of [3H]PCP to
the tissue slice was quantitated by counting the tissue-laden slide
fragment in 10 ml Aquassure scintillation cocktail (New England
Nuclear) after vigorously agitating the vial contents for 30 min.
Specific binding was calculated as the difference in counts bound
in the presence and absence of 0.1 mM PCP. Olfactory bulb slices
were generally utilized because of the availability of many similar
25 µm-thick sections (60-70) from each brain.
Preparation of incubated slides for microscopic visualization was
carried out as follows: at the end of the rinsing period, the
slides were rapidly dried under a stream of cold air and then jux-
taposed tiyhtly with tritium-sensitive film (Ultrafilm, LKB Instru-
ments, Rockville, MD) and stored at room temperature for ten days.
After this exposure, the film was processed in Kodak D19 at 22°C
for 4 min and then fixed for 5 min. We utilized the Goochee et al.
(1980) computer program, which codes optical density data along a
color spectrum, to visualize the distribution of the PCP binding
sites in rat brain.
In preliminary experiments, we have observed that the optimal sig-
nal-to-noise ratio was achieved by preincubating brain slices for
15 min at 0°C, in the presence of 20 mM NaCl in buffer, followed by
a 45-min incubation in 5.0 mM Tris-HCl buffer plus 50 mM sucrose,
pH 7.4 at 0°C  without any added ions. Under these conditions, 60-
70 percent of the total bindiny was displaced by 0.1 mM PCP when
the concentraton of radiolabeled PCP was 8.2 nM. Saturation curves
and Scatchard analysis of [3H]PCP binding revealed a saturable
single class of binding sites with a Kd = 46 mM and a Bmax = 10.5
fmol/slice. Figure 1 shows that a large number of PCP analogs dis-
place [ 3H]PCP in a broad range of concentrations.
FIGURE I
Figure 1. Displacement of [3H] PCP by nonradioactive PCP and var-
ious analogs. Values are expressed as percent inhibition of
specific binding of [3H]PCP and are plotted as Log-Probit plots.
The most potent analog, PCE, displaced [3H]PCP binding about six
times more potently than PCP itself. By contrast, ketamine was 10
times less potent than PCP and PCC was a very weak displacer of
[3H]PCP binding. Also, while morphine, naloxone, and a number of
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opiate peptides failed to significantly displace [3H] PCP binding,
a number of "sigma" opiate agonists potently inhibited [3H] PCP
binding (fig. 2). For the ten PCP analogs for which both biochemi-
cal and behavioral data were available, there is a rather precise
correlation (r= 0.98; p < 0.001) between the ability of these
ligands to displace [3H] PCP binding from brain slices and to act
in the PCP-discriminative stimulus test (fig. 3).
FIGURE 2
Figure 2. Displacement of [3H] PCP by nonradioactive PCP and var-
ious opioid drugs. Values are expressed as percent inhibition of
specific binding of [3H] PCP and are plotted as log-Probit plots.
FIGURE 3
Figure 3. Relative potencies of a series of PCP analogs in displa-
cing specifically bound [3H] PCP vs. the relative potencies of
these compounds in the rat discriminative stimulus test.
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FIGURE 4
Figure 4. Pseudocolor reconstructions of [3H] PCP autoradiographs
of rat brain sections using the computerized densitometry and color
coding technique. Each picture was obtained using the same color
pattern.
As shown in fig. 4, the hippocampus and dentate gyrus contain the
hiyhest levels of specific [3H] PCP binding measured in this
study; label predominates in layers superficial to the pyramidal
and granule cell layers. In neocortex it is more dense in the out-
er five layers; in cerebellum it predominates in the molecular lay-
er. Brainstem areas which stand out against low binding in adja-
cent structures are the central gray, substantia nigra and inter-
peduncular nucleus. These leave moderate [3H] PCP receptor densi-
ties similar to those obtained in the gray matter of spinal cord.
DISCUSSION
Ligand specificity analysis of [3H] PCP binding suggests that we
are visualizing a unique and distinct population of binding sites
which are very similar to those that mediate the pharmacological
PCP effects in vivo.
Maayani and Weinstein (1980) have claimed that [3H] PCP binding is
a technical artifact of the rapid filtration technique. Since
then, Vincent et al. (1980) have demonstrated that the importance
of these technical problems has been overstated. In this study,
using no filters at all, binding to the glass on which the slides
were mounted was less than 5% of the total binding.
181
However, we feel that the strongest evidence for the specificity of
the binding we have observed is the close correlation between the
ligand selectivity pattern of [3H] PCP displacement and the rela-
tive potencies of these drugs in a behavioral-test.
In this study, we have observed that a small number of benzomorphan
opiates with peculiar psychotominetic "sigma" properties potently
interact with [3H] PCP binding sites. While an early study sug-
gested that naloxone blocks these sigma effects (Martin et al.,
1976), recent reports show that the behavioral (Holtzman, 1980;
Shannon, 1981) and biochemical (Wood et al., 1980; Zukin and Zukin,
1981) action of PCP and/or sigma agonists in various species are
not reversed by morphine or naloxone. These results suggest that
the sigma effects of benzomorphan opiates are due to their interac-
tion with the PCP receptor.
The PCP binding site may sometimes or always be a portion of the
receptor-effector complex of other drug receptors. It is interest-
ing that a synthetic drug like PCP is able to interact with a
uniquely patterned population of binding sites in rat brain. At
this time, we are uncertain whether this is due to an accidental
structural similarity to an as yet undiscovered endogenous ligand
or merely a fortuitous ability to interact with ions channels or
other neurotransmitter receptor-effectors.
Finally, our results indicate that the PCP receptor seem to be a
cortical and hippocampal receptor. This cortical distribution
seems appropriate for a receptor of a drug with striking "schizo-
phrenomimetic" properties (Snyder, 1980).
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Behavioral Dependence in Rhesus
Monkeys with Chronic Phencycli-
dine Administration
Barbara Lord Slifer, William L. Woolverton, and Robert L.
Balster
Phencyclidine (PCP) has been shown to function as a reinforcer to
maintain operant responding. Monkeys will intravenously self-
administer large quantities of PCP under unlimited-access con-
ditions (Balster et al., 1973; Balster and Woolverton, 1980). In
addition Balster and Woolverton (1980) recently reported the
occurrence of withdrawal symptoms indicative of physical depend-
ence following unlimited self-administration of phencyclidine for
20-30 days. While obvious physiological abstinence symptoms can
be reliably measured, more subtle, less easily observed disrup-
tions may be overlooked. Schedule-controlled responding has been
successfully used to establish stable and sensitive baseline pat-
terns of behavior. Such procedures are proving useful for quali-
tatively and quantitatively assessing the behavioral effects
associated with discontinuation of chronic drug administration.
In the past, marked alterations in schedule-controlled behavior,
indicative of withdrawal, were demonstrated to occur upon cessa-
tion of chronic morphine administration to rhesus monkeys
(Holtzman and Villarreal, 1973; Thompson and Schuster, 1964) and
rats (Ford and Balster, 1976) and following abstinence from pro-
longed ethanol drinking in rats(Ahlenius and Engel, 1974) and THC
administration in monkeys (Branch et al., 1980). In this study
we report the use of the disruption of operant behavior to examine
the effects of abstinence from chronic phencyclidine infusions in
rhesus monkeys.
METHODS
Four adult, male rhesus monkeys (Macaca mulatta) served as sub-
jects in this study. Two of the animals M566, M314) were experi-
mentally naive, while the remaining two monkeys (M173, 7623) had
previous experience in intravenous self-administration studies.
The animals were individually housed in self-administration
cubicles (0.8 x 0.8 x 1.0 m) and each wore a stainless steel
tubular harness and springarm which was attached to the rear of
the cubicle to restrain the animal and protect the catheter.
This permitted free movement of the monkey within the chamber.
The animals were surgically prepared with chronic indwelling
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catheters under PCP-pentobarbital anesthesia. The silicone rub-
ber catheter (0.8 mm lumen) was inserted into a jugular vein to
the level of the right atrium. The distal end of the catheter
was passed subcutaneously to an exit point on the animals back.
The external catheter was then threaded through the springann
and out the rear of the cubicle where it was connected to a
syringe pump.
Within the cubicle, two response levers were located on the clear
plexiglass door at the front of the chamber. Three red, 28V
lamps were mounted above each lever. The food hopper for the
externally mounted pellet feeder was located between the response
levers. Events within the chamber were controlled and recorded
by solid-state programming equipment located in an adjacent room.
The naive monkeys were trained to respond for banana-flavored
pellets on an FR1 schedule on the lever located to the right of
the feeder by baiting the lever with a raisin. The FR response
requirement was gradually incremented to a terminal value of 100
response (FR100) . Responses on the left lever had no programmed
consequences. Once the FR100 had been established, the animals
were given 30 min periods every 6 hrs during which they earned
their daily food ration. These response periods occurred at 4:00
p.m. (period A), 10:00 p.m. (B), 4:00 a.m. (C), and 10:00 a.m. (D).
During response periods the lights above the right response lever
were illuminated. In addition each response period was signalled
by a white noise alarm which was subject-terminated by the first
response on the FR lever. Following the establishment of food-
reinforced responding, the monkeys were started on continuous
saline infusions via their catheters at a rate of 0.84 ml/hr.
When responding for food reinforcement concurrent with saline in-
fusions had stabilized, the saline was replaced by 0.05 mg/kg/hr
PCP. All drug or saline substitutions took place at 8:00 a.m.,
2 hours prior to response period D (10:00 a.m.). Following 10
days of PCP administration, saline was administered again.
Response rates and food intake in each response period were re-
corded between 2:00-3:00 p.m. In addition, during this time
period the syringes and pellet feeders were refilled and the
monkeys were given fresh water and a vitamin suppliment. If
supplimentary feeding was required it was done at this time also.
Routine morning housekeeping chores (cubicle cleaning, watering
and routine checks) were performed between 7:00-8:00 a.m. daily.
RESULTS
The effects on response rates of the 10-day chronic administration
and subsequent withdrawal of 0.05 mg/kg/hr PCP are illustrated in
figure 1. This figure shows the response rates during each re-
sponse period for monkey M173. The saline control is based on the
5 saline days preceding PCP substitution. It can be seen that
during the first three days of PCP administration the mean re-
sponse rates (indicated by the solid line), were at or below con-
trol rates. The daily rates then increased over the remaining
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days of PCP administration to above saline control levels. On
day 10 the arrow indicates saline substitution for PCP. Eight
hours later during response period A the disruption in respond-
ing is apparent. The animals made very few responses during the
period and even fewer during the following two periods. Operant
responding in this animal was suppressed for 4 days before begin-
ning recovery to baseline levels. Upon observation during the
withdrawal period, the four animals showed signs of illness which
included emesis and refusal of a preferred food. These signs
were observed only during the first 12-24 hours after cessation
of PCP administration.
The averaged data for all 4 monkeys are summarized in Table 1.
The data are presented as overall mean response rates as percent
of control responding. Saline control is again based on the 5
days preceding PCP infusions. Predrug saline control rates for
the four monkeys averaged 1.90 (± .10) responses per second. The
chronic drug regimen significantly increased the mean response
rates above saline control levels and, concomitantly, the food
pellets earned also increased. The animals were generally ob-
served to consume all pellets earned during these periods. During
PCP administration the monkeys were observably intoxicated, exhib-
iting such signs as ataxia, nystagmus and decreased aggressive-
ness.
The response rate disruption during PCP withdrawal illustrated in
figure 1 was seen in all subjects (table 1). The other subjects
also showed a gradual recovery and mean rates of responding did
not return to control levels until day 7 or 8. The number of re-
inforcers earned was also suppressed during recovery and recovered
over 9 days of withdrawal. Due to the few pellets earned during
the early days of withdrawal, the subjects were given a small
amount of supplemental food to maintain their health. Mild phys-
ical signs and symptoms were occasionally observed in most sub-
jects during the first two days of withdrawal.
186
TABLE 1
Response Rates and Number of Reinforcers Earned
During Chronic Phencyclidine Infusion (.05 mg/kg/hr) and
Withdrawal in Four Rhesus Monkeys
aResponse rates for each animal for each response period were
calculated as percent of the mean response rates for that animal
for that period during the 5 days saline control. Numbers in
the table are the means of these values for 4 monkeys.
b Mean food pellets earned across all four response periods for
the days indicated. Values are the means of 4 monkeys.
*Significantly different from saline. p < 0.05
DISCUSSION
The response rate increases on the fixed-ratio schedule produced
by chronic PCP administration differ from other studies which
have reported only rate decreases in FR responding with PCP
(Wenger, 1976; Wenger and Dews, 1976; Chait and Balster, 1978).
These studies, however, were with species other than the rhesus
monkey (e.g. pigeon, mouse, squirrel-monkey). In general, the
overall response rate increases were due to a decrease in post-
reinforcement pause duration. These increases are particularly
interesting because of the very high baseline rates generated by
the FR schedule. The effects of acute PCP on response rates in
rhesus monkeys have been shown to be response-rate dependent
(Brady et al., 1980), with response rates greater than 0.1 resp/
sec generally decreased by PCP. The consistent increases we
obtained in the present study with much higher baseline rates
thus represent a qualitatively different effect of continuous-
PCP administration than is seen with acute administration.
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Following 10 days of PCP infusion at 0.05 mg/kg/hr (1.2 mg/kg/day),
response rates were markedly disrupted by 8 hours after saline
substitution. Average rates on the first day of withdrawal were
only 2% of control values. Responding was also markedly affected
for at least 7 or 8 days but did return to baseline values. We
were surprised by the gradual recovery from the disrupting effects
produced by the withdrawal of PCP. This was particularly inter-
esting in light of the disappearence of the observable physiologi-
cal signs of withdrawal distress within 24 hours following cessa-
tion of drug infusions. During the next few days following the
initial withdrawal, the animals took and consumed banana pellets
when offerred but would not work on the FR schedule to obtain
them. This suggests the sensitivity of the quantitative behav-
ioral measure to the subtle withdrawal effects of chronic PCP.
The suppression of responding upon removal of the drug was a re-
liable effect in all four subjects. This disruption in operant
responding is evidence for a behavioral dependence as defined by
Schuster and Thompson (1969); that is a disruption in behavior
upon termination of chronic drug treatment. Reversal of the
behavioral disruption by PCP administration would be further
evidence for behavioral dependence. We are in the process of
carrying out studies of the reversal of the withdrawal phenomenon
by PCP administration. This definition of behavioral dependence
is thus completely analogus to physical dependence except the
behaviors rather than physical signs and symptoms are assessed.
Therefore, based on the present study and our previous one
(Balster and Woolverton, 1980), PCP has been shown to produce
both behavioral and physical dependence.
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Comparison of Barbiturate and
Benzodiazepine Self-Injection in
the Baboon
Roland R. Griffiths, L. DiAnne Bradford, Scott E. Lukas,
Joseph V. Brady, and Jack D. Snell
ABSTRACT
Self-injection of three barbiturates (amobarbital.
pentobarbital, and secobarbital) and six benzodiazepines
(clonazepam. clorazepate, diazepam, flurazepam, medazepam. and
midatlom) was examined in baboons. Intravenous injections of
drug were dependent upon completion of 160 lever presses (a
160-response fixed-ratio schedule). A three-hour time-out
period followed each injection, pennitting a maximum of eight
injections per day. Before testing each dose of drug,
self-injection performance was established with cocaine.
Subsequently, a test dose was substituted for cocaine. The
three barbiturates maintained the highest levels of
self-injection, which were similar to those maintained by
cocaine, while the six benzodiaiepines maintained relatively
modest levels of self-injection. Of the six benzodiazepines,
the compound with the shortest duration of action, midazolam,
produced the highest levels of self-injection. At the highest
self-injected doses, the barbiturates produced anesthesia in
contrast to the benzodiazepines, which produced only sedation.
None of the drugs affected food intake.. The differences
between the barbiturates and benzodiazepines with respect to
the maintenance of self-injection correspond well with the
results of previous animal and human drug self-administration
studies.
Division of Behavioral Biology
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Experimental Induction of Benzodi-
azepine Physical Dependence
in Rodents
Norman R. Boisse, Ph.D., Gary P. Ryan, B.A., and John J.
Guarino, B.A.
INTRODUCTION
The 20-year mass cultural use of benzodiazepines as minor tranquil-
izers in the practice of medicine has led to a growing concern for
the possible risk of addiction. Hollister et al. (1961) demonstrat-
ed that benzodiazepines are capable of inducing physical dependence
leading to withdrawal hyperexcitability in patients receiving 100 to
600mg chlordiazepoxide (8-20 times therapeutic dose). Little effort
has been directed to reproducing this neuropathic state in animals,
Only Yanagita and Takahashi' (1973) have reported the induction of de-
pendence to chlordfazepoxide and diazepam culminating in nervous hy-
perexcitation including convulsions in the monkey.
Accordingly, we have engaged in chronic studies in rats and mice to
develop a reliable model of benzodiazepine tolerance and physical de-
pendence. Our efforts have focused on the "chronically equivalent
maximally tolerable" dosing paradigm previously developed in cats
(Okamoto et al. 1975). By this approach, the efficient induction of
benzodiazepine dependence is sought by administering the drug in as
large a dose as possible and as often as possible to insure continu-
ous intoxication without impairment of self-sufficient health. Doses
are individually selected to restore the same quantitative peak ef-
fect. This paper summarizes our pilot investigations with chlordiaz-
epoxide administered fntragastrically by gavage in the rat. These
studies led‘to the "chronically equivalent" chlordiazepoxide rat mod-
el (Ryan and Boisse, 1979; 1981). Initial attempts to apply this
dosing paradigm to the mouse were unsuccessful; the mouse could not
accept repeated gavage. Accordingly, we let the mouse take the drug
orally via the drinking water.
METHODS
Chronic Chlordiazepoxide Dosing in the Rat by Gavage
Male Sprague-Dawley rats (Charles River) were treated with chlordiaz-
epoxide hydrochloride (75 mg/ml). Before and at two-hour intervals
after each morning dose a neurological exam was performed on each an-
imal to quantify CNS depression. The exam consisted of ratings on
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screen grip, ladder test, motor activity, walking, crawling, right-
ing, wakefulness, arousability, respiration, wink reflex and flexor
reflex. The grading system and an 11-point scale to quantftate CNS
depression are described elsewhere (Ryan and Boisse, 1979; 1981).
To optimize dose-time coordinates optimal to induce severe dependence
in rats, pilot experiments were conducted to explore the influence of
dose level (anesthetic and ataxic peak effects), dosing fnterval, and
chronicity of treatment upon the severity of the resultant wfthdrawal
reaction. From acute dose-response explorations, the loading dose
was 450 mg/kg for the ataxic and 900 mg/kg for the anesthetic end-
point. Subsequent doses were indfvidually adjusted in 25 mg/kg steps
to restore the initial peak response. The dosing frequency was ei-
ther once daily in the morning or twice daily at 7am and 5pm. Chron-
icity was varied from one to five weeks.
Chronic Chlordiazepoxide in the Mouse via the Drinking Water
Hale Charles River mice (CD-l) were individually housed. Since
chlordfazepoxfde produced an aversion to drink, the initial concen-
tration of the drug was low to deliver only 10 mg/kg/day. In addi-
tion, the drug was dissolved in tap water containing 0.5% sodium
saccharin in an effort to mask the taste and encourage drfnkfng.
Based on the suppression of water fntake for the preceding 3 or 4
days and general condition, the concentration in the drinking water
was adjusted in 50 mg/kg steps to deliver doses that minimally de-
pressed water consumption for 10 weeks.
Quantitative Evaluatfon of Chlordfazepoxide Withdrawal
Following chronic chlordfazepoxfde dosing in the rat, the drug was
abruptly stopped and each animal was carefully observed for behavior-
al signs of wfthdrawal at least at 8am and 6pm untfl all signs disap-
peared. The characteristic signs are predominantly motor, autonomic
and behavioral disturbances (Ryan and Boisse, 1979; 1981). Many
signs were subjectively graded from 0 to 3 (maximum fntensfty.Some
signs that could not be quantitated were recorded as present (+) or
absent (O or N) or by indicating the direction of change. Objectively
measured withdrawal sfgns included body weight and food consumption.
All animals were mafntafned in an activity device to monftor the oc-
currence of convulsions. The protocol was sfmilar in mice.
RESULTS
Chlordiazepoxide Dose-Time Relationships for Dependence in the Rat
Results of the pilot explorations of dose, dosfng frequency, and
chronicity of treatment for induction of dependence is shown in Table
1. At least 4 rats survfved each of the seven treatment plans shown.
Once daily dosing to an ataxic end-point for 5 weeks produced a mild
wfthdrawal reaction based on both the number of withdrawal sfgns and
their peak Intensity which did not exceed grade 1. Since once daily
dosfng often failed to continually depress the CNS according to neuro-
logical criteria, twice daily ataxfc dosfng was explored. The influ-
ence of chronfcfty of dosing was also examined. As shown, wfthdrawal
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severity increased from 1 to 5 weeks. Five weeks produced the most
severe withdrawal reaction. Interestingly, the overall severity of
the withdrawal reaction was about the same for once dafly anesthetic
dosing and twice daily ataxfc dosing for 5 weeks. However, the survi-
val rate was greater (100%) for ataxic dosing. Accordingly, twice
dally ataxfc dosing for 5 weeks was adopted to develop our "chronical-
ly equivalent" chlordiazepoxide treatment plan.
Chronic Chlordiazepoxide in the Rat
Ffgure 1 summarizes the analysts of chronic dose and response through-
out the 5 weeks. The criterion of "chronically equivalent" ataxfc
peak effect was met as demonstrated by the constancy of the average
peak CNS depression rating throughout treatment with a mean of means
equal to 5.20 (± 1% S.E.). Since the total daily dose increased from
an inftial maintenance dose of 163 mg/kg on day 2 to a final mainte-
nance dose of 839 mg/kg on day 34, tolerance developed. The overall
magnftude of this tolerance represented a 5-fold increase in total
daily dose over the course of 5 weeks. Tolerance developed more rap-
idly over the first 3 weeks and then continued to develop more slowly
for the remainder of the treatment.
Chronic Chlordiazepoxide in the Mouse
Figure 2 summarizes the analysis of chronic dose and response (water
consumed) throughout the 10-weeks. Although drinking behavior is no
doubt influenced by chlordfazepoxide in the drinking water as well as
in the CNS, measurements of water consumption during chronic treat-
ment provided a quantitative measurement of the action of this drug
which limits dose increases and thus the utility of the approach.
Since dose was increased as normal levels of water consumption were
restored, dose increases reflect tolerance development. The top
tracing in Figure 3 shows that the level of water consumption was
fairly constant throughout treatment showing a slightly downward
trend only from weeks 8 to 10. Mean of means for daily water con-
sumption throughout treatment was 7.5 (± 0.30 S.E.) ml/mouse, which
is not significantly different from a parallel saccharin free control
(p> ;98). Mice drinkfng water containing only saccharin drank 8.8
ml/day. Since the delivered, dose increased from 9.4 mg/kg Initially
(day 4 to 7) to 742 mg/kg at the-end of chronic treatment (day 66 to
70), tolerance apparently developed. Because the daily water consump-
tfon was not appreciably affected by the fnitial dose, inftfal and
final dose comparisons may be exaggerating the actual magnitude of
tolerance developed. Accordingly, these results in the mouse cannot
be quantitatively compared to the rat data.
Chlordiazepoxide Withdrawal in the Rat and Mouse
All rats abruptly terminated from "chronically equivalent".chlordiaz-
epoxfde dosing showed severe withdrawal. Signs seen in all rats in-
clude twitches, tremors, muscular hypertonus, arched back, high step,
piloerection, apprehensive behavior, increased startle reaction and
weight loss. These rats exhibited 15 different signs. None exhibited
seizures. Figure 3 depicts the tfme-course of selected signs. The
latency to onset varied from 2 to 5 days. Peak was maintained from
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day 6 to 11. Recovery was usually complete 2 weeks after the last
dose.
All mice abruptly tennfnated from 10 weeks exposure in the water ex-
hibited withdrawal. Only 5 signs occurred in all mice: tremors,
tail ereitfon, piloerectfon, apprehensive behavior, and increased
startle reactions. No other sfgns were seen. The onset (Figure 3)
was fairly abrupt from 12 to 24 hours after removal of the drug.
Peak withdrawal persisted from 24 to 60 hours and recovery was com-
plete wfthfn 4 to 5 days. Compared to the rat, chlordfazepoxfde
withdrawal in the mouse was less severe, occurred earlier and within
a shorter time frame.
DISCUSSION
Physical dependence culminating in withbrawal hyperexcitation can be
induced in rats and mice. Like alcohol, barbiturates and opiates, the
severity of the withdrawal reaction varies wfth the magnftude of
chronic dose and duration of chronic treatment. The doses required
to induce severe dependence fn rats were 300 to 400 times greater
than the minimal anti-conflict effective dose (Cook and Davidson,
1973).
None of the rodents exhibited convulsion as has occasionally been re-
ported in man. This outcome mfght be due to the sequential biotrans-
formation of chlordiazepoxfde to pharmacologically active metabolites
which accumulate, and essentially slow, the rate of elimfnatfon of
active drug to facilitate  neuronal re-adaptation before the drug is
completely elfmfnated (cf. Bofsse and Okamoto, 1978b). These obser-
vations support the medical opinion that benzodiazepines are remark-
ably safe drugs from the standpoint of physical dependency.
The intragastric route in the rat is a more effective strategy to in-
duce chlordfazepoxfde dependence than the oral route vfa the drfnkfng
water in the mouse. The aversion of rodents to chlordfazepoxfde sol-
utions limits the future application of this method.
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TABLE I
PILOT EXPLORATION OF DOSE AND TIME
FOR INDUCTION OF CHLORDIAZEPOXIDE DEPENDENCE IN RATS
FIGURE 1
Equivalency of chronic chlordiazepoxide dosing in rat
Abscissa: time in days during chronic treatment
Ordinate, uppermost trace: the average peak depression rating after
each morning dose of chlordfazepoxide
Ordinate, lowermost trace: average total daily dose of chlordiaz-
epoxide.
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FIGURE 2
Analysis of chronic chlordiazepoxide dose and water consumption in
the mouse.
Abscissa: time in weeks during chronic treatment
Ordinate, uppermost trace: average mls of water consumed daily
over 3 or 4 day (biweekly) intervals.
Ordinate, lowermost traces: average daily dose actually con-
sumed: intended doses.
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FIGURE 3
Time course of selected signs during chlordfazepoxfde withdrawal
in rat and mouse
Abscissa: time in days from last dose of chlordiazepoxide
Ordinate, upper four traces: mean intensity of sign
Ordinate, lower two traces: incidence of apprehensive behavior
Solid dots refer to rat; open circles refer to mouse.
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The Etonitazene-Dependent Rhesus
Monkey as a Model to Study
Narcotic Agonist and Antagonist
Activities
Andrew H. Tang
Rhesus monkeys were rendered tolerant to and physically dependent
on the potent narcotic analgesic, etonitazene, when a solution of
etonitazene was available as the only drinking fluid. To maintain
a regular intake of the narcotic and to avoid overdose, the mon-
keys were trained to receive the drug solution by a limited-ac-
cess, self-administration schedule. This procedure can be fully
automated in operation, and withdrawal from etonitazene dependence
has properties similar to that reported for morphine-dependent
rhesus monkeys.
Narcotic agonists and antagonists were evaluated in the etonita-
zene-dependent monkeys by comparing their behavioral depressant
effects with those in a separate group of nondependent monkeys. Cross-
tolerance or precipitated abstinence in the dependent monkeys
could be demonstrated, dependent on the balance of agonist versus
antagonist properties.
INTRODUCTION
The morphine-dependent rhesus monkeys have been used for a number
of years in the evaluation of substances with morphine-like physi-
cal-dependence capacity (Deneau and Seevers 1962). The same pro-
cedure is also useful for the identification of narcotic antago-
nist properties by the precipitated abstinence syndromes
(Villarreal and Karbowski 1973). This procedure usually requires
subcutaneous injections of morphine every 6 hours around the
clock. In rodents, morphine dependence has been maintained with
morphine-containing pellet implantation. Gellert and Holtzman
(1978) were successful in producing stable morphine dependence in
rats by limited access to morphine-drinking solutions. The last
procedure has the advantage of requiring no regular handling for
injections or surgical preparations. We have adopted the same
concept of limited access to drinking of a narcotic solution in the
rhesus monkeys, using the potent narcotic compound, etonitazene.
The extreme potency of etonitazene makes it possible for a dilute
solution to be acceptable to the monkeys (Carroll and Meisch
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1978). The regularly spaced, limited-access schedule provided a
relatively stable blood level of the drug. When the behavioral
effects of drugs are compared between the dependent and nondepen-
dent animals, cross-tolerance to etonitazene or precipitated with-
drawal could be demonstrated.
METHOD
Three adult male rhesus monkeys (body weights between 4 and 6 kg)
were housed continuously in individual cages (18" x 24" x 30") in
a small air-conditioned room with ceiling illumination regulated
at 7 a.m. to 7 p.m. cycles. The cages were partitioned so that
the monkeys could hear but not see each other. The room has a
one-way viewing window open to an adjacent laboratory which housed
programming and recording equipment. The experimental subjects
were removed briefly each week for cage cleaning and weighing.
On the transparent plexiglass front doors of the cages were moun-
ted the following: two large primate response levers about 8"
above the floor and 8" between each other. Above each lever was a
set of three small stimulus lights. The left lever was always for
fluid reinforcement with the corresponding lights illuminated dur-
ing the drinking sessions. The right lever was always for food
reinforcement with the corresponding lights illuminated during the
food sessions. Midway between the two levers was a receiving cup
where the fluid or food pellets were dispensed in the correspond-
ing sessions. Above each cage were two 75 watt light bulbs which
were illuminated during either food or fluid sessions. In addi-
tion, each session was also accompanied by the presence of masking
noise in the room.
Solutions of etonitazene HCl were dispensed from a bottle placed
above each cage through a solenoid-controlled valve and which,
when activated for 0.2 seconds, produced 1 ml of the fluid in the
receiving cup. During food sessions, the reinforcement consisted
of banana-flavored Noyes pellets (190 mg). Experimental schedules
and data collection were controlled by standard programming equip-
ment in the adjacent room. Two TV cameras were mounted on the
wall facing-the front of the cages, and the behavior of the monkeys
during precipitated abstinence was videotaped for later analysis.
The daily routine consisted of 6 drinking sessions and one food
session. Each session lasted 15 minutes and was signaled by the
presence of the overhead lights above each cage, the illumination
of the stimulus light above the appropriate lever, and the white
noise in the room. The drinking sessions were scheduled to com-
mence at approximately 1 p.m., 5 p.m., 9 p.m., 1 a.m., 5 a.m.,
and 9 a.m. The food sessions always preceded the 1 p.m. drinking
session. Since food intake from the scheduled session was rela-
tively small, the animals were also fed regular monkey chow 10-15
pellets each afternoon about 3 p.m. No drinking water was avail-
able other than the etonitazene solution during the sessions.
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In the drinking session, responses on the left lever produced the
etonitazene solution on a FI-15 second schedule, i.e. the first
response, after 15 seconds elapsed from the preceding reinforce-
ment, produced another reinforcement. There was, therefore, a
maximum of about 60 ml of drinking fluid for each drinking session.
Responses on the right lever during this session had no conse-
quence, but were recorded as such. In the food session, responses
on the right lever produced food pellets in the receiving cup ac-
cording to a FR-30 schedule, i.e. every 30th response was rein-
forced.
Training of the monkeys to lever-press for food and drink-took less
than a week's time. The liquid reinforcement was initially tap
water, which was changed to low concentrations of etonitazene (be-
ginning at 0.3 µg/ml) as responses stabilized. The concentration
of etonitazene was increased stepwise to the final concentration
of 7.5 µg/ml after 3 weeks of training. Naloxone was injected
i.m. at weekly intervals to evaluate the level of physiological
dependence.
Drugs to be evaluated for cross-tolerance to etonitazene or preci-
pitated abstinence were injected intramuscularly 15 minutes before
the food-reinforced sessions. The disruption of food-reinforced
behavior in the dependent monkeys was compared to that in 3 nonde-
pendent monkeys. These 3 other male rhesus monkeys (comparable
body weights) lived in their home cages in an adjacent room with
continuous access to drinking water. Each animal was given a 30-
minute daily experimental session during which they were placed in
a restraining chair. The chair was equipped with a response lever
and pellet dispenser and was housed in a sound-attenuated chamber.
These 3 monkeys were trained to lever-press on a VI-60 second
schedule for food reinforcement (190 gm Noyes pellets). Once a
week, a test drug was injected i.m. 15 minutes before the experi-
mental session, and the disruption of this behavior was compared
to the immediately preceding saline-injected sessions.
RESULTS
Figure 1 shows a representative daily record of the responses in
the food and etonitazene-solution-reinforced sessions. The FR-30
schedule for food reinforcement (12:30 p.m.) generated a high rate
of lever presses. In contrast, the FI-15 second schedule for
drinking fluid produced schedule-appropriate lower rates. The
average intake of etonitazene and volumes of fluid consumed in the
6 daily sessions are shown in Figure 2 for the 3 dependent mon-
keys. Except for the 9 a.m. drinking session which is most dis-
tant in time from feeding, the monkeys seldom missed a drinking
session and usually received the maximum number of reinforcements
allowed by the schedule. Computed according to body weights, the
intake of etonitazene ranged between 350-550 µg/kg/day.
The dependent monkeys appeared to be completely tolerant to etoni-
tazene at these maintenance doses as they were healthy and showed
steady weight gain in the course of more than one year. Spontane-
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Figure 1
Cumulative record for one monkey responding for food (12:30 p.m.) and
etonitazene solution (15 minutes/4 hours). Each response moved the
recording pen upward one step, producing food reinforcements (downward
marks). Bottom pen marks fluid reinforcements (1 ml each). Paper did
not advance between sessions.
Figure 2
Average fluid land etonitazene) intake on control days for the three
dependent monkeys.
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ous abstinence occasionally occurred when a monkey missed two or
more consecutive drinking sessions. During the next 6 to 12 hours,
such monkeys displayed withdrawal signs of salivation, irritability,
stressful vocalization and other behaviors suggesting discomfort
(laying on the floor, bearing of teeth, etc.). An i.m. injection
of etonitazene (10/µg/kg) always restored normal behavior promptly.
Using the food-reinforced lever presses for quantitative evalua-
tion, the behavioral disruptive effects of drugs injected i.m. were
compared between these dependent and three nondependent monkeys.
The dose-response relations of several narcotic agonists are shown
in Figure 3. This group of compounds, including etonitazene it-
self, are less potent in the dependent animals, suggesting toler-
ance and cross-tolerance to this narcotic agent. In contrast, com-
pounds known to have narcotic antagonist properties are much more
potent in the dependent monkeys (Figure 4). Since the higher doses
of these antagonists which disrupted the food-reinforced lever
presses also produced signs of withdrawal, the effect on the oper-
ant behavior was probably the result of precipitated abstinence.
The narcotic agonists and antagonists, therefore, have opposite
patterns of effects in the two groups of monkeys.
Figure 5 shows the results of several other opiate derivatives which
disrupted the food-reinforced lever presses in both dependent and
nondependent monkeys with comparable potencies. These compounds
also produced an incomplete pattern of withdrawal syndromes. Sali-
vation and overt sedation were the most common overt effects ob-
served in both sets of monkeys.
DISCUSSION
Carroll and Meisch (1978) have shown that etonitazene solution pre-
sented for oral intake can serve as a reinforcer for lever presses
in nonwater-deprived rhesus monkeys. There are significant dif-
ferences in the two procedures since the dependent monkeys in the
present study had no access to drinking fluid other than the eto-
nitazene solution in the 6 daily drinking sessions. No attempt
was made to demonstrate the reinforcing properties of etonitazene,
Evidences suggest, in fact, that these 3 monkeys lever pressed for
etonitazene solution solely for hydration. For instance, monkeys
often did not work for all the available etonitazene solution in
the 9 a.m. drinking session, a time period furthest removed from
feeding. When a monkey was in a state of mild withdrawal, lever
presses for the etonitazene solution were usually further disrup-
ted rather than accelerated.
The self-administration paradigm in this procedure did provide a
convenient and precise regimen for the intake of the narcotic
agent, sufficient to maintain a stable state of tolerance and
physical dependence. The quantitative comparison in behavioral
effects between the dependent and nondependent monkeys separates
compounds with predominantly narcotic agonist or antagonist pro-
perties.
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Figure 3
Disruption of food-reinforced lever presses by narcotic analgesics in
the etonitazene-dependent and non-dependent rhesus monkeys. Each
point represents the average of three monkeys.
Figure 4
Disruption of food-reinforced lever presses by narcotic antagonists in
the etonitazene-dependent and non-dependent rhesus monkey. Each point
represents the average of three monkeys.
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Figure 5
Disruption of food-reinforced lever presses by some opiate derivatives
in the etonitazene-dependent and non-dependent rhesus monkeys. Each
point represents the average of three monkeys.
Opiate derivatives which have comparable potencies disrupting
operant behaviors in both dependent and nondependent monkeys
(Figure 5) belong to a third category. Two conditions could ex-
plain this phenomenon: For a mixed agonist-antagonist, behavioral
disruption may have been produced in the nondependent monkeys by
the narcotic agonist properties, whereas the same behavior was
disrupted in the dependent animals by the narcotic antagonist pro-
perties (precipitated abstinence). Both properties are expressed
at the same dose range so that the dose-response curves appear
similar, although the mechanisms of action were different. Both
butorphanol and nalbuphine are mixed agonist-antagonists with
relatively weak antagonist potencies. The similarity of the dose-
response curves may reflect their coincidental balance of the two
properties. Ketazocine and ethylketocyclazocine, on the other
hand, are known to have very weak antagonist activities. Both
compounds have been found neither to suppress nor to precipitate
abstinence syndromes in chronic spinal dogs (Martin et al. 1976)
or rhesus monkeys (Woods et al. 1979), both made dependent on mor-
phine. A kappa-type narcotic receptor distinct from the morphine
(mu)-type was postulated to mediate the CNS effects of these two
compounds. Results in this study are consistent with this explan-
ation in that the behavioral depressant effects of ketazocine or
ethylketazocine in the monkeys did not undergo cross-tolerance to
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etonitazene as did other narcotic agonists. The possibility that
butorphanol and nalbuphine may also possess this property in addi-
tion to their narcotic antagonist activities should also be con-
sidered.
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Dependence Potential of Buprenor-
phine Studied in Rhesus Monkeys
T. Yanagita, S. Katoh, Y. Wakasa, and N. Oinuma
Buprenorphine hydrochloride is an analgesic developed by
Reckitt & Colman, U.K.
The drug is an opiate partial antagonist having a high affinity
for opiate receptors and is known to exhibit a strong and
relatively long-lasting analgesic effect in animals and man.1,2
Specifically, the analgesic effect in man is approximately 30
times that of morphine, while the effects of the drug continue
longer than those of equipotent doses of morphine, pethidine,
or pentazocine.3 At the same time, the drug is a potent
opiate antagonist, the effect of which is reported to be nearly
equal to that of naloxone.1
METHODS
Experiment 1. Gross observation of the acute CNS effects of
buprenorphine in normal rhesus monkeys. Single doses of bupre-
norphine at 4, 15, 60 and 250 ug/kg, 1.0 and 4.0 mg/kg were
intravenously administered to 2 monkeys per dose level. In
addition, single doses of the drug at 15 and 250 ug/kg, and
1.0 mg/kg to 2 monkeys per dose level, and at 4.0 and 16.O mg/
kg to 4 monkeys per dose level, were administered subcutaneously.
Experiment 2. Effects of buprenorphine on the morphine with-
drawal signs of mophine dependent rhesus monkeys. Single
dosesofbuprenorphine at l and 16 mg/kg,morphine at 3 mg/kg,
and codeine at 16 mg/kg to 2 monkeys each, and physiological
saline at 0.5 and 5.0 ml/kg to 1 monkey each as control, were
subcutaneously administered in monkeys showing intermediate-
grade withdrawal signs after having been made physically'
dependent on morphine by repeated subcutaneous injection of
morphine HCl at 3 mg/kg 4 times daily (roughly every 6 hr) and
then withdrawn for 13-14 hr. The withdrawal signs were observed
for during 2 hr following administration.
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Experiment 3. Precipitation of withdrawal signs by single
adninistration of buprenorphine in morphine-dependent rhesus
monkeys. Using 8 of the morphine-dependent monkeys employed
in experiment 2, single doses of buprenorphine at 15 and 60
ug/kg, pentazocine at 4.0 mg/kg, and physiological saline were
subcutaneously administered to 2 monkeys each at 2 hr after
their regular dosing of morphine, and the precipitation of
morphine withdrawal sighs and their severity were observed for
during 1.5-2.5 hr following adninistration.
Experiment 4. Physical dependence test in normal rhesus monkeys
by repeated subcutaneous adninistration of buprenorphine.
Buprenorphine at 1.0 mg/kg was subcutaneously administered to
4 normal monkeys 4 times daily (roughly every 6 hr) for 31 days.
After a final administration at 1:00 pm on day 32, withdrawal
observation was conducted for 5 days. Starting on day 36, the
same pattern of repeated administration at 1.0 mg/kg was resumed
for 31 days, and a second 5 days of withdrawal observation was
begun after the final administration at 1:00 pm on day 67.
Precipitation of withdrawal sighs by subcutaneous adninistration
of naloxone at 1 mg/kg 2 hr after the 1:00 pm dosing of bupre-
norphine on days 14, 28, 49, and 63 was tried.
Experiment 5. Intravenous cross self-administration of bupre-
norphine with lefetamine and physiological saline in experienced
rhesus monkeys. The course of the experiment followed a pattern
of 4-hr daily self-administration sessions with the drug to be
self-administered changing every 3 days; first, 3 sessions with
the standard reinforcing drug lefetamine (SPA: 1-1, 2-diphenyl-
dimethyl-aminoethane HCl) at a unit dose of 0.1 mg/kg; next, 3
sessions with physiological saline; and finally, 3 sessions with
buprenorphine. The whole 9-session course was repeated 4 times
with a different unit dose tested for buprenorphine each time,
namely 0.25, 1, 4, and 15 µg/kg.
Experiment 6. Continuous intravenous self-administration of
buprenorphine in rhesus monkeys. Using 2 monkeys each with
and without previous experience in such experiments, self-
administration of buprenorphine under the FR 1 schedule was
observed. The unit dose of buprenorphine was shifted every 24
weeks upon necessity from among the doses of 4, 15, and 60 µg/kg/
inj. Since monkey No. 983 failed to initiate active intake of
the drug during this stage, timer-programmed forced adninistration
of the drug every 2 hr at a unit dose of 60 g/kg/inj was
performed for 2 weeks while self-administration was observed
during and after this period.
Experiment 7. Progressive ratio test of intravenous self-
administrtaion of buprenorphine and pentazocine. Four monkeys
were trained ahead of time to self-administer lefetamine under a
schedule of FR 100. The experiment consisted of 6 trials with
each monkey, each trial beingmadeupof 7 days of responding
under FR 100 and 1 progressive ratio trial beginning with self-
administration at FR 100 followed by increase of this ratio by a
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factor of for each succeeding drug administration until the
monkey ceased attempting toobtainthe drug as determined by the
criterion that the number of lever presses during the final 48 hr
failed to surpass 50% of the number required for the previous
administration, or that no administration had taken place during
72 hr, at which point the number of presses required for the
final delivered administration was taken as the score for the
trial. The order and type of trial in each monkey is shown in
Table 4, where trials 1 and 6 are for saline, while trials 2-5
are for buprenorphine at 15 or 60 µg/kg or for pentazocine at
60 or 250 µg/kg. During all trials, 15 min of time-out followed
each drug administration under either condition.
RESULTS
1. Acute CNS effects of buprenorphine in normal rhesus monkeys.
Immediately after intravenous injection of 4 mg/kg, both monkeys
showed depressed breathing and somewhat asthenic body posture
while sitting on the perch. From several minutes after injection,
eyes were half-closed, often closed, and when not closed the
animals would stare fixedly while holding anunchangingposture,
or engage in incessant skin scratching. This condition continued
for about 3 hr. The dose level at each succeeding observaticn
was l/4 of the previous, down to 4 µg/kg, with the overall result
that eye-closing was seen at mg/kg as well, and decrease in
responsiveness to man or other monkeys as well as to audio stimuli
was found at doses of 15 µg/kg or more. At 4 µg/kg, only slightly
increased skin-scratching was seen.
Subcutaneous adninistration of the drug produced nearly the same
effect as intravenous. That is, skin-scratching and decreased
responsiveness were seen at doses of 15 µg/kg or more. While at
1 and 4 mg/kg, eye-closing and marked depression were noted.
Beyond this, at 16 mg/kg, such signs of motor impairment as loss
of footing fmn the perch were also seen. The duration of the
drug effect was slightly longer than for intravenous adninistration
2. Effect of buprenorphine on the morphine withdrawal signs.
In morphine-dependent and withdrawn monkeys showing intermediate-
grade signs, injection of 1 or 16 mg/kg of buprenorphine tended
to worsen rather than suppress the signs. In contrast, 3 mg/kg
of morphine as well as 16 mg/kg of codeine administered
subcutaneously clearly suppressed the withdrwal signs.
3. Precipitation of withdrawal signs by single administration of
buprenorphine. Within 30 min after subcutaneous injection of
buprenorphine, withdrawal singsofthe intermediate gradewith
15 µg/kg and of the severe grade with 60 µg/kg were observed.
Administration of pentazocine at 4 mg/kg produced withdrawal
signs of approximately identical severity to those produced by
15 µg/kg of buprenorphine.
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4. Physical dependence test in normal rhesus monkeys. Upon
repeated administration of buprenorphine 1.0 mg/kg s.c., the
depressant effects gradually weakened and, except for the skin
scratching, almost completely disappeared by 2 weeks after the
start, showing the development of tolerance.
In the naloxine tests on days 14 and 28, monkeys transiently
exhibited the signs of abnormal posturing and restlessness, but
as autonamic nerve manifestations and nervous irritibility were
not present, these would be considered atypical as morphine-type
withdrawal signs. During the 5-day natural withdrawal observation
starting on day 32, no signs judged to be withdrawal signs were
observed.
In the second 3l days of administration from day 36, no signs of
drug effects other than slight weight loss in all 4 monkeys was
noted. The withdrawal signs were not especially stronger than
before in either naloxone test, and no withdrawal signs of any
drug type noted during the final natural withdrawal test (Table 1).
Table 1. Development of Physical Dependence by Repeated Administration
of Buprenorphine
5. Intravenous cross self-administration of buprenorphine with
lefetamine and saline. The highest intake rates for bupre-
norphine were at 1 µg/kg/inj in 3 monkeys and 4 µg/kg/inj in
the other 3. In spite of the large individual variation. a
significant increase over the rates for saline was recognized at
both doses (Table 2).
Table 2. Intravenous Cross Self-administration of Buprenorphine
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6. Continuous intravenous self-administration of buprenorphine.
The experiment was initiated in experienced monkeys, and because
self-administration of the drug was clear in spite of individual
difference, the experiment was repeated in the 2 naive monkeys.
Again, both monkeys showed self-administration although No. 963
initiated only after the -forced administration (Table 3).
During the periods of buprenorphine intake, the monkeys exhibited
some lessening of voluntary movement and decrease in responsive-
ness to the observer, but without marked depression or change in
general physical condition. No clear withdrawal signs were noted
during the saline period following active drug intake.
Table 3. Average Daily Number of Injection in continuous Intravenous Self-
administraton of Buprenorphine
S: Saline, B: Buprenorphine, Dose: µg/kg/injection, (): period-2weeks each
unless indicated
7. Progressive ratio test of intravenous self-adninistration of
buprenorphine and pentazocine. In contrast to the results with
saline, comparatively large scores were obtained in the following
trials for buprenorphine and pentazocine (Table 4). Specifically,
all monkeys showed higher swres for the larger unit dose of
pentazocine, while with buprenorphine, 3 out of 4 animals showed
higher scores for the lower unit dose of 15 µg/kg/inj.
Table 4. Results of Progressive Ratio Test
212
DISCUSSION
Tolerance and physical-dependence potential. Repeated adminis-
tration of buprenorphine to rhesus monkeys showed that within 2
weeks the depressant effects as seen in the gross behavior of
the monkeys became weak. In the self-adninistration experiment
as well, the effects observed in the animals became less clear
after the early stage, so that here as well the development of
tolerance could be recognized. It has been reported that,while
development of physical dependence on the drug has not been
observed in the various animal studies performed to date4,5),
weak withdrawal signs were observed during the withdrawal period
in man6). In the present study, no cross-physical dependence to
morphine was observed in the suppression test and no withdrawal
sign was observed even in the second natural withdrawal test,
but some minor atypical withdrawal sighs were precipitated in
the naloxone tests which did not exhibit any strengthening in
the sewnd test. Thus, from these results it remains unclear
whether the drug possesses a morphine-like physical dependence
potential or not, but even should there prove to be such a
potential, it would have to be a very weak and prectically
negligible one.
Reinforcing effect. In the intravenous cross self-administration
experiment with lefetamine, buprenorphine was found to have
clear reinforcing effect at the unit-doses of 4 µg/kg/inj or
more. In the continuos self-adninistration experiment also,
all 4 monkeys self-acbninistered the drug. In the progressive
ratio test it was found that, in terms of the highest scores
regardless of dose, 2 out of 4 monkeys scored higher on either
drug. However, the monkeys showing the high swres of 6400
each for pentazocine respectively scored only 2690 and 1350 for
buprenorphine, while on the other hand, the monkeys with higher
buprenorphine scores respectively achieved 3810 and 1600 for
buprenorphine versus 3200 and 1130 for pentazocine. These
results my indicate that the reinforcing efficacy of bupre-
norphine is not as high as that of pentazocine.
Dose level and gross behavioral manifestations during the
continuous self-adninistration experiment. The highest daily
dose of buprenorphine self-administered by any monkey in any
2-week period during this experiment was 3.3 mg/kg, intaken
by one of the naive monkeys (No. 983), while the highest daily
doses self-administered by the other monkeys were 2.51, 1.24,
and 1.07 mg/kg/day. These figures show a relatively wide
individual variation in the average daily dose level but
fall within a non-lethal dose range even if intravenously
injected all in one dose. This may be attributed to be an
extremely wide safety margin of buprenorphine in spite of the
fact that its effects are produced even at very small doses.
In addition, the fact that the monkeys, even though actively
taking the drug, did not at any time self-administer the drug
in excess of the tolerable dose level may be worthy of atten-
tion. Likewise, no monkey during self-administration exhibited
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marked depression or stimulation, nor were any acute toxic
manifestations noted. Taking these facts into consideration
together with the result that the drug's reinforcing efficacy
appearedtobe not so high, it is assumed that the psychological
dependence potential of buprenorphine may be lower than that of
pentazocine.
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Development of Selective
Tolerance to Particular Types of
Opiate Receptors
A. Herz, R. Schulz, and M. Wuster
The observation that certain opiates were unable to
suppress the manifestation of morphine abstinence in
the chronic spinal dog preparation led to the concept
of multiple opiate receptors (Martin et al. 1976). This
concept has subsequently been supported by the results
of a number of in vitro binding studies, whith have de-
monstrated the existence of a heterogeneity of opioid
binding sites within the central nervous system (CNS)
(Chang and Cuatrecasas 1979; Robson and Kosterlitz 1979;
Chang et al. 1980; Pasternak 1980; Snyder and Goodman
1980) and, most convincingly by the use of opioid-sen-
sitive peripheral tissue preparations (Lord et al. 1977;
Leslie and Kosterlitz 1979; Leslie et al. 1980; Hughes
1981). These latter studies were performed mainly upon
the guinea-pig ileum preparation (GPI), which contains
predominantly receptors which mediate the action of mor-
phine-like compounds ('µ-receptors'), and the isolated
mouse vas deferens (MVD) which displays a relatively
higher sensitivity to enkephalin than to morphine and
has, thus, been considered as a receptor preparation
(Lord et al. 1977).
It was recently discovered that the vas deferens of-the
rat (RVD), which is almost insensitive to both morphine
and enkephalin, is quite sensitive to ß-endorphin. This
led to the suggestion of the term -receptor for this
novel type of opiate receptor (Schulz et al 1979; Wuster
et al. 1979).
The data obtained from these three different prepara-
tions (GPI, MVD, RVD) are incorporated into the frame-
work of figure 1. The position of a compound in the tri-
angle reflects its preferential interaction with the
particular receptor type. Accordingly, the position of
[D-Ala2,D-Leu5]-enkephalin (DADL) at 99.1 percent on
the lower part of the MVD-GPI axis represents a 99.1
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FIGURE 1
Relative potencies of various opioids in in-
hibiting electrically induced muscle contrac-
tion in the isolated myenteric plexus-longitu-
dinalmuscle preparation of the guinea-pig ile-
um (GPI), the mouse vas deferens (MVD) and the
rat vas deferens (RVD). The compounds are ar-
ranged in the triangle according to their po-
tencies on the various preparations. The sides
of the triangle represent relative potencies
expressed on a percentage scale. To represent
small differences between compounds a probit
scale is employed for graduation (see Wuster
et al 1979).
percent selectivity of the compound for the MVD and a
0.9 percent selectivity for the GPI. ß-Endorphin, loca-
ted approximately in the center of the triangle has an
about similar activity in all three preparations (for
details see Wuster et al. 1979, 1980).
The interpretation of the data derived from the results
obtained upon these in vitro preparations might be com-
plicated by the possible heterogeneity of opiate recep-
tors in the particular preparations. It has indeed pre-
viously shown by means of the technique radioreceptor-
assay that the MVD also contains p-receptors in addition
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to receptors (Leslie et al. 1980).
If a multiplicity of opiate receptors implies the inde-
pendent occurrence of Certain receptor types, an essen-
tially different approach to the study of these recep-
tors may be achieved by means of their chronic activa-
tion proposed by Martin et al (1976). A prolonged selec-
tive activation of a particular receptor population
should then induce the development of tolerance and de-
pendence in only this specific population, leaving other
opiate receptor types unaffected. It was expected that
the MVD would provide a suitable preparation for the
testing of this hypothesis.
Mouse vas deferens
Mice were chronically treated with particular opiate
receptor agonists, e.g. the specific -receptor agonist
DADL and the µ-receptor agonist sufentanyl (SUF). Long-
term infusion of these drugs was accomplished by means
of subcutaneously implanted minipumps. After 6 days in-
fusion, the isolated vasa were set up in solutions con-
taining concentrations of the respective drug appropri-
ate to the maintenance of tolerance (Schulz et al.
1980a, b).
FIGURE 2
Dose-response curves for [D-Ala2,D-Leu5]-en-
kephalin (DADL) on the electrically stimula-
ted isolated mouse vas deferens.
Data are for preparations from untreated mice
and from mice infused with 0.5 g DADL per h
1.5 g per h and 5 g per h for 6 days.
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Figure 2 represents the dose-response curves of the
vasa deferentia of these chronically treated mice for
DADL in comparison to those obtained from vasa of naive
mice. There is a tremendous shift of the dose-response
curve to the right, indicating an about 800-fold degree
of tolerance, whereas the dose-response curve- for SUF
remains largely unchanged. In contrast, continuous in-
fusion. Of the animals with SUF induced an about 1000-
fold tolerance without changing sensitivity to DADL.
The question arises whether the occurrence of further
receptor types can be demonstrated in the MVD.
Figure 3 depicts the extension of this type of experi-
ment in which, in addition to SUF and DADL, various
agonists (ketocyclazocine, MR 2034 and MRZ) were chro-
nically applied by minipumps (Wuster et al. 1981); the
vasa of these differently treated mice were then tested
with the various opioids. The degree of tolerance re-
vealed in these experiments is expressed as a quotient
Q reflecting the ratio of the inhibitory dose for 50
percent inhibition (ED50) of the tolerant preparation
in comparison to the ED50 of the naive preparation. The
higher this quotient, the higher the degree of toler-
ance. DADL-infused mice exhibit a high degree of toler-
ance when tested with DADL, but no cross-tolerance to
SUF and various -agonists. SUF-infused mice lack cross-
tolerance to both DADL and to -agonists. The various
-agonists employed here also do not show cross-toler-
ance to SUF and DADL. Within this -group, however,
varying degrees of cross-tolerance are seen, indicating
that these -agonists themselves are not homogeneous.
Interesting are the results obtained when these various
preparations are tested with dynorphin (DYN), a recent-
ly detected opioid peptide exhibiting particularly high
potency. There is no cross-tolerance either to µ- and
agonists. Summing up these data, the presence of at
least three types of opiate receptors in the MVD - with
these types not necessarily homogeneous with reference
to agonists - is indicated. There is an indication
that the µ-receptors are also not an uniform population.
The question as to the mechanism this underlying selec-
tive tolerance arises. Attempts to resolve the question
whether this high degree of tolerance is accompanied by
changes in the number of binding sites for the particu-
lar ligand are hampered by methodological difficulties.
Preliminary results seem to support the notion that
this tolerance is not associated with a loss of speci-
fic opioid binding sites. Interestingly, in these high-
ly tolerant preparations, naloxone completely failed to
precipitate a withdrawal sign (Schulz et al. 1980b).
This may be interpreted as an indication that the adap-
tational changes take place at the level of the opiate
receptor and not at subsequent steps in the effector
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Tolerance and cross-tolerance produced by
different opiate receptor agonists in the
mouse vas deferens. The degree of tolerance
measured by calculating the quotient (Q) of
the IC50 values of tolerant and naive pre-
parations is plotted on the ordinate. Q = 1
indicates lack of tolerance. The drug chemi-
cally infused is indicated in each panel.
Abscissa: Opioids tested for tolerance and
cross-tolerance. Each column represents the
quotient of the IC50 values of 6 experiments.
system. In this context, it seems to be important to
note that the MVD does not contain somata and the re-
ceptors are located exclusively at the nerve terminals.
This observation may be of significance since prepara-
tions where tolerance is accompanied by dependence, ex-
pressed as withdrawal signs do apparently contain soma-
ta.
Guinea-pig ileum
There are certain data indicating that the longitudinal
muscle-myenteric plexus of the guinea-pig ileum ("strip")
does not represent a pure µ-receptor preparation, but
also contains -receptors while the possible presence
of functional -receptors remains an open question
(Leslie et al. 1980). In view of the fact that this
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preparation develops tolerance which appears to be cor-
related with the development of dependence (Schulz and
Herz 1976; Herz and Schulz 1979), it was of particular
interests to investigate whether selective tolerance to
various opioid agonists can be demonstrated in this pre-
paration, too.
Guinea pigs were rendered highly tolerant by continuous
infusion of various opioids via osmotic minipumps (a
few compounds i.e. morphine, ethylketocyclazocine,
which were not sufficiently soluble in water, were ad-
ministered via subcutaneously implanted pellets). After
5 days, the "strip-preparations" were set up in solu-
tions containing concentrations of the respective drug
appropriate to maintain tolerance.
The development of tolerance selective to various opioid
agonists, as was seen in the mouse vas deferens, was
observed. There were, however, some remarkable diffe-
rences. When strips obtained from guinea pigs chroni-
cally infused with fentanyl were tested against a se-
ries of opioid agonists, a high degree of cross-toler-
ance between various µ- and -agonists was evident,
whereas the sensitivity to the various -agonists re-
mained largely unchanged. Very similar results were ob-
tained in DADL-infused guinea pigs. The various -ago-
nists revealed a varying degree of cross-tolerance to
µ- and -agonists. From this still incomplete data, it
emerges that various types of opiate receptors, which
can independently develop quite high degrees of toler-
ance, are present in the strip-preparation. It may be
expected that a detailed investigation of the withdra-
wal precipitable in these preparations, showing selec-
tive tolerance to the various agonists, may reveal in-
formation as to how far the various receptors partici-
pate in the development of physical dependence.
Central nervous system
A similar approach was adapted for the investigation of
the central nervous system (Schulz et al 1981). In rats,
SUF was continuously infused by subcutaneously implan-
ted osmotic minipumps and DADL by minipumps which de-
livered the drug directly into the 3rd ventricle. After
5 days, analgesia (vocalization response after electri-
cal tall stimulation) and catatonia (estimated according
to a scoring system) was tested by evaluation of dose-
response curves for DADL (i.c.v. injection) and SUF
(s.c. injection). There was a clear separation of the
development of the tolerance to the particular drugs.
As an example, figure 4 shows that DADL-infused rats
developed a more than 10-fold tolerance for catatonia
when tested with DADL, but not when tested with SUF. An
opposite. pattern of results, was obtained in SUF-infused
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FIGURE 4
Dose-response curves for the catatonic ef-
fect of [D-Ala2,D-Leu5]-enkephalin (DADL)
(A) and sufentanyl (B) in control rats (0,
saline-infused) and rats chronically infused
 with 5 µg DADL per hour 10 g/h and
50 g for 7 days.
rats: 10-fold tolerance when acquired with SUF, lack of
tolerance when tested with DADL. In principle, similar
results were obtained for analgesia - although in this
case, the separation of the effects induced by both
drugs was somewhat smaller.
Thus, these experiments show that selective tolerance
to various agonists may be developed in the central ner-
vous system. It is, on the other hand, interesting to
note that identical (or at least similar) effects, e.g.
analgesia, may be obtained by activation of different
types of receptors. This contrasts to some extent to
some recent results which claim a close relationship
between analgesia and µ-receptor activation (Goodman
and Snyder 1980); they are, however, in accord with the
recent findings showing that the primary afferent fibres
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to the dorsal horn which carry nociceptive information
contain µ- as well as receptors (Fields et al. 1980).
Much more work is, however, needed in order to get more
convincing results for the highly complex central ner-
vous system. There is no information available as to
whether the withdrawal in rats, showing selective to-
lerance to the specific reseptor ligands, differ from
each other.
Concluding Remarks
The significance of studies concerning the development
of selective tolerance to different opioid receptor a-
gonists in view of a differentiation of various types
and subtypes of opiate, receptors is quite evident.
Studies along this line may also offer a promising ap-
proach to an understanding of the problems related to
the development of tolerance/dependence and the mecha-
nisms underlying these phenomena. Answers to the ques-
tions as to tolerance and dependence are separable un-
der certain conditions or whether effects mediated by
different types of opiate receptors underly different
adaptational changes, upon chronic drug supply may be
answered by this methodology.
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Is Drug Abuse Treatment Effective?
A. Thomas McLellan, Ph.D., Charles P. O’Brien, M.D., Ph.D.,
George E. Woody, M.D., Lester Luborsky, Ph.D., and Keith A.
Druley, Ph.D.
INTRODUCTION
The effectiveness of drug abuse treatments has been challenged in
the popular and professional literature and by recent Federal
funding decisions. Yet few evaluation studies have adequately
assessed the effectiveness of these treatments using an appro-
priate range of reliable outcome measures, a representative sample
of treatment modalities, or more than one perspective on treatment
effectiveness. The present paper examines substance abuse treat-
ment effectiveness from five perspectives, using a sample of 282
patients treated in 3 programs and evaluated at six month follow-
up. The five areas examined include:
1. Do patients improve following treatment?
2. Are improvements confined to drug use, or more pervasive?
3. What are the sizes of these improvements in standardized
terms?
4. How do these improvements compare with those from other
treatments?
5. Are these improvements due to treatment?
Due to space limitations, only a summary of some of the salient
findings will be presented. A more detailed account of the
methodology and results for both our drug-abusing (N=282) and
alcoholic (N=460) populations is available, from the senior author.
METHOD
Subjects - All male veterans who were admitted for drug abuse treat-
ment at either the Coatesville or Philadelphia VA Medical Centers
during 1978 were eligible for the study, There were no significant
differences in demographic or background characteristics between
patients in the two hospitals, and approximately 90 percent of all
subjects were Philadelphia residents. There were no treatment ad-
mission criteria other than eligibility for veterans’ benefits.
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We initially evaluated 325 male veterans who were admitted to the
three drug abuse rehabilitation programs at the Coatesville or
Philadelphia VA Hospitals during 1978, and who remained in re-
habilitation treatment at least five inpatient days or five out-
patient visits. We were able to contact approximately 89 percent
of the remaining patients six months after admission to treatment,
thus, complete data were available on 282 subjects.
Treatment Programs - The drug abuse treatment network of the
Veterans Administration in the Philadelphia area consists of 2
inpatient programs at the Coatesville VA Medical Center, plus an
outpatient methadone clinic at the Philadelphia VA Medical Center.
Patients were assigned to one of the rehabilitation programs on
the basis of their personal requests, the clinical judgement of the
admitting staff, administrative considerations such as bed census
or patient visit criteria, and simple chance.
PROCEDURE
Admission - The admission and follow-up evaluations were based upon
data from the Addiction Severity In&x (ASI) (McLellan et al. 1979).
The ASI is a structured, 30-40 minute, clinical research interview
designed to assess problem severity in six areas commonly affected
by addiction. These areas include medical, legal, substance abuse,
employment, family, and psychological problems. In each of the
areas, objective questions are asked measuring the number, extent,
and duration of problem symptoms in the patient’s lifetime and in
the past 30 days. The patient also supplies a subjective report of
the recent (past 30 days) severity and importance of the problem
area. The interviewer assimilates the two types of information to
produce a rating (0-9) reflecting the extent to which treatment is
needed by the patient in each area. These 10-point ratings have
been shown to provide reliable and valid general estimates of
problem severity for both alcoholics and drug addicts (McLellan
et al. 1979), and the individual items offer a comprehensive basis
for clinical and experimental assessment at the time of admission
to treatment and at subsequent evaluation periods.
Follow-up - All follow-up evaluations were done through ASI inter-
views between an independent research technician and the patient,
either in person or over the phone. No information from secondary
sources was used and all data were closely monitored to preserve
confidentiality. The validity of these data were of particular
concern in this study and are discussed separately (McLellan et
al. in press). The reader is referred to that source in the
interests of space limitations.
Outcome Criteria - It was important for the aims of this study to
have general measures of treatment outcome, since single- item
measures can be inherently unreliable. We-therefore constructed
criterion composites from sets of single items within each of the
problem areas. Several items from each problem area were inter-
correlated to exclude those which were unrelated, and the remaining
items were standardized and tested for conjoint reliability. A set
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TABLE 1
ADMISSION TO SIX-MONTH FOLLOW-UP CHANGE
IN MALE DRUG ABUSE PATIENTS
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of 3 to 5 objective items from each ASI problem area was selected
using this procedure, and each set showed a standardized reliability
coefficient of .73 or higher. Seven composites (medical problems,
employment, drug use, alcohol use, legal status, family problems,
and psychological function) were constructed in this manner and
scores on each composite were calculated for all patients at ad-
mission and follow-up.
DISCUSSION
We examined the results of substance abuse treatment in a sample of
male veteran alcoholics and drug addicts treated in our rehabili-
tation programs. Highly reliable composite measures were recorded
at admission in seven areas commonly affected by addiction. These
same measures were again recorded on an 89-percent follow-up sample,
six months later by independent technicians. Results provided data
on five different evaluation issues.
Do Patients Show Significant Improvement Following Substance Abuse
Treatment? Based upon our within-group paired comparisons of
admission and follow-up status (table 1), the answer is unequivo-
cally "yes." Highly significant improvements were seen in both our
composite criteria (indicating general problem status) and in the
single- item measures.
Are Improvements Specific to Drug Use or More Pervasive? Results
of both the within and between-group comparisons indicated signi-
ficant improvements in most of the seven criterion areas. The most
significant improvements were shown in the target area of drug use,
but highly significant improvements were also shown in the areas
of employment, legal, family and psychological status.
Perhaps the only clear exception to this general improvement was
the area of medical status or physical health. We have no reason
to believe that medical treatment was particularly poor for these
patients but rather it is likely that many of the physical problems
of these patients were underreported at treatment admission (due
to the anaesthetic effects of drugs and alcohol) and that many of
the medical problems which were reported by these, patients were
chronic in nature, with little chance of significant remission.
What is the Magnitude of the Improvements? While tests for sig-
nificance of difference measure the likelihood that a difference
between two distributions of scores is due to chance, effect-size
measures assess the amount of difference between the distributions.
These effect-size measures are calculated in terms of the number of
standard deviations (which can in turn be converted to Percentiles)
between the admission and follow-up distributions and are presented
in the last column of table 1.
As in the case of the paired t-test data, the greatest changes
occurred in the target area of drug use but moderate to large
changes also occurred in the areas of employment and legal status.
In practical terms these improvements translated to a 67 percent
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reduction in opiate use, a 50 percent reduction in stimulant tie,
a 67 percent decrease in crime days and a 386 percent increase in
earned income. Thus, the evidence here and from other studies
suggests that the major improvements following drug abuse treatment
are in illicit drug use but that there are several other areas
which show moderate to major changes.
How Do Substance Abuse Treatments Compare With Other Psychological
Treatments? A meta-analysis comparison of treatment effect-sizes
was performed between the fully treated groups of the present study
and data from Smith and Glass’ (1980) study of 475 psychotherapy
studies. Our drug abuse treatment effects were comparable to those
shown by studies of professional psychotherapy in the criterion
areas of drug use, employment, and legal status. However, the
overall levels of treatment effect-sizes were generally higher in
the psychotherapy treatments .
It seems likely that these differences are due in part to the tire
specific orientations of substance abuse treament, in part to
differences in the level of training between the therapists, and in
part to differences in control groups. As indicated, the primary
therapists in the present study were technicians doing rehabilita-
tion counseling, while the majority of psychotherapy studies used
doctoral- level therapists.
Is Patient Improvement Due to Treatment? We recognized that despite
the significant improvements shown, there was no clear evidence
that the changes were due to the treatment process. We had some
indication that greater amounts of treatment were associated with
better outcomes, but in order to evaluate this issue more closely
we required an appropriate control group. In an attempt to provide
such a group, we selected all subjects from our population who had
received more than five but less than fifteen days of rehabilitation
treatment and had received a favorable discharge.
These “shortterm” patients were not assigned to this group in a
random manner. However, in several respects, this group provides
an appropriate and conservative comparison. First, although the
treatment assignments of the long and shortterm patients were not
random, they were made on an equal basis. All patients were
assigned to treatment on the basis of their personal requests, bed
availability and other administrative factors. Since the distri-
bution of treatment program assignments was not significantly
different between the longterm and the shortterm patients, it is
not possible to argue that the ST patients had entered into less-
favored treatments or were assigned differently.
It is possible to argue that these shortterm patients had less
motivation, thereby accounting for their shorter time in treatment.
However, all ST patients completed five to fourteen days of re-
habilitation therapy at their assigned program, Further, all had
received favorable discharges, indicating that they had left with
adequate discharge planning and were not ejected for disciplinary
reasons. Finally, there was no evidence to suggest that these
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patients had a poorer prognosis at the time of treament admission
or at discharge. We cannot completely rule. out the possibility of
differences in nwtivation between the two groups; however our prior
work (Luborsky and McLellan, 1978; McLellan and Druley, 1977) has
shown that neither staff nor patient ratings of motivation are
systematically related to length of time in treatment or to type
of discharge. We do not contend that the shortterm group is the
optimum control group, only that it is a valid and unusually con-
servative comparison to the longterm group, providing a useful
estimate of actual treatment effects.
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cantly better outcomes and several large treatment effects in com-
parison. We would argue that these data provide a clear and valid
demonstration of substance abuse treatment effectiveness. The
important questions of cost-effectiveness and cost-benefit remain
to be adequately assessed, and we will address these issues in
future reports.
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Withdrawal from Heroin in Three or
Six Weeks: Comparison of LAAM
Versus Methadone
James L. Sorensen, Ph.D., Wm. A. Hargreaves, Ph.D., and J.
Arthur Weinberg, M.D.
In this paper we abstract a clinical trial in outpatient detox-
ification with heroin addicts. A full report of the study will
appear in the Archives of General Psychiatry, in an article of
the same title.
One of the problems with drug treatment is that short-term detox-
ification is ineffective in encouraging heroin users to adopt a
drug-free lifestyle, even though a three week time limit has been
set by Federal law. Another problem is that outpatient detoxifi-
cation programs require patients toattendaclinic everyday.
There is some evidence that a longer detoxification may allow
clients to give up opiates. In addition, a longer-acting opioid
like levo-alpha acetylmethadol (LAAM) allow alternate-day
clinic attendance. To sum up, both LAAM as an alternative to
methadone and a withdrawal program longer than three weeks may be
more useful than the standard 21-day methadone detoxification.
In this study 61 heroin addicts were randomized to one of four
study groups: six weeks of LAAM, six weeks of methadone,three
weeks of LAAM, or three weeks of methadone. The six-week proced-
ures included three weeks of steady dosing before the dose de-
creased to zero. Outcome measures included length of stay in the
program, use of illicit drugs, withdrawal symptoms, patient satis-
faction, clinician ratings of global progress, and status at fol-
lowup three months later.
As expected, subjects assigned to six weeks stayed in treatmnt
longer, although subjects in the three-week LAAM group were most
likely to stay until the end of active dosing. Most patients
used heroin during treatmant,with few differences among experi-
mental groups. Those assigned to six weeks were more likely to
be opiate free in the third week of treatment. Comparisons among
treatment groups on withdrawal discomfort showed no differences:
Initial doses of LAAM suppressed withdrawal symptoms the same as
initial doses of methadone, and withdrawal symptoms appeared in
both LAAMM and methadone subjects at the end of dosing. The re-
sults did not support the idea that LAAM is "self-tapering."
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Subjects in the six-week groups were rated more improved in their 
global progress and in halting the use of opiates. 86 percent of
the subjects were reached for followup approximately three months
after intake. The effects of treatment had not endured-only two
subjects had remined continuously abstinent from heroin. Sub-
jects who had received LAAM tended to return to heroin use more
quickly than those who had received methadone.
To sum up, there were some temporary benefits to extending the
time limit on detoxification to six weeks; however, the benefits
did not endure. This wasthe first attempt to evaluate the use
of LAAM in detoxification programs. LAAM performed similarly to
methadone. Detoxification programs need many further improvements
if they are to bring narcotic addicts to a drug-free state.
Lengthening detoxification beyond 21 days may not improve the
ultimate "abstinence rate" of patients, but it may improve effect-
iveness on more limited indicators of outcome.
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Self-Regulated Opioid Detoxifica-
tion by Humans: Effects of
Methadone Pretreatment
Daniel R. McLeod, Ph.D., George E. Bigelow, Ph.D., and Ira A.
Liebson, M.D.
Relatively little experimental attention has been devoted to
study of the opioid detoxification process. Despite the fact
that in clinical practice most detoxifications are conducted
gradually, virtually all experimental data characterizing the
opioid withdrawal syndrome involve abrupt termination of opioids
(e.g., Martin et al. 1973).
The withdrawal syndrome is typically characterized as being sub-
jectively severe but objectively mild (Senay et al. 1977), and
adjunct medications frequently are prescribed to relieve insomnia
and subjective discomfort of detoxifying patients (Jaffe 1980;
Washton and Resnick 1980; Razani et al. 1975). Few data are
available concerning the utility of such adjunct medications,
however.
In the present experiment we have used an experimental human drug
self-administration methodology to evaluate the effects of pharma-
cological pretreatments upon opioid drug-seeking and self-admin-
istration behavior, as well as upon the signs and symptoms of
gradual opioid detoxification.
METHODS
Participants. Six male volunteers between the ages of 25 and 37
participated. All were methadone-maintenance patients requesting
detoxification from methadone. Methadone-maintenance doses at
enrollment ranged from 30 to 80 mg. Addiction histories ranged
from 7 to 20 years duration (x = 12.0). Each patient gave written
informed consent prior to participation.
General method. Within an eight-bed residential behavioral
pharmacology research laboratory human drug self-administration
methods were used to assess the effects of pretreatment with
placebo and two doses of methadone upon methadone self-administra-
tion behavior and upon the signs, symptoms, subjective and behavi-
oral effects of methadone detoxification. Patients engaged in
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self-regulated methadone detoxification by engaging in operant
responding to obtain 4-mg doses of methadone. Pharmacological
pretreatments occurred on a randomized schedule as described below.
Instructions. Patients enrolled for a six-week study duration.
They were informed that their methadone detoxification would be
totally self-regulated, with their total daily methadone intake
being determined by their own performance on the simple operant
task described below. Patients were given no recommended schedule
of detoxification except that they should plan to be totally drug-
free for at least one week prior to their scheduled hospital dis-
charge. Patients were informed that on some days they would re-
ceive pretreatment medication bottles which might contain either
inactive placebo or various doses of methadone. Patients were
informed that no drugs other than methadone would be administered
either for experimental reasons or for relief of withdrawal dis-
comfort.
Methadone self-administration. Daily six-hour sessions of metha-
done self-administration occurred between 12:00 p.m. and 6:00 p.m.
During this period subjects could earn 4-mg doses of methadone-by
completing a specified fixed number of responses on a portable
radio transmitter operant-response console (fixed-ratio schedule).
This hand-held operant-response console permitted patients to work
for methadone while ambulatory within the research ward dayroom
and while concurrently engaged in other activities. Each effective
response on the console required that the button be depressed for
one second. The fixed-ratio requirement was initially 300 (FR 300)
and was increased as described below. Unless a pretreatment bottle
was dispensed, the only methadone received was that earned during
the daily self-administration session. The maximum dose available
for self-administration each day was equal to the patient’s main-
tenance dose or the next larger multiple of 4 mg. Methadone
earned during the daily self-administration sessions was either
dispensed in individual 4-mg doses as earned (three subjects) or
accumulated and dispensed as a single dose at the end of the ses-
sion (three subjects).
Methadone pretreatment. For each patient, days on which a pre-
treatment was administered alternated with days on which no pre-
treatment was administered. When two patients on the ward were
participating in the study, only one received a pretreatment on
any given day. On pretreatment days subjects were required to
consume the contents of a bottle containing either placebo, 15 mg,.
or 30 mg of methadone at 9:00 a.m., three hours prior to the start
of the daily self-administration session. Procedures were double-
blind, and neither the subjects nor the nursing staff were in-
formed of the magnitudes of the doses under study. All doses were
dispensed as liquid prepared from cherry-syrup solution (Metha-
dose). To minimize the possibility that a subject could deduce
either the presence or the dose of methadone given, dextromethor-
phan was used as a taste mask, and the total volume of liquid in
any pretreatment bottle was varied in a randomized block fashion
among 30, 60, or 90 cc so that no dose was correlated with any
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given volume of medication.
Each of the three pretreatment conditions was administered five
times to each patient. The order of administration was scheduled
in randomized block fashion. No pretreatments were scheduled for
at least the first five days of methadone self-administration.
Then the effects of the first block of pretreatment doses were
assessed while the FR requirement remained at 300 responses.
Effects of the second, third, fourth, and fifth blocks of doses
were assessed at FR requirements of 600, 1200, 1800, and 2400 re-
sponses, respectively.
Psychophysiological measures. For each patient, temperature,
pulse, respiration rate, blood pressure, and pupillary diameter
(measured photographically) were recorded daily at 8:30 a.m. and
11:00 a.m.
Subjective measures, Multiple subjective effect measures were
recorded daily. At 8:30 a.m. patients completed a 60-item symptom-
rating scale developed in our laboratory which is a sensitive
measure of opiate withdrawal effects; this reported on their ex-
periences during the preceding 23-24 hours (effects of the pre-
ceding day’s methadone). At 11:00 a.m. patients completed three
true/false scales of the Addiction Research Center Inventory
(Haertzen 1974): the Morphine-Benzedrine Group scale (MBG,. 49
items), a version of the Weak Opiate Withdrawal scale (WOWs, 35
items), and the Chronic Opiate scale (ChrO, 26 items); these re-
ported on their immediate experiences. At 6:00 p.m. patients
completed the Profile of Mood States (POMS), a 65-item mood-rating
scale providing scores on multiple mood dimensions; this reported
on their mood throughout that day.
Performance measures. Each patient’s psychomotor performance was
assessed daily at 8:30 a.m. and 11:00 a.m. using a commercially
available Saccadic Fixator and Sequence Rotator (Wayne Engineer-
ing). In a standing position patients faced a circular panel of
lights and associated pushbuttons; throughout a one-minute trial
single lights in the array were illuminated in a random order and
remained illuminated until the subject pressed the associated
pushbutton, at which time another light position in the array was
illuminated. Performance score was a count of the number of
lights extinguished per one-minute trial.
RESULTS
Five of the six participants successfully reduced their methadone
intake to zero in this self-administration paradigm. Thus, the
effects of methadone pretreatment upon methadone self-administra-
tion were assessed relative to a changing control condition. To
characterize the trend of self-regulated detoxification over con-
trol days a linear regression line was fit to the amounts of
methadone self-administered on control days during the pretreat-
ment period, and the data from pretreatment days were expressed
as deviations from the trend of control days.
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Figure 1 presents group mean data summarizing the effects of
methadone pretreatment upon methadone self-administration and
upon subjective, physiological, and behavioral measures. Sub-
jective report measures tended to show trends over the course of
the experiment; therefore,’ linear regressions were fit to these
trends and data are presented as deviations from the control re-
gression. Physiological variables and psychomotor performance
were measured twice daily, and these data are expressed in
Figure 1 as within-day difference scores; measures taken one-half
hour prior to pretreatment were subtracted from those taken two
hours following pretreatment.
A one-way analysis of variance for repeated measures revealed
significant pretreatment effects for total symptom score (p<0.005),
ARCI MBG scale (p<0.01), and pupil diameter (p<0.005); a border-
line, though nonsignificant, trend was found for methadone self-
administration (p<0.10). The p-values shown in Figure 1 indicate
the results of this analysis of variance. Further statistical
analyses were performed by means of pair-wise t-tests for corre-
lated samples (one-tailed).
Examination of individual subject data revealed that for six out
of six subjects mean methadone self-administration in the 30-mg
pretreatment condition was somewhat below mean self-administration
in both the control and the placebo conditions. Pairwise t-tests
for the group data revealed that subjects self-administered sig-
nificantly less methadone in the 30-mg pretreatment condition than
in the control condition (p<0.05) or in the placebo condition
(p<0.05). Overall, following 30-mg pretreatment, average methadone
self-administration was reduced by 4.7 mg below the level predicted
by the control day regression line.
Pairwise t-tests revealed that the reductions in total symptom
score relative to the placebo condition were significant for both
the 15-mg and the 30-mg pretreatment conditions (p<O.OO5, in both
cases). Scores on the ARCI MBG scale were significantly elevated
in the 30-mg pretreatment condition both relative to the placebo
condition (p<0.005) and relative to the 15-mg pretreatment con-
dition (p<0.05). The other self-report measures -- the Total Mood
Disturbance score of the Profile of Mood States, the ARCI Chronic
Opiate scale, and the ARCI Weak Opiate Withdrawal scale -- showed
no significant effects of methadone pretreatment.
Pupil diameter was the only physiological measure to be signifi-
cantly influenced by methadone pretreatment. Pupil diameters were
significantly constricted in the 30-mg pretreatment condition com-
pared to the control condition (p<O.OO5) and to the placebo con-
dition (p<0.01). Psychomotor performance was not influenced by
methadone pretreatment.
DISCUSSION
Six inpatient subjects on methadone maintenance were exposed to a
self-regulated methadone detoxification procedure. This procedure
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FIGURE 1
Effects of methadone pretreatment. X-axis: Methadone pretreat-
ment dose; Y-axis: Mean deviation from control regression (left
panels) and mean difference between pre- and post-treatment
measures (right panels). The vertical brackets indicate the
standard errors of the means.
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included progressively increasing fixed-ratio schedules of metha-
done reinforcement with occasional methadone pretreatments. Five
of the six subjects successfully reduced their methadone intake to
zero. Pretreatment with 15 mg methadone reduced the total symptom
score of the PSQ (a measure of subjective discomfort) but affected
no other measures. Pretreatment with 30 mg methadone reduced
methadone self-administration, the total symptom score of the PSQ,
and pupil diameter, while increasing the ARCI MBG score (a pur-
ported measure of subjective euphoria). No pretreatment dose of
methadone significantly modified heart rate, blood pressure, or
psychomotor performance. No pretreatment dose significantly modi-
fied scores on the POMS, ARCI ChrO, or ARCI WOWS scales.
One purpose of the present study was to assess the utility of this
detoxification self-administration paradigm for evaluating the
effects of adjunct medications upon the methadone detoxification
process. The present data clearly support the utility of this
human drug self-administration procedure for conducting such
studies. Although all of the relevant data are not presented
here, this study has found that the typical signs and symptoms of
opioid withdrawal occur during this process of gradual self-regu-
lated methadone detoxification. Further, it has shown that these
signs and symptoms can be attenuated by pharmacological pretreat-
ments. In particular, these data show that methadone-tolerant
subjects undergoing detoxification remain sensitive to the acute
effects of supplemental methadone.
Perhaps the most unique feature of the present study is its in-
clusion of the behavior of methadone self-administration as a
dependent variable and its demonstration that this behavior is
sensitive to pharmacological treatments. Thus, this study has
demonstrated that pharmacological pretreatments can affect not
only the signs and symptoms of methadone withdrawal but can also
influence the probability of opioid self-administration by detoxi-
fying addicts.
Overall, we feel that this procedure appears to be a promising and
useful technique, not only for the study of the signs and symptoms
of gradual opioid withdrawal but for the assessment of pharma-
cologioal treatment influences upon methadone self-administration
and withdrawal. The procedure would appear to hold promise as a
potentially useful baseline with which to examine the effects of
various adjunct medications other than methadone (e.g., sedative-
hypnotics, minor tranquilizers, clonidine) which are frequently
used or proposed as adjuncts to methadone detoxification.
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Comparison of Three Outpatient
Methadone Detoxification
Procedures
Maxine L. Stitzer, Ph.D., George E. Bigelow, Ph.D., and Ira A.
Liebson, M.D.
In studies of outpatient opioid detoxification the parameter
which has no doubt received most attention is the pharmacological
one of the speed or schedule of dosage reduction, with detoxifi-
cations ranging in duration from seven days (Silsby and Tennant
1974) to 30 weeks (Senay et al. 1977). Response to detoxifica-
tion may also be influenced by psychological variables related to
degree of patients’ knowledge of and participation in the dose-
reduction process (Razani et al. 1975).
The present study compared three detoxification procedures which
involved comparable-dose reduction periods but which differed in
the amount of information available to patients and the degree of
self-control which patients could exert over the dose-reduction
schedule. In particular, blind, informed, and self-regulated
detoxification procedures were compared. All detoxifications
were conducted on an outpatient basis and involved a 6-week dose-
reduction period scheduled within the context of a 90-day (13
week) detoxification program. Procedures were compared on several
variables considered important indicators of success: (1) success
at dose reduction; (2) retention in treatment; (3) patient sympto-
matology; (4) illicit drug use; and (5) follow-up status.
METHODS
Participants. Participants were 60 male opioid addicts who applied
to this clinic for outpatient methadone detoxification. Average
age was 28.4 years; average number of years since first opioid
addiction was 8.3 years; 58 percent were black, and 42 percent
were white; at the time of entering this study, 23 percent were
enrolled in methadone maintenance treatment and the remaining
77 percent were addicted to illicit opioids (i.e., “street
addicts”).
Procedure. Volunteers provided written informed consent and
enrolled’in a 90-day detoxification program. They were informed
that they might or might not be given information about their
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dose level and that they might or might not be given self-control
over their methadone intake. Volunteers were not told the details
of the detoxification procedures or dose-reduction schedules to be
studied.
The program consisted of a three- to four-week baseline period
during which patients were maintained on a stable dose, followed
by a six-week active detoxification phase. During the first few
days of the baseline period all patients were stabilized at 30 mg
methadone p.o. daily. At the end of the baseline period patients
were stratified according to whether they entered the program
from methadone maintenance or as street addicts, and each group
was independently randomly assigned among three treatment condi-
tions: (1) blind, clinic-controlled detoxification (N=20);
(2) informed, clinic-controlled detoxification (N=21); or (3) self-
regulated detoxification (N=19). In all three conditions patients
visited the clinic seven days per week and received liquid metha-
done under nurses’ observation in a standard 60 cc volume.
Patients in the blind and informed conditions received pharmaco-
logically identical detoxifications; they differed only in terms
of whether the patients were informed of the dosage schedule.
Patients in the blind condition were given no information con-
cerning the start, course, or end of the dose-reduction period.
Patients in the informed condition were informed each day during
the dose-reduction period of the dose they were receiving; they
were not informed in advance of what the schedule of dose reduc-
tions would be. For patients in both of these groups methadone
dosage was reduced by 5 mg per week in alternating 2 mg and 3 mg
decrements. Patients in the self-regulated condition were given
almost total dose self-control, with minimal clinic restrictions.
On day 1 of the dose-reduction period they were informed that
their previous day’s dose had been 30 mg and that henceforth they
would be free to choose whatever dose they wished each day within
the range of 0 to 45 mg (i.e., up to 150 percent of their stabili-
zation dose); they were told that they should have their detoxifi-
cation completed within six weeks and that any patients failing
to do so would receive a rapid clinic-controlled detoxification
to complete the process during the remainder of the 90-day period.
At each daily clinic visit patients completed a 59-item symptom
self-report rating scale (Physical Status Questionnaire or PSQ)
describing the symptoms they had experienced during the preceding
24 hours. Under staff observation patients provided twice-weekly
urine samples which were analyzed for evidence of methadone,
opioids, quinine, barbiturates, amphetamines, and a variety of
miscellaneous sedatives, major tranquilizers, and antidepressants;
half of these urine samples were analyzed for evidence of benzo-
diazepines.
Approximately two weeks after a patient’s last clinic visit an
effort was made to contact the patient in the community and he was
requested to make a follow-up clinic visit for which $20 compensa-
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tion was provided. Patients were interviewed about their drug
use at this time and a urine sample for laboratory analysis was
collected.
RESULTS
Outcomes were assessed and compared in five dimensions: (1) dose
reduction; (2) retention in treatment; (3) symptom self-reports;
(4) urinalysis evidence of supplemental drug use; and (5) short-
term follow-up status.
Dose Reduction. The three treatment procedures were compared with
respect to the minimum methadone dose which patients received
during the six-week dose-reduction period. The two clinic-con-
trolled detoxification procedures (Blind and Informed) were equally
effective in achieving methadone dose reduction and they were sub-
stantially more effective than the Self-Regulated procedure. In
the Blind group 13 patients (65.0 percent) achieved a methadone
dose of 5 mg or less, and in the Informed group 15 patients (71.4
percent) did so; only five patients (26.3 percent) in the Self-
Regulated group achieved a methadone dose of 5 mg or less. These
proportions were compared using a z-test for independent propor-
tions (with the Blind and Informed procedures collapsed into a
single group) and the difference between the clinic-controlled
and the Self-Regulated procedures was found to be statistically
significant (p<0.003, two-tailed). The ineffectiveness of the
Self-Regulated procedure is further indicated by the fact that
five patients (26.3 percent) always self-selected methadone doses
in excess of their 30-mg stabilization dose.
Retention in Treatment. The Blind and Informed conditions were
compared via t-test with respect to the mean number of days of
treatment participation prior to drop-out. Patients in the Blind
condition remained in treatment for an average of 8.3 days longer
(69.8 vs. 61.5 days). This difference was of borderline statisti-
cal significance, with p = 0.07 (two-tailed). Patients in the
Self-Regulated condition had an average treatment duration of
74.1 days, but this group was not included in statistical compari-
sons since these patients tended not to detoxify during the self-
regulation period.
Symptom Self-Reports. Total symptom scores on the daily symptom
questionnaire during the six-week dose-reduction period were
examined in relationship to symptom scores during the last Base-
line week of stabilization at 30 mg. Since patients in the Self-
Regulated condition tended not to detoxify, emphasis was on
comparison of the Blind and Informed groups. These two groups
tended to show different patterns of symptomatology in response
to pharmacologically identical detoxifications, as illustrated in
Figure 1. The figure shows the average total symptom change score
for each group during the six dose-reduction weeks relative to
each patient’s symptom level during the final baseline week of
stabilization at 30 mg. Only patients who remained in the study
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FIGURE 1
SYMPTOM RATINGS
DETOXIFICATION WEEKS
Mean symptom rating scores, as change from baseline.
into the sixth week of detoxification are included in this analysis.
Symptoms tended to increase among patients in the Blind condition
and tended to decrease among patients in the Informed condition.
Linear regression lines were fit to the average data in Figure 1,
and subsequent comparison of the correlation coefficients showed
these trends to be significantly different (p<0.02, two-tailed).
In addition, linear-regression trend lines were fit to the daily
symptom data of each of these individual subjects, and these
correlation coefficients were averaged using Fisher’s z’ trans-
formation. The Blind group showed a statistically significant
positive mean correlation (r = +0.33, p<0.05), and the Informed
group showed a nonsignificant negative mean correlation (r = -0.02);
these two mean correlations were not, however, statistically
significantly different from one another.
Urinalysis Results. Only patients whose three final urine samples
of the Baseline period were free of morphine, quinine and other
opioids (excluding methadone) were considered appropriate for
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inclusion in this analysis. This criterion eliminated 41.7 per-
cent of the total sample who showed evidence of supplemental
illicit opioid use shortly prior to their methadone dose reduction
even beginning. Because of the small sample sizes remaining no
significant differences between groups could be detected. However,
the patterns of urinalysis results over weeks of detoxification
warrant description. The Self-Regulated group showed no trend in
their pattern of drug supplementation, which is compatible with
their general failure to detoxify. The two clinic-controlled
groups both showed similar patterns (Fig. 2); the probability of
FIGURE 2
URINALYSIS RESULTS
DETOXIFICATION WEEKS
Percent of patients providing opiate-positive urine samples as a
function of weeks in detoxification.
a dirty urine remained relatively steady at approximately 20 per-
cent for the first four weeks of detoxification and then increased
to 50 percent in week 5 (when methadone dose fell below 10 mg).
Follow up. Short-term follow-up data were obtained on 55 patients
(91.7 percent).  Tweylve of these were free of opioids (including
methadone) and quinine; this is 20.0 percent of the entire study
population (21.8 percent of those contacted in follow-up). The
interval from last active methadone dose until follow-up was
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typically two to three weeks, but was occasionally as much as
two and one-half months. There were no differences between the
treatment groups in follow-up status. The number of patients
opioid-free at follow-up was four, three, and five for the Blind,
Informed, and Self-Regulated groups, respectively.
DISCUSSION
The primary point to be emphasized in this comparative evaluation
of outpatient methadone-detoxification procedures is the relative
ineffectiveness of the self-regulated procedure in contrast to
the clinic-controlled procedures in achieving substantial reduc-
tion of methadone dosage. While it may be the case that self-
regulated detoxification procedures are effective for selected
groups of patients, the present data indicate that their applica-
tion with unselected groups will be largely ineffective. In
contrast, both clinic-controlled detoxification procedures were
quite effective in achieving substantial dose reduction.
It should be noted also that the Blind and Informed conditions
appear to differ in the duration of their retention of patients
in treatment participation. In certain clinical settings a
longer duration of treatment retention might be desirable. For
example, in clinics which wish to maintain patients at zero metha-
done dose for several days in order to enter in narcotic antagonist
treatment the present data suggest that a blind detoxification
procedure might be most appropriate.
The present data suggest that the patterns of symptomatology by
blind and informed detoxification procedures may differ. In
particular, it appears that patients in the Blind procedure tended
to show patterns of increasing symptom complaints as methadone
dose reduction progressed, whereas patients in the Informed condi-
tion did not. Thus, knowledge of the dose-reduction schedule may
serve to dampen the symptom complaints associated with detoxifica-
tion. Alternatively, these data might be viewed as suggesting
that much of the symptomatology reported by detoxifying patients
results from anxiety and uncertainty concerning pharmacological
status. In either case the present data suggest that informed
detoxification procedures may result in improved levels of sub-
jective comfort for detoxifying patients.
While no differences between treatment groups in the overall rates
of illicit drug supplementation have been observed, interesting
patterns of relapse to illicit drug use have been observed in the
two clinic-controlled detoxification groups. Throughout the first
four weeks of dose reduction the probability of illicit opioid
supplementation remained at a relatively steady level and then
increased abruptly in week 5 when methadone levels fell below
10 mg. This relationship is quite similar to what we have observed
in residential laboratory studies of methadone self-administration
in detoxifying patients (Bigelow et al. 1981). Thus it appears
that illicit opioid supplementation is not a graded function of
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decreasing methadone dosage but may instead be selectively associ-
ated with the terminal portions of the detoxification process.
Finally, it should be emphasized that in terms of clinical outcome
at follow-up none of these detoxification procedures differed
significantly. This is not intended to be a pessimistic comment
but rather is intended to emphasize that procedural differences in
the detoxification process may influence outcomes which are measured
during that process while being unrelated to the problem of relapse
after the detoxification process is completed. Independently of
long-term outcome there are certainly a number of outcome variables
which are of concern to clinicians during the detoxification pro-
cess itself; patient symptomatology, illicit drug use, reduction
of methadone dependence, and retention in treatment are among these.
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Propoxyphene Napsylate Mainten-
ance Treatment of Narcotic Depen-
dence: Use of a Non-Methadone
Model
Forest S. Tennant, Jr., M.D., Dr. P.H., and Richard A.
Rawson, Ph.D.
ABSTRACT
One hundred seventy-eight (178) heroin addicts entered pro-
poxyphene napsylate (PN) maintenance. Patients attended a
general medical clinic two times each week and took home a
three- to four-day supply of PN which was usually taken in
doses of 300 to 400 mg three to four times per day. Over a
21-month period, the subjects entered and re-entered PN
treatment 166  times (1.5 times per patient) and remained a
mean of 10.6 weeks per treatment. A comparison with a group
of methadone maintenance patients indicated similar per-
formance in employment and heroin use. The ability to take
PN, attend a clinic less often than daily, and discontinue
and re-enter treatment on a discretionary basis is preferred
treatment approach for same narcotic addicts.
INTRODUCTION
In 1973 the relatively weak agonist, propoxyphene napsylate
(PN), was introduce for narcotic treatment.1 Since this
time studies have demonstrated that PN is more effective
than placebo but less effective then methadone in reducing
narcotic withdrawal symptoms.2,3 A double-blind comparison
of methadone and PN maintenance treatment of heroin
addicts revealed that, although methadone retained subjects
in treatment longer, many addicts safely and effectively
maintained with PN.4,5 Despite the findings, PN is still
the treatment agent preferred over methadone, clonidine, and
naltrexone by some narcotic addicts who attended our facilities.
In 1979, we began using PN for maintenance treatment of
opiate addicts by use of a non-methadone model. Patients
attend the clinic only two times per week and take medica-
tion home rather than attend daily as with methadone. Re-
ported here is our experience with 178 patients.
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In January, 1979, the project was initiated by informing all
patients in short-term, out-patient detoxification treatment
that PN maintenance was available as an alternative to metha-
done maintenance. Criteria for admission were as follows:
METHODS
1. History of compulsive opiate use:
2. One or more relapses following short-term detoxifi-
cation in our facilities;
3. Voluntary desire of patient to be on PN maintenance.
Patients attended the clinic twice per week. One dose of 200
to 400 mg of PN was given during each clinic visit, and a three-
or four-day supply of PN was given to take home. Patients
were instructed to take the medication two to four times per
day in intermittent doses.
All patients were instructed that they could discontinue or
drop out of the treatment at any time and be subsequently re-
admitted whenever they desired. They were informed they
could remain for any length of time they desired and that
they could transfer to methadone maintenance or other treat-
ment at any time. A urine analysis was collected monthly to
screen for abusable drugs.
Patients were treated in three general medical clinics located
in Eastern Los Angeles County. These clinics did not have a
methadone program on premises. One room in the clinic was
assigned for program use where patients could be counseled,
medication dispensed, and records maintained. In two clinics
attending, staff were: physician, nurse practitioner, licensed
vocational nurse and psychologist. In the third clinic, the
staff did not have a psychologist. Patients paid a regular
medical clinic visit fee each time they attended, clinic.
During this period, methadone maintenance fees were equal or
less.
During the week of March 20, 1981, patients who were in PN
maintenance treatment at this time completed a questionnaire
which inquired about their perceptions and satisfaction with
PN maintenance using a non-methadone model. Also during this
week, each patient gave a urine test and a breath-alcohol test and
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underwent examination for needle marks. These patients were
compared with 149 methadone maintenance patients in two clinics
in Eastern Los Angeles who, during the same week, completed
the same questionnaire and had the same tests.
RESULTS
Table One shows characteristics of the entire group of 178
patients. Persons who entered PN maintenance were chronic
heroin users with a mean total use of 10.7 years. They had
attempted a mean of 3.2 previous treatments.
This group engaged in 266 Separate treatment episodes which
averaged 10.6 weeks each (Table Two). The mean maintenance
dosage was 1100 mg daily; and patients usually took this in
three to four separate, divided doses of 300 to 400 mg each.
Approximately 25% of urine speciments collected month
from patients contained morphine.
The 44 PN patients who were compared to 149 methadone patients
appeared to be quite similar (Table Three). Mean age, employ-
ment status, total years of heroin use, and the percent who
showed morphine in urine, alcohol in breath or fresh needle
marks on an arm were not statistically different. A higher
percent of PN patients, however, stated that they could dis-
continue maintenance medication and not experience withdrawal
sickness.
The major reasons given by patients for choosing PN over metha-
done were that methadone was too addictive and PN worked better
(Table Four). The majority of PN patients reported that treat-
ment helped themreduce street drug consumption and avoid
arrests.
DISCUSSION
Patients who selected PN maintenance were generally long-
experienced, heroin addicts who perceived PN to be less
addicting and more effective than methadone. Many (43.2%)
Stated that they liked to carry PN with them rather than take
maintenance medication in a single daily dose. A likely
explanation for this may be related to the plasma half-life
of maintenance medication. Although the PN plasma half-life
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is longer than that for heroin, it is shorter than that for methadone-
In tolerant persons, the plasma half-life of methadone averages
about 24 hours.6 PN is absorbed more slowly than propoxy-
phene hydrochloride and has a plasma half-life of 6 to 12
hours.7 Patients reported in this study that they usually
had to carry PN with them and take 300 to 400 mg three to four
times per day. This schedule is compatible with the plasma
half-life of PN, and the ability to take it in multiple,
rather than a singledose, in a 24-hour period probably
explains why many addicts perceive it to be more effective
than methadone.
Those addicts who maintained well on PN appeared little dif-
ferent from a comparison group of methadone patients on
indicators of employment heroin use. Similar findings
were also found in a double-blind maintenance comparison of
PN and methadone. Maintenance periods were short in this study
(mean: 10.6 weeks), and most addicts relapsed after voluntary
termination and required readmissions to treatment. PN is not
apparently a potent enough agonist drug to retain many addicts
for long periods. Approximately 41% of subjects stated they
could skip a day of PN without withdrawal sickness. Almost
21% indicated they could totally stop PN without sickness
compared to less than 1% of methadone patients. The ability
to enter and discontinue maintenance treatment on voluntary
discretion is apparently an attribute of significant enough
value that many addicts reject methadone in favor of PN.
TABLE ONE
DEMOGRAPHIC AND DRUG-USE
CHARACTERISTICS OF PN MAINTENANCE PATIENTS
N = 178
No.
125 (70.2%)
53 (29.8%)
75 (42.2%)
99 (55.6%)
2 ( 1.1%)
2 ( 1.1%)
98 (55.1%)
73 (41.0%)
Males
Females
White
Hispanic
Black
Asian
Employed
Married
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Education Range (years)
Mean Education (years)
Parole/Probation
Age Range (years)
Mean Age (years)
Total Heroin Use Range (years)
Mean Heroin Use (years)
Daily Heroin Use Range Before
Admission (days)
Mean Daily Heroin Use Before
Admission (days)
Number of Heroin Injections Per
Day
Mean Number of Heroin Injections
Per my
Number Previous Heroin Treatments
(range)
Mean Number Previous Heroin treatments
TABLE TWO
PERFORMANCE ON PN MAINTENANCE
N = 178
Number of Separate Treatment Episodes
Mean Number of Episodes Per Patient
Weeks in Each Treatment Episodes (range)
Mean Number of Weeks in Each Episode
Daily Dosage Range (MGS)
Mean Daily Dosage (MGS)
Mean Number Self-Reported Ingestions Per Day
Number of Urine Specimens Collected
Number Urine Specimens Which Contained
Morphine
6 - 16
11.5
39 (21.9%)
19 - 51
30.7
.4 - 30
10.7
1 - 720
75.1
0 - 12
2.7
1 - 15
3.2
No.
266
1.5
1 - 108
10.6
600 - 1600
1100
3.7
427
109 (25.6%)
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TABLE THREE
COMPARISON OF PN AND METHADONE MAINTENANCE
PATIENTS IN TREATMENT ON MARCH 20, 1981
PN
N=44
Mean Age (years) 32.1
Employed 27 (61.4%)
Mean Total Heroin
Use (years) 9.9
Length of Time on
Maintenance (mos.) 11.3
Can skip Day of Medi-
cation Without
Sickness 18 (40.9%)
Can Totally Stop
Medication Without
Withdrawal Sickness 9 (20.5%)
No. of Urines That
Contain Morphine 6 (13.6%)
No. of Breath tests
That show Alcohol 0 (0%)
No. With Fresh Needle
Marks 1 (2.3%)
METH
N=149
32.5
80 (53.7%)
STAT
10.9
20.6
20 (13.4%)
1 (.7%)
24 (15.8%)
2 (1.3%)
6 (4.0%)
SIG
NS
NS
NS
P<.05
P<.001
P<.001
NS
NS
NS
TABLE FOUR
SELF-REPORT ATTRIBUTES OF PN
N = 44
Reason(s) For Choosing PN Rather Than Methadone
Methadone too addictive
Methadone disagress with me
PN works better
I like to carry PN with me
With methadone, I have to attend
clinic daily
PN helped to reduce use of
street drugs
Arrested less when I take PN
31 (70.5%)
11 (25.0%)
27 (61.4%)
19 (43.2%)
9 (20.5%)
43 (97.8%)
31 (70.5%)
251
REFERENCES
1.
2.
3.
4.
5.
6.
7.
Tennant, FS Jr: Treatment of Heroin Addicts with Pro-
poxyphene Napsylate. Presented Before the Committee
on Problems of Drug Dependence of the National Academy
of Sciences. Chapell Hill, No. Carolina, May 23, 1973.
Tennant, F Jr; Russell, BA; Casas, SK; et al: Heroin
Detoxification: A Comparison of Propoxyphene and Metha-
done. JAMA 232: 1019-1022, 1975.
Tennant, FS Jr; Russell, BA; Tate, J.; et al: Comparative
Evaluation of Propoxyphene Napsylate. Intern J Addictions
12:565-574, 1977.
Wood, GE; Mintz, J; Tennant, FS Jr.: et al: Lack of
Toxicity of High Dose Propoxphene Napsylate When Used
for Maintenance Treatment of Addiction. Clin Toxicol
16:473-478, 1980.
Woody, GE; Mintz, J; Tennant, FS Jr.; et al: Usefulness
of Propoxyphene Napsylate Maintenance Treatment of Nar-
cotic Addiction; Arch Gen Psychiat (In Press).
Inturrusi, CE; Verebely, K: The Levels of Methadone in
the Plasma in Methadone Maintenance. Clin Pharm Ther
13:633-637, 1972.
Wolen, RL; Gruber, CM; Kiplinger, GF; et al: Concentra-
tion of Propoxyphone in Human Plasma Following Repeated
oral Doses. Toxicol Apple Pharmocol 19: 493-497, 1971.
AUTHORS
Forest S. Tennant, Jr., M.D., Dr. P.H.
Community Health Projects, Inc.
336½ South Glendora Avenue
West Covina, California 91790
Richard A. Rawson, Ph.D.
Community Health Projects, Inc.
336½ South Glendora Avenue
West Covina, California 91790
252
Clinical Comparison of Propoxy-
phene Napsylate and Methadone in
the Treatment of Opiate
Dependence
Richard I. H. Wang, M.D., Ph.D., Carol Kochar, R.N., Andrew
T. Hasegawa, M.S., and Byung L. Roh, M.D., Ph.D.
SUMMARY
In this double-blind comparison of propoxyphene napsylate (PN)
800 mg in two divided doses versus methadone 20 mg, methadone 10 mg
or placebo methadone, it was found that PN: 1) did not alleviate
withdrawal symptoms in patients previously maintained on methadone
20 mg; 2) produced a slightly over-medicated effect in the detoxified
group of exmethadone patients; and 3) compared favorably to metha-
done 10 mg in suppressing withdrawal symptoms without producing evi-
dence of overmedication in those patients previously stabilized on a
methadone maintenance dose of 10 mg.
Since PN cannot be studied at doses higher than 800 mg per day if
undesirable side effects are to be avoided, it is concluded that
PN can be of value only in the treatment of mildly addicted patients
requiring 10 mg of methadone or less per day.
INTRODUCTION
Early clinical investigations by Tennant suggested that PN could be
of value in the treatment of opiate dependent persons (Tennant et
al. 1974; Tennant et al. 1975). His findings indicated that PN
acted in a manner similar to methadone by suppressing withdrawal
symptoms and eliminating the craving for heroin. Pilot studies by
Inaba et al. (1974) proposed that PN be viewed as a promising thera-
peutic tool and possible alternative to methadone. However, high
doses of PN were required to suppress-abstinence symptoms; Dis-
turbing side effects such as nausea, dysphoria, restlessness, hallu-
cinations and seizure-like activity were noted especially when
these high doses of PN (up to 1600 mg) were given in one single dose
(Tennant 1973).
Dependence studies by Fraser and Isbell in the early 1960’s demon-
strated that propoxyphene produced mild morphine-like activity that
only partially suppressed abstinence symptoms (Fraser and Isbell
1960). They concluded that the addiction liability of propoxyphene
was substantially less than that of codeine. More recently, Jasinski
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reported that the maximum doses of PN used to treat heroin addicts
(1200 mg/day) produce a degree of morphine-like activity equal to
that produced by 20 to 25 mg/day of subcutaneously given morphine
or 10 mg/day of oral methadone (Jasinski et al. 1977).
Double-blind comparisons between PN and methadone in narcotic detox-
ification (Tennant et al. 1975) and maintenance (Woody et al. 1980)
revealed that methadone suppressed abstinence significantly better
than PN. These findings are substantiated by the work of Jasinski
who found that mild abstinence was still present in addicted pa-
tients during a PN maintenance regime of 1200 mg/day (Jasinski et
al. 1977).
preliminary work at the Wood VA Medical Center indicated that single
doses of PN should not exceed 600 mg to avoid undesirable side
effects. However, when PN was given in divided doses (800 mg/day in
two equal doses), no significant adverse reactions were noted.
These findings are consistent with the work of Woody et al. (1980),
who found no clear evidence of serious toxicity when PN was used
for maintenance in divided doses.
These previous investigations indicate that although PN appears to
be generally less effective than methadone, there may be indications
for its use in the treatment of certain narcotic-dependent persons.
The need for further exploration was clearly evident. The study
presented here was conducted in a double-blind manner among estab-
lished heroin addicts on controlled levels of methadone maintenance
to determine the pharmacological response of PN 800 mg divided in
two equal doses as compared to methadone 20 mg, methadone 10 mg or
placebo methadone.
METHOD
Adult male inpatients with a history of opiate addiction were stud-
ied at the Drug Treatment Ward of the Wood Veterans Administration
Medical Center after informed written consents were obtained. A
history of at least two years of recent continuous heroin use with
established evidence of current dependence on methadone was re-
quired. Only those patients placed on a methadone detoxification
schedule or those who recently completed detoxification with metha-
done were selected to participate in the study.
All patients received a history and physical examination including
laboratory tests. Individuals with a history of seizure, heart,
liver or kidney diseases were excluded. In addition, the subjects
were required to have expressed a desire to detoxify from methadone
and were judged physically and psychologically suitable for detoxi-
fication by the principal investigator.
During the study, assessments of objective as well as subjective
signs of either withdrawal or overmedication, as listed in table 1,
were performed by the nurse observer. The rating of each response
was arbitrarily assigned the following scores: 0 = absent; 1 =
mild; 2 = moderate; 3 = severe. In other words, a higher score
indicates greater withdrawal or overmedication. Scores for a
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patient were obtained daily by averaging his withdrawal and over-
medication scores separately. Comparisons of treatment efficacy
were based on the mean values. Random urine surveillance for drugs
of abuse was performed three times weekly. Electrocardiograms and
vital signs were monitored at regular intervals. Electroencephalo-
grams were recorded before and after the study periods. No other
narcotic analgesics were given although prestudy major or minor
tranquilizers were continued without change during the study.
TABLE 1
Signs and Symptoms Used to Assess Response to Treatment
Withdrawal: anorexia, nausea, vomiting, abdominal cramps,
diarrhea, aches/pains, rhinorrhea, sneezing, yawning,
lacrimation, perspiration, goose flesh, chilliness/
flushing, agitation, anxiety, irritability, restlessness,
depression, tremors, fatigue, weakness, insomnia.
Overmedication: lightheadedness, ataxia, dizziness, nodding,
drowsiness, euphoria, intoxication, sedation, speech
impediment, constipation.
Three groups of patients were studied. Before the study, the pa-
tients were on daily maintenance doses of either methadone 20 mg
(Group A), methadone 10 mg (Group B), or were recently detoxified
from methadone (Group C). During the seven-day study period,
Group A received either PN 800 mg or methadone 20 mg; Group B re-
ceived either PN 800 mg or methadone 10 mg; Group C received either
PN 800 mg or placebo methadone. Medication assignments in each
group were randomized and the study was double-blind. All medica-
tion was dispensed twice daily in identically appearing capsules
with appropriate substitution of active drug or placebo. Bach cap-
sule contained either PN 400 mg, methadone 10 or 20 mg or placebo.
The methadone was administered once daily in the morning and a pla-
cebo capsule was given in the evening to those patients randomly
assigned to the methadone treatment groups. The daily dose of PN
800 mg was divided in two equal doses for those patients assigned
to the PN treatment groups.
A total of 30 adult male inpatients were studied whose ages ranged
from 22 to 55 years (mean of 33 years). Seventeen (57%) were black,
ten (33%) were white and three (10%) were Spanish American. Sympto-
matology of withdrawal and overmedication was assessed preceding the
study and daily for seven days.
Group A - Methadone 20 mg vs Propoxyphene Napsylate 800 mg
Ten patients were stabilized on methadone 20 mg daily prior to the
study. Six of these patients received PN and four continued to re-
ceive methadone 20 mg. The mean withdrawal scores on Day 0 were
0.39 ± 0.07 (S.E.) in PN patients and 0.26 ± 0.06 in methadone
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patients. However, there was no significant difference in the ini-
tial status between the two groups of patients. As shown in table 2,
during the seven-day treatment with PN the mean withdrawal score
increased significantly. Withdrawal in this PN group became more
noticeable on days 3, 4, 5, 6 and 7. On the other hand, the seven-
day treatment with methadone reduced the mean withdrawal score.
Hence, the average of the daily mean withdrawal score for the seven-
day period was significantly greater in patients receiving PN
(0.54 ± 0.09) than in patients receiving 20 mg methadone (0.18 ±
0.03) (P<0.001).
Symptomatology of overmedication was not observed in these patients.
There was no significant difference between the two treatments
(table 3).
Group B - Methadone 10 mg vs Propoxyphene Napsylate 800 mg
Ten patients were stabilized on methadone 10 mg daily prior to the
study. Five of these patients received PN and five continued to
receive methadone 10 mg daily. On Day 0, there was no statistical
difference in the mean withdrawal scores between PN (0.45 ± 0.07)
and methadone (0.64 ± 0.11) patients. Significant reduction in
mean withdrawal scores was observed with both PN and methadone
treatments (table 2). The average of the daily mean withdrawal
scores for the seven-day period in PN and methadone patients was
0.24 ± 0.04 and 0.36 ± 0.07, respectively.
Symptomatolgoy of overmedication was negligible in these patients,
and no statistically significant changes were observed with either
treatment (table 3).
Group C - Placebo Methadone vs Propoxyphene Napsylate 800 mg
The 10 patients in this. group were completely detoxified from metha-
done just prior to the study. Five of these patients received PN
and five received placebo methadone. There was no significant dif-
ference in the 0-day withdrawal scores between PN (0.60 ± 0.09) and
placebo (0.77 ± 0.11) patients. Both treatments were effective in
significantly reducing the mean withdrawal scores (table 2). The
average daily mean withdrawal scores for the treatment period were
significantly lower in PN patients (0.37 ± 0.05) than in placebo
methadone patients (0.56 ± 0.07).
In patients receiving PN, overmedication scores increased signifi-
cantly from a mean of 0 on Day 0 to a mean of 0.34 ± 0.07 for the
seven-day period (table 3). The overmedication scores were signifi-
cantly higher in PN patients than in placebo methadone patients on
days 2, 4, 5, 6 and 7. No change in overmedication score was ob-
served in patients receiving placebo.
Another way of analyzing the results of the above three groups was
the use of linear regression. Linear regression analysis of the
withdrawal and overmedication scores showed that symptom change can
be attributed to treatment in the following three groups: for
withdrawal, Group A receiving propoxyphene napsylate (86%), and
for overmedication, Group A receiving methadone 20 mg (55%) and
Group C receiving propoxyphene napsylate (67%).
Although the mean headache scores decreased in all three treatment
groups, the changes were not statistically significant. There were
no clinically significant changes in vital signs, electroencephalo-
grams or laboratory examinations of urine and blood among the entire
study population.
Fourteen out of 90 (15.6%) urine samples taken during the seven-day
study periods were positive for opiates among the 30 patients.
There was no statistical difference in the number of opiate-positive
urines between the PN, methadone or placebo methadone patient groups.
EKG changes were noted on two patients on PN at the end of the seven-
day treatment. One patient (Group A) showed flattening of T-waves
in V4 and V6. Another patient (Group A) exhibited sinus tachycardia
and nonspecific S-T and T changes. After a seven-day treatment
with placebo methadone, one patient also showed sinus tachycardia
and nonspecific S-T and T changes. There were no significant
changes in EKG with methadone-treated patients.
DISCUSSION
The efficacy of PN 800 mg to control withdrawal symptomatology in
methadone tolerant patients was compared in a double-blind manner
to methadone 20 mg, methadone 10 mg and placebo methadone.
It was interesting to note that withdrawal scores before adminis-
tering study medications were lowest in those patients stabilized
on methadone 20 mg and highest in the detoxified group of exmetha-
done patients.
When PN was compared to methadone 20 mg, the PN-treated patients
exhibited significantly more withdrawal symptomatology. On the
other hand, when PN was compared to methadone 10 mg, both the PN
and the methadone treatments were equally effective in subduing
withdrawal symptomatology. The comparison of PN versus placebo
methadone in recently detoxified exmethadone patients indicated
that PN was more effective in controlling withdrawal than placebo
methadone.
Cur results show that PN 800 mg produced a degree of morphine-like
activity equal to that produced by methadone 10 mg thus indicating
that methadone is 80 times more potent than PN on a mg-for-mg basis.
The use of PN for purposes of substitution or withdrawal from
opiates would therefore require levels of drug administration in
excess of the maximum approved amounts—nearly two times the
approved total daily dose and four times the approved single dose.
Based on these findings, it is concluded that patients mildly
addicted to narcotics requiring methadone treatment of 10 mg or
less daily will find PN adequate to control drug-seeking behavior
or to satisfactorily attentuate narcotic deprivation.
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TABLE 2
Mean Withdrawal Scores (± S.E.) with Propoxyphene Napsylate (PN),
Methadone (MD) and Placebo Treatment
* P<0.05 Difference between PN and MD 20 mg or MD 10 mg or placebo
Mean Overmedication Score (± S.E.) with Propoxyphene Napsylate (PN),
Methadone (MD) and Placebo Treatment
TABLE 3
* P<0.05 Difference between PN and placebo
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Opiate Detoxification Using
Lofexidine
Arnold M. Washton, Ph.D., Richard B. Resnick, M.D.,
Joseph F. Perzel, Psy.D., and John Garwood, M.D.
We have found clonidine to be useful in easing the pain and dis-
comfort of opiate withdrawal in outpatients attempting to detox-
ify from heroin or methadone1-3. However, clonidine's potent
sedative and hypotensive effects have limited its clinical use-
fulness with outpatients2,3. A nonopiate anti-withdrawal agent
with greater specificity and fewer side effects might be safer
and more effective for outpatient detoxification.
We now report preliminary findings with lofexidine (Merrell-Dow
Pharmaceuticals), a structural analogue of clonidine that my have
milder sedative and hypotensive effects4,5. Lofexidine has been
shown to suppress withdrawal signs in morphine-dependent rats6
but no previous studies have explored its efficacy in opiate
addicted humans.
METHODS
Our subjects were fifteen methadone-dependent male outpatient
volunteers who showed no evidence of medical or psychiatric
illness and gave informed consent to the study which involved an
abrupt switch from methadone to lofexidine. On day 1 subjects
received their usual methadone dose (10-25 mg) and began a self-
administered lofexidine dose regimen of 0.1 mg two or three times
daily. On day 2, methadone was abruptly discontinued with sub-
jects receiving a matched placebo methadone solution and the
lofexidine dosage was increased to 0.1 mg four times daily.
Subsequently, the lofexidine dose was increased as needed to no
more than 0.4 mg four times daily according to symptoms and side
effects. All subjects were told that the detoxification pro-
cedure would take 11 days and that naltrexone could be started on
day 11 (10 days post methadone) provided that they used no
illicit opiates during the study as confirmed by the absence of
a precipitated withdrawal reaction to intravenous naloxone chal-
lenge (2.0 mg) on day 11. Subjects who did use illicit opiates
during the first 10 days post methadone were allowed to continue
on lofexidine and the naloxone challenge was postponed to the
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first opportunity where it posed minimal risk of precipitating a
withdrawal reaction (i.e., to at least 5 days after the last
opiate use) but no later than day 21 of the study. Subjects who
passed the naloxone challenge and started naltrexone on days 11-
21 were considered successfully detoxified. Those who returned
to using opiates and failed to begin naltrexone by day 21 were
considered unsuccessful.
RESULTS
Successful detoxification and induction onto naltrexone was
accomplished with ten of the fifteen subjects. All patients
rated lofexidine as moderately to extremely effective in reducing
most of the commonly experienced withdrawal symptoms: insomnia,
lethargy, and muscle/bone pain were the most frequent residual
complaints. None of the ten subjects reported unacceptable
withdrawal symptoms while taking lofexidine. Those who failed to
complete the detoxification procedure cited opiate craving rather
than withdrawal discomfort as the major reason for returning to
opiate use. No one reported oversedation, dizziness, or light-
headedness from lofexidine, despite rapid increases in the dose
to as much as 1.6 mg per day within the first 5 days. The
maximum daily lofexidine dose ranged from 0.6 mg to 1.6 mg
across the ten subjects with an average of 1.2 mg. There was
no significant lowering of blood pressure even at the maximum
lofexidine dose (mean pre-lofexidine BP=115/74 mm. Hg; mean BP
at maximum dose=115/76 mm Hg). Dry mouth and mild drowsiness
were the most commonly reported side effects. Upon study com-
pletion, reductions in the daily lofexidine dose by 0.2 to 0.6 mg
per day produced no symptomatic complaints or significant changes
in blood pressure.
COMMENT
This open clinical trial provides preliminary evidence of
lofexidine's efficacy in reducing opiate withdrawal. The find-
ings are similar to our results with clonidine1-3 in terms of
detoxification success rates and withdrawal symptom relief, but
lofexidine seems to be considerably less sedating and hypotensive.
Lofexidine may therefore prove to be safer and more clinically
useful than clonidine, especially in outpatient detoxification.
Our findings suggest that lofexidine might allow opiate-addicted
outpatients even greater access to naltrexone or drug free
nodalities without hospital admission. Controlled studies are
needed to compare lofexidine with clonidine and/or methadone
detoxification procedures.
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Lofexidine Blocks Acute Opiate
Withdrawal
Mark S. Gold; M.D., A. Carter Pottash, M.D., Donald R.
Sweeney, M.D., Ph.D., Irl Extein, M.D., and William J.
Annitto, M.D.
We have described potent antiwithdrawal effects for clonidine, the alpha-
2 adrenergic agonist (1-6) which reduces brain noradrenergic activity.
On the basis of clonidine’s efficacy in human opiate withdrawal (1-6)
we have again suggested that the opiate withdrawal syndrome might be
better understood from the point of view of final, symptom-generating-
events. The neurobiological events that we were particularly interested
in were those which follow the discontinuation of chronic opiate
administration and results in clinical signs and symptoms (7,8). We have
reviewed rodent, primate, and human data which have supported an
endorphin-locus coeruleus (LC) disinhibition hypothesis and a
norepinephrine (NE) hyperactivity hypothesis for opiate withdrawal (7,8).
While other hypotheses are quite viable, we have used this NE
hyperactivity hypothesis to explain a large body of preclinical and clinical
research and in screening potential antiwithdrawal treatments for clinical
use. We tested the efficacy of clonidine in opiate withdrawal not only
to demonstrate that clonidine might be a new and important treatment
for addicts but also to determine which of the myriad of physiological
and affective variables associated with withdrawal would be completely
reversed and thereby attributable to specific agonistic effects of low
dose clonidine at presynaptic alpha-2 receptors on the LC. The more
complete the opiate reversal or opiate substitution by clonidine the more
support for the NE hyperactivity hypothesis. After we administered
clonidine to methadone addicts who had their methadone abruptly
discontinued we recognized that clonidine was effective in reversing the
full spectrum of acute withdrawal signs, symptoms and affects (3,4). In
addition, clonidine when given chronically continued to suppress (nearly
complete) the re-emergence of the withdrawal syndrome and could be
safely discontinued without a withdrawal syndrome of its own (5,6).
While the efficacy of clonidine offered strong support for the LC
disinhibition NE hyperactivity hypothesis on the basis of the known
effects of low dose clonidine on the LC and NE activity, it was only
one test of the hypothesis. In addition, clonidine by virtue of its
hypotensive and sedative effects was a clinical treatment which was
ideally suited for rapid opiate detoxification in a hospital setting. More
recently, we have suggested that lofexidine, an imidazoline derivative
which is a structurally related analogue of clonidine, may be the ideal
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non-opiate antiwithdrawal agent for outpatients (9). Lofexidine is a
weak antihypertensive agent which has substantial affinity for clonidine
binding sites in brain (8) and is believed to have similar anti-NE effects
in brain without opiate receptor binding or opiate activity (10-12). We
have recent data from 15 male chronic methadone addicts which
demonstrate potent antiwithdrawal activity for lofexidine and offer
additional support for the NE hyperactivity hypothesis of opiate
withdrawal. The patients had been addicted to opiates for at least one
year and to methadone for at least 6 months. All patients had previous
unsuccessful detoxification attempts. All expressed interest in
discontinuing methadone and all gave informed consent to the study,
which required abrupt discontinuation of methadone and at least 36 hours
with no opiate administration. All had objective ‘signs of opiate
withdrawal and urine specimens showing only residual methadone. The
patients were observed for withdrawal signs and symptoms as reported
previously (1-6) every 60 minutes from 8 a.m. while the patients were
at bed rest and rated for 19 items associated with withdrawal as severe
(3), moderate (2), mild (1) or absent (0). The withdrawal score was added
to give a measure of withdrawal severity.
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The number of withdrawal signs increased during the pre-lofexidine
baseline period. All patients had objective signs as well as symptoms
of moderate opiate withdrawal. After lofexidine 3 ug/kg was
administered, the withdrawal score was significantly reduced (p<0.01)
from 29.0 ± 8.3 to 14.1 ± 7.9 at 120 minutes after lofexidine (See Figure
1).
Systolic and diastolic blood pressure were not significantly decreased
and. remained in the normal range. Systolic blood pressure was 118.9
± 13.8 pre-lofexidine and 111.3 ± 13.5 at 120 minutes. Diastolic blood
pressure was 75.0 ± 13.9 pre and 75.4 ± 9.4 post-lofexidine. There were
no significant changes in alertness, sedation or mood. Anxiolytic activity
and relief from subjective distress was significant. All 15 patients felt
that they were in withdrawal or “kicking” prior to lofexidine
administration while only 3 of these patients stated that they were
“kicking” at 120 minutes after lofexidine; All elected to remain in the
hospital where they were given lofexidine 20 ug/kg/day in divided doses
for at least 10 days. All patients were successfully detoxified from
chronic methadone addiction in this inpatient study. During the first 5
days of lofexidine administration, there were consistent reductions in.
the withdrawal ratings (See Figure 2).
Fig. 2
In addition the antiwithdrawal response was quite variable among
individual patients (See Figure 3).
Fig. 3
The only consistent patient complaint was difficulty falling and/or staying
asleep.
Opiate interactions with noradrenergic areas such as the locus coeruleus,
which are regulated by both alpha-2 adrenergic and opiate receptors,
may mediate the effects of exogenous and endogenous opiates which
result in clinical signs and symptoms in association with the hyperactivity
seen in opiate withdrawal (1-6,9). The effects of clonidine and now
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lofexidine in opiate withdrawal support this hypothesis and suggest these
medications reverse opiate withdrawal by replacing opiate-mediated
inhibition, with alpha-2 adrenergic inhibition of noradrenergic activity.
Clonidine, while a potent and effective nonopiate treatment for opiate
withdrawal, has a number of properties which limit its usefulness for
outpatient detoxification (2,9). Clonidine is sedating and hypotensive
in doses necessary to reverse methadone withdrawal. However, with
this dose of clonidine, withdrawal symptoms are abruptly terminated
during acute withdrawal and continually suppressed during detoxification.
Our data with a fixed dose of lofexidine suggest that antiwithdrawal
effects can be separated from antihypertensive and sedating effects.
However, the lofexidine effect appears incomplete and less potent than
that observed for clonidine. Further studies are necessary to confirm
the lack of hypotensive and sedating properties of lofexidine reported
here. Further studies are also necessary to determine whether higher
doses of lofexidine are necessary to produce the marked and near
complete antiwithdrawal effects demonstrated for clonidine and whether
these doses are also without sedative and hypotensive effects. In
addition, the antiwithdrawal efficacy of clonidine and lofexidine should
be tested in randomized double-blind studies where identical rating
instruments are utilized. However, our demonstration of significant
antiwithdrawal efficacy in chronic methadone addicts reported here and
elsewhere (10,11) and the report by Dr. Resnick, Washton and co-workers
in this volume for the nonopiate medication lofexidine suggest that an
additional new treatment may be available for outpatient opiate
detoxification and in the transition from opiate dependence to drug-free
or naltrexone maintenance (3-5,9,10).
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Methodology for Assessing Agents
That Suppress Methadone
Withdrawal: A Study of Baclofen
Jerome H. Jaffe, M.D., Maureen Kanzler, Ph.D., Ronald Brady,
M.D., and Larry Friedman, Ph.D.
Recent reports that clonidine suppresses opioid withdrawal symptoms
(Gold et al., 1980; Washton et al., 1980) and permits a more rapid
withdrawal from opioids have rekindled hope that other non-opioid
agents might also have value for those purposes.
We describe here (1) the development of an outpatient methodology
for assessing agents that might be of value in suppressing metha-
done withdrawal and (2) some results of a pilot study of the effects
of baclofen. Baclofen (LioresalR) is 4-amino-3(p-chlorophenyl)
butyric acid (GABA), yet it does not seem to act via GABA mechanisms
(Beart & Johnston, 1973). At present, baclofen is used primarily
to reduce spasticity in neuromuscular disorders. It inhibits both
monosynaptic extensor and polysynaptic reflexes without inhibiting
neuromuscular transmission (Bein, 1972; Pierau & Zimmerman, 1973).
In dogs, large doses produced a hypnotic effect (Fehr &C Bein, 1974).
The drug inhibits withdrawal jump in opioid dependent mice and na-
loxone-induced jumping, writhing, salivation and other withdrawal
signs in morphine-dependent rats; it does not appear to have a sig-
nificant abuse potential, and it is not self-administered by baboons
in standard self-administration tests (CIBA-GEIGY, unpublished). It
does not suppress ethanol withdrawal in rhesus monkeys (Tarika &
Winger, 1980).
The two major problems in assessing effects of pharmacological
agents on opioid withdrawal syndromes are great variability among
patients in terms of drug history and metabolism and the preponder-
ance of physiological withdrawal items on existing rating scales,
which require that relatively severe withdrawal be manifest before
the items are scored positively. We have addressed these problems
by using patients as their own controls in cross-over designs and by
developing methods for assessing intensity of very early stages of
opioid withdrawal with instruments weighted more toward psychologi-
cal and subjective than physiological effects.
METHODS AND PROCEDURES
The studies to be described represent distinct stages in the refine-
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ment of method. All subjects were volunteers recruited from metha-
done maintenance programs. Before beginning each study, the proto-
col was discussed with the subjects who signed informed consents.
All studies were double-blind.
Pre-Pilot Work. Twenty-four hours after ingesting their regular
dose of methadone, twelve subjects, chosen because they had stated
that they often experience withdrawal within 24 hours after the last
dose, were given either their regular dose of methadone or a placebo
and were then observed for varying lengths of time up to 36 hours
after their last regular dose. Subjects completed several self-
report assessment forms at 2-hour intervals while observers rated
certain behaviors. The assessment measures are described below.
The purpose of this stage was to determine which of these measures
could discriminate a methadone from a placebo condition during the
early stages of withdrawal.
Form I was a nine-point global self-assessment of the subject's
feeling with respect to degree of stabilization on methadone. The
scale ranged from 1 - "very loaded, can't function" through 5 -
"feel O.K., straight," to 9 - "terrible withdrawal sickness." Form II
consisted of 38 items and included symptoms taken from the literature
on opiate withdrawal, to which were added items obtained during in-
terviews with methadone patients on the kinds of symptoms typically
experienced if they missed their usual dose. Items on Form II were
scored on a 0 to 3 scale (not at all, slight or a little, moderate,
or very much). Form III was an observer rating of behaviors, such
as yawning, sweating, tremor, frequently found in withdrawal, as
well as the manifest psychological state described by adjectives
such as "talkative, relaxed, irritable, happy." Each item was rated
on a four-point scale, from 0 (none) to 3 (severe). The Weak Opiate
Withdrawal (WOW) Scale (Haertzen, 1974), a battery of 35 true-false
statements, was also administered.
This pre-pilot study demonstrated the feasibility of the outpatient
study but also indicated that only low levels of withdrawal occur
over the 36-hour period following the last dose of methadone. We
concluded that a longer period of observation, i.e., at least 40
hours from last dose; would be needed to obtain reliable differences.
Pilot Study. Thirteen male subjects, ages 20 to 55, patients at a
methadone clinic in New York City. came to the clinic on Thursday
mornings and completed the four instruments described above. Oral
temperature and pulse were also recorded.
After ingesting either methadone or placebo (dextromethorphan), in
orange juice at approximately 8:30 A.M., subjects and staff went to
a nearby motel and remained'there until the following morning. Sub-
jects were under continuous staff observation. The four forms were
filled out again at noon, 4 and 8 P.M. and midnight and pulse and
temperatures were recorded. Urine specimens were obtained at the
end of the session to determine whether any non-prescribed medica-
tions had been ingested during the preceding 24 hours, Subjects
could drop out of the session by asking to take their "emergency
dose" -- the subject's usual dose of methadone or a placebo, de-
pending on what the subject had taken in the morning, prepared in
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orange juice. Subjects were paid for their participation and were
given a bonus if they completed both the experimental sessions. How-
ever, changes in schedules, employment demands and other considera-
tions were such that only 7 of 13 subjects participated in bath con-
ditions of the experiment. Of the remaining 6 subjects, 3 had metha-
done only and 3 placebo only, making a total of 10 observations for
each condition.
Main Study. This study involved 11 male subjects (mean age, 29;
range 23 to 40), 4 of whom had participated in some aspect of the
pilot study. To further control the pre-study dose, subjects were
required to come to the clinic on the Wednesday morning prior to the
experimental session on Thursday. On Wednesdays the regular doses
of methadone (mean dose, 66.4 ± 23; range 30-100 mg) were reduced
by approximately 25% and ingested under direct observation. Because
it was dispensed in multiples of 10 mg, precise reductions of 25%
were not possible (range of reductions was 17-33%; mean reduction,
25.5%).
On Thursdays at 9 A.M., after a breath alcohol test, recording of
temperature, pulse and blood pressure and completion of self-report
instruments I and II, the subjects ingested either methadone (their
usual dose in mg) or placebo. Methadone was dispensed as an elixir
in cherry syrup (10 mg/cc) diluted with 6 oz of Tang solution; the
placebo consisted of dextromethorphan in cherry syrup diluted with
Tang solution to the same volume. As in the pilot study, an "emer-
gency dose" consisting of the subject's usual dose of methadone or a
placebo (depending on which he had ingested in the morning) was pre-
pared and sealed by a research assistant (who did not participate in
observations) and held by one of the observers. Subjects were free
to discontinue the experiment at any time by asking to take the
"emergency dose" and all were free to ingest the dose after the
2 A.M. completion of assessment instruments.
Form I (global self-rating) and Form II (symptom rating) were com-
pleted by subjects at 9 A.M., 12 noon, 2, 4, 8 and 10 P.M., 12 mid-
night, 2 and 8 A.M. Each of two observers filled out an observer
checklist (Form III) at each of the times noted above. Subjects
remained at the motel until 8 A.M. the following morning, at which
time a urine specimen was obtained for subsequent screening for a
variety of drugs of abuse. Oral temperature, pulse and blood pres-
sure were recorded at 9:30 A.M., 12 noon, 4 and 10 P.M., and 2 A.M.
An electronic sphygmomanometer was used to record blood pressure
and pulse.
During the experimental day, the test medication was administered as
follows. Immediately after completing the forms at 2, 6 and 10 P.M.
subjects ingested two tablets of either baclofen or placebo. There
were four experimental conditions: (1) methadone at 9:30 A.M. and
placebo at 2, 6 and 10 P.M., (2) placebo at 9:30 A.M. and placebo at
2, 6 and 10 P.M., (3) placebo at 9:30 A.M. and baclofen 10 mg at
2 and 6 P.M. and 20 mg at 10 P.M., (4) placebo at 9:30 A.M. and bac-
lofen 20 mg at 2, 6 and 10 P.M. To control for'the effect of order
of administration, subjects were assigned to these conditions in a
Latin Square design.
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Two different, groups of subjects participated on four consecutive
Thursdays in two four-week time periods: June/July and September/
October, 1980.
Results from Pre- and Pilot Studies. The pre-pilot and pilot studies
demonstrated that three of the assessment measures (Global self-
rating, Symptom rating, and Observer rating) effectively discrimi-
nated scores during baseline states (12 noon and 4 P.M.), from scores
during expected withdrawal states (8 P.M. and midnight) under the
placebo condition at a statistically significant level (p < 0.05).
As illustrated in Figure 1, the scores on the fourth assessment meas-
ure, the Weak Opiate Withdrawal Scale, did not change significantly
over the course of the day under the placebo condition; and it was,
therefore, not used in the main study.
Figure 1
Main Study Results. Ten subjects completed all four conditions,
one additional subject was absent for the session on low-dose baclo-
fen.
An item analysis of Form II carried out after completion of the main
phase using the placebo and methadone scores permitted us to identify
those items which increased substantially during the placebo but not
during the methadone condition; In addition, certain items were
consistently scored higher during the methadone condition. These,
therefore, were scored inversely, i.e., yielding negative scores.
In all, 26 items are scored on Form II, five of them inversely, and
a negative score indicating methadone effects rather than withdrawal
is theoretically possible.
The results of the main study are summarized in Table 1. To obtain
the summary scores shown in Table 1, the scores for each form were
summed across the 8 P.M., 10 P.M., midnight and 2 A.M. points. The
resultant sums were averaged for‘each treatment.
On Form I (Global self-rating), three subjects showed no change what-
ever in their scores between methadone and placebo conditions. We
believe that including these non-discriminating subjects would
inappropriately dilute the results of the other subjects on this
form. Using a paired t test comparison of the Form I scores, the
other eight subjects showed statistically significant differences
(paired t test) between their own placebo and methadone treatments,
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and these eight "discriminators" were used in subsequent analysis
of Form I data.
Table 1
NOTE: For From I, N - 8; for Forms II and III, N - 11 for methadone, placebo
and baclofen 60 mg; N - 10 for beclofen 40 mg.
On Form II; all 11 subjects showed differences between their own
placebo and methadone conditions (using paired t test) and, there-
fore, all were used.
The two observers, both blind to the experimental conditions, used
Form III to rate all subjects under each test condition; the anal-
ysis of the scores for Form III presented in Table I is based on
averaging the ratings of both observers.
Subjects had been assigned to treatments by a project monitor using a
4 x 4 Latin square repeated twice. For the Latin-square analysis,
the eight who first completed the design were used. Since there was
no order effect it appeared appropriate to use all available data in
subsequent analysis including that from the extra subjects included
in case of drop-out (see footnote 1). A repeated measure ANOVA of
the subjects' summed scores was done for all three measures. All F's
were statistically significant. On all three measures, the placebo
and methadone mean scores were widely separated with the baclofen
scores intermediate. It is obvious that there is almost no differ-
ence between the two baclofen conditions. A one-tail t test compar-
ing the scores for the 11 subjects who had baclofen (60 mg) and
placebo was statistically significant for Form I (p = .0315); and
for Form II (p = .0420). Differences on the observer rating were
borderline significant (p = .0611).
Changes among the means of the four treatments on Form I across the
duration of the experimental day are shown in Figure 2. Despite the
reductions in dose the day before the average score on the global
self-rating in the morning (Form I) was 5.1 (5 = "feeling O.K.,
straight"). Under the placebo/placebo conditions, as the day pro-
gressed subjects rated themselves as feeling progressively less
comfortable, and by 2 A.M. the mean score was 6.875 (7 = "definitely
273
sick but not enough to bother me much"). Under the methadone con-
dition; there was a relatively prompt and dramatic change in the
Form I group mean which continued to drop until 4 P.M. when the score
was 4.125 (4 = "feel really good, but not loaded"); the scores pro-
gressively increased until 8 A.M.
Time
Figure 2
The changes in the reported symptoms (Form II) over the same period
produced curves which are remarkably similar to those for Global
self-rating shown in Figure 2. There were no significant differences
among the four conditions for either blood pressure or oral tempera-
ture for any of the time periods.
DISCUSSION
When the Himmelsbach and related scales were developed, two assump-
tions were generally valid: (1) intervention to terminate the exper-
ience would be needed only in special circumstances; (2) patients
undergoing withdrawal would exaggerate their distress in order to
increase the chances of getting drugs and therefore the overall with-
drawal score should give greater weighting to objective physiological
signs (sweating, dilated pupils, blood pressure changes, etc.) than
to verbally reported subjective changes (anxiety, depression, aches,
pains, etc.).
In the present studies, there were few incentives for distorting or
exaggerating the degree of distress and minimal penalties for opting
to terminate the experience. Subjects seemed to understand what was
expected and to take pride in their selection as "good discrimina-
tors." Under such circumstances, we felt that subjective reports
might be more sensitive indicators of low-level withdrawal than the
physiological aberrations which are given greater weight in the more
traditional approaches. On the other hand, the decision to limit the
period of observation to about 40 hours makes it difficult to know
how severe the withdrawal syndrome might have been had it been allow-
ed to run its course over several more days. We wish to emphasize
that although the mean dose of methadone was 66 mg/day only relative-
ly mild opioid withdrawal was studied in this experiment. On Form I
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(Global self-rating) only two of the 11 Subjects ever rated them-
selves as "8" (very sick, hard to keep going with other activities")
and such ratings occurred only under placebo conditions. Four addi-
tional subjects reported a maximum Global score of "7" (definitely
sick, but not enough to bother me much") at some point during the
study. Three subjects rated themselves almost consistently as "5"
("feeling O.K., straight") across all experimental conditions,
although they reported more symptoms during the placebo conditions
using Form II.
The low level of withdrawal can also be inferred from the observation
that a number of the items on Form II that are usually associated
with opioid withdrawal (e.g., nausea, diarrhea, backpains, goose-
flesh) were not significantly greater under placebo than methadone
conditions for the group as a whole.
The results of this study show that baclofen had a statistically sig-
nificant suppressant effect on both self- and observer-rated manifes-
tations of early and relatively mild methadone withdrawal with no
significant difference between the dose levels (see footnote 1). We
cannot account for the observation that, as a group, Subjects rated
themselves as experiencing less withdrawal on Forms I and II at 12
noon and 2 P.M., on the days they were scheduled to receive baclofen,
but before they actually received it. While these differences are
not statistically significant they provoke curiosity. Were subjects
able to decode the design with better than chance accuracy using
their own internal perceptions as cues? Baclofen, in these subjects
and at these doses, seemed remarkably benign. Especially interesting
was the absence of sedation, which we had expected to be a problem,
and of hypotension, which has proven to be a significant drawback in
the use of clonidine.
In conclusion, we found that some signs and symptoms of mild metha-
done withdrawal were alleviated by baclofen. Whether the aspects of
withdrawal alleviated were those associated with drug-seeking behav-
ior is not known.
REFERENCES: Available from senior author upon request.
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Urine Monitoring of Methadone
Maintenance Clients: Does it Pre-
vent Illicit Drug Use?
Barbara E. Havassy, Ph.D., and Sharon M. Hall, Ph.D.
Federal and State of California regulations require that mainten-
ance clients provide urine specimens under observation. All urine
specimens are analyzed for the presence of morphine. Urine speci-
mens are also analyzed for the presence of methadone, barbiturates,
and amphetamines, but on a less frequent schedule. The urinalyses
are used as an objective measure of whether clients are 1) ingesting
their methadone dose and 2) using illicit drugs.
The collection and analysis of urine specimens is a costly aspect
of maintenance, especially when the staff time to maintain a random
system and to observe clients urinating are added to the laboratory
costs of drug screens. Furthermore, clients dislike the procedure
and often successfully subvert it (Lewis, et al. 1972).
Whether the urine monitoring procedure prevents use of illicit
drugs has not been demonstrated. Goldstein and Judson (1974)
failed to find significant differences in illicit drug use over
a three month period between monitored and unmonitored maintenance
clients. The data are only suggestive, however, due to a high at-
trition rate, the resultant small sample size, marked inter-clinic
variability and a short study period.
Equally problematic is the correct identification of drugs present
in urine specimens. While accurate identification of commonly
abused drugs is technically possible, low degrees of accuracy are
found in the actual day-to-day identification of drugs (Gottheil,
et al. 1976; Trellis, et al. 1975).
The purpose of the present study was to determine whether the man-
dated urine monitoring system deters illicit drug use of mainten-
ance clients. The major hypothesis was that monitored subjects
would provide more specimens that were free of illicit drugs than
unmonitored subjects.
METHOD
Subjects were 431 methadone maintenance clients (271 males and 160
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females) recruited from five diverse clinics in northern California.
Mean age of the sample was 32 years, mean dose was 50 mg. and the
modal time in treatment was 12 months. The demographic and treat-
ment data collected on subjects were: time in treatment, sex,
criminal justice status, results of urinalysis for a baseline
period of six months prior to study-start, employment status, and
ethnic group.
Subjects were recruited at their clinic by research staff and writ-
ten informed consent was obtained. No clients were recruited for
whom the risk of participation was judged to be unacceptable by
clinic staff, generally clients who were extreme polydrug abusers
or those undergoing involuntary detoxification. (Three of the
five clinics did not exclude any clients; one clinic excluded 32
of 138 clients {23%}; another excluded 2 of 113 clients {1.8%}).
Subjects were stratified on the basis of age, sex, parole/probation
status and urinalysis results during baseline and randomly assigned
to the unmonitored or the monitored condition from within stratified
blocks.
The Methadone Monitoring Unit of the Food and Drug Administration’s
Bureau of Drugs allowed suspension of Federal urine regulations
and the California Research Advisory Panel allowed suspension of
State urine regulations for the unmonitored group for one year.
These subjects did not provide the clinic with any urine specimens
for that period. In all other respects, these subjects received
standard methadone treatment.
Clinic staff could require unmonitored subjects to leave a urine
specimen when it was deemed clinically imperative (discretionary
specimens). Each collection of a discretionary specimen was noted.
Monitored subjects continued to adhere to Federal and State urine
monitoring requirements.
At four and eight months after the study began, research staff
arrived unannounced at the clinics and conducted “surprise” urine
tests in which specimens were collected from unmonitored and moni-
tored subjects. No clinic staff knew how many surprise tests there
would be, how many days the surprise tests would last, nor at what
intervals they would be conducted.
Illicit drug use was measured via analysis of the urine specimens
provided. A urine was considered drug-positive if it was positive
for morphine, amphetamines, or barbiturates or negative for metha-
done and/or methadone metabolites.
Urines were analyzed by a commercial laboratory licensed by the,
State of California. The laboratory used thin-layer chromatomo-
graphy (TLC) with confirmation of drug-positive specimens. The
laboratory was blind to the purpose of the study and to study
conditions.
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Six months after study-start a modification of the Client Satisfac-
tion Questionnaire (Larsen, et al, 1976) was administered to both
monitored and unmonitored subjects.
RESULTS
At baseline, treatment groups did not differ on the stratifying
variables, or on employment status, ethnicity, age, methadone dose,
year of first heroin use, year of first continuous heroin use, or
year of last continuous use.
Urinalyses
Urine monitoring, as conducted in the five participating clinics,
did not significantly affect outcome of the urine tests, We found
no statistically significant difference between monitored and un-
monitored conditions on the proportion of drug-free specimens.
Two parallel series of chi-square analyses were completed in which
the data from all five clinics and all four indicators of illicit
drug use (positive morphine; positive barbiturates; positive am-
phetamines; negative methadone) were combined. In the first series
of chi-square tests, we eliminated from the analyses subjects in
either, treatment group who refused to provide specimens. In the
second series, we counted subjects who refused as having provided
drug-positive specimens.
Results are shown in Table 1. When refusals are not counted in
the analyses, urine monitoring does produce a slightly greater num-
ber of drug-free urines than unmonitored methadone maintenance, but
only after eight months (urine test 2), x2 (1)=3.21, .10>p>.05. This
difference does not reach traditionally acceptable levels of signi-
ficance. The results for four months (urine test 1) are x2(1)=0.304,
.70>p>.50. When refusals are counted as drug-positive specimens,
differences are further attenated. For urine test 1, x2(1)=0.190,
.70>p>.50; for urine test 2, x2(1)=1.046, .30>p>.20. Our overall
N was 343 for urine test 1 and 298 for urine test 2. The remainder
of the 431 subjects were either no longer in treatment when the sur-
prise tests were conducted or were not available for participation
on test days (i.e., in jail, in hospital).
We also examined differences between conditions for each of the
four indicators of illicit drug use separately (collapsing data on
each individual indicator across the five clinics). There was no
association of treatment condition to presence or absence of the
indicator.
Discretionary urines. Data on discretionary urines were examined
to ascertain whether any unmonitored subjects might have been ac-
tually monitored by virtue of multiple discretionary urines. We
found discretionary specimens were taken infrequently and only in
two of the five clinics.
Recalculating the chi-square tests for just the three clinics that
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did not take discretionary specimens did not alter the chi-square
values or their associated p levels to any important extent.
Table 1
Outcome of Surprise Urine Tests 1 and 2
URINE TEST 1
Refusals Not
Counted
Refusals-Drug
Positive
URINE TEST 2
Refusals Not
Counted*
Refusals-Drug
Positive
*p<.10.
Unmonitored
%n
Drug-free specimen 109 (66)
Drug-positive specimen 55 (34)
Drug-free specimen 199 (63)
Drug-positive specimen 65 (37)
Drug-free specimen 93 (68)
Drug-positive specimen 43 (32)
Drug-free specimen 93 (60)
Drug-positive specimen 62 (40)
Monitored
n %
102 (69)
45 (31)
102 (60)
67 (40)
94 (78)
26 (22)
94 (66)
49 (34)
Demographic variables and outcome. The demographic variables were
not differentially associated with the two conditions with respect
to urine test outcomes.
Experimental Participation and Termination from Treatment
Participation status in the surprise tests (partitioned by subject
provided specimen; subject refused to provide specimen; subject
terminated treatment; and subject not available) was differentially
associated with experimental condition on urine test 1 at p<.01
but did not reach significance on urine test 2.
Post hoc analyses on the data partitioned into terminated treatment
versus in-treatment indicated that termination from treatment dur-
ing the study period was differentially associated with experimen-
tal condition. By urine test 1, 16% of the monitored subjects had
terminated versus 8% of the unmonitored group, x2(1)=6.16, p<.05;
by test 2, 26% of the monitored subjects had terminated as com-
pared to 18% of the unmonitored subjects, x2(1)=3.60; p<.10.
Client Satisfaction with Treatment
Monitored and unmonitored subjects did not differ in overall client
satisfaction. When client satisfaction items were partitioned a
priori into those having a relationship to the urine-monitoring
system and those not, three of the six items judged to be related
did discriminate unmonitored and monitored conditions at p<.05.
In all instances, the unmonitored subjects rated the clinic and
their treatment more favorably. None of the items judged to be
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unrelated to monitoring discriminated the two groups.
DISCUSSION
Effect of Monitoring on Illicit Drug Use
The major outcome of this study is that no consistent differences
between the two groups on illicit drug use emerged, despite our
examining the data from several perspectives.
It is important to note that, similar to others, we tested the
system as it actually was implemented, not the system as it might
be implemented in a laboratory research study (Milby & et al. 1978).
While it is possible that improved monitoring systems might achieve
better results (Harford & Kleber 1978), the ability of such systems.
to do so across a diverse sample of clients remains to be demon-
strated.
Termination from Treatment
The higher rate of treatment termination observed in the monitored
condition merits further study. We propose two alternative hypo-
theses regarding the relationship: (1) urine monitoring may increase
the subjective “cost” of participation in maintenance, so more
clients drop out when monitored than when not; and (2) urine moni-
toring may be of particular value to clients attempting to taper off
methadone and that successful tapers are reflected in termination
statistics. We have no data to suport these hypotheses. If this
question is to be resolved, further research is needed.
Client Satisfaction with Treatment
While there were no observed differences between treatment groups
regarding overall satisfaction with treatment, unmonitored subjects
reported a more general satisfaction with some aspects of treatment,
and they were more likely to perceive an improvement in their avoid-
ance of illicit drug use. These findings are not surprising, given
clients’ dislike of the disciplinary consequences of urine monitoring
(Lewis et al. 1972, Trellis, et al. 1975).
In conclusion, results. of this study do not indicate that urine
monitoring is a strong uniform deterrent to illicit drug use for
methadone clients in general or for any particular subgroup of them.
REFERENCES
Goldstein, A., Judson, B.A. Three critical issues in the manage-
ment of methadone programs. In: Bourne, P., (ed): Addiction
New York. Academic Press, 1975, p129-148.
Gottheil, E., Caddy, G.R., Austin, D.L.: Fallibility of urine
drug screens in monitoring methadone programs. JAMA 236:1035-
1038, 1976.
280
Harford, R.J., Kleber, H.D.: Comparative validity of random inter-
val and fixed interval urinalysis schedules. Arch Gen Psychiatry
35:356-359, 1978.
Larsen, D., Attkisson, C., Hargreaves, W.: Client Satisfaction
Questionnaire, 1976.
Lewis, V.A., Petersen, D.M., Geis, G., Pollack, S.: Ethical and
social-psychological aspects of urinalysis to detect heroin use.
Brit J Addiction 67:303-307, 1972.
Milby, J., Toro, C., Thornton, S., Rickert, D., Clark, C.: Some
urine surveillance effects on drug abusers in psychotherapy.
Brit J Addict 143:1-2, 1978.
Trellis, E.S., Smith, F.F., Alston, D.C., Siassi, I.: The pit-
falls of urine surveillance: the role of research in evaluation
and remedy. Addic Behav 1:83-88, 1975.
ACKNOWLEDGEMENTS
This research was performed undercontract AGR-NDA-44071 from the
California State Office of Narcotics and Drug Abuse, and was sup-
ported in part by grants 1 RO1 DA 01936, 1 RO1 DA 01910, and 1 KO2
DA 00065, all from the National Institute on Drug Abuse. The
authors thank the clinical and administrative staff of the partici-
pating clinics for their participation and invaluable assistance.
AUTHORS
Barbara E. Havassy, Ph.D.
Sharon M. Hall, Ph.D.
Department of Psychiatry
School of Medicine
University of California
San Francisco, CA 94143
A more extensive report of this investigation is available from
Dr. Havassy. Mailing address: University of California Psychiatry
Service, San Francisco General Hospital, 1001 Potrero Avenue, San
Francisco, CA 94110.
281
Contingent Reinforcement of
Benzodiazepine-Free Urines From
Methadone Maintenance Patients
Maxine Stitzer, Ph.D., George Bigelow, Ph.D., and Ira
Liebson, M.D.
Supplementation with illicit drugs is commonly observed among
patients enrolled in methadone maintenance treatment, and
represents continuation of the behavioral problem which brought
these individuals into treatment in the first place. Although
reduction or elimination of supplemental drug use is invariably
seen as a primary goal of treatment, it is somewhat of a paradox
that few specific therapeutic techniques are available for deal-
ing with on-going drug use among drug abuse patients. Treatment
clinics commonly employ two tactics for dealing with on-going
drug use: verbal encouragement to eliminate use and threats of
expulsion from the clinic followed by actual expulsion if drug
use does not cease. The present paper reports on a specific
intervention designed to reduce or eliminate supplemental drug
use among methadone maintenance patients. The intervention
involves providing alternative reinforcers contingent upon
urinalysis-evidence of reduced drug use. The benzodiazepine
class of drugs was chosen as a focus for evaluation of this
contingent reinforcement intervention both because these drugs
appear to be widely abused among methadone patients (Bigelow
et al. 1980; Kleber and Gold 1978; Woody et al. 1975) and because
an objective and rapid urinalysis test is available for detecting
the use of drugs from this class.
METHODS
Ten study participants were selected on the basis of urinalysis
evidence of continuing use of benzodiazepine drugs following
enrollment in the methadone maintenance clinic. All were male,
nine were white and one was black. Table 1 presents demographic
characteristics of these patients as well as self-report informa-
tion obtained from eight of the ten study participants in an
unrelated survey study concerning dosages and patterns of
benzodiazepine drug use. This self-report information, summarized
in Table 1, suggests that these patients by and large used
benzodiazepine drugs in an abusive rather than a therapeutic
dose range. Furthermore, six of the eight survey participants
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TABLE 1
CHARACTERISTICS OF STUDY PARTICIPANTS (N=10)
Average Range
Age (years) 28.2 24 - 33
Years of addiction 10.0 5 - 12
Methadone dose (mg) 55.0 30 - 80
SELF-REPORTED BENZODIAZEPINE USE (N=8)
Median Inter-quartile
Range
Usual daily dose (mg) 72.5 25.0 - 187.5
Highest daily dose (mg) 225.0 60.0 - 482.5
reported taking the daily dose of benzodiazepines all at once
generally within an hour of the time they ingested their metha-
done.
Study participants came to the clinic daily to drink a methadone
and cherry syrup solution (Methadose) under nursing supervision
and gave urine samples twice weekly on Monday and Friday. Urine
samples were tested for benzodiazepines using an on-site EMIT
system and were tested for a wide range of other drugs of abuse
by TLC analysis provided by an outside laboratory. During pre
and post intervention baseline periods of approximately 12 weeks
duration, no consequences were attached to results of urinalysis
testing. At the start of the contingent reinforcement inter-
vention period, subjects were told that, until further notice,
they would be able to obtain a reward for providing benzo-
diazepine-free urines at the clinic. Subjects were told that
this was a voluntary program and that they were free to do as
they wished with regard to their extra drug use. During the
intervention period, if the urine sample was benzodiazepine-free,
subjects could choose one of three incentives offered: 1) two
methadone take-home doses; 2) $15 cash payment; 3) two opportuni-
ties to regulate the methadone dose received by as much as
± 20 mg. These positive incentives were available twice weekly
during the intervention period which generally lasted 12 weeks
and were delivered immediately after determination of a benzo-
diazepine-free urinalysis test result. There were no consequences
if the urine sample was positive for benzodiazepines.
RESULTS
Figure 1 shows a dramatic increase in benzodiazepine-free urine
samples for the group of subjects during the contingent
reinforcement intervention period compared to the pre and post
intervention periods. A specific influence of the contingent
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FIGURE 1
Percent of urine samples which were free of benzodiazepine drugs
is shown for the group of ten study subjects during three study
phases: pre intervention baseline (pre), contingent reinforce-
ment intervention (rft) and post intervention baseline (post).
Brackets indicate ± 1 S.E.M.
284
reinforcement intervention is apparent since benzodiazepine
negative tests returned to previous low levels when the inter-
vention was withdrawn. The effect on urinalysis test results
was significant (p<0.05) in a repeated measures analysis of
variance. Eight of the ten study participantsreduced their
benzodiazepine use during the contingent reinforcement inter-
vention; five remained benzodiazepine-free during the entire 12-
week period, while three relapsed to benzodiazepine use during
the inter-vent ion.
Figure 2 shows results of urinalysis testing for drugs other
than benzodiazepines. No systematic changes in use of drugs
from other classes were noted during the period when benzodiaze-
pine use was reduced.
DISCUSSION
This within-subject evaluation demonstrates that a therapeutic
intervention which offers positive incentives for clean urines
can have a dramatic impact in reducing supplemental benzodiazepine
use as revealed by urinalysis testing. This result was obtained
in a group of methadone clinic patients who were, by urinalysis
and self-report evidence, chronic abusers of the class of drugs
upon which the intervention focused. This study replicates and
extends to the benzodiazepine drug class positive results which
have been reported for contingent reinforcement procedures when
incentives have been offered to heroin supplementers for providing
opiate-free urines at the treatment clinic (Hall et al. 1977 1979;
Stitzer et al. 1980).
A previous study (Stitzer et al. 1979) showed that reinforcement
contingent on refusal of available drugs was effective in re-
ducing requests for benzodiazepine drugs at the clinic dispensary.
The present study extends the use of contingent reinforcement
procedures for abstinence to drug use which is occurring in the
natural environment. The efficacy of these procedures is
impressive since reinforcers offered at the clinic must compete
with the intrinsic reinforcing efficacy of the drug of abuse.
Reinforcement of clean urines appears to be an effective and
practical technique when applied in an outpatient methadone
maintenance treatment setting. No adverse side-effects of
positive incentive procedures were noted in the present study or
in previous studies. The results of this study suggest that more
widespread application of contingent reinforcement procedures may
be warranted for influencing on-going drug use among drug abuse
patients enrolled in treatment clinics.
REFERENCES
Bigelow, G., Stitzer, M., Lawrence, C., Krasnegor, N.,
D’Lugoff, B., and Hawthorne, J. Narcotics addiction treatment:
Behavioral methods concurrent with methadone maintenance.
Int J Addict, 15:427-437, 1980.
285
FIGURE 2
Percent of drug-positive samples are shawn for a group of ten study subjects during three study phases.
From left to tight within each panel these study phases are pre intervention baseline, contingent
reinforcement intervention and post intervention baseline. Opiate positives include morphine, quinine,
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indicate ± 1 S.E.M.
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Clinical Analgesic Assay of Sublin-
gual Buprenorphine and Intramus-
cular Morphine
Stanley L. Wallenstein, Robert F. Kaiko, Ada G. Rogers, and
Raymond W. Houde
Buprenorphine, a C-ring bridged oripavine, is a strong analgesic
derived from thebaine which has demonstrated both narcotic agon-
ist and antagonist activity in man and animals. Its analgesic
activity as determined in studies carried out by us(Houde 1979)
and others (Heel et al. 1980, Robbie 1979) indicate that intra-
muscular buprenorphine is 25 to 30 times as potent as intramus-
cular morphine. As a narcotic antagonist, buprenorphine is esti-
mated to be equal in potency to naloxone on a milligram basis.
Sublingual buprenorphine has been employed with sane success in
the management of pain due to cancer at The Royal Marsden Hospi-
tal in London (Robbie 1979). Individual doses as high as 0.8 mg
have been reported to be particularly useful in the management
of pain in patients with head and neck and gastrointestinal can-
cer, and is said to have little constipating effect.
Cur previous study (Houde et al. 1977) of intramucularly admin-
istered buprenorphine was carried out in 136 patients (126 with
postoperative pain and 8 with chronic cancer pain) as a series
of sequentially-related twin crossover assays in doses ranging
from 0.1 to 1.6 mg. Only small numbers of patients received the
extreme lower and upper doses, and all series were eventually
combined in a single estimate of relative potency = 28) with
rather tight 95% confidence limits for an assay of this type
= 21 to 35). There was no significant change in the relative
potency estimates when the series with the extreme doses were
eliminated fran the analysis; nevertheless, the possibility that
curvature is present at the high or low doses of the buprenor-
phine dose-response curve cannot be ruled out, as the test for
parallelisn is relatively insensitive in the twin crossover
assay. This test is a non-crossover one; and significant effects
may merely represent patient group differences.
This present report represents a study in progress of the rela-
tive potency of sublingual buprenorphine and intramuscular nor-
phine in patients with postoperative pain and a methodological
report of an incomplete block assay designed both to cover a
288
wide range of doses and to provide sane estimate of the presence
or absence of curvature in the dose-effect curves of the drugs
under study.
METHODS
The basic methodology employed in this assay adheres to the prin-
ciples of clinical study design employed by this group and pre-
viously reported (Wallenstein and Houde 1975). Male and female
inpatients with postoperative pain were included in the assay if
the following conditions were met: The presence of severe or
moderate pain; the ability to communicate; age over 18 years; no
medical contraindications to narcotic-type drugs; approval of the
attending physician or Service to which the patient had been ad-
mitted; and the written consent of the patient. patients were
seen hourly fran 9 a.m. to 5 p.m. by analgesic nurse observer who
recorded the patients' subjective reports of pain intensity and
pain relief employing both categorical and visual analogue scales
(VAS). Pertinent concomitant signs and symptoms and volunteered
side effects are-also recorded. Only one study medication per
day was administered and no study drug given within three hours
of a prior analgesic. Observations were continued-for either six
hours or until pain returned to the premedication level at which
time the patient's regular non-study analgesic was administered.
The assay consisted of three equi-log-spaced doses of the stan-
dard drug (intramuscular morphine) and of the test drug (subling-
ual buprenorphine). To maintain double-blind conditions, each
patient received both an injection and a sublingual tablet, one
of which was a dummy medication and one the active drug as pre-
scribed by the study design. Each patient received only two medi-
cations on separate days; a lower dose of one drug and an upper
dose of the other, or the middle dose of each drug on a double-
blind, randomized basis, but balanced for order. The design is
a modification of the sequential twin crossover assay previously
employed by us, and has the advantage of covering a wide range of
doses without the need for sequential adjustments during the
course of the assay. It also has the advantage of providing sane
estimate of the curvature of the dose-response slopes of the two
drugs. For an ideal assay, the drugs should be evaluated in the
same effect range (insignificant drug differences), slope effects
should be highly significant with minimal deviations from para-
llelism and the comparisons made in the straight-line portion of
the dose-effect curves of the two drugs (insignificant curvature
and deviation in linearity effects).
Of 140 patients started in the assay, 108 have contributed to
completed balanced blocks and are included in the relative potency
analysis. Patient characteristics of age, sex, race, height and
weight were comparable for the three treatment groups, and there
were no significant differences in the level of pain at the time
of medication for the six doses of study drug.
RESULTS
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FIGURE 1
Time-effect curves for 4, 8 and 16 mg of intramus cular morphine
(M, solid lines and symbols) and 0.2, 0.4 and 0.8 mg of subling-
ual buprenorphine (B, broken lines and open symbols).
The time-action characteristics of the two drugs demonstrate a
somewhat earlier and more intense peak effect for morphine than
for buprenorphine (figure 1). At doses that produced about the
same peak intensity (4 mg of morphine, IM and 0.8 mg of buprenor-
phine, SL), buprenorphine produced a longer lasting analgesic
effect. These results are in marked contrast with those we pre-
viously obtained with intramuscular buprenorphine, whose time-
effect curves were indistinguishable fran morphine.
Statistically valid relative potency estimates were obtained
in terms of total relief estimates on both VAS and categorical
scales, (table 1). Highly significant slopes with no significant
deviations in parallelism or linearity were obtained. The best
estimate of relative potency was that sublingual buprenorphine
was 15.5 times as potent as intramuscular morphine in terms of
total effect. As would be expected fran the shape of the time-
effect curves, sublingual buprenorphine is considerably less
potent in terms of peak than total effect, and some extrapolation
is required to arrive at a relative potency estimate. The best
estimate of relative potency in terms of peak action was obtained
with the VAS relief scores and indicated buprenorphine to be
9.4 times as potent as morphine.
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TABLE 1
Relative potency estimates of intramus cular morphine and subling-
ual buprenorphine in terms of peak and total categorial (CAT)
and visual analog (VAS) measurements of pain relief.
RELIEF SCORES
M 4
M 8
M 16
B 0.2
B 0.4
B 0.8
CAT VAS
Peak Total Peak Total
79 195 2044 5236
86 236 2258 6189
81 288 7515
77 197 1908 5178
66 194 1858 5310
77 277 2324 7256
MEAN SQUARES
M - B 6.0** 12 2185* 6600
Slope 1.0 208** 4876** 131950*
Parallelism 1.0 1 0.3 275
Linearity 0.9 22 602 11092
Dev. in Lin. 1.3 13 631 4820
Within Pts. 0.6 13 400 8850
15.2
Limits (7.1, 27.3) (2.4, 17.9) (7.0 28.6)
*P<0.05, **P<0.01
Total and peak relief Were also analyzed using only first-
data to provide information for a single dose, non-crossover
analysis. Valid assays were again obtained in terms of total
relief. The results using crossover and non-crossover CAT and
VAS data are graphically compared in figure 2. The relative
potencies are all similar, indicating no apparent-interaction ef-
fect When a second dose was given, but the crossover comparisons
were the most efficient providing the narrowest confidence limits.
Patients were not questioned directly about side effects but ob-
served or volunteered side effects were recorded. All patients,
including those who failed to complete the crossover assay are
included in the analysis of side effects, Which Were observed in
44 percent of the 122 patients who received morphine and 42 per-
cent of the 137 patients Who received buprenorphine. Side effect
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occurrence was essentially similar for the two drugs, the most
common being sleepiness (47 on M and 54 on B), followed by groggi-
ness (7 on M, 8 on B), lightheadedness (5 on each), nausea (5 on
M, 4 on B) and headache (4 on M, 5 on B). More patients were
dizzy, sweating and jittery on buprenorphine; and more were warm,
stimulated and weak on morphine.
FIGURE 2
BUPRENORPHINE, SL VS MORPHINE IM - RELATIVE POTENCY
TOTAL RELIEF SCORES, 108 PATIENTS
Relative potency esimates of sublingual buprenorphine to
intramuscular morphine in terms of crossover and first dose only
data using CAT and VAS total relief scales with corresponding
95 percent confidence limits.
SUMMARY
A six-point, incomplete block assay of sublingual buprenorphine
and intramuscular morphine has been carried out, providing valid
relative potency estimates of the two drugs in terms of total re-
lief on both categorical and visual analog scales. Sublingual
buprenorphine was about 15.5 times as potent as intramuscular
morphine in term of these total relief estimates. Similar
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relative potency estimates were obtained using first-dose-only
data. There was no evidence of interaction by day in the cross-
over data, and the crossover study proved more efficient and pro-
vided tighter confidence limits. Sublingual buprenorphine pro-
duced a lower peak effect than intramuscular morphine. At equi-
valent peak effects, it produced longer-lasting analgesia. Side
effect occurrence was roughly comparable for the two drugs, and
no evidence of narcotic antagonist activity was seen after bupre-
norphine. The six-point assay proved to be effective in defining
the dose-effect curves and relative potencies of the two drugs.
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Sources of Variation in Morphine
Analgesia in Cancer Patients With
Chronic Pain
Robert F. Kaiko, Stanley L. Wallenstein, Ada G. Rogers, and
Raymond W. Houde
The amount of pain relief has been found to vary greatly among pa-
tients receiving identical analgesic treatments. The clinical
evaluation of analgesics incorporates various methods in an attempt
to control for both known and unknown factors influencing the anal-
gesic response. Such methods as the randomization of treatments,
crossover designs, stratification and matching of patients for par-
ticular characteristics, and techniques to minimize bias are com-
only employed. Large numbers of subjects are often required for
analgesic assays in order to provide valid and reproducible results
because of the variation fran subject to subject in analgesic re-
sponse. Identification of sources of variation within any given
assay is difficult due to their multiplicity and potential for
interaction with one another. However, we do know that, in post-
operative pain, the age of the patient and the intensity of the
pretreatment pain are significant sources of variation in the re-
sponse to narcotic analgesics. It has been shown that morphine
and pentazocine provide more pain relief in postoperative pain in
direct relation to age (Bellville et al. 1971; Kaiko 1980); nar-
cotics provide more relief when postoperative pain is moderate as
compared to severe (Gravenstein and Beecher 1957), and when wound
pain is steady as compared to sharp (Keats 1956). Less information
is available in terms of sources of variation in the relief of
chronic pain.
The objective of this retrospective survey w-as to determine the
influence of age, race, sex, pretreatment pain intensity, pain
character and pain site on the relief of chronic pain due to cancer
by graded doses of intramuscular morphine sulfate.
METHODS
Relative analgesic potency assays carried out over a period of ap-
proximately twenty years in cancer patients with chronic pain
served as the source of data. These assays were double-blind, com-
plete crossover studies in which morphine, 8 and 16 mg, was the
standard of comparison in the evaluation of investigational
analgesics.
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The method of the complete crossover analgesic assay has been pre-
viously reported in detail (Houde et al. 1960; Wallenstein and
Houde 1975). Briefly, consenting patients had been seen hourly and
questioned about the severity of their pain. Pain intensity was
categorized as none, slight, moderate and severe. When the patient
requested medication for pain which was reported as moderate or
severe, a study medication was given. Patients received study med-
ication according to a design randomized for drug, dose and order
of administration. Estimates of analgesia, including pain relief,
were obtained hourly until pain returned to the premedication level,
or up to six hours. Pain relief was categorized as none (0),
slight (1), moderate (2), lots (3) and complete (4). Total pain
relief (TOTPAR) is the sum of the hourly pain relief scores for
the observation period for each study drug administration.
Data were surveyed fran 715 patients receiving 565 8-mg doses and
538 16-mg doses of intramuscular morphine sulfate. Data from pa-
tients who failed to complete the crossover were also included.
TOTPAR scores were separated into categories according to the pa-
tients's age, race and sex and according to the pretreatment pain
intensity, pain character and site of pain. Patient and pain char-
acteristic data were complete for 97 percent of the sample.
RESULTS
Mean TOTPAR was 5.95 ± 0.23 (SE) and 8.13 ± 0.27 for the 8- and
16-mg doses, respectively. Subsequent patient- and pain character-
related differences will be compared to these scores and to the
dose-related difference of 2.2 in terms of TOTPAR. Table 1 shows
the TOTPAR scores in relation to categories of patient and pain
characteristics following the 8- and 16-mg morphine doses.
The data were arbitrarily divided into four age groups: 18 to 29
year olds, 30 to 49, 50 to 69, and 70 to 89 year olds. The major-
ity of the sample was between 30 and 69 years with about 100 pa-
tients less than 30 and about 50 who were 70 years and older. The
difference in TOTPAR between the youngest and oldest groups was
4.4 for 8-mg doses and 4.6 for 16-mg doses, as compared to the
overall dose-related difference of 2.2 in terms of TOTPAR. Pain
relief privided by 8-mg doses in middle-aged groups was comparable
to relief provided by 16-mg doses in the youngest group. Relief
provided by 8-mg doses in the oldest group was comparable to relief
provided by 16-mg doses in the middle-aged groups.
Most patients were white. There were about 125 black patients and
relatively few oriental patients. Race-related differences in
relief were significant after both doses. While the limited num-
ber of oriental patients make their statistical contribution insig-
nificant, it is clear that black patients obtained significantly
greater pain relief than white patients after both doses. The dif-
ference in TOTPAR between black and white patients was 2.8 for the
8-mg doses and 2.7 for the 16-mg doses, as compared to the overall
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TABLE 1. Total Pain Relief Scores in Relation to Patiaent and
Pain Characteristics in Cancer Patients with chronic Pain
following Intramuscular Morphine Sulfate.
CHARACTERISTIC TOTAL PAIN RELIEF (x ± SE, N)
8 mg Morphine 16 mg Morphine
(Overall) 5.95 0.23 565 8.13 0.27 538
Age (yr)
18 - 29 4.13 0.61 45 5.92 0.71 48
30 - 49 5.95 0.38 205 7.99 0.42 215
50 - 69 6.13 0.35 267 8.46 0.40 254
70 - 89 8.56 1.03 27 10.52 1.57 21
(F 3.74; df 543; P<0.05) (F 3.36; df 537; P<0.05)
Race
White 5.58 0.23 495 7.75 0.28 466
Black 8.38 0.92 64 10.43 0.84 61
Oriental 10.50 3.22 6 11.80 2.00 10
(F 9.73; df 564; P<0.01) (F 6.82; df 536; P<0.01)
Sex
Male
Female
Initial Pain
Severe
Moderate
Pain Character
Throbbing
Radiating and
Shooting
Sharp
Burning
Pulling
Soreness
Pressing or
Tight
Dull, Aching
and Diffuse
5.76 0.36 237
6.25 0.31 315
(t 0.47; df 540; NS)
7.65 0.42 213
8.41 0.35 324
(t 1.36; df 535; NS)
5.82 0.26 449
6.65 0.54 108
(t 1.43; df 552; NS)
7.72 0.28 4 4 7
9.12 0.63 1 1 5
(t 2.17; df 557; P<0.05)
3.81 0.65 16 6.00 1.22 13
4 . 0 0 1.58 4
4 . 4 5 0.35 151
5 . 2 0 1.00 25
6 . 3 3 2 . 3 2  6
6 . 3 4 0.78 59
6 . 4 2 0.69 52 7 . 4 5 0.68 6 7
6 . 8 2 0.43 187 8 . 9 9 0.46 184
18.00 0 2
7 . 2 0 0.45 1 6 0
6 . 1 9 1.57 16
7 . 6 7 2.84 6
6 . 6 5 0.86 51
Crampy 11.92 0.58 13 11.05 1.77 20
(F 4.74; df 512; P<O.01) (F 3.05; df 518; P<0.01)
Pain Site
Head 8.30 1.97 1 0 4.69 1.05 13
Neck 6.11 1.24 19 6.11 1.19 18
Arm 5.24 0.83 49 6.12 0.70 43
Chest 5.24 0.60 72 6.41 0.72 61
Pelvis and
Perineum 4.72 0.82 36 7.69 1.05 36
Leg 6.15 0.59 91 7.81 0.59 9 9
Face 5.80 2.00 5 8.00 4.01 2
Abdanen 7.39 0.73 66 8.83 0.73 82
Back 6.04 0.43 161 9.07 0.52 161
(F 1.28; df 508; NS) (F 2.58; df 514; P<0.01)
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dose-related difference of 2.2 in terms of TOTPAR. Pain relief
provided by 8-mg doses in black patients was comparable to relief
provided by 16-mg doses in white patients.
The ratio of female to male patients was 3 to 2. Sex-related dif-
ferences were not significant. The trend toward greater pain relief
in women is consistent with a lower mean body weight of 60 kg as
compared to 65 kg for men in this sample.
Initial pain intensity was reported as severe in 80 percent of cases
and as moderate in only 20 percent. Relief was not significantly
different in terms of initial pain intensity after the 8-mg doses,
but was significantly greater with moderate as compared to severe
initial pain after the 16-mg doses of morphine. The difference in
TOTPAR after 16-mg doses was 1.4 as compared to the overall dose-
related difference of 2.2 in terms of TOTPAR.
The majority of patients reported their pain either as sharp or as
dull, aching and diffuse. The categories of pain character are
arranged in Table 1 in order of increasing relief for the 8-mg dose.
Pain character-related differences in TOTPAR were significant after
both doses. The difference in TOTPAR with dull as compared to
sharp pain was 2.4 after the 8-mg doses and 1.8 after the 16-mg
doses. Pain relief provided by 8-mg doses in dull pain was compa-
rable to relief provided, by 16-mg doses in sharp pain. Most other
categories had insufficient data to allow for valid individual com-
parisons. Nevertheless, an intuitively logical trend of increasing
pain relief was observed from throbbing pain through sharp to dull
and crampy pain.
Relief was not significantly different in relation to categories
of pain site after the 8-mg doses but was significantly different
after the 16-mg doses. The categories of pain site are arranged
in Table 1 in order of increasing pain relief for the 16-mg doses.
After both the 8- and 16-mg doses, relief of abdominal pain was
significantly greater than relief of thoracic pain or pain in the
am. Other significant pain site-related differences are apparent
but were not always consistent in terms of dose.
The independence of the various characteristics were assessed by
use of Chi-square analyses and Pearson's coefficient of contingency
(Pearson 1901). Some significant, but relatively low degrees of
association were observed. There was a relatively greater propor-
tion of black patients in the younger age group as compared to
white patients. A greater proportion of black patients than white
patients had abdaninal pain as compared to thoracic pain. A great-
er proportion of patients reporting moderate pretreatment pain than
reporting severe pain had dull as compared to sharp pain. Patients
with abdominal pain as compared to pain in the arm reported pain
as sharp disproportionately more than as dull. Most of these
associations would have tended to operate in opposite directions
and to have "masked" the influence of the various characteristics,
rather than to have "exaggerated" their influence on pain relief.
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DISCUSSION
The age-related increase in pain relief is consistent with data
reported by Bellville and associates (1971) and by Kaiko (1980)
in patients with postoperative pain. The most unexpected observa-
tion was the race-related difference in pain relief. While we have
observed, but not yet reported, that black patients obtain signifi-
cantly greater pain relief than white patients with postoperative
pain after both intrarmuscular morphine and methadone, we are not
aware of any similar reports of racial differences in the analgesic
response to narcotics. We were also surprised to find that the
difference in relief between the treatment of severe and moderate
pain was considerably less than differences in relief associated
with differences in other patient and pain characteristics.
The data reported here provides additional evidence of the enor-
mous interindividual variation in the analgesic response to morphine.
The clinical use of narcotic analgesics requires careful titration
of dose and dosing interval according to an appropriate balance
between analgesic and side effects in individual patients. This
should be appreciated regardless of what may be considered the stan-
dard or "optimal" dose and dosing regimen in patients with particu-
lar characteristics.
The data reported here provides a more rational basis for the choice
of experimental controls for the clinical evaluation of analgesic
drugs in various types of pathological pain models. For example,
while investigators using noncrossover designs often stratify pa-
tients according to pretreatment pain intensity, stratification
according to age, race, sex, pain site or pain character is infre-
quent (Bell et al. 1976). It is likely that this is due, in part,
to limited, and often conflicting,infomation as to what variables
are actually associated with significant differences in analgesic
response. The use of matched pairs, based on stratification of
patients according to any characteristic, is also infrequent in
analgesic assays. One reason for this may be the limited availa-
bility of qualifying patients. This is the most difficult problem
encountered in the conduct of analgesic assays (Dell et al. 1976).
Matching patients according to a set of the most significant in-
fluencing characteristics would place additional strains on pa-
tient availability. Nevertheless, our data in chronic cancer pain
indicates that stratification and matching patients according to
age, race and selected categories of pain character and pain site
may improve study sensitivity to a greater extent than stratifica-
tion and matching of patients according to sex or even pretreatment
pain intensity, in the treatment of moderate to severe pain. Of
course, the use of crossover designs, where appropriate, is a most
powerful tool for control of most of these variables.
In summary, pain relief after intramuscular morphine is directly
related to the age of the patient. Middle-aged patients obtained
relief after 8-mg doses of morphine comparable to relief obtained
by younger patients after 16-mg doses. Oldest patients obtained
relief after 8-mg doses comparable to relief obtained by middle-aged
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patients after the 16-mg doses. Black patients receiving 8-mg
doses obtained pain relief comparable to relief obtained by white
patients receiving 16-mg doses of morphine. Pain relief reported
after 16-mg doses was significantly greater in patients With mod-
erate as compared to severe pretreatment pain, whereas there was
no significant pretreatment pain intensity-related difference in
pain relief after the 8-mg doses. Patients reporting dull pain
obtained relief with 8-mg doses comparable to relief obtained by
patients with sharp pain after 16-mg doses of morphine. Patients
With abdominal pain obtained pain relief With 8-mg doses comparable
to relief of pain in the chest or arm after 16-mg doses. The anal-
yses of the degree of independence among the various characteristics
indicated that sane significant, but relatively low, degrees of
association existed.
In conclusion, our results demonstrate and quantify sources of
variation in analgesic response due to particular patient and pain
characteristics for which appropriate controls should be considered
in the evaluation of analgesics in a population of cancer patients
with chronic pain.
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Physiological and Subjective
Effects of Hydromorphone in
Postaddict Volunteers
Mary McCaul, Ph.D., Maxine Stitzer, Ph.D., George
Bigelow, Ph.D., and Ira Liebson, M.D.
The present study examined the physiological and subjective
effects of intravenous hydromorphone (Dilaudid). The experiment
is based on methods for abuse liability testing of opiate-like
drugs developed at the USPHS Addiction Research Center (Jasinski
1977) but introduces a number of modifications in these pro-
cedures. First, it is a relatively rapid procedure for determin-
ing dose-effect relationships. Data collection can typically be
completed within 3-4 weeks per subject, conducting three sessions
per week for approximately three hours per session. Second,
dose-effect relationships are established on a wide variety of
standard physiological and subjective measures. We are therefore
able to examine the associations between the physiological and
subjective effects of the drug. Third, a number of the physio-
logical measures are continuously collected throughout the
experimental session on a PDP-8 minicomputer. This has permitted
a detailed time course analysis of the drug effect. Finally,
drugs are administered intravenously, rather than by the more
typical oral or-subcutaneous route. We were therefore able to
assess the practicality of intravenous drug administration on a
regular basis in subjects with a history of intravenous opiate
use.
METHODS
Subjects. The subjects were five males, ranging in age from 28 to
35. All subjects had a history of intravenous opiate use, but
were opiate-free at the start of the study. They lived on an
eight-bed research unit during the experiment. Subjects were
fully informed of the experimental protocol and risks at the
start of the study, at which time they signed informed-consent
agreements. Subjects were reimbursed for their participation.
was placed in the subject’s arm prior to the start of the session.
The vein was kept patent by a saline drip, which was removed
Procedure. Sessions were conducted three days per week, usually
on Monday, Wednesday and Friday afternoons. A venous catheter
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approximately one-half hour following the injection. Subjects
were seated in an isolated room with the experimenter during
sessions of approximately three-hour duration.
There was always a minimum of a half hour between the start of the
session and drug administration. Physiological measures stabilized
during the first 15 minutes. Baseline data for each session were
collected during the next ten-minute period. Five more minutes
then elapsed before drug administration. This design ensured that
baseline data do not include fluctuations in physiological measures
resulting from the presence of the syringe or the injection pro-
cedure itself. At the end of this half-hour period, the saline
drip was clamped off and the injection was given via the catheter.
Data collection continued for two hours following the injection.
Four of the five subjects received 0-, 2-, 4- and 6-mg doses of
hydromorphone. One subject only received doses of 0, 2 and 4 mg.
Doses were administered under a double-blind procedure in a
randomized block design, with subjects receiving each dose at
least twice.
The following measures were continuously recorded throughout each
session: 1) heart rate, using EKG leads on the chest; 2) skin
temperature, using a probe on the finger tip; 3) respiration,
using a mercury strain gauge stretched across the abdomen; and
4) blood pressure, using a cuff that automatically inflated and
recorded pressure once every minute (Roche Arteriosonde #1216).
In addition, a number of measures were intermittently recorded
during each session. A pupil photograph was taken approximately
15 minutes prior to, and 5, 15, 30, 60, 90 and 120 minutes
following the injection, using a Polaroid camera with 3X magnifi-
cation. Subjective report forms were also administered approxi-
mately 15 minutes prior to the injection and four times following
the injection at half-hour intervals. Subjective report forms
included: 1) an analogue high scale on which subjects were asked
to rate their current degree of “high” from 0 to 100; 2) the short
form of the Addiction Research Center’s MBG (Morphine-Ber-edrine
Group) scale; and 3) a 32-item adjective checklist, which included
the Fraser single-dose opiate questionnaire (Fraser et al. 1961)
as well as additional signs and symptoms characteristic of opiate
effects. Subjects were instructed to complete all subjective
report forms by referring to the way they felt at the present
moment.
Data analysis. With the exception of skin temperature, physio-
logical data are presented using “difference from control” scores.
These were calculated by subtracting postinjection measures from
baseline measures for each session. These difference scores were
averaged across replications at each dose for each subject and
were then summarized across subjects at each dose. Responses to
the short form of the MBG and- the full 32-item adjective checklist
were also adjusted with respect to predrug data using difference
scores. When included in the full checklist, items from the
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Fraser single-dose opiate questionnaire were treated as all other
items, but when presented separately, scores on the questionnaire
were derived using the weighted scoring system introduced by
Martin and Fraser (1961). Time course and dose-effect data are
presented graphically for the group of subjects.
RESULTS
There were graded changes in most physiological measures as a
function of the dose of hydromorphone in the present experiment.
Figure 1 summarizes these drug effects on pupil diameter. Follow-
ing the administration of placebo, pupil diameter remained at
baseline levels. A dose of 2 mg of hydromorphone constricted
pupils an average of 2.0 to 2.5 mm. Pupil diameter decreased 3.0
to 3.5 mm following 4 mg of hydromorphone and 3.6 to 3.8 mm
following 6 mg. Since drug was administered intravenously, there
was a very rapid onset of the drug effect at all doses, with
maximum pupil constriction occurring within 15 minutes to a half
hour following the injection. There was little or no recovery of
pupil diameter during the two hour postinjection period.
FIGURE 1
MINUTES POST-INJECTION
The effects of 0 (o), 2 4 and 6 mg of hydromorphone
on pupil diameter as a function of time since injection. Vertical
lines indicate ± 1 S.D.
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Figure 2 summarizes the dose-dependent effects of hydromorphone
on respiration. Control respiration rates tended to decrease
slightly during placebo control sessions. Hydromorphone produced
additional dose-related decreases in respiration. The high doses
of 4 and 6 mg produced an average respiratory depression of three
breaths per minute. These decreases persisted throughout the
session.
FIGURE 2
MINUTES POST-INJECTION
The effects of 0, 2, 4 and 6 mg of hydromorphone on respiration.
As shown in Figure 3, baseline skin temperature averaged 93° F.
Following placebo administration, skin temperature increased to
a maximum of 94° F 20 minutes following the injection, and then
decreased throughout the rest of the session. Hydromorphone
produced dose-dependent increases in skin temperature. Skin
temperature increased to 95° F following 2 mg of hydromorphone
and to 95.5° F following the highest doses. Skin temperature
decreased slightly in the final hour of the session following
2 and 4 mg of hydromorphone but remained elevated throughout the
experimental session following 6 mg.
Placebo administration produced a slight, very brief increase in
systolic blood pressure, which then decreased below baseline
levels throughout the rest of the session. All doses of hydro-
morphone produced a similar initial increase in systolic blood
pressure of 12 to 13 mm Hg. Systolic blood pressure gradually
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FIGURE 3
MINUTES POST-INJECTION
The effects of 0, 2, 4 and 6 mg of hydromorphone on skin
temperature.
decreased and returned to placebo levels by the end of the two-
hour session following the low doses but remained elevated
throughout the two-hour period following the highest dose of drug.
Diastolic blood pressure showed less consistent dose-related
effects than systolic blood pressure. Following placebo, diastolic
pressure remained at baseline levels. Following drug administra-
tion, diastolic pressure immediately increased and remained
elevated for approximately one hour before returning to placebo
levels.
The effects of hydromorphone on heart rate were generally dose-
dependent within each subject, although there were substantial
individual differences across subjects. In general, the overall
effects appeared to be biphasic: first, accelerating heart rate
above placebo levels and then decreasing heart rate to or below
placebo levels. Subjects differed in the duration of each phase
of the effect.
Figure 4 summarizes the effects of hydromorphone on the four sub-
jective report measures. Placebo produced little change from
baseline on any of these. There were dose-related increases on
all subjective measures following 2 and 4 mg of hydromorphone,
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FIGURE 4
MINUTES POST-INJECTION
The effects of 0, 2, 4 and 6 mg of hydromorphone on several
subjective report measures. Brackets indicate ± 1 S.D. for
baseline scores.
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with little or no further increase following 6 mg. At the low
dose of hydromorphone, responses on all measures generally de-
creased to baseline levels by the end of the two-hour postinjec-
tion period. Responses on the analogue high scale and adjective
checklist also decreased during the two-hour period following
4 and 6 mg of hydromorphone, although they were still considerably
elevated above baseline levels at the end of the session. Scores
on the single-dose opiate questionnaire and the MBG scale remained
elevated during the entire two-hour session following the 4- and
6-mg doses.
DISCUSSION
The present study determined the effects of several doses of
hydromorphone on multiple physiological and subjective measures.
Clear dose-effect relationships emerged on all measures. In-
creasing the dose of hydromorphone generally resulted in an
increase in the magnitude of the effect on all measures for doses
of 2 and 4 mg, with little further increase in effect at the
highest dose. Pupils constricted, respiration decreased and skin
temperature increased. These effects are similar to those re-
ported for opiates in other studies.
While hydromorphone produced similar initial effects on all the
subjective report measures, there were differences in the time
course of the drug effects following the high doses of drug.
Following 4 or 6 mg, responses on the adjective checklist and the
analogue high scale decreased over time. In contrast, responses
on the MBG scale and Fraser single-dose opiate questionnaire re-
mained relatively constant throughout the two-hour postinjection
period. This suggests that the adjective checklist and analogue
high scale may provide a measure of a transient drug effect
commonly associated with intravenous opiate administration and
frequently described as the “rush”; whereas, the MBG and single-
dose opiate questionnaire may be measuring relatively more stable
effects induced by the drug. Thus, there were large changes in
some components of subjective effects throughout the two-hour
session, although physiological measures such as pupil diameter,
skin temperature, and respiration remained stable.
The results of this study demonstrate that the current procedure
permits the rapid determination of dose-effect functions for both
subjective and physiological measures. Data on a single subject
were generally completed in 10 three-hour sessions within a three-
week period. Such a restricted time frame makes intravenous drug
administration feasible in a postaddict population and also would
permit the extension of these procedures to an outpatient setting.
Comparisons across drugs or of the effects of various environmental
interventions could be quickly and reliably assessed using this
procedure.
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A Comparison of Some Subjective
Effects of Prazepam, Diazepam, and
Placebo
Maressa Hecht Orzack, Ph.D., Jonathon 0. Cole, M.D., Martin
Ionescu-Pioggia, A.B., Barbara J. Beake, A.B., Michael P.
Bird, A.B., and Marci Lobel
Over the past two decades, the abuse potential of sedative and
anxiolytic drugs has become a matter of increasing scientific concern.
In particular, distinguished efforts have been made by Jasinski et
al. (1977), Bigelow (1976), Griffiths et al. (1976, 1981) and others
to assess the subjective effects and reinforcing properties of these
substances in man. Paradoxically, despite interest in this area, a
recent literature review revealed few studies dealing directly with
the abuse potential of anxiolytics, even though they are among the
most widely prescribed and easily accessible of psychoactive sub-
stances. As part of a survey on college student drug use, Pope et
al. (1981) observe in an unreported finding that 13% of students at
one major university campus use minor tranquilizers recreationally,
while Woody et al. (1975) report that, beginning in 1972, diazepam
became one of the most popular street drugs available. Johnston et
al. (1980) have also noted the relatively frequent use of tranquili-
zers among high school students. Bliding (1974) assumes that diaze-
pam’s risk of abuse is related to the subjective experience it pro-.
duces, which he concludes depends to a large extent on its unusually
rapid rate of absorption. Finally, in a behavioral study of human
preference for 400 mg of pentobarbital, 200 mg of diazepam and place-
bo, Griffiths et al. (1981) found that both substances produced simi-
lar ratings in magnitude of drug effect and both were preferred to
placebo; however, pentobarbital was consistently preferred over
diazepam. This study indicates that high doses of diazepam have
reinforcing subjective effects which approach those of a highly
abusable barbiturate.
In a previous study by our group (Cole et al. 1978), the subjective
effects and abuse potential of nefopam, a nonopiate analgesic agent,
were examined by comparing the subjective effects experienced by
normal recreational users of illegal stimulant drugs, after they
had taken 10 mg of amphetamine, 90 mg of nefopam, 300 mg of caffeine,
or placebo in a naturalistic setting. Using the Profile of Mood
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States - POMS (McNair et al. 1971) and List 116 of the Addiction Re-
search Center Inventory - ARCI (Haertzen 1974), it was possible to
discriminate between the effects of the different treatments.
The present study utilized a similar methodology to assess the sub-
jective effects and abuse potential of prazepam, a relatively new
benzodiazepine. In this experiment, the subjective effects of 20 mg
of prazepam were compared to those of 10 mg of diazepam and placebo.
These doses were selected as clinically equivalent high-standard
dosage units, although Woody et al. (1975) note anecdotally that the
standard recreational dose of diazepam ranges between 30 and 80 mg.
Diazepam produces peak blood concentration at 30-90 minutes after
ingestion, while the peak blood level of desmethyldiazepam, prazepam’s
active metabolite, occurs at about six hours.1 It seems reasonable
that a benzodiazepine which produces a slower rise to peak serum
level, such as prazepam, may induce less reinforcing subjective ef-
fects than diazepam and hence have a lesser propensity for abuse.
SUBJECTS
Twenty-three subjects, 12 males and 11 females, ranging in age from
18 to 28, were included. Subjects were divided into four groups of
six subjects each (two groups of males and two of females), except
for one group of females which had five subjects. They were recruit-
ed by notices posted in various local colleges. Most were students
from socio-economically upper middle or upper-class families who were
college educated. All participants were casual users of sedative-
hypnotics, such as barbiturates, methaqualone, and benzodiazepines
and had used one or more of these drugs at least six times in doses
above the usual prescribed levels. Subjects were required to com-
plete the Minnesota Multiphasic Personality Inventory - MMPI (Dahl-
strom et al. 1972) and undergo a clinical interview. The latter was
conducted by a clinical psychologist, who determined previous drug
usage, probed for areas of personality dysfunction and for adverse
reactions to stress, in addition to reviewing the psychiatric history
of the subject and his family of origin. Results from both the MMPI
and the clinical interview were used as criteria on which to judge
the subjects’ suitability for participation. The mean MMPI profile
of male and female subjects showed elevations, though below a T-score
of, 70, of scales 4 (Pd - Psychopathic deviate) and 9 (Ma - Mania).
This pattern is characteristic of a hypomanic and sociopathic per-
sonality style that is generally within the range of normal behavior
(Dahlstrom et al. 1972).2 Subjects showed no abnormality during a
physical examination, were not dependent on any drug including alco-
hol, and had had no unusual side effects during their previous drug
experiences. A twelve-lead EKG was also used as a screening pro-
cedure.
MEASURES
TIhe two major dependent measures were the POMS and the ARCI. The
POMS consists of 72 five-point adjective rating items which break
down into eight factors designed to measure identifiable subjective
mood states, including Elation, Confusion and Fatigue. It has been
shown to be-sensitive in discriminating effects of different drugs
and it is reliable as a repeated measure over relatively brief
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periods of time (Cole et al. 1978).
List 116 of the ARCI is a 102 item inventory which characterizes the
subjective effects of a drug compared with those of other well-known
drugs of abuse. This version contains seven standard scales in addi-
tion to an llitem Amphetamine scale developed by Martin et al. (1971)
plus Euphoria and Sedation scales established by Jasinski and his co-
workers (1977). The utility of these scales in investigating the
subjective effects of various substances is well documented (Martin
et al. 1971, Jasinski 1977, Jasinski et al. 1977).
TESTING PROCEDURES
Subjects were run in groups of six, with each group coming in for
three five-hour sessions, one week apart. Each subject in fact re-
ceived all three treatments (20 mg of prazepam, 10 mg of diazepam,
and placebo) in random order and double-blind. Thus, each subject
served as his or her own control for the experiment. Randomization
of treatments ensured that only two subjects in each group were re-
ceiving the same drug during each session. Subjects themselves were
not aware that they would receive a different treatment at each
session, and only knew the possible treatments they could receive.
Subjects were instructed to abstain from drug usage for 48 hours and
alcohol for 12 hours prior to each session; they were asked to give
a urine sample at the beginning of the session to be screened for
illicit drug usage that might interfere with the validity of their
ratings. No illicit use was detected. Initial physiological meas-
ures were taken, including pulse, temperature, and blood pressure.
Pulse determinations were repeated hourly, and blood pressure at the
end of the session, for medical monitoring.
Subjects rated their subjective experiences on the two self-rating
questionnaires, the POMS and the ARCI. These were administered at
baseline (predrug) and hourly for five hours following drug inges-
tion. They were also asked to rate which drug they thought they
and the other subjects received, what they would pay for what they
received, and how high they felt during the session.
Groups were run in a living-room-like atmosphere, where subjects were
free to play games, talk, read, listen to music, etc. during the
times when they were not filling out ratings. Each rating took about
twenty-five minutes; thus the subjects had a substantial amount of
free time.
DATA ANALYSIS
The F values and corresponding probabilities for main drug effects,
time effects, sex effects, and interaction among these variables
were obtained by an analysis of covariance, grouped by sex, which
adjusted for variations in the subjects’ predrug ratings. The
baseline scores (predrug) depicted in the figures represent raw
means for each scale, while postdrug scale scores have been covaried.
No significant differences between the three treatment groups were
observed on baseline ratings. Results of this analysis are presented
in table I for the ARCI and table II for the POMS. Where main drug
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effects, drug-by-time interactions, or trends were observed, an
analysis of variance of adjusted mean scores was performed for each
separate time point on that measure, and significant results are
portrayed below each figure (Figs 1-10). Differences between drug
conditions at these time points were analysed using a Newman-Keuls
multiple comparison statistic. Results of posthoc drug comparisons
are displayed below each figure.
RESULTS AND DISCUSSION
Preliminary findings indicate that it is possible to discriminate
between the subjective effects of prazepam, diazepam and placebo at
relatively low doses.
An examination of tables I and II reveals a number of significant
drug, time and sex effects, as well as interactions. The most con-
sistent pattern of interactions occurs between the drug and time
variables, with significant effects being observed on 9 out of 18
scales, indicating that the methodology is able to detect drug-induced
mood changes over time.
Significant main drug effects were found only on the ARCI Drunkenness
scale (Fig 1), with trends noted on Sedation (Fig 3) and Fatigue (Fig
1) at .07 and .11 alpha levels, respectively. Drug-time interac-
tions in all these scales as well as PCAG (Fig 2), however, demonstrate
the drugs’ general sedative-like effect over time. On all sedative
measures, prazepam and diazepam are distinguishable from placebo at
hour one (Figs 1-4), and generally at hours two and three. However,
there appeared to be no detectable difference between diazepam and
prazepam on any of these scales. By visual inspection of the figures,
diazepam appears to reach peak effect at about one hour, while praze-
pam’s rise to peak effects is less steep and seems to induce the
strongest changes between two and three hours, suggesting a slower
course of action. However, by Newman-Keuls analysis, all significant
prazepam-placebo differences are noted first at one hour, though some
are also noted at two or, in one case, three hours.
It is important to note that even if the peak blood level of des-
methyldiazepam occurred at six hours in our prazepam subjects, the
peak subjective effects obviously occur substantially earlier.
A significant drug-by-sex interaction on the POMS Fatigue factor
(Figs 5, 6) was noted. Examination of these drug comparisons grouped
by sex indicates that the women became more fatigued earlier on
diazepam than on prazepam. Men, however, seem to become mildly
more fatigued on prazepam than diazepam, and both drugs seem to have
a similar time course on this factor in males. Clearly, for all
subjects, both prazepam and diazepam increased fatigue by the end of
the five-hour study session.
The ARCI LSD scale (Fig 7) and the POMS Confusion factor (Fig 8) both
display significant drug effects, with Confusion also exhibiting a
drug-by-time interaction. Roth are indices of dysphoric psychological
and physical states.3 Prazepam and diazepam produce more dysphoria
than placebo at one hour and at other time points, but again, they
are not significantly different from one another.
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The ARCI Excitation scale (Fig 9) shows an overall trend attributable
to the drugs alone, as well as a drug-time interaction. It is at one
hour on this scale that the only significant difference between drugs
can be detected, with diazepam causing more excitation than prazepam.
The fact that both drugs appear to be equally sedating precludes the
possibility that such an effect is dose-related. The Euphoria scale
(Fig 10) shows a drug-time interaction, and an effect at the one-
hour time point, but no significant drug differences by Newman-Keuls
analyses. The diazepam scores showed the greater effect at one hour.
These two scales measure states of pleasurable stimulation and their
courses are quite similar, suggesting that diazepam may be the more
euphoriant of the two drugs, while prazepam induces less excitation.
Subjects’ posthoc guesses regarding which treatment they received
were not better than chance; however, trends (p=.10) indicate that
they were generally able to distinguish both drugs from placebo but
not from each other. No significant differences were observed on a
16-cm scale rating highness; the mean rating for prazepam was 3.9
(SE=3.38), 3.7 for diazepam (SD=3.25), and 2.2 for placebo (SD=2.66).
From these results and findings presented earlier, we strongly sus-
pect that thesesubstancesproduce subjectively different states of
euphoria but that they are probably not evident at such low doses.
The inability of subjects to identify treatments better than chance
may be further indication of this contention. By way of contrast,
in two studies, one investigating stimulants (Cole et al. 1978) and
another examining the subjective effects of 200 and 400 mg of metha-
qualone (Orzack et al, in preparation), participants were able to
identify drug at a rate better than chance, and the highness rating
was relatively sensitive to drug-induced mood changes.
It is difficult to generalize about a substance’s subjective effects
and abuse liability from a single-dose study, particularly with the
levels of drugs employed. Thus, the second phase of this preliminary
investigation will focus on these drugs at higher doses, which more
realistically resemble those used for recreational purposes.
Accurate estimation of abuse liability requires as much methodologi-
cal precision as possible. Consequently, the areas to be considered
in subsequent studies include investigating the ecological validity
of the laboratory versus the naturalistic setting, looking at inter-
action between personality and drug response, and examining group
interaction patterns as an index of abuse liability.
References available on request from senior author.
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TABLE I: A Summary of Analyses of Covariance of Arci Scores
TABLE II: A Summary of Analyses of Covariance of Poms Scores
FIGURE 1
ARCI DRUNKENNESS: DRUG COMPARISON
Men-Woman Combined
FIGURE 2
ARCI PCAC: DRUG COMPARISON
Men-Women Combined
FIGURES 3
ARCI SEDATION: DRUG COMPARISON
Men-Women Combined
FIGURES 5
POMS "FATIGUE": DRUG COMPARISON
M e n
FIGURE 4
POMS "FATIGUE": DRUG COMPARISON
Mem-Women Combined
FlGURE 6
POMS "FATIGUE": DRUG COMPARISON
W o m e n
FIGURE 7
ARCI LSD: DRUG COMPARISON
Men-Women Combined
FIGURE 8
POMS 'CONFUSION': DRUG COMPARISON
Men-Women Combined
FIGURE 9
ARCI EXCITATION: DRUG COMPARISON
Men-Women Combined
FIGURE 10
ARCI EUPHORlA DRUG COMPARISON
Men-Woman Combined
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Differential Motor and State Func-
tioning in Newborns of Women on
Methadone
J. Marcus, S. L. Hans, and R. J. Jeremy
Abstract
Motor and state functioning of 20 infants born to meth-
adone-maintained women and 25 born to controls was as-
sessed at 1 day and 1 month of age using Brazelton
Neonatal Behavioral Assessment Scale with Kansas Sup-
plements (NBAS-K). The infants were of mothers who
were Black, of low SES, between the ages of 18 and 35
years, and who had good prenatal care. Motor behaviors
were scored on 3 NBAS-K items: General Tonus, Motor
Maturity, and Tremulousness. State behaviors were
scored on 2 items: Alertness and General Irritability.
Guttman's Multidimensional Scalogram Analysis (MSA)
of individual profiles revealed an orthogonal relation-
ship between motor and state functioning, with motor
functioning being a much clearer discriminator between
methadone and non-methadone infants than state func-
tioning. With age, both groups generally improved,
but non-methadone infants maintained some of their
advantage in motor functioning. Both groups showed
a variety of behavior patterns during the neonatal
period. The results suggest that methadone acts
differentially on CNS functioning, with strong effects
on neuro-motor functioning.
Department of Psychiatry
University of Chicago
Chicago, Illinois 60637
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The Effects of Perinatal Addiction
on Pulmonary Function in the
Newborn
Loretta P. Finnegan, Tsun-Hsin Lin, Dian S. Reeser,
Thomas H. Shaffer, and Maria Delivoria-Papadopoulos
Opiate dependence during pregnancy is overwhelming to the physi-
cal condition of the woman, the fetus, and ultimately the newborn
infant. The vast majority of addicted women neglect general
health care and therefore are predisposed to a host of obstetri-
cal complications during pregnancy. These obstetrical complica-
tions as well as other medical complications in pregnant drug
dependent women predispose infant to pulmonary illness.
(Finnegan, 1980) When the pregnant addicted woman suffers from
septicemia, urinary tract infection, amnionitis, chorioamnionitis,
premature rupture of the membranes, or septic thrombophlebitis,
her infant may be predisposed to pneumonia. Neonatal hypovolemia
and shock may occur if the mother develops abruptio placenta,
which is a common occurrence in these women, especially if
abstinence. is frequent. Maternal withdrawal may occur when the
woman cannot obtain the drugs that she needs'to maintain her
habit or when she has been involved in a therapeutic detoxifica-
tion regimen which has been poorly controlled.
With the extremely unstable, intrauterine milieu and exposure of
the infant to chronic fetal hypoxia owing to repeated episodes.
of withdrawal and overdose, the, infant may be prematurely born.
These episodes of maternal withdrawal cause uterine irritability
which may progress to the premature onset of labor. The infant
who is born early may suffer from respiratory distress syndrome
with the possibility of pulmonary hemorrhage as a complication.
Additional difficulties which occur because of fetal distress
precipitated by repeated episodes of withdrawal and/or overdose
may cause the expulsion of meconium in utero, therefore predis-
posing the neonate to meconium aspiration syndrome.
Pneumothorax, a frequent complication of the aspiration syndrome,
may follow. Chronic fetal hypoxia in association with maternal
hypertension, venereal disease, preeclampsia, placental insuffi-
ciency or the inhibitory effect of heroin upon fetal growth may
cause the birth of an infant with intrauterine growth retardation.
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Therefore, the infant may have the possibility of developing an
aspiration pneumonia, hypoglycemia or hypocalcemia. Hypervisco-
sity, an occasional complication of growth retardation in the
fetus, may be manifested. Both hypoglycemia and hyperviscosity
may be associated with respiratory symptomatology (Finnegan, 1980).
Occasionally, the pregnant drug-dependent woman is concerned as
to whether she will be treated appropriately with analgesics
during labor. Therefore, she may take an increased amount of
heroin or other illicit drugs in order to alleviate her labor
pains. As a result, respiratory depression immediately post-
partum may be encountered in the infants of mothers who use
illicit heroin or methadone. Fetal depression may be due
either to asphyxia or to narcotic induced depression of the
respiratory center (Finnegan, 1980).
Currently, it is fortunate that the majority of pregnant addicted
women are treated as high-risk and provided with appropriate
prenatal and addictive care which has been shown to eliminate
many of the obstetrical and medical complications as well as the
subsequent neonatal morbidity (HEW, 1979). Since most of these
mothers are maintained on methadone, the major problem that is
encountered in over 60 percent of the infants is that of neonatal
abstinence. Neonatal narcotic abstinence is described as a
generalized disorder characterized by signs and symptoms of cen-
tral nervous system hyperirritability, gastrointestinal dysfunc-
tion, respiratory distress and vague autonomic symptoms which
include yawning, sneezing, sweating, stuffy nose, mottling, in-
creased lacrimation, and fever. Infants that are afflicted
generally develop tremors which are initially mild and occur
only when the infants are disturbed but which progress to the
point where they occur spontaneously without any stimulation.
High-pitched cry, increased muscle tone, and irritability develop.
The infants tend to have increased deep tendon reflexes and a
hyperactive moro reflex. The rooting reflex is exaggerated, and
the infants are frequently seen sucking their fists or thumbs,
yet when feedings are administered, they have extreme difficulty
and regurgitate frequently. The feeding difficulty occurs because
of an uncoordinated and ineffectual sucking reflex. The infants
may develop loose stools and therefore are susceptible to de-
hydration and electrolyte imbalance (HEW, 1979).
In addition to the above, previous studies have described tachyp-
nea, hypocapnia, and alkalemia secondary to hyperventilation, de-
creased birthweight, and less than expected incidence of respira-
tory distress syndrome (RDS) (Glass, et al., 1971; Klain, et al.,
1972; Taeusch, et al., 1973; Glass, et al., 1972). Studies of
passively addicted newborn animals demonstrated improvement in
lung function attributed to induced surfactant synthesis
(Taeusch, 1973).
The abstinence-induced tachypnea in these neonates can be a very
confusing symptom. The physician must decide whether the tachyp-
nea is simply a result of abstinence or whether it is an initial
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symptom of the many conditions previously noted, since these in-
fants are so frequently predisposed to respiratory conditions due
to the maternal complications. Clinicians have also been con-
cerned as to the impact of this tachypnea on lung function in
these infants during the abstinence syndrome. Therefore, the
purpose of the present study was to investigate the relationship
between tachypnea, as seen in the neonatal abstinence syndrome
and lung function in infants born to opiate-dependent mothers in
comparison to normal controls of equivalent age and birth weight.
METHODS
The infants studied were born to opiate-dependent women enrolled
in Family Center Program in Philadelphia. The program provides
comprehensive obstetrical, medical, addictive and psychosocial
care to these women and their children. All infants included
in the study were normal except for symptoms of neonatal narcotic
abstinence. They were admitted to the intensive-care nursery of
our Hospital for observation and assessment of abstinence.
During the first 24 hours of life, each newborn was scored by a
neonatal abstinence scoring system which we have developed and
which has been previously published (HEW, 1979). The infants
were scored at birth and once every hour during the first day,
and on the second day the infants were scored every two hours.
After 48 hours of life, the infants were scored every four hours.
As per the protocol of the scoring system, no infant was treated
with pharmacologic agents for abstinence if his score was 7 or
less. The infants were treated with either paregoric, phenobar-
bital or diazepam according to a specially devised dosing regimen
(HEW, 1979; Finnegan, et al., 1975) which is dependent on a
combination of score and infant's weight. The dose was escalated
if the Infant maintained a score greater than 7 at a given assess-
ment period and continued that high score for three assessments.
Therefore, all infants were treated similarly from the standpoint
of assessment as well as pharmacologic treatment.
Sequential pulmonary function measurements were made as soon as
possible during the first 24 hours following birth and were re-
peated at 48 and at 72 hours of age in both study and control
infants. Tidal volume was determined by electrical integration
of air flow obtained from an infant pneumotachograph calibrated
previously with known air flows. The pneumotachograph was at-
tached to an infant rubber mask and applied over the infant's
face. The total dead air space of this system was approximately
5 ml. Esophageal pressure was measured using a latex balloon
which tested for linear pressure response between ± 10 CM H20.
Grass transducers were used to measure air flow and esophageal
pressure. These signals were amplified and recorded on a four-
channel recorder from which dynamic lung compliance and resist-
ance were calculated by dividing the tidal volume by the change
in esophageal pressure, at the time of zero flow, trying to
avoid periods of grunting or irregular respiration.
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RESULTS
The clinical data of the 18 infants born to opiate-dependent
women and the 13 control infants were compared. There was
similar distribution of males and females in both groups. Aver-
age gestational age for both the study and control infants was
39 weeks. Mean birth weight for the study infants was 2890
grams, and for the controls, it was 3050 grams. Mean one-minute
Apgar score for the study infants was 7.8 in contrast to 8.8 for
the control infants. This difference was statistically signifi-
cant but both are in the normal range. At five minutes, mean
Apgar score was 9 for the study infants and 9.7 for the controls.
Infant morbidity was 50 percent in the study infants and 38 per-
cent in controls.
None of the study or the control infants had hyaline-membrane
disease or any other major neonatal complications throughout the
study period. Infant morbidity in the study group included intra-
uterine growth retardation, gonococcal conjunctivitis, asphyxia
neonatorum, tiyperbilirubinemia, prematurity, and oral moniliasis.
Infant morbidity in the control group included prematurity, hyper-
bilirubinemia, and postmaturity.
'The mothers of the infants in the study group had used heroin for
a mean duration of about 3 1/2 years with a reported mean use of
16 bags per day. The mothers had been maintained on methadone
ranging from one week to eight months prior to delivery. The
amount of methadone used by these mothers was from 10 to 70
mg/day. Maternal complications occurred in 61 percent of the
study group and 30 percent of the control group. The mothers of
the study infants had a mean of 4.8 prenatal visits in contrast
to the control infants for which it was 7.8 prenatal visits.
Fifty percent of the infants in the study group necessitated
pharmacologic treatment for abstinence. The agents utilized
were phenobarbital in 4, paregoric in 3, and diazepam in 2.
Initiation of treatment ranged from 4 hours to 5 days with a
mean of 36 hours. Figure 1 shows the lung compliance and lung
tidal volume in study infants and control infants. (All the data
in the Figures are presented as a mean ± standard error, repre-
sented by the vertical bars.) The asterisk indicates that the
values are significantly different between infants of drug-de-
pendent mothers and control infants on the first day. On the
third day, it is noted that lung compliance and tidal volume
were significantly different than on day 1. With regard to
inspiratory and expiratory resistance (not shown in Figures),
no significant differences were noted for study or control in-
fants, either on day 1 or day 3.
Figure 2 compares respiratory rate and minute volume of the study
and control infants. The asterisk indicates that the infants of
drug-dependent mothers and control infants are significantly dif-
ferent with regard to respiratory rate on days 1, 2 and 3. With
regard to minute volume, the infants of drug-dependent mothers
are significantly different than the controls on day 3 and also
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significantly different on day 3 in comparison to day 1. As
shown in Figures 1 and 2, sequential pulmonary function measure-
ments of the 13 control babies showed no significant variation
throughout the first 3 days of life and were in agreement with
the literature for normal term infants (Cook, et al., 1955).
Pulmonary function measurements of the 18 infants of drug-depend-
ent mothers were evaluated sequentially. Both lung compliance
and tidal volume were significantly increased from day 1 to day
3. Inspiratory and expiratory resistance, as well as respiratory
rates varied, but not to a significant degree. Minute volume was
increased significantly from day 1 to day 3. Comparison of pulmo-
nary function for infants of drug-dependent mothers with that of
control infants has shown that tidal volume and lung compliance
were decreased significantly on day 1 for infants of drug-depend-
ent mothers. However, respiratory rate was increased signifi-
cantly. By day 3, pulmonary function of the infants of drug-
epen ent mothers had returned to control levels with the
exception of respiratory rate and minute ventilation, which were
both significantly higher.
DISCUSSION
Neonatal abstinence and the associated tachypnea, characterized
by respiratory rates occasionally rising above 100 breaths per
minute, have been studied by Glass and colleagues (Glass, et al.,
1972). The abstinence-induced tachypnea has been found to be
continuous, differing from the occasional bursts of rapid re-
spirations commonly occurring in normal infants during the first
few weeks of life. In adults, these findings have also been seen
and the etiology thought to be an increased sensitivity of the
respiratory center to carbon dioxide (Glass, et al., 1972).
Pulmonary function studied from birth to 24 hours of age in in-
fants of drug-dependent mothers appears to be characterized by
transient decrease in lung compliance and tidal volume when com-
pared with normal control infants. By 3 days of age, lung
compliance and tidal volume returned to normal control levels
in spite of persistent tachypnea. Although tachypnea in infants
of drug-dependent mothers has been previously demonstrated and
explained as central nervous system hyperirritability (Klain,
et al., 1972) the transient alteration in lung function has not
been extensively studied.
The relationship between transitory alterations of lung mechanics
and persistent tachypnea in infants of drug-dependent mothers sug-
gests uneven ventilation during the early phases of withdrawal.
The evidence of uneven ventilation is indirectly supported by the
possibility of pulmonary edema and increased capillary permeabi-
lity demonstrated in human heroin use (Katz, et al., 1972). Non-
uniform ventilation concomitant with rapid breathing has been
shown to result in a decreased dynamic compliance as exhibited
by infants of drug-dependent mothers on day 1 (Woolcock, et al.,
1969; Otis, et al., 1956).
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If ventilation is uniform, dynamic compliance will remain un-
altered in spite of rapid breathing rates such as those observed
in the study infants on day 3.
In summary, it has been shown by sequential pulmonary function
studies herein described that infants with abstinence-induced
tachypnea are transiently affected with regard to pulmonary
function. Despite continuous abstinence and tachypnea, though,
the infants appear to be able to compensate by the third day
of life, at which time pulmonary dynamics return to normal
levels.
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L U N G C O M P L I A N C E
FIGURE 1
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FIGURE 2
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Patient Self-Adjustment of
Methadone Maintenance Dose
Richard B Resnick, M.D., Patricia Butler, R.N., and
Arnold M. Washton, Ph.D.
During the course of methadone maintenance treatment, patients of- 
ten request a change in their daily methadone dose. In most meth-
adone programs the usual procedure for handling such requests is
for the patient to first discuss the request with the counselor and
then to see the clinic physician who would review the requested dose
change and, if approved, transmit orders for the new methadone dose
to the dispensing nurse. The purpose of this procedure is to safe-
guard patients against inappropriate or otherwise contraindicated
dose changes. An inordinate mount of staff time appeared to be
consumed on this issue, since only in rare instances was there
reason to deny requests for a dose change. Also, patients fre-
quently felt frustrated and expressed discontent for the time they
often. have to spend waiting to see the physician and for having to
relinquish control over an important aspect of their treatment. It
is probably the case that the patients themselves best know the dose
of methadone they need in order to function optimally. This view
is supported by the fact that almost all the requested dose changes
were implemented and tended to be rather modest changes of only 5
or 10 mg.
We decided to undertake a trial period during which patients would
be allowed to adjust their own methadone dose without having to see
their counselor or the clinic physician in hopes that this would
both reduce the staff time required to service routine dose changes,
without compromising patient well-being, and also reduce the pat-
ient's dissatisfaction with the usual procedure.
METHODS
All methadone maintenance patients who were stabilized on at least
20 mg methadone were given the option of adjusting their own meth-
adone dose up or down by 5-mg steps without having to see their
counselor or the clinic physician. patients wishing to detoxify be-
low 20 mg were excluded. Requests for dose changes were: (a) imple-
mented on the patient's next visit to the clinic; (b) limited to two
changes per week (10 mg per week maximum); and (c) reviewed at a
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weekly staff meting. In order to obtain a dose change either
larger than 5 mg at a single request, or on the day of the request,
prior approval of the clinic physician was required. Requests for
dose adjustments were made on a written form on which the patient
would circle the word "increase" or decrease", fill in the new dose
and circle "yes" or "no" to the statement, "I would like to see the
doctor about my request." For patients maintained on LAAM, the Mon-
day and Wednesday or Friday dose could be changed either separately
or all at the same time. Signed forms were returned to the dispens-
ing nurse, the new dose entered on the order sheet, signed by the
physician and implemented on the patient's next clinic visit: Pat-
ients' dose-change activity was reviewed at a weekly interdiscipli-
nary staff meting as a safeguard against potential misuse of the
dose-adjustment privilege.
RESULTS
Slightly less than half the patient sample exercised the option of
adjusting their own methadone dose and slightly less than half had
no dose changes, while a much smaller percentage had the physician
implement their dose changes (Table 1).
TABLE 1
UTILIZATION OF DOES-CONTROL OPTIONS
First 16 wks Second 16 wks
(N=149) (N=157)
N (%) N (%)
Used self-adjusted dose change 63 (42%) 74 (47%)a
Used physician-adjusted dose change 22 (15%) 17 (11%)a
No Dose changes 64 (43%) 77 (49%)
aEleven individuals took both self-adjusted and physician-adjusted
dose changes.
The patients who, on sane occasions, used physician-adjusted dose
changes rather than self-adjusted changes, did so to obtain the
dose change immediately, rather than at the next clinic visit. Only
one of these patients asked not to have the option of controlling
his own dose. The average methadone maintenance dose for all eli-
gible clinic patients did not change over the 32-week study period
(Table 2).
TABLE 2
MEAN METHADONE DOSE AT SUCCESSIVE TIME INTERVALS
At 16 weeks before study (N=149) 54 mg
At start of study (N=149) 60 mg
After 16 weeks of study (N=149) 60 mg
After 32 weeks of study (N=157) 60 mg
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Among patients who utilized the dose-control option, the majority
took increases in their maintenance dose, with substantially fewer
patients taking decreases (Iable 3).
TABLE 3
UTILIZATION AND MAGNITUDE OF SELF-ADJUSTED DOSE CHANGES
First 16 wks Second 16 wks
(N=63) (N=74)
Mean Mean
% of Dose % of Dose
Patients Change Patients Change
Took increases only 6 % +10 mg 54% +13 mg
Took decreases only 21% -15 mg 31% -13 mg
Tbok increases & decreases 12% -.8 mg 15% + 9 mg
Net changes in self-adjusted maintenance dose over the 32-week per-
iod tended to be small and less than ± 15 mg in nearly all cases.
Most patients adjusted their dose by a net of only 5 or 10 mg; the
largest overall change for one patient was an increase of 40 mg.
There was some concern that patients might misuse this privilege
and seek to elevate their methadone dose to a maximum or to keep
themselves in a state of continuous intoxication. The clinical re-
view of dose adjustments made by patients over the 32-week study
period indicated that none were contraindicated or clinically in-
appropriate. In no case was the privilege of self-adjustment
of the methadone dose suspended for any patient because of mis-
use.
COMMENT
Our findings are consistent with an earlier report of Goldstein et
al (1975), who also found little change in methadone maintenance dose
under patient control and an overwhelming preference for this pro-
cedure by patients and staff as compared to the usual physician con-
trol of maintenance dose. In that study the patients' motivation
to increase their dose was curtailed by not allowing take-home meth-
adone to individuals whose dose was greater than 50 mg. In our
study there were no constraints on patients to request a change in
their dose.
Thus far, none of our patients have used their dose-control privi-
leges inappropriately. However, continuous monitoring of patient
dose-adjustment activity is a necessary feature of the self-adjust-
ment procedure in order to prevent possible misuse and to identify
the potential need for clinical interventions other than methadone
dose changes that may be indicated and more appropriate. Positive
acceptance with the present system by patients and staff have led
us to adopt it as an ongoing clinical procedure. These findings
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underscore the potential value of having patients povide input
into the conduct of their treatment.
REFERENCE
Goldstein, A., Hanstein, R.W. and Horns, W.N. Control of metha-
done dosage by patients. JAMA, 234 (7): 734-737, 1975.
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Progress Reports
Biological Evaluation of
Compounds for Their Dependence
Liability.
V. Drug Testing ‘Program of the
Committee on Problems of Drug
Dependence, Inc. (1981)
A. E. Jacobson
In my last annual report (1980), I discussed the procedures which
were used to evaluate compounds for their dependence liability, the
sources of support for the testing, and the work which is done by
the involved scientists at the Medical College of Virginia (MCV)
and the University of Michigan (UM). I will not try to repeat that
data; however. I would like to discuss some of the results from
this joint effort. The MCV/UM/NIH/NIDA groups have held 3 meetings
this year, at UM during the Interim CPDD meeting in November, at
Atlanta during the FASEB meeting in April, and preceding this
meeting in San Francisco. Dr. Sorer and, occasionally, Dr. Braude
join us as representatives of NIDA. Discussions at these meetings
relates to further work which one or both groups should do on
compounds of interest. This cooperation has resulted in the
preparation of three papers for publication in various journals.
There will be a paper on zomepirac, one on an interesting group of
homobenzomorphans, and a third, which I will present at this
meeting; on some curious 4-methoxy-6-keto-morphinans. The
cooperative effort provides, I believe, an extremely valuable
resource to the CPDD. Thus, let me mention some of the scientists
to whom the Committee owes its thanks: Drs. Harris, Aceto, May,
Balster and Dewey, and their co-workers at MCV, and Drs. Woods,
Katz, Smith, Medzihradsky, Young, Winger, and Swain and their
co-workers, at UM.
Although we examined about the same number of new compounds this
year as we did last year, more tests were done on them and each
group saw a large increase in the number of compounds which was
sent to them, We have, thus, more information on a larger number
of compounds than in previous years, and this will become ever
larger in the future. The UM group has begun to computerize the
obtained data and, one day, it will be more easily retrieved in any
number of recombinations. I am happy to report that, in general,
the reports are being delivered with great efficiency and the
backlog, although variable with the particular assay, is in most
instances quite reasonable.
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COMPOUNDS RECEIVED UNDER AUSPICES OF CPDD, INC.
In order to provide comparisons with previous data, I have adopted
the same time frame as in 1980, calling May 1, 1980 to April 30,
1981 the "evaluation year”. During that period of time, 25
compounds were sent to UM for primary screening (SDS), and 29
compounds were sent to MCV. These were new compounds. In that
same time period, however, a total of 67 compounds were sent to MCV
for various tests, and 81 compounds were sent to UM. It is
apparent that further testing is being carried out, beyond SDS, on
a considerable number of compounds from former years. Also, many
compounds are sent to me for mouse antinociceptive screening and/or
receptor affinity experiments, rather than SDS, due to an
insufficient supply of compound, or for other reasons. In the 1981
edition of “Problems of Drug Dependence” there will be reports from
MCV on 50 compounds, and reports on 45 compounds from UM. This
represents a ca. 10 percent increase over the past year.
SOURCES OF NEW COMPOUNDS RECEIVED -
The percentage of compounds received from pharmaceutical industry
and other sources was the inverse of that noted in my 1980 report:
20 percent were from U.S. industry, and 24 percent from foreign
industry; 16 percent from U.S. universities, 26 percent from
foreign universities, 12 percent from NIH, and 2 percent (1
compound) from the DEA. This ratio of 44 percent from industry and
56 percent from universities, et al., is fairly close to the 1:1
ratio noted heretofore. It should be noted that the university
sources are not disparate. The U.S. and foreign university
compounds are, mostly, from 1 U.S. and 1 foreign university. The
industrial sources are considerably more disparate.
TYPES OF COMPOUNDS EXAMINED -
Tables 1 - 8 include most of the compounds released for publication
in 1981. I have tried to condense the information given by MCV and
UM in their 1981 reports so that the structures of related
compounds could be compared. In order to put a sufficient amount
of data on these compounds in the tables, many abbreviations were
used, and these are listed below.
Table 1 lists the morphine-like structures of interest. I rather
doubt whether NIH 9735 is new to the literature; Fishman and
Lewenstein refer to it, obliquely, in their 1967 patent. However,
it is apparently new to our program. Table 2 considers new types
of morphinans. Table 3 shows the effect of a new type of
side-chain in the benzomorphans (NIH 9805, 9809). The
homobenzomorphans, which I mentioned earlier, are shown in table 4.
The considerable amount of new work on phenylmorphans is shown in
table 5; and an apparent ketobemidone-type of antagonist is shown
in table 6. Table 7 shows the structure of one of the few
isoquinoly phenols or pyrindinyl phenols which does not appear to
suppress withdrawal in SDS. The miscellaneous compounds examined
are listed in table 8. Zomepirac, on which further work was done
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this year, is shown. The compound which DEA sent to us, through
NIDA, was “China White”, alpha-methylfentanyl. It was suspected to
have caused deaths among some individuals who thought it was
heroin. It is, in fact, considerably more potent than heroin and,
as might be expected a priori, was shown to have high PDC in our
assays. The two peptides listed in table 8 join the one observed
last year in having high estimated PDC. Again, we have not
observed any peptide which did not have high PDC, or which had any
narcotic antagonist activity.
Detailed information on all of the compounds listed in these tables
is given in the MCV - UM annual reports.
ABBREVIATIONS USED IN TABLES
Antinociceptive ED50 values - HP = hot plate assay, SC injection,
mice; N = Nilsen assay, sc, mice; PPQ = phenylquinone writhing
assay, sc, mice; TF = tall flick assay, sc, mice; TFA = tail-flick
antagonism vs. morphine, sc, mice. I = inactive, without a
reasonable dose-response relationship, or insufficiently active for
statistical analysis.
Receptor binding affinities in rat brain membranes and smooth
muscle preparations - RBH = binding affinity, without sodium, to
rat brain membranes, in nM (parenthesized number is ratio of
+Na/-Na); GPI = electrically stimulated guinea pig ileum EC50
values. E = x10; parenthesized numbers are maximum percent
inhibition at EC50; bracketed letters: A = antagonized by
naltrexone, NA = not antagonized by naltrexone. No Effect = no
inhibition of twitch. VD = electrically stimulated vas deferens
EC50 values. Parenthesized numbers and bracketed letters are as
listed under GPI.
SDS single dose suppression, rhesus monkeys: NS = no
suppression, CS = complete suppression, PS = partial suppression.
Parenthesized numbers = dose range studied.
NW = studies in non-withdrawn monkeys: PW = precipitated
withdrawal at dose levels indicated in parentheses &/or potency
comparison with N (naloxone).
The numbers used in the tables are rounded. For precise values,
and details of the procedures, see the Annual Reports of MCV and
UM.
AUTHOR
A. E. Jacobson. Ph.D. Medicinal Chemistry Section, Laboratory of
Chemistry, National Institute of Arthritis, Mabetes and Digestive
and Kidney Diseases, National Institutes of Health, Bethesda,
Maryland 20205
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TABLE 1. MORPHINE-LIKE STRUCTURES
TABLE 2. MORPHINAN-LIKE STRUCTURES
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TABLE 3. BENZOMORPHAN-LIKE STRUCTURES
TABLE 4. HOMOBENZOMORPHANS
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TABLE 5. PHENYLMORPHANS
TABLE 6. PETHIDINE-LIKE AND KETOBEMIDONE-LIKE STRUCTURES
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TABLE 7. ISOQUINOLYL PHENOLS AND PYRINDINYL PHENOLS
TABLE 8. MISCELLANEOUS COMPOUNDS
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Dependence Studies of New
Compounds in the Rhesus
Monkey, Rat, and Mouse (1981)
M. D. Aceto, L. S. Harris, and E. L. May
All the test drugs were supplied by Dr. Arthur Jacobson, Medici-
nal Chemistry Section, NIAMDD, under the auspices of the Commit-
tee on Problems of Drug Dependence, Inc. Morphine was supplied
by Dr. Robert Willette, NIDA. The chemical structures of the
test compounds excluding pentazocine were unknown to us when they
were originally submitted.
For the most part, the procedures described by Seevers and his
colleagues (1936, 1963) and Deneau (1956) regarding the facili-
ties and training of the monkeys were used and a brief descrip-
tion follows. The monkeys were injected with 3 mg/kg/sc of
morphine sulfate every 6 hours for at least 90 days before being
used. This dose schedule was reported by Seevers and Deneau
(1963) to produce maximal physical dependence. In addition, in
order to determine whether or not clonidine and pentazocine
would substitute for morphine in monkeys dependent on a lower
dose of morphine, ten monkeys of 2 groups were made dependent
This study was supported by a contract (#271-77-3404) from the
National Institute on Drug Abuse, Dr. Heinz Sorer, Contract
Officer. Technical assistance was provided by F. Tom Grove,
R. F. Jones, and S. M. Tucker; Medical College of Virginia,
Department of Pharmacology, Virginia Commonwealth University,
Richmond, Virginia 23298
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using 1.5 mg/kg every 6 hours., Modified procedures for the
precipitated withdrawal (PPt-W) and single dose suppression
(SDS) tests were reported by Aceto and co-workers (1977 and
1978). The PPt-W test was initiated by the injection
of a test drug 2½ hours after an injection of morphine and the
animals were observed for signs of withdrawal. The SDS test
was started approximately 15 hours after the last dose of mor-
phine at which time the animals were showing withdrawal signs.
The test compound was injected and the animals were observed
for the suppression of abstinence signs. The onset and dura-
tion of action of the test drug were noted. In both tests, a
vehicle control and an appropriate positive, control [naloxone
0.05 mg/kg or morphine sulfate 3.0 (mg/kg)] along with 3 dif-
ferent treatments (doses) of a test compound were randomly
allocated to the 5 monkeys of a group. Occasionally 4 monkeys
comprised a group and 2 doses of test compound were studied.
Usually, 3 or 4 groups per compound were used. All drugs were
given subcutaneously in a volume of 1 ml/kg and the vehicle
used is indicated for each compound. The observer was "blind"
with regard to the treatment given. A minimum 2-week washout
and recuperation period between tests was allowed. In the
primary physical dependence (PPD) test, the animals of a group
received the drug every 6 hours for 30-50 days. They were placed
in abrupt withdrawal and challenged with naloxone periodically,
and were observed for signs of physical dependence. All potency
estimates are approximations only.
The rat-infusion method was reported by Teiger (1974) and certain
modifications are indicated below. Semi-restrained male, Sprague-
Dawley rats were medicated by continuous infusion through in-
dwelling, intraperitoneal cannula for 6 days with the drugs. Rats
were anesthetized and each was fitted with a specially prepared
cannula which was passed subcutaneously from the nape of the neck
to the lateral side of the lower abdomen and then inserted in the.
peritoneal'cavity. The cannula was anchored at both ends with
silk sutures and attached to a flow-through; swivel mechanism
which allowed the animal to move about in the cage and eat and
drink normally. The swivel was connected to a syringe which
was attached to a syringe pump. The animals received 7 to 10 mls
of solution every 24 hours.
In the substitution for morphine (SM) test, the animals first
received morphine (50 mg/kg/24 hrs on the first day, 100 mg/kg/24
hr on‘the second day, and 200 mg/kg/24 hr from days 3-6). Then,
a test drug was substituted for 2 days. The morphine controls
received an infusion of water. The animals were observed for
changes in body weight and for behavioral-withdrawal signs for ½
hour at 6, 24, 48, 72 and/or 96 hours after stopping the infusion of
m o r p h i n e .
In the primary physical dependence (PPD) study, the animals
received test compound for 6 days and then were placed in abrupt
withdrawal and observed as above.
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Table 1
Comparative Data-ED50 mg/kg/sc (95% C.L.) of Selected
Standards in 3 Mouse Agonist-Antagonist Tests
Drug Tail-Flick Tail-Flick An- Phenylquinone
Test tagonism Test Test
Pentazocine 15% at 10.0 18 (12.4-26) 1.65 (1.0-2.5)
Cyclazocine 17% at 1.Oa 0.03 (0.12-.78 0.011 (0.0046-
03)
Nalorphine None at 10.0 2.6 (O.-69-9.75) 0.6 (0.25-1.44)
.HCL
Naloxone
.HCL
None at 10.0 0.035 (010-0.93) No Activity
Naltrexone None at 10.0 0.007 (0.002-0.02) No activity
.HCL
Morphine 5.8 (5.7-5.9) ----- 0.23 (0.20-
Sulfate 0.25)
aMice were ataxic at 3.0 and 10.0 mg/kg but no further increase
in-reaction time was seen.
Three mouse tests were used in our laboratory at the Medical
College of Virginia to provide a preliminary estimate of the,
potency and profile of activity of each test compound. The
tests were the tail-flick agonist (TF) and the morphine
antagonist (TF vs M) tests and the phenylquinone (PPQ) test
(Dewey et al., 1970; Dewey and Harris, 1971). Reference-
standard data for these-tests are shown in table 1. In
addition, Dr. Jacobson supplemented these data and estimated
starting doses which were based on results obtained from the
mouse hot plate (HP) (Eddy and Leimbach, 1953; Jacobson and
May, 1965; Atwell and Jacobson, 1978) and Nilsen (N) (Perrine
et al., 1972) tests from his laboratory. Reference data for
these tests are shown in table 2.
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Table 2
Comparative Data (ED50 mg/kg/sc) [95% S.E.] from the Hot Plate
and Nilsen Test
Hot Plate Test Nilsen Test
Subcutaneous Subcutaneous
Oral Oral
Compound
Morphine Sulfate 0398(0.83-1.1) 1.3(1.0-1.7)
6.3(4.7-8.3) 8.3(6.0-11.4)
Codeine Phosphate 6.8(4.5-10.2) 7.4(4.9-11.0)
13.5(9.7-18.7) 14.7(9.2-23.3)
Levorphanol Tartrate 0.2(0.1-0.3) 0.2(0.16-0.3)
2.5(1.7-3.7)
Meperidine .HCL
(-)-Metazocine.HBr 0.5(0.3-0.7)
26.0(21.0-33.0)
Dihydromorphinone 0.2(0.15-0.3)
.HCL 0.9(0.7-1.2) 1.8(1.5-2.1)
Nalorphine .HCL
Cyclazoc ine
Pentazoc ine
Chlorpromazine .HCL
5.3(4.0-7.1)
0.6(0.5-0.9)
10.6(8.0-14.1)
0.19(0.15-0.25)
9.9(5.7-17.1)
1.5(1.1-2.1)
9.3(6.7-12.8)
1.1(0.9-1.5)
23.0(16.2-32.7)
0.1(0.07-0.16)
6.5(4.4-8.8)
Naloxone .HCL and Naltrexone HCL No dose response
Phenobarbital, Amobarbital, Valium, Oxazepam, Flurazepam,
Mepromate and Mescaline are inactive on the hot plate test.
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COMPOUND #
MCV NIH UM
4102 9342 1124
4145 9540 1169
4155 9549 1151
4157 9576A 1242
4158 9580A ---
4167 9612 1267
4168 9913 1268
4169 9614 1269
4170 9618 ---
4172 9616 ---
CHEMICAL CLASS
A Phenyldeca-
hydroisoquinoline
A 4-Phenylpiperi-
dine
Clonidine-See MCV
4183
An Octahydropyrin-
dine
Phencyclidine
A Homobenzomorphan
A Homobenzomorphan
A Homobenzomorphan
An Octahydropyrin-
dine
An Octahydropyrin-
dine
TABLE III
SUMMARY OF TESTS REPORTED
MOUSE RAT
TF, TFvsM, PPQ, HP, N SM, PPD
MONKEY
SDS PPt-W
(special)
PPD
COMPOUND #
MCV NIH UM
4173 9617 ---
4176 9625A ---
4183 9571 1151
4187 9724 1212
4190 9650 1198
4192 9730 1217
4196 9736 1224
4197 9737 1225
4206 8834A 972
4208 9787 ---
4210 9791 1238
4212 9804 1245
CHEMICAL CLASS
A 4-Phenylpiperi-
dine
A 3-Benzaracine
Clonidine-See MCV
4155
A (small) peptide
A Ketobemidone
Zomepirac
A Morphinan
A Epoxymorphinan
A Tetrahydronaph-
thalene
An Epoxymorphinan
A (small) peptide
A Benzomorphan
TABLE III (Cont'd)
MOUSE
TF, TFvsM, PPQ, HP, N
RAT
SM, PPD
MONKEY
SDS PPt-W PPD
TABLE III (Cont'd)
COMPOUND # CHEMICAL CLASS
MCV NIH UM
4213. 9805 1246
4217 9809 ---
4218 9810 ---
4219 9821 1252
4220 9824 1253
4221 9825 1254
4222 9826 ---
4223 9827 ---
4225 9839 1259
4226 9840 1260
4227 9832 1261
MOUSE
TF, TFvsM, PPQ, HP, N
A Benzomorphan
A Benzomorphan
A Phenyldihydroin-
dole
Oripavine
A Phenyldecahydro-
isoquinoline
A Phenyldecahydro-
isoquinoline
Oxazepam
Flurazepam
An Octahydropyrin-
dine
An Octahydropyrin-
dine
An Endoethenomor-
phine
RAT
SM, PPD
MONKEY
SDS PPt-W PPD
COMPOUND #
MCV NIH UM
4228 9872 1266
4229 9873 ---
4230 9874 1322
4231 8508A 809
4232 8509A 810
4233 9886 ---
4235 9895 ---
4236 9896 ---
4237 9899 ---
4238 9900 ---
4241 9884 1273
4242 9885 1274
4247 9894 1276
4249 9898 1280
CHEMICAL CLASS
TABLE III (Cont'd)
MOUSE
TF, TFvsM, PPQ, HP, N
Nabilone
A Phenylmorpholine
An Epoxymorphinan
A Phenylmorphan
A Phenylmorphan
A Phenylmorphan
A 4-Benzazonine
A 4-Benzazonine
A 4-Benzazonine
A 4-Benzazdnine
A Phenylmorphan
A Phenylmorphan
A Phenylmorphan
A Benzazonine
RAT
SM, PPD SDS
MONKEY
PPt-W PPD
TABLE III (Cont'd)
COMPOUND # CHEMICAL CLASS MOUSE R A T MONKEY
MCV NIH UM TF, TFvsM, PPQ, HP, N SM, PPD SDS PPt-W PPD
4250 9901 1277 A 4-Benzazonine
4251 9902 1281 A 4-Benzazonine
4268 7958 381 Pentazocine
(special)
4287 9961 1324 4-Anilinopiperidine
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MCV 4102-NIH 9342-UM 1124. (-)-m-[2-(Cyclopropyl-
methyl)-1,2,3,4,4a,5,6,7,8,8a -decahydro-4aß-isoquinol-
yl]phenol succinic acid salt.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF-7.3 (2.8 - 18.6)
2) TF vs M-16% at 1.0, 43%
at 10.0 and 22% at 30.0
3) PPQ-2.0 (1.0 - 3.9)
4) HP-4.4 (2.9 - 6.6)
MONKEY DATA # ANIMALS 3 , 3 , 3 ,
(SDS) Doses (mg/kg/sc) 1.0 2.0 4.0
Vehicle-H20
MCV 4102 substituted completely for morphine. At the lowest
dose, drowsiness was noted in 1/3 animals. Ataxia, salivation,
body sagging, ptosis and drowsiness were noted at the 2
higher doses. Its potency is about that of morphine.
MCV 4145-NIH 9540-UM 1169. trans-3-(1,2-Dimethyl-4-propyl-4-
piperidinyl)phenol hydrobromide.
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-1.1 (0.5 - 2.3)
2) Tf vs M-Inactive at 0.5,
1.0, and 3.0
3) PPQ-0.4 (0.2 - 0.9)
4) HP-O.81 (0.62 - 1.06)
MONKEY DATA
(SDS)
#ANIMALS 4 , 4 , 4 ,
Doses mg/kg;sc) 0.4, 0.8 1.6
Vehicle-H2O
MCV 4145 substituted briefly for morphine. Some drowsiness
was noted at all doses tested. The drug is 2-4 times as
potent as morphine.
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MCV 4155, 4183-NIH 9549, 9571-UM 1151. 2-(2,6-Dichloroanilino)-
2-imidazoline (Clonidine) hydrochloride.
MOUSE DATA-ED50 (95% C.L.)
1) TF-1.23 (0.23-6.65)
2) TF vs M-Inactive at 0.3
1.0 and 30.0
3) PPQ-0.005 (0.001-0.02)
4) HP-1.0 (0.7-1.5)
MONKEY DATA #ANIMALS 2 , 2 , 2 ,
Doese (mg/kg/sc) 0.0625 0.25 0.1
Vehicle-H2O
1) Special "Lower dose" morphine-dependent monkeys SDS study
(1.5 mg/kg/q 6 hours).
MCV 4155 substituted partially for morphine. The drug also pro-
duced drowsiness and eyelid ptosis. It does not appear that
these lower dose morphine-dependent animals react differently
from. he animals dependent on 3.0 mg/kg q 6 hours. Partial
substitution does not necessarily indicate that the drug has
morphine-like'effects.
MCV 4157-NIH 9576A-UM 1242. (-)-cis-(octahydro-2-methyl-1H-2-
pyrindin-4a-yl)phenol, (Z)-2-butenedioic: acid salt.
MOUSE DATA-ED50 (95% C.L.)
1) TF-10.4 (3.3-33.2)
2) TF vs M-60.5 (12.8-286.8)
3) PPQ-0.6 (0.3-1.9)
4) HP-2.4 (1.6-3.7)
5) N-2.3 (1.7-3.0)
MONKEY DATA
(PPD)
Four rhesus monkeys that had not received any drug for at least
2 months were given MCV 4157 dissolved in H2O every four hours,
unless indicated otherwise.
Day Dose Comments
mg/kg/sc/times/day The principal drug effects
1 4.0 noted during this study were
2 8.0 scratching, restlessness
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Day
3
Dose Comments
16.0 and staring. Convulsions were
4 32.0 observed on days  5, 6, 8, 12,
5 48.0 14, and 26. Infrequently seen
Skipped 6 p.m. signs were tremors, wet dog
35.0 (2xd) shakes and fighting.
6
7
8
9-14
15
35.0
37.0 35.0 (lxd)
35.0 (3xd)
35.0
PPt-W
0.05 mg/kg naloxone
8:35 a.m.
15 - noon 30.0
16
17 - 22
30.0
32.0
22 8:30 a.m. PPt-W
5.0 mg/kg naloxone
Precipitated withdrawal
signs noted were: 4/4
drowsy, 2/4 wet dogs and
restlessness; 1/4 fight-
ing, avoids contact,
yawning, and tremors
Precipitated withdrawal
signs noted were:
4/4 wet dogs; 3/4 rest-
less, retching vocalized
when abdomens palpated,
rigid abdominal
muscles, and drowsy; 2/4
lying on side or
abdomens; 1/4 fighting,
avoid contacts, and
coughing.
22 - noon 33.0
23-30 32.0
31 Abrupt Withdrawal - Abrupt withdrawal signs noted were:
Twelve hours after last injection
3/4 vocalized when abdomens pal-
pated and vocalized; 1/4 wet dogs.
Eighteen hours after last injec-
tion peak withdrawal 3/4 vocalized
when abdomens palpated; restless
and rigid abdomens; 2/4 vocalized;
1/4 fighting, avoids contact,
tremors and retching. Thirty-
six hours after the last injec-
tion 2/4 vocalized when abdomens
palpated.
350
Conclusion
MCV 4157 produced opiate-like signs of physical dependence
after naloxone challenge and during abrupt withdrawal.Convul-
sions were frequently observed in the dose range of 32.0-48.0
mg/kg. The drug probably has an intermediate to high physical
dependence liability.
MCV 4158-NIH 9580A. 1-(Phenylcyclohexyl)piperidine hydrochloride
(Phencyclidine).
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF-Inactive at 1.0, 3.0
and 10.0
2) TF vs M-0.3 (0.1-1.0)
3) PPQ-1.4 (0.5-4.1)
4) HP-Inactive, convulsion
at 10.0
5) N-See HP
MONKEY DATA
PPD (second study - See 1980 Report for First Study).
Five monkeys received MCV 4158, 6 x d subcutaneously as in-
dicated below. The animals had not received any drugs for at
least 2 months. The drug was dissolved in H2O and the animals
were observed for behavioral signs 15-30 minutes after drug
for 15 minutes.
Day Dose mg/kg/sc (6 x day) Comments and Signs
6 and 9 a.m., noon, 3 Dose-related side
and 6 p.m. and midnight effects ranging
1 0.1 from wet-dog shakes
2 0.2 and tremors, ataxia
3-9 0.3-0.45 and slowing at the
9.14 0.45-0.6 lower doses to severe
ataxia, incoordination
falling and an inabi-
lity to pick themselves
up. The onset was
rapid; the effects
peaked in 1/2 hour and
had abated by 1 to
1 1/2 hours.
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Day
15
Dose
16-22 0.6
23-
24-30 - 0.6-0.7
3 1
32-39 0.7
40
PPt-Withdrawal - At 8:45 a.m., after
a 5.0 mg/kg naloxone challenge, 5/5
wet dog shakes, 1/5 restlessness and
1/5 avoids contact were the only signs
noted.
Abrupt Withdrawal
The principal signs noted during
the 24 hr. abrupt withdrawal
period were fighting, avoids
contact, restless, tremors,
wet-dogs shakes.
Abrupt Withdrawal
The principal signs noted were:
1/5 fighting, 2/5 avoids con-
tact, 4/5 restlessness, 5/5
tremors. This cluster of symp-
toms started at 2 hours and
peaked at 6 hours. All the
animals developed diarrhea 10
hours into withdrawal and it
was still evident in 2/5 the
following morning. At this
time staring was also noted.
Myoclonic jerks were noted
15 hours into withdrawal.
PPt-W - Received a total
of 10 mg/kg/sc
of naloxone
within 1 hour.
Withdrawal signs noted were: 1/5 fighting, 2/5
restless, 5/5 drowsy, 3/5 tremors, 5/5 wet-dog
shakes, 1/5 vocalizes when abdomen palpated, 3/5
rigid abdominal muscles, 2/5 stretching and rubbing.
41-44 0.75
45 Abrupt Withdrawal - The principal sign noted
during the first 5 hours
was tremor. Other signs
noted were 1/5 lying on
side or abdomen (at 5
hours only), fighting,
avoids contact, rest-
less, wet-dog shakes.
Few signs were seen
after 24 hours.
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Conclusions
MCV 4158 produced signs indicating the development of
some degree of physical dependence. The syndrome may be
characterized by the signs fighting,, tremor, restlessness,
and wet-dog shakes, Since some of these signs are also
seen while the animals are on lower doses of MCV 4158 and
since the last abrupt-withdrawal reaction was noticeably
weaker than the first, it is difficult to make firmer con-
clusions.
The results noted with precipiated withdrawal suggest that
naloxone at very high doses may produce a mild withdrawal
r e a c t i o n .
Approximately one month after the study was terminated, one
of the animals delivered an apparently healthy baby that appeared
to be doing well at 4 months.
MCV 4167-NIH 9612-UM 1267. (±)-9-Hydroxy-4,7-dimethyl-C-homo-
benzomorphan hydrobromide.
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
Rat Infusion (SM)
1) TF-1. 6.4 (3.9-10.5)
2. 15.5 (7.4-32.2)
2) TF vs M-1. 19.8 (10.5-37.2)
2. 24.9 (10.8-57.4)
3) PPQ-0.5 (0.2-1.3)
4) HP-1. 0.4 (0.25-0.6)
2. 0.49 (0.36-0.65)
MCV 4167 did not substitute for morphine at doses of 50 and
200 mg/kg/24 hours. The-animals receiving MCV 4167 lost nearly
as much weight as the morphine infusion - water substitution
group as shown in the figures. In addition, no significant
differences were calculated between these two groups regarding
withdrawal signs.
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MCV 4168-NIH 9613-UM1268. (+)-9-hydroxy-4,7-dimethyl-C-homobenzo-
morphan hydrobromide.
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1)
2)
TF-1. 8.2
2. 6.7
TF vs M-1.
2.
(3.1-21.8)
(2.5-18.4)
Inactive at 3.0,
6.0, 10.0, and
30.0
Inactive at 3.0,
3.0, 10.0, and
30.0
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3) PPQ-1. 0.3 (0.1-1.0)
2. 0.9 (0.4-2.2)
4) HP-1. 2.6 (2.1-3.4)
2. 2.4 (1.4-4.0)
Rat Infusion (SM)
We conclude that MCV 4168 did not substitute for morphine at doses
of 100 and 200 mg/kg/24 hours. As shown in the figures, the ani-
mals receiving MCV 4168 lost nearly as much weight as the morphine
infusion - water substitution group. No significant differences
in withdrawal signs were calculated at 6, 24, 48 and 72 hours be-
tween these two groups.
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MCV 4169-NIH 9614-UM 1269 (-)-9-Hydroxy-4,7-dimethyl-C-homobenzo-
morphan hydrobromide.
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-1. Inactive at 3.0, 6.0,
10.0, and 30.0
2. Inactive at 3.0, 10.0,
and 30.0
2) TF vs M-1. 13.4 (5.7-31.3)
2. 5.5 (1.2-25.9)
3) PPQ-1. 0.5 (0.2-1.7)
2. 0.4 (0.1-1.3)
Rat Infusion (SM)
MCV 4169 did not substitute for morphine at doses of 100 and
200 mg/kg/24 hours. As shown in the figures, the animals
receiving this compound lost nearly as much weight as the
morphine infusion - water substitution group. Significant
differences for withdrawal signs were not calculated between
morphine controls and the MCV 4169-dosed rats.
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MCV 4170-NIH 9618. cis-3-Octahydro-1ß,2-dimethyl-4aH-
2-pyrindin-4a-yl)phenol, (Z)-2-butenedioic acid salt.
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-39.7 (13.6-115.9)
2) TF vs M-13% at 10.0, 29% at
30.0 and 36% at 100.0
3) PPQ-2.2 (1.0-5.1)
4) HP-4.1 (3.0-5.7)
MCV 4172-NIH 9616. cis-3-(Octahydro-1 ,2-dimethyl-4H-2-
pyrindin-4a-yl)phenol, (Z)-2-butenedioic acid salt.
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-13.1 (4.3-40.3)
2) TF vs M-None at 3.0, 10.0
and 30.0
3) PPQ-1.4 (0.4-2.3)
4) HP-1.8 (1.5-2.2)
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MCV 4172-NIH 9616.
MONKEY DATA # ANIMALS 3 , 3 , 3 , Vehicle-
(SDS) Doses (mg/kg/sc) 2.5 5.0 10.0 H 2O
At the highest dose, MCV 4172 substituted completely and
briefly for morphine. Its potency is estimated as 1/3 that of
morphine.
MCV 4173-NIH 9617. cis-2-(1,2-Dimethyl-4-propyl-4-piperidinyl)
phenol, (Z)-2-butenedioic acid salt.
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1)
2)
3)
4)
MONKEY DATA #ANIMALS 3 , 3 , 3 , Vehicle-
(SDS) Doses (mg/kg/sc)
TF-Inactive at 1.0, 10.0
and 30.0
TF vs M-13.3 (3.6-49.6)
PPQ-1.8 (0.7-4.6)
HP-4.4 (3.5-5.4)
2.0 4.0 8.0 H 2 O
A dose-related reduction in withdrawal signs was noted. The
drug substituted completely for morphine at the highest dose.
The onset of action is prompt and the duration appears to be
approximately 3 hours. It is about 1/3 as potent as morphine.
MCV 4176-NIH 9625A. 1-[(2-alpha,6-alpha,11S)-(±)-1-(1,2,3,4,5,
6-Hexahydro-8-hydroxy-3,6,11-trimethyl-2,6-methano-3-benzazocin-
11-yl)]-6-methyl-3-hepatanone methanesulfonate.
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-Inactive at 3.0, 10.0, and
30.0
2) TF vs M-14.8 (3.7-58.6)
3) PPQ-0.002 (0.0003-0.01)
4) HP-1.1 (0.8-1.3)
MONKEY DATA
(PPD)
Five monkeys that had not received any drug for at least
2 months were medicated with MCV 4176 as indicated below. The
drug was dissolved in H2O and given every 6 hours unless othemise
noted.
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Day
1
2
3
4
5
6
7
8
9
10-12
13-14
15
Dose
mg/kg/sc (times/day)
1.0
2.0
4.0
8.0
8.0 (1 x d) and
6.0 (3 x d)
6.0 (3 x d)
5.0
6.0
7.0
8.0
9.0
10.0
16 8:30 a.m.
PPt-W
2.0 mg/kg naloxone
16 5.0 (2 x d)
17 Stopped Study
Conclusion
Comments
During the first 4 days,
scratching, fighting,
avoiding contact, and
restlessness were noted.
When the dose was raised
to 8.0, all the
animals stopped eating
and had jaw sag, were
slow and salivated.
The dose was lowered.
On the sixth day, one
monkey became unconscious
and was removed from
study.
By day 12, one monkey
was bleeding from the
site of injection
and on day 13 all
bled from sites of
injection.
4/4 drowsy; 3/4 wet
dogs, restlessness;
2/4 retching; 1/4
coughing, fighting,
crawling.
On day 16, 2 monkeys
became unconscious
after injection and
one had an ulcer on
its back.
MCV 4176 may have an opiate-like dependence liability
but because the drug caused bleeding at the site of injec-
tion which progressed to ulcers in one monkey, and due to
the severe drug effects, the study was terminated.
MCV 4187-NIH 9724-UM 1212. L-Tyrosyl-D-alanylglycyl-L-N
allylphenylalanine amide acetate.
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MCV 4187NIH 9724-UM 1212.
MOUSE DATA-ED5O (95% C.L.)-(mg/kg/sc)
1) TF-4.5 (2.3-8.7)
2) TF vs M-24% at 0.01; 11%
at 0.1; 11% at 1.0 and
0% at 5.0
3) PPQ-0.2 (0.05-0.6)
4) HP-1.9 (1.4-2.6)
MCV 4190-NIH 9650-UM 1198. N-4-Methylpentylnorketobemidone
hydrobromide.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF-1.0 (0.3-3.9)
2) TF vs M-Inactive at 1.0 and 30.0
3) PPQ-0.45 (0.3-0.8)
4) HP-3.2 (2.3-4.4)
MONKEY DATA #ANIMALS 3 , 3 , 3 , Vehicle-
(SDS) Doses (mg/kg/sc) 2.5 5.0 10.0, H 2O
MCV 4190 did not substitute for morphine in the dose range tested.
Severe tremors were noted in one animal receiving the highest dose.
Tremors were also noted in one animal at the lowest dose and in two
at the intermediate dose.
MCV 4192-NIH 9730-UM 1217. Sodium 5-(4-Chlorobenzoyl)-1,
4-dimethyl-1H-pyrrole-2-acetate (Zomepirac).
MOUSE DATA-ED50 (95% C.L.)
(mg/kg.sc)
1) TF-Inactive at 1.0, 10.0
and 30.0
2) TF vs M-Inactive at 0.1
and 10.0
3) PPQ-1.8 (0.6-5.7)
4) HP-Inactive
5) N-No dose-response, 2/8 at 50.0
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MCV 4192-NIH 9730-UM 1217.
MONKEY DATA # ANIMALS 3 , 3 , 3 , Vehicle-
(SDS) Doses (mg/kg/sc) 2.5 5.0 10.0 H 2O
MCV 4192 did not substitute for morphine in the dose range tested.
Body tremors were noted at the highest dose.
Rat Infusion (PPD)
At two dose schedules, MCV 4192 did not produce physical
dependence (See Figures). The drug is toxic at doses of 50
mg/kg/24 hours or higher. A naloxone challenge did not precipi-
tate withdrawal sians in the animals receiving the lowest dose
schedule. No behavioral withdrawal signs or weight loss (See
Figures) were noted.
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MCV 4196-NIH 9736-UM 1224. N-Cyclobutylmethyl-3-hydroxy-6-
methylene-8ß-methylmorphinan.
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-8% at 0.1; 48% at 1.0;
12% at 10.0 and 8% at 30.0
2) TF vs M-O% at 0.01; 48%
at 0.1; 44% at 1.0, 54% at
10.0 and 61% at 30.0
3) PPQ-0.02 (0.002-0.18)
4) HP-Inactive
5) N-1.3 (0.73-2.4)
MONKEY DATA #ANIMALS
A (SDS) Doses(mg/kg/sc)
acid + H2O (cloudy solution).
3 , 2 , 3 , Vehicle-lactic
1.0 2.0 4.0
The drug did not substitute for morphine. Salivation was noted
in one monkey receiving the high -and low doses. Jaw sag and
eyelid ptosis were also noted at the 2 higher doses.
#ANIMALS 1  , 1 , 2 ,
B. PPt-W Doses (mg/kg/sc) 0.125 0.25 0.5
3 , 2 , 1 -Vehicle-See
2.0 4.0 8.0 SDS Study above.
The drug precipitated withdrawal signs at all doses tested.
Onset of action was rapid and duration of action was longer
than for naloxone. Jaw sag and salivation were seen. The
animal receiving the highest dose had a pale face.
MCV 4197-NIH 9737-UM 1225. 17-Cyclopropylmethyl-7,7-dimethyl-
3-methoxy-4,5 -epoxymorphinan-6-one.
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-Inactive at 0.1,
1.0, 10.0 and 130.0
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MCV 4197-NIH 9737-UM 1225.
2) TF vs M-1.3 (0.2-7.7)
3) PPQ-1.1 (0.2-6.2)
4) HP-5.2 (3.5-7.8)
5) N-11.5 (7.2-18.4)
MONKEY DATA #ANIMALS 3 , 3 , 3 , 1 , 1
(SDS) Doses (mg/kg/sc) 0.75 1.5 3.0 6.0 12.0
Vehicle-lactic acid and H2O
At the 3 higher doses, MCV 4197 substituted completely and
briefly for morphine. Its potency is like that of morphine.
MCV 4206-NIH-8834A-UM 972. (-)-13ß-Amino-5,6,7,8,9,10,11,
12-octahydro-5 -methyl-5,11-methanobenzocyclodecen-3-ol
hydrobromide.
MOUSE DATA-ED5O (95% C.L.)-
(mg/kg/sc)
1) TF-2.6 (0.8-8.1)
2) TF vs M-16% at 1.0, 18%
at 10.0 and 61% at 30.0
3) PPQ-0.3 (0.07-1.0)
4) HP-O.7 (0.5-0.9)
5) N-0.9 (0.7-1.1)
MONKEY DATA #ANIMALS 2 , 2 , 2 ,
(SDS) Doses (mg/kg/sc) 1.25 2.5 5.0 ,
Vehicle-H2O
MCV 4206 did not substitute for morphine. The drug exacer-
bated withdrawal. Two monkeys at the 2 higher doses were
given morphine after 2 hours to terminate severe withdrawal.
At 12 noon, they still showed signs of withdrawal. Drug supply
was exhausted.
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MCV 4208-NIH 9787. 17-Cyclopropylmethyl-6,7-didehydro-4,
5 -epoxy-6-fluoro-3-acetoxymorphinan.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF-17% at 0.1, 23% at 1.0
and 4% at 30.0
2) TF vs M- 0.03 (0.01-0.06)
3) PPQ-0.24 (0.03-2.1)
4) HP-No dose response
5) N-No dose response
MONKEY DATA #ANIMALS
Doses (mg/kg/sc)
2 , 2 , 2 ,
0.25 0.5 1.0 ,
Vehicle-H2O
1) SDS - The drug exacerbated withdrawal. The onset of action
was rapid; it had a long duration of action. All the monkeys
receiving the drug in the first group were given morphine 90
minutes after drug to terminate severe withdrawal. In the
second group tested, all the monkeys receiving MCV 4208 still
vocalized after abdominal palpation even though they had
received the noon time injections of morphine. This drug may
produce an insurmountable or irreversible antagonism.
2) PPt-W - 2  , 2  , 3  , 1 , 2 , 1 , 1 , Vehicle-
0.001 0.004 0.015 0.06 0.25 0.5 1.0 H2O
MCV 4208 precipitated withdrawal signs at all the doses
tested. The drug acted promptly and its duration of action
was at least 2½ hours. The duration of action of naloxone
is about 90 minutes. This drug is approximately 10 x more
potent than naloxone. Severe tremors were noted at the
highest dose and at the 0.25 dose. The incidence of
tremor was greater in all the animals receiving doses
of 0.004 or higher.
Rat Infusion (SM)
At 50.0, 100.0 or 200.0 mg/kg/24 hr. MCV 4208 did not
substitute for morphine in morphine-dependent rats. The drug
was lethal at the intermediate and high doses (See Figure).
The drug did not suppress behavioral withdrawal signs.
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MCV 4210-NIH 9791-UM 1238. N-Methyl-L-tyrosyl-D-seryl-glycyl-
N-methyl-L-phenylalanyl-D-serinamide monoacetate.
MONKEY DATA
(SDS)
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF-3.5 (1.1-11.3)
2) TF vs M-Inactive at 1.0,
10.0 and 30.0
3) PPQ-0.1 (0.05-0.3)
4) HP-1.4 (1.1-1.8)
5) N-1.5 (1.1-2.1)
# ANIMALS 1 , 2 , 3 , 4 ,
Doses (mg/kg/sc) 4.0 8.0 16.0 32.0
3 , 2 , Vehicle-H2O
48.0 64.0
At the highest dose, the drug may have substituted completely
for morphine. More animals should be studied at this dose.
The drug effectively suppressed retching at all doses.
RAT DATA
Rat Infusion - (PPD) MCV 4210 produced primary physical
dependence of the opiate type. The animals lost weight
(See Figure) and showed typical withdrawal signs when the
infusion was stopped. The drug was lethal to 2 of 6 animals. It
is about as potent as morphine.
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MCV 4212-NIH 9804-UM 1245. (-)-(1R,5R,9R,2"S)-5,9-Dimethyl-
2'-hydroxy-2-(2-methyltetrahydrofurfuryl)-6,7-benzomorphan,
L-tartrate.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF-Inactive at 1.0 and
Text
2) TF vs M-3.1 (1.2-8.0)
3) PPQ-0.06 (0.01-0.28)
4) HP-Inactive (toxic at
20.0)
5) N-7.7 (5.6-10.5)
MCV 4213-NIH 9805-UM 1246. (-)-(1R,5R,9R)-5,9-Dimethyl-2'-
hydroxy-2-(2-methoxyisobutyl)-6,7-benzomorphan.
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-0.5 (0.06-3.6)
2) TF vs M-Inactive at
1.0 and 30.0
3) PPQ- Inactive at 1.0 and
30.0
4) HP-O.8 (0.6-1.1)
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MCV 4217-NIH 9809. (-)-(1R,5R,9R,2"S)-5,9-Dimethyl-2'-
hydroxy-2-(2-methoxypropyl)-6,7-benzomorphan hydrobromide.
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-0.008 (0.003-0.02)
2) TF vs M-Inactive at 0.01,
0.1 and 1.0
3) PPQ-0.008 (0.002-0.02)
4) HP-O.008 (0.006-0.01)
MONKEY DATA #ANIMALS 1 2 3
(SDS) Doses (mg/kg/sc) 0.016 0.008 0.004
3 3 2 1
0.002 0.001 0.00025 0.00006
At doses of 0.001 or less, this drug substituted partially for
morphine. In 2/3 monkeys at 0.002 and 1/3 at 0.004, the drug
substituted completely for morphine. At doses of 0.004 or
higher, substitution was also seen but other agonist side
effects such as jaw and body sag, slowing and tremors
developed. Severe ataxia was also noted at highest dose.
In a preliminary study after receiving a dose of 0.04 mg/kg,
the animal lost its righting reflex. A dose of 0.05 mg/kg
ip of naloxone appeared to ameliorate this situation. The
animal was able to sit and looked much more normal. The drug
is about 1000 x as potent as morphine.
MCV 4218-NIH 9810. 2,3-Dihydro-2-methyl-3-[2-(dimethylamino)-
propyl]-3-phenyl-1H-indol-1-carboxaldehyde methanesulfonate.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF-Inactive at 1.0, 10.0
and 30.0
2) TF vs M-Inactive at 1.0,
10.0 and 30.0
3) PPQ-15.4 (2.5-94.2)
4) HP-Inactive
MONKEY DATA #ANIMALS 2 ,
(SDS) Doses (mg/kg/sc) 5.0
2 ,
10.0
2 ,
20
Vehicle-
H2O
The drug did not substitute for morphine at doses of 5.0,
10.0 and 20.0 mg/kg. At the highest dose, severe tremors
were noted in one animal.
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MCV 4219-NIH 9821-UM 1252. Oripavine hydrochloride.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF-3.0 (1.4-6.6), Toxic
at 10.0
2) TF vs M-(Inactive at 1.0
and 10.0; Toxic at 10.0
3) PPQ-1.7 (0.8-3.3)
4) HP-1.5 (1.1-2.0)
MONKEY DATA #ANIMALS 2 , 2 , 2 , Vehicle-
(SDS) Doses (mg/kg/sc) 0.5 1.0 2.0 H 2 O
In a preliminary study the animal developed severe
tremors after receiving a cumulative dose of 5.6 mg/kg in
45 min. (0.8, 1.6 and 3.2 at 15 min. intervals). The animal
was-given pentobarbital (60 mg) and morphine (1.5 mg/kg)
ip. to terminate these severe tremors.
The drug did not substitute for morphine 'at any of the
doses tested.
MCV 4220-NIH 9824-UM 1253. (-)-trans-[(2-Methyl)-1,2,3,4,
4a,5,6,7,8,8a -decahydro-4aß-isoquinolyl]phenol hydrobromide.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF-10.7 (3.7-31.1)
2) TF vs M-Inactive at 1.0
and 30.0
3) PPQ-1.2 (0.4-3.4)
4) HP-2.1 (1.6-2.8)
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MCV 4221-NIH 9825-UM 1254. (+)-trans-[2-(Methyl)-1,2,3,
4,4a,5,6,7,8,8a decahydro-4aß-isoquinolyl]phenol hydro-
bromide.
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-0.6 (0.15-2.4)
2) TF vs M-Inactive. at 1.0
and 3.0
3) PPQ-0.3 (0.1-0.7)
4) HP-O.5 (0.4-0.7)
MCV 4222-NIH 9826. 7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-
2H-1,4-benzodiazepin-2-one (Oxazepam).
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF-Inactive at 1.0 and 30.0
2) TF vs M- 22% at 1.0, 29%
at 10.0
3) PPQ-1.2 (0.3-5.5)
4) HP-No dose-response
MONKEY DATA # ANIMALS 2 , 2 , 2 ,
(SDS) Doses (mg/kg/sc) 15.0 30.0 60.0
Suspended in 1/2% carboxymethylcellulose aqueous solution.
MCV 4222 did not substitute for morphine in the dose range
tested. The drug appeared to suppress retching at all doses.
Drug supply was exhausted.
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MCV 4223-NIH 9829. 7-Chloro-1-[2-(diethylamino)ethyl]-5-
(o-fluorophenyl)-1,3-dihydro-2H-1,4-benrodiazepin-2-one
dihydrochloride (Flurazepam).
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF-Inactive at 1.0 and
30.0
2) TF vs M-Inactive at 1.0
and 30.0
3) PPQ-15.7 (10.5-23.6)
4) HP-Inactive
MONKEY DATA #ANIMALS 4 , 4 , 4 , Vehicle-
(SDS) Doses (mg/kg/sc) 3.75 7.5 15.0 H 2O
MCV 4223 substituted partially for morphine at the highest
dose. A reduction in the number of withdrawal signs
designated: vocalizes when adbomen palpated, lying on side
or abdomen, and retching was evident. In addition, the
drug produced ataxia which was still obvious in all animals,
9 hours after receiving drug. Drowsiness and relaxed abdo-
minal muscles were also noted. Partial substitution does not
necessarily imply that a drug has morphine-like dependence
properties.
MCV 4225-NIH 9839-UM 1259. (-)-trans-3-(Octahydro-2-methyl-
1H-2-pyrindin-4a-yl)phenol (Z)-2-butanedioate.
MOSUE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF-2.9 (1.0-8.3)
2) TF vs M-Inactive at 1.0
and 30.0
3) PPQ-3.1 (0.9-10.0)
4) HP-8.1 (5.8-11.3)
370
MCV 4226-NIH 9840-UM 1260. (+)-trans-3-(Octahydro-2-methyl-
1H-2-pyrindin-4a-yl)phenol (Z)-2-butanedioate.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF-0.9 (0.4-2.0)
2) TF vs M-Inactive at 1.0 and
30.0
3) PPQ-0.4 (0.1-1.0)
4) HP-1.1 (0.8-1.3)
MCV 4227-NIH 9832-UM 1261. N-(6,14-Endoetheno-7,8-dihydro-
morphine-7 -carbonyl)-L-leucine ethyl ester hydrochloride.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF-3.1 (1.0-9.3)
2) TF vs M-Inactive at 1.0
3) PPQ-0.9 (0.3-2.5)
4) HP-O.8 (0.6-1.0)
MONKEY DATA #ANIMALS 2 , 3 , 3 ,
(SDS) Doses (mg/kg/sc) 4.0 8.0 16.0 ,
Vehicle-H2O
MCV 4227 substituted completely, but briefly in 2 of 2
monkeys at the highest dose, and in 1 of 3 monkeys at the.
intermediate dose. Its potency is about 1/5 that of morphine.
MCV 4228-NIH 9872-UM 1266. (±)-trans-3-(1,1-Dimethyl
heptyl)-6,6aß,7,8,10,10a -hexahydro-1-hydroxy-6,6-dimethyl-
9H-dibenzo[b,d]pyran-9-one (Nabilone).
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF-Inactive at 1.0 and
30.0
2) TF vs M-1.5 (0.3-8.1)
3) PPQ-2.5 (0.9-6.7)
4) HP-3.6 (2.5-5.2)
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MCV 4228-NIH 9872-UM 1266.
MONKEY DATA #ANIMALS 1  , 1 , 1  ,
(SDS) Doses (mg/kg/sc) 0.025 0.05 0.075
Vehicle-H2O-1 , 1 , 1 , 1
alcohol and Tween 800.15 0.5 1.0 2.0
The drug did not substitute for morphine. It did suppress
the withdrawal signs retching and vomiting at doses of 0.15
or higher. The drug had strong depressant properties and
a long duration of action. Slowing was observed at all doses
but one namely, 0.075 mg/kg. Monkeys receiving 2.0, 1.0
and 0.5 mg/kg appeared ill for about 2 weeks. In addition,
monkeys receiving 0.05 and 0.025 mg/kg did not appear to
recover completely for nearly 9 hours after drug in spite
of the fact that they had received the noon injection of
morphine.
MCV 4229-NIH 9873.
phenol.
3-(2-Ethyl-4,6-dimethyl-2-morpholinyl)
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF-4.9 (1.4-17.4)
2) TF vs M-Inactive at 1.0
and 30.0
3) PPQ-7.9 (0.4-1.8)
4) HP-2.1 (1.6-2.8)
MONKEY DATA #ANIMALS 2 , 2 , 3 , 1 ,
(SDS) Doses (mg/kg/sc) 0.19 0.75 1.5 3.0
Vehicle-H20
At the 2 higher doses, this compound substituted completely
and briefly for morphine. The onset of action was prompt
and the duration was approximately 1½ hrs. The duration of
action of morphine is at least 2½ hrs. It is equipotent with mor-
phine.
MCV 4230-NIH 9874-UM 1322. 17-Cyclopropylmethyl-4,5 -epoxy-6,-
6-difluoro-3-acetoxymorphinan.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF-Inactive at 1.0 and 30.0
2) TF vs M-0.0008 (0.0002-
0.003)
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3) PPQ-0.1 (0.02-0.9)
4) HP-No dose-response
5) N-19.8 (12.9-30.2)
MONKEY DATA #ANIMALS 3  , 3  , 2 ,
A. (SDS) Dose (mg/kg/sc) 0.003 0.0125 0.5
Vehicle-HCl + H2O
The drug did not substitute for morphine. At the 2 higher doses,
tremors were noted in all the animals. One monkey receiving
the intermediate dose retched frequently. The drug may
exacerbate withdrawal.
MCV 4231-NIH 8508A-UM 809. (-)-5-(m-Hydroxyphenyl)2-methylmorphan
hydrochloride.
MOSUE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF-6.1 (1.9-19.4)
2) TF vs M-Inactive at 1.0 and 30.0
3) PPQ-0.9 (0.4-2.0)
4) HP-1.5 (1.2-1.5)
MONKEY DATA #ANIMALS 2 , 2 , 2 ,
(SDS) Doses (mg/kg/sc)
Vehicle-H20
0.31 1.25 5.0
MCV 4231 did not substitute for morphine: One monkey receiving
the highest dose was given morphine after 35 min to relieve
repeated retching. The drug seemed to exacerbate withdrawal.
B. (PPt-W) - 1 , 3 , 2 , Vehicle-H2O
0.5 4.0 8.0
This drug precipitated withdrawal in morphine-addicted monkeys.
Naloxone appears to be approximately 80 times more potent;
however, MCV 4231 has a longer duration of action than naloxone.
It was still active 2½ hrs after its administration. The
duration of action of naloxone is approximately 90 minutes.
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MCV 4232-NIH 8509A-UM 810. (+)-5-(m-Hydroxyphenyl)-2-methylmorohan
hydrochloride.
MONKEY DATA
(SDS)
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF-4.8 (1.5-15.5)
2) TF vs M-O% at 1.0; 18%
at 30.0
3) PPQ-O.5 (0.3-0.9)
4) HP-O.35 (0.28-0.45)
#ANIMALS 3 , 3 , 4 , Vehicle-
Doses (mg/kg/sc) 2.0 4.0 8.0 H2O
MCV 4232 substituted completely for morphine in 3/4 animals at the
highest dose and in all 3 at the next lower dose. The drug acts
promptly and has a duration of action of about 90 min. Morphine's
duration of action is at least 2½ hrs. The potency is estimated
to be 1/2-1/3 that of morphine.
MCV 4233-NIH 9886.
hydrochloride.
(-)-5-(m-Hydroxyphenyl)-2- n-pentylmorphan
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF-0% at 1.0 and 28% at
30.0
2) TF vs M-1.2 (0.6-2.5)
3) PPQ-14% at 1.0 and 20%
at 30.0
4) HP-Inactive to 50.0
5) N-Inactive to 50.0
MONKEY DATA #ANIMALS 3 , 3 , 1 ,
A. (SDS) Dose (mg/kg/sc) 0.156 0.625 2.5
Vehicle-H20
The drug did not substitute for morphine. One monkey at the
highest dose and another two at the intermediate dose were
given morphine to suppress repeated retching. Severe tremors
were also noted at the highest dose.
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B. (PPt-W) - 2 , 2 , 2 ,
0.156 0.625 2.5
This compound promptly precipitated withdrawal in a dose-related
manner. The drug is approximately 1/50th as active as the
reference standard naloxone and its duration of action is
about 2 1/2 hrs. whereas that of naloxone is about 1 1/2 hrs.
MCV 4235-NIH 9895. (+)-4-Allyl-1-methyl-10-hydroxy-2,3,4,5,6,
7-hexahydro-1,6-methano-1H-4-benzazonine.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF-23% at 1.0 and 22% at
30.0
2) TF vs M-13% at 1.0, 42%
at 10.0 and 46% at 30.0
3) PPQ-0.6 (0.3-1.0)
4) HP-6/10 convulsed at 1.0
md/kg
5) N-Inactive to 5.0, con-
vulsions at 5.0
MONKEY DATA #ANIMALS 2  , 2  , 2 ,
(SDS) Doses (mg/kg/SC) 0.006 0.0125 0.025
2 , 1 , 1 , 1 ,
0.1 0.2 0.5 2.0 Vehicle-H2O
At the 2.0 mg/kg dose, the animal appeared anesthetized, within
10 min. Naloxone at 0.025 mg/kg had no effect. After 90
min, the animal was able to move and 2 hours later could sit.
The 0.5 mg/kg dose also produced anesthesia within 10 min
and this animal was able to sit in 90 minutes. The drug
caused ataxia and slowing at 0.2 and 0.1 mg/kg, produced some
abdominal relaxation and appeared to suppress vocalization
accompanying abdominal palpation for the first 1/2 hr.
Suppression of retching and vomiting was evident at all
doses tested for 30-90 minutes. The drug does not substi-
tute completely for morphine.
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MCV 4236-NIH 9896. (-)-4-Allyl-1-methyl-10-hydroxy-2,3,4,5,
6,7-hexahydro-1,6-methano-1H-4-benzazonine.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF-Inactive at 0.3, 1.0,
3.0, 10.0 and 30.0
2) TF vs M-6.7 (3.2-13.7)
3) PPQ-4.3 (1.4-13.1)
4) HP-Insuff. activity
at 50.0
Convulsions at 50.0
5) N-Inactive at 5.0
MONKEY DATA #ANIMALS 2  , 3 , 3 ,
(SDS) Doses(mg/kg/sc) 0.125 0.5 2.0
Vehicle-dil HCl + H20
In the dose range 0.125 - 2.0 mg/kg, this compound does not sub-
stitute for morphine. Ataxia was noted at the highest dose.
MCV 4237-NIH 9899. (+)-1-Methyl-4-cyclopropylmethyl-10-
hydroxy-2,3,4,5,6,7-hexahydro-1,6-methano-1H-4-benzazonine.
MOUSE DATA -ED50 (95% C.L.)
(mg/kg/sc)
1) TF vs M-O% at 1.0, 3.0,
10.0 and 30.0
2) TF-1.5 (0.5-4.2)
3) PPQ-4.7 (1.9-11.0)
4) HP-Insufficient activity
convulsions at 20.0
5) N-Inactive at 5.0
MONKEY DATA #ANIMALS
(SDS) Doses (mg/kg/sc)
3 , 2 , 3 ,
0.06 0.25 1.0
Vehicle-dil HCl + H20
The drug substituted partially for morphine at all doses.
Severe ataxia, slowing, incoordination, and staring were noted
at the highest dose. In the preliminary study, in one monkey
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given 1.0 mg/kg the following signs were noted: ataxia,
catalepsy, lying'on side, unable to walk. The animal was able
to move about after 1 hour. Partial substitution does not
necessarily imply that the drug has morphine-like activity.
MCV 4238-NIH 9900. (-)-1-Methyl-4-cyclopropylmethyl-10-hydroxy-
2,3,4,5,6,7-hexahydro-1,6-methano-1H-4-benzazonine.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF-25% at 1.0, 0% at 30.0
2) TF vs M-O% at 1.0, 17% at
10.0 and 29% at 30.0
3) PPQ-0.02 (0.007-0.08)
4) HP-Insufficient activity
at 50.0
5) N-Insufficient activity
at 50.0
MONKEY DATA #ANIMALS
(SOS) Doses (mg/kg/sc)
Vehicle-HCl + H20
2 4 4 1
1.25 2.5 5.0 10.0
In the dose range tested, MCV 4238 did not substitute for morphine.
Convulsions were noted at the highest dose which were terminated
by the injection of 60 mg/ip of pentobarbital. In addition,
ataxia, sagging, slowing and relaxed abdominal muscles were
seen at 5.0 mg/kg. Relaxed abdominal muscles and ataxia were
also seen at the 2.5 mg/kg dose.
MCV 4241-NIH 9884-UM 1273.
propylmorphan hydrochloride.
(-)-5-(m-Hydroxyphenyl)-2- n -
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF-Inactive at 1.0 and 30.0
2) TF vs M-0.9 (5.4-15.4)
3) PPQ-0% at 1.0 31% at 10.0
and 39% at 30.0
4) HP-Inactive - 6/10 dead
at 100.0
5 ) N-Inactive
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MCV 4242-NIH 9885-UM 1274. (-)-2-n-Butyl-5-(m-hydroxyphenyl)
morphan hydrochloride.
MOUSE DATA- ED50 (95% C.L.) -
1) TF-Inactive at 1.0 and 10.0
2) TF vs M-3l% at 0.1, 44% at
0.3, 21% at 1.0 and 22%
at 30.0
3) PPQ-Inactive at 1.0and
30.0
4) HP-Incompletely active and
Convulsions at 50.0
5) N-Inactive
MCV 4247-NIH 9894-UM 1276. (+)-2-n-Hexyl-5-(m-hydroxyphenyl)
morphan hydrochloride.
MOUSE DATA-ED50 (95% C.L.)-
1) TF-12% at 1.0 and 30.0
2) TF vs M-14.2 (6.1-32.9)
3) PPQ-1.7 (0.5-5.3)
4) HP-Inactive at 50.0 -
Convulsions
MCV 4249-NIH 9898-UM 1280. 1,12 Dimethyl-4-allyl-10-hydroxy-
2,3,4,5,6,7-hexahydro-1,6-methano-1H-4-benzazonine.
MOUSE DATA-ED50 (95% C.L.) -
1) TF-0% at 1.0 and 24% at
30.0
2) TF vs M-15% at 1.0, 16%
at 10.0, 41% at 30.0
3) PPQ-0.1 (0.01-1.10)
4) HP-Insufficient activity -
Convulsions at 5.0
5) N-Inactive at 5.0
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MCV 4250-NIH 9901-UM 1277. (±)-1-Methyl-4-cyclopropylmethyl-
10-hydroxy-2,3,4,5,6,7-hexahydro-1,6-methano-1H-4-benzazonine.
MOUSE DATA -ED50 (95% C.L.) -
(mg/kg/sc)
1) TF-Inactive at 1.0 and 30.0
2) TF vs M-7.3 (3.2-16.5)
3) PPQ-3.0 (1.0-9.3)
4) HP-Insufficient activity
at 50.0 - Convulsions
5) N-Inactive at 50.0
MCV 4251-NIH 9902-UM 1281. 1,12 Dimethyl-4-cyclopropylmethyl-
10-hydroxy-2,3,4,5,6,7-hexahydro-1,6-methano-1H-4-benzazonine.
MOUSE DATA-ED50 (95% C.L.) -
(mg/kg/sc)
1)
2)
3)
4)
5)
TF-Inactive at 1.0, 10.0
and 30.0
TF vs M-10% at 1.0, 12%
at 10.0 and 22% at 30.0
PPQ-3.5 (1.2-10.1)
HP-No dose response
N-Inactive at 50.0
MCV 4268-NIH 7958-UM 381. (±)-2'-Hydroxy-5,9 dimethyl-2-
(3,3-dimethyla'llyl)-6,7-benzomorphan (pentazocine ampuls).
MOUSE DATA-ED50 (95% C.L.) -
(mg/kg/sc)
1) TF-
2) TF vs M-
3) PPQ-
4) HP-g.3 (6.7-12.8)
5) N-6.5 (4.4-8.8)
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MCV 4268-NIH 7958-UM 381.
MONKEY DATA #ANIMALS 1 , 2 , 2 ,
(SDS) Doses (mg/kg/sc)
Vehicle-
2.5 5.0 10.0 H
2
O
At the highest dose, both monkeys had relaxed abdomens, did
not vocalize when their abdomens were palpated and did not retch
or vomit. However, one of these monkeys developed severe tre-
mors and convulsions. Sixty mg of pentobarbital was given ip
to control these convulsions. Penfazocine substitutes partially
for morphine: Partial substitution does not necessarily indi-
cate that the drug has morphine-like properties.
(SOS) Lower dose addicted monkeys
1 , 2 , 1 , 2 ,
2.5 5.0 10.0 20.0
Vehicle H20
In order to determine whether or not MCV 4268 would substitute for
morphine in monkeys addicted to a lower dose of morphine namely,
1.5 mg/kg/sc, we initiated this study. At the highest dose,
the monkey promptly developed convulsions and was treated with
24 mg pentobarbital ip. At 10.0 mg/kg, one animal also
developed convulsions and was treated with pentobarbital.
Severe tremors were noted in the second monkey at this dose.
However, this animal did not vocalize-when its abdomen was
palpated and the abdominal muscles were relaxed'for
approximately 1½ hours after injection. In addition, other
withdrawal signs such as retching and vomiting were not
observed. Thus, the drug substituted partially for morphine.
MCV 4287-NIH 9961-UM 1324. 1-(1-Methyl-2-phenylethyl)-
4-(N-propanilido)piperidine hydrochloride
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-0.002 (0.00007-0.004) 
2) TF vs. M-INactive at.0.01,
0.03 and 0.1
3) PPQ-0.0016 (0.0010-0.0027)
4) HP-0.006 (0.004-0.009)
MONKEY DATA
(SDS)
Vehicle-H 2 O
#ANIMALS 1 , 3 , 3 ,
Doses (mg/kg/sc) 0.0025 0.005 0.01
At the highest dose, the compound substituted completely and
briefly for morphine. It had a quick onset and short duration of
action (<90 min.). The drug is about 300 x more potent than mor-
phine.
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1981 Annual Report: Evaluation of
New Compounds for Opioid Activity
James H. Woods, Jonathan L. Katz, Fedor Medzihradsky,
Charles B. Smith, Alice M. Young, and Gail D. Winger
The evaluation of new compounds by the programs at the University
of Michigan and  the Medical College of Virginia is coordinated by
Dr. Arthur E. Jacobson, Medicinal Chemistry Section, NIAMDD,
National Institutes of Health, Bethesda, MD. The drugs, which
come originally from pharmaceutical companies, universities, and
government laboratories, are submitted to Dr. Jacobson, who
performs the MOUSE ANALGESIA tests. Values obtained in these
tests for some representative opioid drugs are given in Table 1.
At the UM and MCV laboratories, drug samples arrive from Dr.
Jacobson with only the following information: (1) an identifying
NIH number, (2) molecular weight, (3) solubility information and
(4) a recommended starting dose. Only after the evaluation is
canplete and the report submitted back to Dr. Jacobson are the
chemical structure and the mouse-analgesia data released to the
evaluating laboratory.
The single dose suppression test (SDS) determines the ability of
a drug to suppress the signs of withdrawal in monkeys which have
been made dependent by the chronic administration of morphine (3
mg/kg every six hours). Compounds suspected of having morphine-
antagonist properties are tested for their ability to precipitate
the withdrawal syndrome in nonwithdrawn (NW) morphine-dependent
monkeys. Nondependent monkeys (Normals) are used to determine
whether the acute effects of the test drug are reversible by
nalorphine or naloxone. In a primary dependence study (PDS),
non-dependent  monkeys receive the test. drug every six hours for
30 days to determine whether withdrawal signs will appear when
the animals are challenged with an antagonist or when drug
administration is discontinued.
Details of these techniques have been presented in the ANNUAL
REPORT to the Committee in 1963 (Minutes of the 25th Meeting) by
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TABLE I
MOUSE ANALGESIA. Before  submission to The University of Michigan, all compounds are evaluated for analgesic
activity by Dr. Arthur E. Jacobson.  Shown below are comparative data (ED 50 mg/kg) (95% Confidence Inter-
val) from Hot Platea-c and Nilsend assays. umol/kg
TABLE I continued
Deneau and Seevers (1963) and by Villarreal (1973).
SELF-ADMINISTRATION BY MONKEYS
Tests of self-administration determine the ability of the drug to
maintain responding in monkeys trained to self-inject codeine.
Each of at least three monkeys was studied with saline as a
negative control and a number of doses of the test compound until
a maximum rate of responding was obtained or until, in the absence
of evidence of a reinforcing effect, directly observable changes
in behavior were produced by the compuond.
The schedule of intravenous drug delivery was a fixed-ratio 30;
when a light above a lever was illuminated, the 30th response
produced a five-second intravenous drug injection accompanied by
another light that was illuminated during drug delivery. After
each injection, a ten-minute timeout condition was in effect
during which responses had no scheduled consequence and neither
light was illuminated. Each of the two daily sessions consisted
of 13 injections or 130 minutes, whichever occurred first. Other
details of the procedure and initial findings with a variety of
narcotics are given in previous reports (Woods, 1977; 1988).
Doses of the drugs are typically described in terms of moles/kg/
injection (inj), to facilitate direct comparisons among drugs.
Duplicate observations of codeine (7.5 x 10-5 mol/kg/inj; 0.32
mg/kg/inj) and of saline were obtained for each monkey. A saline
substitution was conducted before and after the series of
observations on a test drug; the control rates of codeine-
reinforced responding were obtained by, a random sampling of two
sessions interpolated between the drug-substitution sessions.
These data are represented in the following graphs with individual
symbols for each of the monkeys; each symbol is the mean of
duplicate observations for a given dose in each monkey. There are
two additional types of averaged data presented. The closed
circles indicate the averaged data for observations on the subset
of monkeys used to study each drug under each of the experimental
conditions. The open circles indicate the codeine and saline
rates of responding of 20 monkeys studied under the same
conditions. The brackets indicate ± 3 standard errors of the
codeine mean, and + 3 standard errors of the saline mean for the
group of 20 monkeys. In all cases, the rates of responding given
are those calculated during only the fixed-ratio portion of each
session.
DISPLACEMENT OFDI- OF STEREOSPECIFIC 3H-ETORPHINE BINDING
Details of the binding assay were described in the 1978 ANNUAL
REPORT (Swain et al., 1978). Briefly, aliquots of a membrane
preparation from rat cerebrum were incubated with 3H-etorphine
in the absence and presence of 150 mM NaCl, and in the presence of
different concentrations of the drug under investigation.
Stereospecific, i.e., opioid-receptor related, binding of
etorphine was determined and the potency of the drug in inhibiting
binding of etorphine was obtained from log-probit plots of the
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TABLE II
Values for the EC 50 (M) of representative compounds in
displacing 3H-etorphine from membrane preparations of rat cerebrum.
NOTE: Binding data for a number of other compounds are included
in the 1978 ANNUAL REPORT.
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data. Values obtained with this method for some representative
opioid drugs are given in Table II.
INHIBITION OF TWITCH OF ELECTRICALLY-STIMUKLATED GUINEA-PIG ILEAL
AND MOUSE VAS DEFERENS PREPARATIONS
submitted drugs are evaluated on two smooth muscle preparations,
the details of which were described in the 1978 ANNUAL REPORT
(Swain et al., 1978). Shown in the following pages are the EC 50’s
for the tested drug alone, for the drug in the presence of
naltrexone (a pure opioid antagonist which is more effective
against so-called "mu" agonists than against so-called “kappa"
agonists), and for the drug in the presence of UM 979 (an
antagonist which appears to be more effective against "Kappa" than
against “mu” drugs) (Smith, 1978). The maximum depression of the
electrically-induced twitch in each of the preparations is also
indicated. The concentrations of both naltrexone and UM 979
always used in tests of antagonism are for the guinea-pig ileum,
10-7 M, and for the mouse vas deferens, 10-8 M.
SUMMARY OF TESTS-PERFORMED
The Compounds which were evaluated at The University of Michigan
during the past year and the individual tests which were
performed are shown in Table III. Also shown are dates of Annual
Reports in which results are reported of earlier tests on those
compounds conducted at Michigan.
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TABLE III
SUMMARY OF TESTS PERFORMED
TABLE III Continued
SUMMARY OF TESTS PERFROMED
TABLE III Continued
SUMMARY OF TESTS PERFORMED
SDS = Single-dose suppression of withdrawal signs in morphine-dependant monkeys
NW = Attempted precipitation of withdrawal in non-withdrawn, morphine-dependant monkeys
N = Attempted reversal by nalorphine end naloxone of effects in nondependent monkeys
SA = Teat of reinforcing properties in monkeys which normally self-administer codeine
GPI = Suppression of twitch in electrically driven guinea-pig ileum preparation
MVD = Suppression of twitch in electrically driven mouse vas deferens preparation
BIND = Stereospeciflc displacement of 3H-etorphine in membrane preparation from rat cerebrum
PDS = Primary dependence study In monkeys
UM 747 NIH 8439
MOUSE ANALGESIA, ED50 (mg/kg)
Hot plate: 0.07 (0.05 - 0.09)
Nilsen:
COMMENT
(-)-5,9 Diethyl-2'-hydroxy-2-methylenecyclopropylmethyl-6,7-
benzomorphan hydrochloride
DRUG SELF-ADMINISTRATION IN RHESUS MONKEYS
UM 747 maintained, at one or more doses, average rates of
responding in each monkey slightly above those maintained by
saline.
UM 747 is a unique opiate because it produces naloxone-
reversible increases in the turnover of dopamine and
norepinephrine in mouse brain but does not increase
locomotor activity in the mouse (Smith and Sheldon, 1973).
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UM 952 NIH 8805 BUPRENORPHINE
MOUSE  ANALGESIA
Hot plate: 0.04
Nilsen: 0.04
ED 50 (mg/kg)
(0.03-0.04)
(0.03-0.06)
N-Cyclopropylmethyl-7 [1-(S)-hydrOxy-l,2,2-
trimethyl-propyl]-6,14-endoethano,6,7,8,14-
tetrahydxonororipavine
OBSERVATIONS IN MORPHINE DEPENDENT RHESUS MONKEYS
Doses studied: 0.001 to 0.3 MG/KG, S.C.
SDS: Buprenorphine exacerbated withdrawal signs at doses of
0.17 and greater.
SUMMARY
Buprenorphine has been reported to suppress signs of withdrawal
in morphine dependent dogs as well as precipitate withdrawal in
nonwithdrawn subjects (Martin et al., 1976). No evidence of
suppression of withdrawal was obtained in these experiments.
UM 961 NIH 8833
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: 15.6 (11.4 - 20.4)
Nilsen: No dose response
(-)-cis-2-(Dimethylamino-m-hydroxybenzyl)cyclohexanol
hydrochloride
OBSERVATIONS IN MORPHINE DEPENDENT RHESUS MONKEYS
Doses studied: 0.31 to 5.0 mg/kg, S.C.
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NW: UM 961 precipitated withdrawal with a potency of about one
thirtieth of naloxone. Additionally it produced ataxia
and decreased responsivity to external stimuli. The drug
had a long duration of action.
SUMMARY
UM 961 represents a novel structure for a narcotic antagonist.
Its actions should be studied more fully in other preparations.
UM 972 NIH 8834 WY 16225
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: 0.7 (0.5 - 0.9)
Nilsen: 0.9 (0.7 - 1.1)
1-13-Amino-5,6,7,8,9,10,11,12-octahydro-
5-inethyl-5,11-methano-benzocylodecen-3ol
hydrobromide
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
BC 50 (M) 5.4 x 10-8 6.6 x 10
-8 0 . 8 1
DRUG SELF-ADMINISTRATION IN RHESUS MONKEYS
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In two of three monkeys UM 972 (0.1 to 0.3 mg/kg/inj) main-
tained responding (self-administration) at rates between
codeine and saline levels. For a third monkey, responding was
maintained marginally above saline levels only at 0.3
mg/kg/inj.
UM 973 NIH 8835
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: 1.3 (1.1 - 1.7)
Nilsen:
2,3,5,6,11,11b-Hexahydro-11,11b-dimethyl-
1H-pyrido[3',2':4,5]pyrrolo[3,2- g ]
indolizine dihydrochloride
DRUG SELF-ADMINISTRATION IN RHESUS MONKEYS
UM 973 failed to maintain responding (drug self-administration)
at levels above saline over the tested range of doses (0.0001
to 0.032 mg/kg/inj).
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MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: 0.92 (0.74 - 1.2)
Nilsen:
N-( Pyridyl),N-(1-ß-phenylethyl-4-
piperidyl)-ethylcarbamate hydrochloride
The three highest doses tested maintained average rates of
responding similar to those maintained by codeine. For one
monkey, 7.7 x 10-8 and 2.6 x 10-7 mol/kg/inj (0.032 and 0.1
mg/kg/inj) doses maintained rates over 3 responses/second.
Doses of 2.6 or 7.7 x 10-9 mol/kg/inj (0.0001 or 0.0032
mg/kg/inj) maintained rates no higher than those maintained by
saline; the lowest dose (7.7 x 10-10 mol/kg/inj 0.00032
mg/kg/inj) maintained rates higher than saline for all three
monkeys.
394
UM 983 NIH 8863
DRUG SELF-ADMINISTRATION IN RHESUS MONKEYS
UM 1076 NIH 9112
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: 0.01 (0.0096 - 0.017)
Nilsen:
d1-3-Allyl-1,3-dimethyl-4-phenyl-
4-propionoxypiperidine hydrochloride
DRUG SELF-ADMINISTRATION IN RHESUS MONKEYS
UM 1076 maintained responding (self-administration) at one or
more doses in each monkey; average rates maintained by UM 1076
were slightly less than those maintained by codeine. UM 1076
maintained maximal rates of responding at 1.0 x 10-3
mg/kg/inj in two monkeys and maintained much higher maximal
response rates at 3.2 x 10-3 mg/kg/injection in the third
monkey. The lowest and highest injection dose of UM 1076
maintained rates no higher than those maintained by saline.
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UM 1103 NIH 9256
MOUSE ANALGESIC, ED 50 (mg/kg)
Hot plate: Inactive
Nilsen: Inactive
2-Cyclopropylmethyl ethyl-2'-
hydroxy-5-methyl-6,7-benzomorphan
DRUG SELF-ADMINISTRATION IN RHESUS MONKEYS
UM 1103 did not maintain responding (self-administration) over
the tested range of doses (0.00032 to 0.032 mg/kg/inj). 
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UM 1124 NIH 9342 MCV 4102
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: 4.4 (2.9 - 6.6)
Nilsen:
(-)-m-[2-(Cyclopropylmethyl)-1,2,3,4,4a,5,6,7,8,8a-
decahydro-4a-isoquinolyl] phenol succinic acid salt
DRUG SELF-ADMINISTRATION IN RHESUS MONKEYS
UM 1124 maintained rates of responding (self-administration)
slightly above saline over the ranqe of 3.5 x 10-9 to 1.05 x
10-7 mol/kg/inj. UM 1124 did not maintain rates of
responding equivalent to those maintained by codeine.
For comparison see compound UM 1112 (Swain et al. 1978; Woods
et al. 1979).
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UM 1160 NIH 9521
H O
MOUSE ANALGESIC, ED 50 (mg/kg)
Hot plate: 2.9 (2.2 - 3.8)
Nilsen:
3 alpha-(1,2 beta,3 beta,4-Tetramethyl-
4-piperidinyl)phenol hydrobromide
DRUG SELF-ADMINISTRATION IN RHESUS MONKEYS
We reported in 1978 that UM 1160 was a short-acting, less
potent morphine-like drug in the morphine-withdrawn rhesus
monkey. In addition, it produced some signs of possible
disorientation and muscle incoordination at doses that
completely suppressed withdrawal. UM 1160 maintained
responding (self-administration) at one or more doses in each
monkey; on average, at rates slightly less than those
maintained by codeine. The maximal rates maintained, however,
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differed among subjects.
9.55 x 10-7 or 3.18 x 10-6 mol/kg/inj (0.32 or 1.0
For two monkeys, UM 1160 doses of
mg/kg/inj) maintained ,response rates slightly hi her than those
maintained by codeine. At 3.18 x 10 - 6 mol/kg/inj
(1.0 mg/kg/inj) the total dose of UM 1160 was equal to that
which produced muscle incoordination in the morphine-withdrawn
monkey. For these two subjects, the three highest doses of
UM 1160 maintained response rates above those maintained by
saline; lower injection doses maintained rates no different
from those maintained by saline. For the third monkey, UM 1160,
3.18 x 10-7mol/kg/inj (0.10 mg/kg/inj), maintained rates
slightly above those maintained by saline: lower and higher
doses maintained rates no different from those maintained by
saline. Higher doses were not tested because the drug supply
was depleted. It appears that the direct, observed effects
mentioned above did not interfere with the capacity of UM
1160 to maintain responding.
UM 1169 NIH 9540 MCV 4145
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: 0.81 (0.62 - 1.1)
Nilsen:
trans-3-(1,2-Dimethyl-4-propyl-4-
piperidinyl) phenol hydrobromide
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+ N a - N a +Na/-Na
EC 50 (M) 3.3 X 10-7 1.4 X 10-7 2 . 2 9
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM
EC 50 (M) MAXIMUM RESPONSE (%)
Drug alone 1.9 x 10-7 100
After naltrexone unchanged unchanged
After UM 979 unchanged unchanged
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UM ll69, unlike morphine, produced a complete inhibition of the
twitch in this preparation. Additionally, it further inhibited
the twitch after a maximally effective concentration of
morphine. At concentrations from 10-5 M to 3 x 10-4 M, the
drug produced a forceful, sustained contracture equivalent to
50% of that produced by carbachol.
Drug alone 8.4 x 10-7 57
UM 1169 was different from morphine in that it did not
completely inhibit the twitch of this preparation. At
concentrations from 10-5 to 3 x 10-4 M the drug enhanced
the twitch. Neither naltrexone nor UM 979 altered the
responses to UM l169.
Doses studied: 0.4 to 3.2 mg/kg, S.C.
SDS : UM 1169 had morphine-like agonist actions and
was about three times as potent as morphine.
DRUG SELF-ADMINISTRATION IN RHESUS MONKEYS
UM 1169 maintained responding (self-administration) at levels
approximating those maintained by codeine and with about ten
times the potency of codeine.
INHIBITION OF TWITCH OF ELCETRICALLY-DRIVEN MOUSE VAS DEFERENS
EC 50 (M) Maximum Response (%)
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SUMMARY
The in vivo and in vitro action of this drug clearly differ
fran each other. UM 1169 is more potent than morphine in the
dependent monkey but less potent in the displacement of 3H-
etorphine and in both smooth muscle preparations. The sodium
ratio for displacement of 3H-etorphine is consistent with a
morphine-like action. However, although UM 1169 suppresses
the twitch in both smooth muscle preparations, its actions
differ from morphine in that in neither preparation are the
effects of UN 1169 antagonized by naltrexone or UM 979.
UM 1170 NIH 9541
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: 21.8 (14.6 - 32.7)
Nilsen:
4ß-(m-Methoxyphenyl)l,3-dimethyl-4
piperidinol propionate hydrochloride
DRUG SELF-ADMINISTRATION IN RHESUS MONKEYS
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UM 1170 did not maintain responding (self-administration) over
a range of doses from 9.8 x 10-9 to 3.0 x 10-6 mol/kg/inj.
SUMMARY
UM 1170 is interesting in several respects. First, like
meperidine, UM 1170 has virtually no activity in displacing
tritiated etorphine from its binding site, however, it has
typical morphine-like agonist actions in the morphine-
dependent rhesus monkey (Swain et al., 1979). Second, the drug
has actions upon both smooth muscle preparations which are
unlike morphine (Swain et al., 1979). Finally, the drug is one
of two compounds that have been identified (see UM 1167 in
woods et al. 1981) that act as morphine-like agonists in the
dependent monkey but do not maintain responding in the drug
self-administration procedure.
A previous report (Swain et al., 1979) of responding maintained
by UM 1170 comparable to that maintained, by codeine was in
error.
UM 1195 NIH 9637
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot Plate: 15.0 (11.3 - 19.8)
Nilsen:
s-N-sec-Butylnormorphine hydrochloride
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DRUG SELF-ADMINISTRATION IN RHESUS MONKEYS
UM 1195 did not maintain responding (self-administration)
comparable to codeine at any dose studied. At one dose, 8.8 x
10-8 mol/kg/inj (0.032 mg/kg), rates were maintained margin-
ally above saline levels (15% of the codeine maintained
response rate).
SUMMARY
On the basis of results reported previously (Woods et al. 1981)
in the binding and guinea-pig ileum assays, UM 1195 had some
low potency morphine-like agonist actions. In the dependent
monkey and mouse vas deferens, however, the drug appeared to be
non-narcotic. It also appears unlike morphine in self-
administration.
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UM 1200 NIH 9674
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: 1.6 (1.2 - 2.1)
Nilsen:
(-)-4-Hydroxy-N-methylmorphinan-6-one
hydrobromide
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC 50 (M) 1.2 x 10-7 5.5 x 10-8 2.20
OBSERVATIONS IN MORPHINE DEPENDENT RHESUS MONKEYS
Doses studied: 1.0 to 4.0 mg/kg, S.C.
SDS: UM 1200 had morphine-like agonist actions and was
slightly more potent than morphine. Its duration of
action was longer than that of morphine.
UM 1201 NIH 9677
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: 1.6 (1.2 - 2.3)
Nilsen:
(-)-4-Hydroxy-N-methylmorphinan hydrochloride
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DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC 50 (M) 5.1 x 10- 1.5 x 10-7 3.42
OBSERVATIONS IN MORPHINE DEPENDENT RHESUS MONKEYS
Doses studied: 1.0 to 4.0 mg/kg, S.C.
SDS: UM 1201 had morphine-like agonist actions with a potency
similar to that of morphine. Its duration of action was
shorter than that of UM 1200.
SUMMARY
The change in the hydroxy from 'the phenolic 3-position
(levorphanol) to the I-position (UM 1201) decreased potency in
the analgesic assay by a factor of eight, however, its potency
in the dependent monkey was only decreased by a factor of four.
A recent study of displacement of 3H-naltrexone has shown
slightly larger changes in EC 50 with the same change in
position of the hydroxy substituent (Simon et al., 1981).
UM 1212 NM 9724 MCV 4187
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: 1.9 (1.4 - 2.6)
Nilsen:
L-Tyrosyl-D-alanylglycyl-L-N allyl-
phenylalanine amide acetate
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na
EC 50 (M) 1.2 X 10-8
-Na
6.7 x 10-9
+Na/-Na
1.74
The slope of the concentration-displacement curve was markedly
lower than most compounds previously studied.
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INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM
EC 50 (M) Maximum Response (%)
Drug alone 9.5 x 10 - 1 0 45.7
Afternaltrexone 2.1 x 10
- 7
10 - 8
unchanged
After UM 979 2.7 x 30.1
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INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS
EC 50 (M) Maximum Response
Drug alone 4.0 x 10
-9
98.4
After naltrexone 1.1 x 10
-7
unchanged
After UM 979 9.9 x 10
-9
unchanged
OBSERVATIONS IN MORPHINE DEPENDENT RHESUS MONKEYS
Doses studied: 1.0 to 16.0 mg/kg, s.c.
SDS: UM 1212 had morphine-like agonist actions but with a
short duration of action and about one-fifth of the
potency of morphine.
SUMMARY
This drug is morphine-like in all preparations. The in vitro
potency of UM 1212 did not predict the in vivo potency.
UM 1217 NIH 9730 MCV 4192 ZOMEPIRAC
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: Inactive up to 100 mg/kg
Nilsen: No Dose
Sodium 5-(4-chlorobenzoyl)-1,4-dimethyl-
1H-pyrrole-2-acetate
DISPLACEMENT OF STEREOSOECIFIC 3H-ETORPHINE BINDING
+Na -Na
EC 50 (M) >2 x 10-5 >2 x 10-5
INHIBITION OF ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM
EC 50 (M) Maximum Response (%)
Drug alone 3.4 x 10
-5
After naltrexone
44.8
9.9 x 10-5 unchanged
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS
EC 50 (M) Maximum Response (%)
Drug alone 7.8 x 10-5 59.3
After naltrexone unchanged unchanged
After UM 979 unchanged unchanged
SELF-ADMINISTRATION IN RHESUS MONKEYS 
No dose studied maintained responding above vehicle levels.
The highest dose was administered in a vehicle consisting of
95% ethanol (33%), propylene glycol (19%) and water (48%).
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UM 1218 NIH 9585
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot Plate: No dose response
Nilsen:
N-Cyclohexylmethylnorketobemidone
hydrobromide
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC 50 (M) 1.7 x 10
-6 1.5 x 10-6 1.10
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM
Concentrations lower than 10-5 M did not alter the magnitude
of the twitch. From 10-5 M to 10-4 M UM 1218 increased
baseline tension. Neither naltrexone nor UM 979 altered this
response.
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS
Concentrations from 10-6 M to 3 x 10-5 M increased the
twitch without increasing baseline tension indicating that the
drug did not directly contract the vas deferens.
SUMMARY
See UM 1237.
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UM 1221 NIH 9741
MOUSE ANALGESIA, ED 50 (mg/kg)
riot plate: No dose response
Nilsen:
N-2-Hexylnorketobemidone hydrobromide
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC 50 (M) 1.5 x 10-6 1.8 x 10-6 0.84
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM
UM 1221 was inactive to a concentration of 3 x 10-6 M. At
concentrations of 10-5 M and higher a sustained increase in
baseline tension was obtained that was not altered by
naltrexone or UM 979.
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS
UM 1221 increased the magnitude of the twitch at concentrations
of 10-9 M and higher. This response was not affected by
either naltrexone or UM 979.
SUMMARY
See UM 1237
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UM 1223 NIH 9735 Mcv 4195
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: Inactive up to 50 mg/kg
N-Cyclopropylmethyl-7,8-
dihydronormorphinone
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC 50 (M) 7.2 x 10-10 1.2 x 10
-9
0.58
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM
EC 50 (M) Maximum Response (%)
Drug alone 1.4 x 10
- 9 53.8
After naltrexone 6.5 x 10
- 8 unchanged
After UM 979 7.6 x 1 0
- 8
unchanged
INHIBITON OF TWITCH OF ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS
UM 1223 was inactive with an occasional increase in magnitude
of the twitch at 3 x 10-4 and 10-4 M.
SUMMARY
UM 1223 is very potent in the binding assay and has a low
sodium ratio. It is morphine-like upon the ileum but ten
times more potent. However, it is inactive upon the vas
deferens.
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UM 1224 NIH 9736 MCV 4196
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: Insufficient activity
Nilsen: 1.3 (0.73 - 2.4)
N-Cyclobutylmethyl-3-hydroxy-6-
methylene-8ß-methylmorphinan
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC 50 (M) 1.4 x 10-9 1.7 x 10
-9
0.80
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM
EC 50 (M) Maximum response (%)
Drug Alone 1.0 x 10-5
After naltrexone Biphasic dose-
response curve
with EC 50 for
57.6
After UM 979
the first phase:
5.1 x 10-9
second-phase:
8.5 x 10-6
1.1 x 10-5
33.4
58.9
unchanged
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS
EC 50 (M) Maximum Response (%)
Drug alone 2.8 x 10-8 41.4
After naltrexone 3.4 x 10-8 unchanged
After UM 979 3.0 x 10-8 unchanged
411
UM 1225 NIH 9737 MCV 4197
17-Cyclopropylmethyl-7,7-dimethyl-3-
methoxy-4,5 epoxymorphinan-6-one
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC 50 (M) 2.4 x 10
-7 2.0 x 10-7 1.24
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM
EC 50 (M) Maximum Response (%)
Drug alone, 9.5 x 10-6 38.9
After naltrexone 8.0 x 10-6 58.3
After UM 979 8.4 x 10-6 57.3
UM 1225 alone produced increases in baseline tension at
3 x 10-5 M and 10-4 M.
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS
EC 50 (M) Maximum Respinse (%)
Drug alone 4.1 x 10-8 39.7
After naltrexone 1.8 X 10-7 unchanged
After UM 979 6.6 x 10-8 unchanged
Small increases in twitch magnitude above maximal inhibitory
response occurred with UM 1225 at 10-5 M and 3 x 10-5 M.
At 10-4 M there was an initial complete suppression of twitch
followed by a gradual recovery to a force 2.9 times baseline
level.
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MOUSE ANALGESIA, ED 50 (mg/kg)
Hot Plate: 5.2 (3.5 - 7.8)
Nilsen: 11.5 (7.2 - 18.4)
UM 1226 NIH 9738 MCV 4199
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: 3.7 (2.3 - 5.7)
Nilsen: 5.8 (4.1 - 8.4)
2-Nitronaltrexone
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na
EC 50 (M) > 2 x 10
-5 > 2 x 10-5
INHIBITION OF TWITCH OF ELECTRICALLT-DRIVEN GUINEA-PIG ILEUM
EC 50 (M) Maximum Response (%)
Drug alone 1.6 x 10-4 97.9
After naltrexone 6.0 x 10-5 unchanged
After UM 979 4.0 x 10-5 unchanged
INHIBITION OF ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS
UM 1226 did not inhibit the twitch up to a concentration of 3 x
10-6 M above which the magnitude of the twitch was increased.
Neither naltrexone nor UM 979 altered the response to  UM 1226.
SUMMARY
The 2-nitro substitution on the phenyl ring markedly decreases
potency in displacing etorphine and thus inhibits antagonist
activity (See Aceto et al., 1981).
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UM 1237 NIH 9789
MOUSE ANALGESIA ED 50 (mg/kg)
Hot plate: Incompletely active at
100 mg/kg
Nilsen:
5-Hydroxypentylnorketobemidone
hydrobromide
INHIBITION OF TWITCH ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM
EC 50 (M) Maximum Response (%)
Drug alone 2.6 X 10-5 36.9
After naltrexone 2.5 X 10-5 Unchanged
After UM 979 3.0 X 10-5 unchanged
Concentrations of 10-4 M and 3 x 10-4 M increased baseline
tension.
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS
EC 50 (M) Maximum Response (%)
Drug alone 5.1 x 10-9 51.3
After naltrexone
After UM 979
1.6 x 10-8 36.4
1.4 x 10-8 42.2
At higher concentrations (10-6 to 3 x 10-4 M), the compound
enhanced the twitch; neither antagonist altered this response.
SUMMARY
UM 1237, like UM 1218 and UM 1221, has in vitro actions like
the quasi-withdrawal inducing agents, UM 1037 and UM 1046
(valentino et al., 1981), however at the doses tested, these
canpounds failed to show any in vivo actions (Woods et al.,
1981).
414
UM l238 NIH 9791 MCV 4210
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: 1.4 (1.1 - 1.8)
Nilsen: 1.5 (1.1 - 2.1)
N-Methyl-L-tyrosyl-D-serylglycyl-N-methyl-
L-phenylalanyl-D-serinamide monoacetate
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC 50 (M) 2.5 x 10-7 1.3 x 10-7 1.87
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM
EC 50 (M) Maximum Response (%)
Drug alone 6.1 x 10-8 55.9
After naltrexone 2.3 x 10-6 unchanged
After UM 979 4.1 x 10-7 Unchanged
Both antagonists increased the slope of the concentration-
effect curve.
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS
Drug alone
After naltrexone
After UM 979
EC 50 (M)
7.2. x 10 - 8
1.3 x 10 - 6
1.6 X 10 - 7
Maximum Response (%)
97.4
Unchanged
unchanged
SUMMARY
UM 1238 is morphine-like in all three preparations.
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UM 1243 MIANSERIN
1,2,3,4,10,146-Hexahydro-2-
methyldibenzo{c,t}pyrazino{l,2a}azapine
DISPLACEMENT OF TWITCH OF ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM
+Na -Na +Na/-Na
EC 50 (M) >2.0 x 10-5 >2.0 x 10-5
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM 
EC 50 (M) Maximum response (%)
Drug alone 1.8 x 10 - 6 91.8
After naltrexone 1.8 x 10 - 5
4.8 x 10-5
unchanged
After UM 979 unchanged
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS 
EC 50 (M) Maximum response (%)
Drug alone 1.1 x 10 - 8 60.2
After naltrexone 5.9 x 10 - 9 37.4
After UM 979 2.1 x 10 - 8 unchanged
Concentrations of 3 x 10-6 M and higher produced marked
increases in the magnitude of the twitch but did not alter
the baseline tension.
OBSERVATIONS IN MORPHINE-DEPENDENT AND NON-DEPENDENT RHESUS
MONKEYS
Doses studied: 5.0 to 20.0 mg/kg, s.c.
SDS: UM 1243 neither suppressed nor exacerbated withdrawal
signs across the dose range studied. At the highest
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dose there were signs of sedation.
Nondependent subjects: Effects of 20.0 mg/kg included
sedation and dozing, slight ataxia and increased
respiratory rate. None of these effects was
reversed by naloxone (2.0 mg/kg, i.v.).
UM 1243 is an example of a drug which appears to be morphine-
like upon the guinea-pig ileum but is devoid of opiate activity
in all of the other preparations.
UM 1245 NIH 9804 MCV 4212
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: Inactive
Toxic at 20 mg/kg
Nilsen : 7.7 (5.6 - 10.5)
(-)-(lR,5R,9R,2"S)-(5,9-Dimethyl-2'-hydroxy-2-
(2-methyltetrahydrofurfuryl)-6,7-benzamorphan)
L-tartrate
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC 50 (M)
+Na -Na + N a / - N a
1.9 x 10-8 1.8 x 10
-8 1.07
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM
EC 50 (M) Maximum Response (%)
Drug alone 2.5 x 10 - 6 69.8
After naltrexone 5.1 x 10-7 86.4
After UM 979 7.5 x 10 - 7 82.6
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS
EC 50 (M) Maximum response (%)
Drug alone 4.3 x 10 - 8 100
After naltrexone 1.4 x 10-6 unchanged
After UM 979 7.8 x 10 - 8 unchanged
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SUMMARY
OBSERVATIONS IN MORPHINE-DEPENDENT RHESUS MONKEYS
Doses studied: 0.03 to 1.0 mg/kg, s.c.
NW: UM 1245 precipitated narcotic withdrawal signs promptly
with a potency about one-tenth that of naloxone in the
morphine-dependent monkey.
UM 1246 NIH 9805 MCV 4213
MOUSE ANALGESIA,ED 50 (mg/kg)
Hot plate: 0.83 (0.62 - 1.1)
Nilsen:
(-)-(1R,5R,9R)-5,9-Dimethyl-2'-hydroxy-2-
(2-methoxyisobutyl)-6,7,benzomorphan
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC 50 (M)
+Na - N a +Na/-Na
2.0 x 10-7 2.5 x 10-7 0.79
INHIBITION OF THE TWITCH OF ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM
EC 50 (M) Maximum Response(%)
Drug alone 4.1 x 10-10 58.3
After naltrexone 2.4 x 10-7 unchanged
After UM 979 3.2 x 10-7 unchanged
INHIBITION OF TWITCH OF ELCTRICALLY-DRIVEN MOUSE VAS DEFERENS
EC 50 (m) Maximum Response
Drug alone 2.3 x 10-8 100
After naltrexone 3.7 x 10-8 unchanged
After UM 979 5.2 x 10-8 unchanged
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OBSERVATIONS IN MORPHINE DEPENDENT AND NON-DEPENDENT RHESUS
MONKEYS
Doses studied: 0.2 to 0.8 mg/kg, s.c.
SDS: UM 1246 (0.2 - 0.8 mg/kg, s.c.) failed to suppress the
withdrawal signs in morphine-dependent rhesus monkeys
though the compound produced marked signs of motor in-
coordination and sedation. The compound is similar to
ethylketazocine in this regard.
Nondependent subjects: UM 1246 (0.4 mg/kg, s.c.) produced
ataxia, pupil dilation, decreased responsivity to
external stimuli, ptosis, dozing, and increased
respiratory rate. All effects except those on respiration
were antagonized by 1.7 mg/kg naloxone. Additionally
these effects, except those on respiration, are similar
to those produced by ethylketazocine.
DRUG SELF-ADMINISTRATION IN RHESUS MONKEYS
UM 1246 did not maintain responding (self-administration
across a range of doses from 9.87 x 10-10 to 9.87 x 10-7
mol/kg/inj (0.03 to 30 µg/kg/inj).
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UM 1246 is an atypical narcotic agonist; it appears to be
unlike morphine in that it fails to suppress narcotic
withdrawal signs in the dependent monkey, it does, not maintain
responding in the self-administration procedure, and it has an
intermediate sodium response ratio. Its direct CNS effects in
normal monkeys, however, are reversed by the narcotic
antagonist naloxone. These findings are typically associated
with ethylketazocine-like compounds in these preparations. On
the guinea-pig ileum, UM 1246 is very potent, and it is
markedly antagonized by both naltrexone and UM 979. In
contrast, on the mouse vas deferens UM 1246 is an agonist which
is as potent as, and equally efficacious to morphine. However,
neither antagonist reverses the effects of UM 1246 upon this
preparation. Thus, UM 1246 does not appear to be either
morphine- or ethylketazocine-like in its actions on the mouse
vas deferens. In conclusion, UM 1246 appears to be a narcotic
with an important spectrum of agonist actions warranting
further study.
UM 1252 NIH 9821 MCV 4219 ORIPAVINE
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: 1.5 (1.1 - 2.0)
Nilsen:
Oripavine hydrochloride
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+ N a - N a +Na/-Na
EC 50 (M) 8.0 x 10
-7 4.3 x 10-7 1.88
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM
EC 50 (M) Maximum Response (%)
Drug alone 5.3 x 10
-7 52.0
After naltrexone > 3 x 10
-4
After UM 979 1.7 x 10
-5
unchanged
SUMMARY
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INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS
Drug alone
After naltrexone
After UM 979
EC 50 (M) Maximum Response (%)
3.5 x 10-6 88.7
5.4 x 10-5 unchanged
2.7 x 10-6 unchanged
UM 1253 NIH 9824 MCV 4220
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: 2.1 (1.6 - 2.8)
Nilsen:
(-)-trans-3-(Octahydro-2-methyl-4a(2H)-
isoquinoline)phenol hydrobromomide
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na - N a +Na/-Na
EC 50 (M) 1.4 x 10-7 7.6 x 10-8 1.84
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM  
EC 50 (M) Maximum Response (%)
Drug alone 6.3 x 10-7 78.6
After naltrexone 1.6 x 10-5 unchanged
After UM 979 7.4 x 10-6 unchanged
Both antagonists increased the slope of the concentration-
effect curve.
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS
EC 50 (M) Maximum Response (%)
Drug alone 2.3 X l0-5 92.6
After naltrexone 4.8 X 10-5 unchanged
After UM 979 9.7 x 10-5 unchanged
UM 979 increased the slope of the concentration-effect curve.
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Doses tested: 1.0 to 8.0 mg/kg, s.c.
SDS: UM 1253 had morphine-like agonist actions and was
approximately equal in potency to morphine.
UM 1254 NIH 9825 MCV 4221
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: 0.53 (0.42 - 0.67)
Nilsen:
(+)-trans-3-(Octahydro-2-methyl-4a(2H)-
isoquinoline)phenol hydrobromide
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC 50 (M) 2.8 x 10
-8 1.4 x 10-8 1.94
INHIBITION OF TWITCH ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM 
EC 50 (M) Maximum Response (%)
Drug alone 2.2 x 10-7
1.2 x 10-5
72.2
After naltrexone unchanged
After UM 979 3.7 x 10-6 unchanged
Both antagonists increased the slops of the concentration-
effect curve
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS
EC 50 (M) Maximum Response(%)
Drug alone 9.3 x 10-7 95.1
After naltrexone 2.0 x 10-6 unchanged
After UM 979 3.9 x 10-4 unchanged
OBSERVATIONS IN MORPHINE-DEPENDENT RHESUS MONKEYS
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OBSERVATIONS IN MORPHINE-DEPENDENT RHESUS MONKEYS
Doses tested: 0.15 to 0.6 mg/kg,s.c.
SDS: UM 1254 had morphine-like agonist actions and was
greater than 5 times as potent.
SUMMARY
UM 1254 and UM 1253 are a pair of stereoisomers that show
potency differences but share qualitatively similar actions.
For a comparison with the stereoisomeric cis pair see Aceto et
al. (1981).
UM 1258 NIH 9624 MCV 4175
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: 2.4 (1.7 - 3.3)
Nilsen:
dl-1-[(2 11S)-l-(1,2,3,4,5,6-Hexahydro-
8-hydroxy-3,6,11-trimethyl-2,6-methano-3-
benzazocin-ll-yl)]-3-octanone methanesulfonate
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC 50 (M) 3.3 x 10
-9 3.1 x 10-9 1.07
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM
UM 1258 (10-9 to 10-4 M) failed to inhibit the twitch
sufficiently to obtain an EC 50; the slight inhibition obtained
at high concentrations was not changed by naltrexone or UM 979.
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS
EC 50 (M) Maximum Response (%)
Drug alone 1.8 x 10 - 8 50.3
After naltrexone 8.5 x 10 - 9 unchanged
After UM 979 2.2 x 10 - 8 unchanged
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UM 1259 NIH 9839 MCV 4225
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: 8.1 (5.8 - 11.3)
Nilsen:
(-)-trans-3-(0ctahydro-2-methyl-lH-2-pyrindin-
4a-yl) phenol (Z)-2-butanedioate
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC 50 (M) 2.8 x 10
-7 2.2 x 10-7 1.28
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM
EC 50 (M) Maximum Response (%)
Drug alone 1.1 x 10-7 33.8
After naltrexone insurmountable antagonism
After UM 979 insurmountable antagonism
Concentrations of UM 1259 above 10-6 M in the presence of
either antagonist increased the magnitude of the twitch without
affecting baseline.
EC 50 (M) Maximum Response (%)
Drug alone 2.2 x 10-7 62.8
After naltrexone 4.6 x 10-6
After UM 979
unchanged
1.1 x 10-6 unchanged
Doses tested: 2.0 to 8.0 mg/kg, s.c.
SDS: UM 1259 had morphine-like agonist actions and was about
one-half as potent as morphine.
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UM 1260 NIH 9840 MCV 4226
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: 1.1 (0.83 - 1.3)
Nilsen:
(t)-trans-3-(Octahydro-2-methyl-1H-2-pyrindin-
4a-yl)phenol (Z)-2-butanedioate
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na - N a +Na/-Na
EC 50 (M) 8.8 x 10-8 3.6 x 10
-8 2.43
INHIBITION OF TWlTCH OF ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM
EC 50 (M) Maximum Response (%)
Drug alone 2.8 x 10-7 58.1
After naltrexone 4.8 x 10-6 unchanged
After UM 979 1.2 x 10-6 unchanged
Both antagonists increased the slope of the concentration
effect curve.
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS
EC  50 (M) Maximum Response (%)
Drug alone
After naltrexone
After UM 979
98.2
unchanged
unchanged
OBSERVATIONS IN MORPHINE-DEPENDENT RHESUS MONKEYS
Doses tested: 0.3 to 1.2 mg/kg, S.C.
SDS: UM 1260 had morphine-like agonist actions and was about
5 times more potent than morphine.
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SUMMARY
UM 1260 and UM 1259 are a pair of stereoisomers that show
qualitatively similar actions with correlated potency
differences in binding and'behavioral effects. For a
comparison with the stereoisomeric cis pair see Aceto et
al. (1981) and also Woods et al. (1981).
UM 1261 NIH 9832 MCV 4227
N-(6,14-Endoetheno-7,8-dihydromorphine- -carbonyl)-
L-leucine ethyl ester hydrochloride
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na - N a
EC 50 (M) 2 to 3 x 10-9 1 to 2 x 10
-9
Heterogeneous log probit plots makes it impossible to give
exact EC 50 values.
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM
EC 50 (m) Maximum Response (%)
Drug alone 4.0 x 10-9 60.2
After naltrexone 1.7 x 10-7 unchanged
After UM 979 9.1 x 10-9 unchanged
Naltrexone slightly increased the slope of the concentration-
effect curve.
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS
EC 50 (M) Maximum Response (%)
Drug alone 2.8 x 10-8 95.3
After naltrexone 1.4 x 10-7 unchanged
After UM 979 4.4 x 10-8 unchanged
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: (0.59 - 1.0)
Nilsen:
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UM 106
UM 1262 NIH 4591 DEXTRORPHAN
d-3-Hydroxy-N-methyl-morphinan tartrate
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC 50 (M) 1.8 x 10-5 1.4 x 10
-5
1.32
OBSERVATIONS IN MORPHINE-DEPENDENT RHESUS MONKEYS
Doses tested: 3.0 to 10.0 mg/kg, s.c.
SDS: Dextrorphan neither suppressed nor exacerbated withdrawal
signs in the monkey but produced marked ataxia and
decreased responsivity to external stimulation. See UM
1264.
UM 1263 KETAMINE
dl-2-(o-chlorophenyl)-2-(methylamino)
cyclohexanone hydrochloride
427
OBSERVATIONS IN MORPHINE-DEPENDENT RHESUS MONKEYS
Doses tested: 1.0 to 5.6 mg/kg, s.c.
SDS: Retamine neither suppresssed nor exacerbated withdrawal
signs in the monkey but produced marked ataxia with
decreased responsivity to stimulation from observers.
See UM 1264.
UM 1264 NIH 9580 MCV 4158 PHENCYCLIDINE
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate:
Nilsen:
1-(1-Phenyclohexyl) piperidine
hydrochloride
OBSERVATIONS IN MORPHINE-DEPENDENT RHESUS MONKEYS
Doses tested: 0.1 to 0.56 mg/kg, s.c.
SDS: Phencyclidine neither suppressed nor. exacerbated
withdrawal signs in the monkey but produced marked
ataxia and decreased responsivity to stimulation from
observers. Phencyclidine was about ten times more
potent than ketamine and thirty times more potent than
dextrorphan in producing these effects.
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UM 1265 NIH 9596 MCV 4161 LEVONANTRADOL
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: 0.15 (0.13 - 0.19)
Nilsen:
(-)-trans-5,6,6aß,7,8,9,10a -Octahydro-
1-acetoxy-9ß-hydroxy-6ß-methyl-3-(5-
phenyl-2-pentyloxy)phenanthridine
hydrochloride
OBSERVATIONS IN MORPHNE-DEPENDENT RHESUS MONKEYS
Doses tested: 0.03 to 0.56 mg/kg, s.c.
SDS: Levonantradol produced neither overall suppression nor
exacerbation of withdrawal signs in the monkey although
there was relaxation of the abdominal musculature that
is typically contracted during morphine withdrawal.
Other effects included ataxia, ptosis and pupil dilation.
At doses of 0.3 and 0.56 mg/kg, onset of action was
definite by one hour following injection. Levonantradol
was approximately twice as potent as UM 1266 (nabilone)
and about ten times as potent as UM 1270 9-tetra-
hydrocannabinol).
DRUG SELF-ADMINISTRATION IN RHESUS MONKEYS
GRAND AVERAGE
L E V O N A N T R A D O L AVERAGE
M C V 4 1 6 1
1086
1235
1261
MOL/KG/INJECTION
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Across the range of doses studied, levonantradol did not
maintain responding (self-administration).
PRIMARY DEPENDENCE STUDY
Animals. Rhesus monkeys numbered 279, 347, and 392 were used.
Throughout the study their weights changed less than five
percent of their predrug values and none of the monkeys showed
any apparent ill-effects from the drug.
Dosage schedule. The drug was suspended in a mixture of
emulphor, ethanol (95%) and distilled water, and administered
subcutaneously every six hours. The starting dose was 0.17
mg/kg/6 hr and was incremented as follows:
Day
1
4
6
9
10
15
17
19
Dose (mg/kg/6 hr)
0.17
0.3
0.56
1.0
1.7
3.8
5.6
10.0
On day 14 the subjects were tested for precipitation of
withdrawal signs with nalorphine and were tested with naloxone
on days 16 and 21. On the thirtieth day the drug administra-
tions were discontinued. Additionally subjects were tested
on days 20 through 30 for cross tolerance to morphine,
UM 1072, 9-THC, and UM 1266 (nabilone).
Acute effects. Administration of UM 1265 caused marked
effects characterized by ptosis, dozing, pupil dilation,
ataxia and a reduced responsivity to stimulation from
observers and cagemates. Each of these signs was given
a score of 0, 1 or 2 depending on whether the sign was
absent, present, or present to a marked degree, respectively.
A composite score for drug effect then ranged from zero to
ten. As can be seen in the figure, over a one log unit range
of doses, effects ranged from near zero to 10. The ED 50 for
these effects was appoximately 0.13 mg/kg.
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Chronic effects. Upon repeated administration of UM 1265
effects decreased. Initially, some of the effects could be
recaptured with dosage increments (up to 1.7 mg/kg), however,
once tolerance developed to effects of 1.7 mg/kg, further
increases in dose had virtually no effects at all. Doses
as high as 100.0 mg/kg had virtually no effect in subjects
receiving 10.0 mg/kg/6 hrs. Additionally in those subjects,
normally effective doses of 9-THC and UM 1266 were without
effect. In contrast there was minimal, if any, cross
tolerance to the effects of morphine and UM 1072. Some
tolerance to effects of UM 1265 lasted 6 weeks after the dis-
continuation of drug treatment.
Dependence. Neither nalorphine nor naloxone administration
precipitated clear withdrawal signs in these subjects. Upon
abrupt discontinuation of UM 1265 there was some irritability
due to handling of the subjects and sane latency above normal
to eat food at daily feeding time. Marked signs similar to
those of narcotic withdrawal were not observed.
Summary. Chronic administration of UM 1265 produced a marked
degree of tolerance to its effects such that doses about 1000
times the original ED 50 had no ef feet. Additionally cross-
tolerance was conferred to 9-THC and UM 1266, but not to
morphine or UM 1072. Moreover, neither the administration of
narcotic antagonists nor discontinuation of the drug resulted
in any clear signs of withdrawal.
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UM 1266 NIH 9872 MCV 4228 NABILONE
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: 3.6 (2.5 - 5.2)
Nilsen:
dl-trans-3-(1-1-Dimethylheptyl)-6,6aß,7,8,10,10a
hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-
9-one
OBSERVATIONS IN MORPHINE-DEPENDENT RHESUS MONKEYS
Doses studied: 0.01 to 1.0 mg/kg, s.c.
SDS: Nabilone produced neither overall suppression nor
exacerbation of withdrawal signs in the monkey although
there was occasional relaxation of the abdominal
musculature that is contracted during morphine
withdrawal. Other effects included pupil dilation,
ptosis, ataxia and some decreased responsivity to
stimulation from observers. At doses of 0.3 and 1.0
mg/kg the onset of action occurred at 3 hrs.
SELF-ADMINISTRATION IN RHESUS MONKEYS
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SELF-ADMINISTRATION IN RHESUS MONKEYS
GRAND AVERAGE
AVERAGE
1389
N A B I L O N E
1387
1064
M G / K G / I N J E C T I O N
Across the range of doses studied (3.2 x 10-4 to 3.2 x
10-2 ms/kg/inj), nabilone did not maintain responding
(self-administration).
PRIMARY DEPENDENCE ESTUDY
Animals. Rhesus monkeys numbered 115-A and 334 were used.
Initially both monkeys lost weight (115-A to a greater extent
than 334) but gained all (334), or most (115-A) of it back by
the end of the study. Both monkeys also developed abscesses at
injection sites and additionally developed scrotal edema. The
abscesses and edema may have been due to the vehicle.
Dosage schedule. The drug was suspended in a mixture of
Tween 80, alcohol (95%), and distilled water, and administered
subcutaneously. At higher doses little or no water was used in
the vehicle. The starting dose was 0.3 mg/kg every 12 hrs
since the drug has a slow onset and long duration of action.
on the third day, and thereafter, injections were given every
6 hrs. The increments in dosage were as follows:
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Day
1
3
5
6
13
16
17
18
20
21
Dose (mg/kg)
0.3 (every 12 hrs)
0.3 (every 6 hrs)
0.53 (every 6 hrs)
1.0 (every 6 hrs)
1.7 (every 6 hrs)
3.0 (every 6 hrs)
5.6 (every 6 hrs)
10.0 (every 6 hrs)
17.0 (every 6 hrs)
30.0 (every 6 hrs)
On days 15 and 22 the subjects were tested for precipitation of
withdrawal with naloxone administration. On the thirtieth day
drug administrations were discontinued. Additionally on days
24 through 30 subjects were tested for cross tolerance to
morphine, UM 1072, 9-THC and UM 1265 (levonantradol).
Acute effects. Administration of UM 1266 caused marked
effects characterized by ptosis, dozing, pupil dilation, ataxia
and a reduced responsivity to stimulation from observers and
cagemates. Each of these five signs was scored as either 0, 1,
or 2 depending on whether the sign was absent, present, or
present to a marked degree, respectively. A composite score
for drug effect than ranged from zero to ten. As can be seen
in the figure, the dose-effect curve was steep and varied from
near zero-to 10 within about a single log unit range of doses.
The ED 50 for these effects was approximately 0.24 mg/kg.
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Chronic effects. Upon repeated administration of UM 1266
effects decreased. Initially sane effects could be recaptured
by 1/4 log unit increments in dose, however, beyond a dose of
1.7 mg/kg (day 13) further dose increments had no effects on
the scored signs. Although these signs were absent, the
subjects did not look canpletely normal. They had a general
appearance of malaise and were often observed to be lying
prostrate on the cage floor. Usually when lying prostrate they
could be aroused by the observer. Doses as high as 170 mg/kg
of UM 1266 had virtually no effect in monkeys receiving 30
mg/kg/6 hrs. Additionally in those subjects, normally
effective doses of 9-THC and UM 1265 were without effect.
In contrast there was minimal, if any, cross tolerance to
morphine and UM 1072.
Dependence. With administration of naloxone there was no
indication of precipitation of any withdrawal signs; neither
was there indication of withdrawal signs upon discontinuation
of UM 1266. Subjects spent most of the time huddled on their
perch and there was some hindlimb rigidity and some perinasal
redness. Effects on posture and movement may have been due to
the scrotal edema that developed.
Summary. Chronic administration of UM 1266 produced a marked
degree of tolerance such that doses about 1000 times an
effective dose in normal subjects were without effect.
Additionally cross-tolerance was conferred to effects of
9-THC and UM 1265, but not to morphine or UM 1072. Finally,
neither the administration of naloxone nor discontinuation of
drug treatment resulted in clear signs of withdrawal.
UM 1267 NIH 9612 MCV 4167
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: 0.49 (0.36 - 0.65)
Nilsen:
dl-9-Hydroxy-4,7-dimethyl-C-
hanobenzanorphan hydrobromide
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DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC 50 (M) 5.4 x 10
-6
3.6 x 10-6 1.51
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM
UM 1267 did not inhibit the twitch of this preparation. At a
concentration of 10-9 M it increased the magnitude of the
twitch and at concentrations of 3 x 10-5 M and higher it
increased baseline tension.
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS
EC 50 (M) Maximum Response (%)
Drug alone 6.1 x 10-7 68.7
After naltrexone 6.8 x 10-9 unchanged
After UM 979 4.0 x 10-8 decreased
Concentrations of UN 1267 alone greater than 3 x 10-5 M
produced increases in baseline tension.
UM 1268 NIH 9613 MCV 4168
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: 2.4 (1.4 - 4.3)
Nilsen:
(+)-9-Hydroxy-4,7-dimethyl-C-
hanobenzomorphan hydrobromide
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC 50 (M) 9.7 x 10-6 3.2 x 10-6 3.05
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INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM
UM 1268 did not inhibit the twitch of this preparation. At
concentraton of 3 x 10-9 M and greater the magnitude of
the twitch was increased.  At concentrations of 10-5 M and
higher the baseline tension was increased. Neither naltrexone
nor UM 979 had any effect on the response to UM 1268.
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS
EC 50 (M) Maximum Response (%)
Drug alone 2.7 x 10-7 34.4
After naltrexone 3.0 x 10-5 unchanged
After UM 979 1.2 x 10
-6
unchanged
Concentrations of UM 1268 alone greater than 10-4 M produced
increases in the magnitude of the twitch as well as increases
in baseline tension.
UM 1269 NIH 9614 MCV 4169
MOUSE ANALGESIA, ED 50 (mg,kg)
Hot plate: 2.5 (1.9 - 3.3)
Nilsen: 13.0 (9.6 - 17.7)
(-)-9-Hydroxy-4,7-dimethyl-C-
homobenzomorphan hydrobromide
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na - N a +Na/-Na
EC 50 (M) 4.8 x 10-6 3.8 x 10-6 1.27
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM
EC 50 (M) Maximum response (%)
Drug alone 2.5 x 10-6 82.0
After naltrexone 2.5 x 10-7 unchanged
After UM 979 unchanged unchanged
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INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS
Over a range of concentrations from 10-9 M to 3 x 10-4 M,
UM 1269 did not inhibit the twitch of this preparation. At
10-6 M, UM 1269 failed to reverse the inhibitory effect of
morphine (10-9 M to 3 x 10-4 M).
DRUG SELF-ADMINISTRATION IN RHESUS MONKEYS
U M  1 2 6 9
GRAND AVERAGE
AVERAGE
166
1387
1389
M O L / K G / I N J E C T I O N
Responding was maintained at rates only marginally above saline
and at only one dose (0.3 mg/kg/inj). The maximal percentage
of the codeine-maintained response rate at that dose was 26.
Following the administration of 20 mg/kg, i.v., subjects were
sedated, occasionally dozed, and showed marked ataxia. Naloxone
(0.32 mg/kg) failed to reverse these effects of UM 1269.
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UM 1270
9-TETRAHYDROCANNABINOL
9-Tetrahydrocannabinol
OBSERVATIONS IN MORPHINE-DEPENDENT AND NON-DEPENDENT RHESUS
MONKEYS
Doses studied: 0.1 to 3.0 mg/kg, s.c.
SDS: 9-Tetrahydrocannabinol neither suppressed nor
exacerbated withdrawal signs in the rhesus monkey.
Other effects included ataxia, ptosis, pupil
dilation, dozing and decreased responsivity to
stimulation from observers. At 3.0 mg/kg the onset
of effect occurred by one hour after injection.
Nondependent subjects: Effects in normal subjects included:
ataxia, pupil dilation, ptosis, dozing and decreased
responsivity to stimulation from observers and
ca emates. Compared to UM 1265 (levonantradol),
9-THC was one-tenth as potent in producing these
effects. The above effects were not reversed by
naloxone (1.7 mg/kg, i.m.).
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SELF-ADMINISTRATION IN RHESUS MONKEYS
GRAND AVERAGE
AVERAGE
171
9-TETRAHYDROCANNABINOL
212A
1392
M G / K G / I N J E C T I O N
Across the range of doses studied (1 x 10-3 to 1 x 10-1
mg/kg/inj, 9-tetrahydrocannabinol did not maintain
responding (self-administration).
UM 1273 NIH 9884 MCV 4241
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: Incompletely active
and toxic at 100 mg/kg
Nilsen: Inactive
(-)-5-( m -Hydroxyphenyl)-2-n-propylmorphan
hydrochloride
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DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC 50 (M)
+Na - N a +Na/-Na
2.0 x 10-6 4.2 x 10-6 0.48
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM
EC 50 (M) Maximum Response (%)
Drug alone 6.3 x 10-4 68.7
Both naltrexone and UM 979 produced an unsurmountable
antagonism of the effects of UM 1273 up to a concentration
of 10-4 M at which point a decrease in the amplitude of
the twitch occurred which was accompanied by spontaneous
contractions of the ileum.
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS
UM 1273 produced a slight (less than 10%) decrease in twitch
starting at a concentration of 10-7 M. At 3 x 10-6 M and
higher concentrations there was an increase in magnitude of
the twitch without a change in baseline tension. These
responses to UDM 1273 were not altered by naltrexone or UM 979.
OBSERVATIONS IN MORPHINE-DEPENDENT RHESUS MONKEYS
Doses tested: 1.0 to 3.0 mq/kg, s.c.
NW: UM 1273 precipitated withdrawal with 0.006 times
the potency of naloxone.
SUMMARY
See UM 1276.
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UM 1274 NIH 9885 MCV 4242
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: Incompletely active
and convulsive at
50 mg/kg
Nilsen: Inactive
(-)-2-n-Butyl-5-(m-hydroxyphenyl)morphan
hydrochloride
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC 50 (M) 6.3 x 10-7 1.8 x 10-6 0.35
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM
EC 50 (M) Maximum Response (%)
Drug alone 3.3 x 10-5 83.7
After naltrexone 5.7 x 10-4 unchanged
After UM 979 9.9 x 10-4 unchanged
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS
UM 1274 did not inhibit the twitch of this preparation.
At 10-5 M there was an increase in the magnitude of the
twitch which was not altered by either naltrexone or UM 979.
OBSERVATIONS IN MORPHINE-DEPENDENT AND NON-DEPENDENT RHESUS
MONKEYS
Doses studied: 1.0 to 5.6 mg/kg, s.c.
NW: UM 1274 precipitated withdrawal with one-hundredth
the potency of naloxone.
SUMMARY
See UM 1276
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UM 1276 NIH 9894 MCV 4247
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: Incanpletely active
and convulsive at
50 mg/kg
Nilsen:
(+)-2-n-Hexyl-5-(m-hydroxyphenyl)morphan
hydrochloride
DISPLACEMENT OF SPEREOSPECIFIC 3H-ETORPHINE BIHDING
+Na - N a +Na/-Na
EC 50 (M) 5.1 x 10-8 1.2 x 10-7 0.43
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM
EC 50 (M) Maximum Response (%)
Drug alone 2.5 x 10-5 100.0
After naltrexone unchanged unchanged
After UM 979 unchanged unchanged
The complete inhibition of the twitch of this preparation with
did not appear to be mediated by narcoticmsns.
UM 1276 occcurred at a very high concentration (10-4 M) and
INHIBITION OF TWITCH ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS
UM 1276 produced a slight (less than 10%) inhibition of the
twitch of this preparation at 3 x 10-9 M. At concentrations
of 10-6 M and greater the magnitude of the twitch was
increased.
OBSERVATIONS OF MORPHINE-DEPENDENT RHESUS MONKEYS
Doses studied: 0.3 to 5.6 mg/kg, s.c.
N W : UM 1276 precipiated withdrawal with one-thirtieth the
potency of naloxone.
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SUMMARY
UM 1273, UM 1274, and UM 1276 represent a novel set of
phenylmorphan narcotic antagonists capable of precipitating
withdrawal in the morphine-dependent monkey. As the alkyl
chain length is increased from three to seven carbons,
antagonist potency increases as does affinity for the narcotic
receptor. Each drug had low sodium ratio. Each compound also
inhibited the twitch of the guinea-pig ileum. Increases in
alkyl chain length were correlated with decreases in the
ability of the antagonists, naltrexone and UM 979, to
antagonize the actions of the phenylmorphans. The absence
of narcotic agonist activity in the mouse vas deferens is an
interesting feature of their spectrum of actions.
UM 1277 NIH 9901 MCV 4250
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: Insufficient activity
and convulsive at
50 mg/kg
Nilsen: Inactive at 50 mg/kg
d l-1-Methyl-4-cyclopropylmethyl-10-
hydroxy-2,3,4,5,6,7-hexahydro-1,6-
methane-1H-4-benzazonine
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC 50 (M) 6.9 x 10
-6 5.9 x 10-6 1.19
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM
At concentrations of 10-9 M to 3 x 10-5 M UM 1277 was
inactive. At 10-4 M, UM 1277 increased the magnitude of the
twitch.
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS
At 3 x 10-8 M, UM 1277 produced a slight (less than 10%)
inhibition of the twitch. At 3 x 10-5 M, there was a large
increase in the magnitude of the twitch. These effects were
not altered by either naltrexone or UM 979.
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OBSERVATIONS OF MORPHINE-DEPENDENT AND NON-DEPENDENT RHESUS
MONKEYS
Doses studied: 0.3 to 3.0 mg/kg, s.c.
S D S : UM 1277 neither suppressed nor exacerbated withdrawal
Signs. In addition the drug produced severe ataxia.
Nondependent subjects: Doses of either 1.0 or 1.7 mg/kg
produced ataxia, pupil dilation, and decreased
responsivity to observers and cagemates. These effects
appeared to be partly antagonized by naloxone (1.7 mg/kg,
s.c.
SUMMARY
See UM 1281.
UM 1280 NIH 9898 MCV 4249
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: Insufficient activity;
convulsions at 5.0
mg/kg
Nilsen: Inactive at 5.0 mg/kg
1,12 -Dimethyl-4-allyl-10-hydroxy-
2,3,4,5,6,7-hexahydro-1,6-methano-
1H-4-benzazonine
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC 50 (M) 3.4 x 10
-6 3.1 x 10-6 1.09
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM
At concentrations between 3 x 10-6 M and 3 x 10-5 M,
UM 1280 produced a small (less than 10%) inhibition of the
twitch that was completely antagonized by either naltrexone or
UM 979. At concentrations above 3 x 10-5 M, UM 1280
increased the amplitude of the twitch.
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INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS
UM 1280 did not inhibit the twitch at any concentration
studied. At 10-6 M and greater, UM 1280 increased the
amplitude of the twitch. Neither naltrexone nor UM 979
altered the response to UM 1280.
OBSERVATIONS IN MORPHINE-DEPENDENT AND NON-DEPENDENT RHESUS
MONKEYS
Doses studied: 0.1 to 1.0 mg/kg, s.c.
SDS: UN 1280 neither suppressed nor exacerbated with-
drawal signs in the monkey. Other effects included
ataxia, pupil dilation and decreased responsivity
to stimulation from observers.
Nondependent subjects: UM 1280 produced ataxia, pupil
dilation and decreased responsivity to external
stimuli. These signs were not reversed by 1.7 mg/kg
naloxone, s.c.
SUMMARY
See UM 1281.
UM 1281 NIH 9902 MCV 4251
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: No dose response
Nilsen: Inactive at 50 mg/kg
1,12 -Dimthyl-4-cyclopropyl,mthyl
hydroxy-2,3,4,5,6,7-hexahydro-1,6-
methano-1H-4-benzanine
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC 50 (M)
+Na
3.8 x 10-6
-Na +Na/-Na
3.6 x 10-6 1.05
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INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN GUIEA-PIG ILEUM
UM 1281 was inactive up to a concentration of 3 x 10-6 M
where it produced a small (less than 5%) inhibition of the
twitch. Both naltrexonee and UM 979 completely blocked this
effect. At concentrations of 10-5 M and higher the magnitude
of the twitch was increased.
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN MOUSE VAS DEFERNS
At no concentration did UM 1281 decrease the magnitude of
the twitch. At concentrations of 3 x 10-6 M and higher,
the magnitude of the twitch was. increased without changes
in baseline tension. Neither naltrexone nor UM 979 altered
the response to UM 1281.
OBSERVATIONS IN MORPHINE-DEPENDENT AND NON-DEPENDENT RHESUS
MONKEYS
Doses studied: 1.0 to 3.0 mg/kg, s.c.
SDS: UM 1281 neither suppressed nor exacerbated withdrawal
signs in the monkey but produced other effects including:
ataxia, pupil dilation, ptosis, and reduced responsivity
to external stimuli.
Nondependent subjects: UM 1281 produced ataxia, pupil
dilation, salivation, ptosis, and decreased responsivity
to external stimuli. There was a partial reversal of
these effects by 1.7 mg/kg s.c., naloxone.
SUMMARY
UM 1277, UM 1280, and UM 1281 are interesting structural
analogs of cyclazocine and SKF-10,047 with decreased affinity
for the opiate receptor and an elimination of antagonist
action.
447
UM 1322 NIH 9874 MCV 4230
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: No dose response
Nilsen: 19.8 (12.9 - 30.2)
17-cyclopropylmethyl-4,5 -epoxy-
6,6-difluoro-3-acetoxymorphinan
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC 50 (M) 2.1 x 10-9 4.2 x 10
-9 0.50
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM
EC 50 (M) Maximum Response (%)
Drug alone 2.6 x 10-9 45.9
After naltrexone 2.2 x 10-7 unchanged
After UM 979 2.0 x 10-8 22.9
At concentrations of 3 x 10-5 M and higher, UM 1322
increased the magnitude of the twitch.
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS
UM 1322 did not decrease the magnitude of the twitch; at
concentrations of 3 x 10-6 M and higher, the magnitude
was increased. Neither naltrexone nor UM 979 altered the
response to UM 1322.
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UM 1324 NIH 9961 MCV 4287 CHINA WHITE
MOUSE ANALGESIA, ED 50 (mg/kg)
Hot plate: 0.006 (0.004 - 0.009)
Nilsen:
1-(-Methyl-2-phenylethyl)-4-(N-
propranilido)piperidine
hydrochloride
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC 50 (M) 4.2 x 10-8 2.3 x 10-8 1.80
UM 1324 was unusual in that the slope of its concentration-
displacement curve was lower than most compounds that have
been studied. The heterogeneous log probit plot makes it
impossible to given exact EC 50 values.
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN GUINEA-PIG ILEUM
EC 50 (M) Maximum Response (%)
Drug alone (1) 9.0 x 10-12
3.1 x 10-7
61.6
Drug alone (2) 89.6 (28% further)
After naltrexone 1.5 x 10-7
6.2 x 10-8
unchanged
After UM 979 unchanged
UM 1324 was unusual in that it had two inhibitory effects the
first producing a 61.6 percent inhibition of the twitch and
the second, at higher concentrations, producing a further 28%
inhibition of the twitch. The results with the antagonists
suggest that they virtually abolish the inhibitory effects
obtained at low concentrations of UM 1324 but leave the
effects of higher concentrations unchanged.
INHIBITION OF TWITCH ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS
EC 50 (M) Maximum Response (%)
Drug alone 7.5 x 10-10 100
Drug naltrexone 5.6 x 10-8 unchanged
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After UM 979 2.2 x 10-9 unchanged
Both antagonists decreased the slope of the concentration-
effect curve.
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Use of Contingency Contracts in
Specialty Clinics for Cocaine Abuse
Antoinette L. Anker, Ph.D., and Thomas J. Crowley, M.D.
ABSTRACT
Animal research reveals that cocaine is a highly reinforcing
drug, and patients &scribe it as “compelling”; the drug maintains
vigorous self-administration behavior in animals and humans de-
spite its clear adverse effects. This suggests that the drug is
very difficult for experienced users to give up. It further sug-
gests a need for vigorous treatment to produce and maintain ab-
stinence, thus permitting patients to relearn drug-free behaviors
which are alternative to continued cocaine use.
This 12-month pilot study aimed to determine 1) whether cocaine
abusers would enter and remain in treatment, and 2) whether
contingency contracts appear to complement standard clinical
treatment in initiating and maintaining abstinence. We estab-
lished cocaine clinics in Denver and Aspen. Of the first 67
patients admitted into those clinics, 32 (48 percent) elected to
utilize contingency contracts. Thirty-one of those completely
abstained from cocaine use during the treatment. Of the 35
patients who did not elect to use contingency contracts, no one
remained abstinent and in treatment for more than four weeks.
The results indicate that cocaine abusers will enter treatment,
and that contingency contracting may contribute to a favorable
outcome.
INTRODUCTION
This pilot study demonstrates that users of a very popular and
highly reinforcing drug can be attracted into treatment, and it
suggests that contingency contracts may help these patients to
abstain from the drug.
Cocaine abuse has become a significant clinical problem in Colo-
rado. A 1979 Colorado survey estimated that cocaine had been
consumed at least once in the previous year by 5.5 percent of the
12-and-older population (Booth, 1979). Seven percent had used
cocaine in the Denver metropolitan area, and 26 percent had used
452
the drug during the previous year in the region of the major ski
resorts. Of these Colorado users, over 75 percent reported mod-
erate to severe problems related to their use. CODAP reports
that 4.4 percent of 1980 (January-September) admissions to drug
abuse programs nationwide were cocaine abusers; as compared to
1.7 percent in 197% Colorado cocaine admissions were 14.0 percent,
and in the Denver area they were 18.2 percent (NIDA, 1980). Den-
ver had the highest incidence of cocaine admissions of all cities
reporting; Miami was second highest with 12 percent.
Nationally, a trend of increasing cocaine abuse is also evident.
In 1975 CODAP reports (Thomas Coughlin, NlDA, personal communica-
tion, April 1981 that there were 2,195 patients admitted to
treatment for cocaine abuse; in 1980 that figure rose to 11,110
(an increase of 500%). The 1979 national survey on drug abuse
(Miller, Cisin, 1979) indicated that 28 percent of young adults
had used cocaine at some time in their lives as opposed to ap-
proximately 3 percent in 1967. Moreover, about 46 percent now
feel that they have an opportunity to use this drug, as opposed
to approximately 6 percent in 1967. Thus, exposure to cocaine
is quite common--a worrisome trend if the drug is likely to be
repeatedly self-administered by those exposed to it.
Cocaine does vigorously reinforce self-administration behavior in
animals, with dire consequences for the organism. Deneau et al.
(1969) demonstrated that monkeys with unlimited access to cocaine
overdosed and died within 30 days. Similarly, Wilson (1970),
Pickens and Thompson (1968), Woods and Schuster (1968), and Gold-
berg and colleagues (1970, 1979a, 1979b, 1976) demonstrated that
cocaine potently reinforced self-administration behavior. There
is some evidence that certain monkeys which fail to self-adminis-
ter opioids or amphetamine-like drugs will work for cocaine in-
jections (Young, Woods, 1980).
The potency of cocaine as a reinforcer of self-administration be-
havior suggests that patients might be unlikely to seek abstinence-
directed treatment for cocaine abuse before they suffer severe
consequences, and it further suggests that during treatment pa-
tients might have difficulty in remaining abstinent. Moreover,
medical treatments comparable to methadone maintenance are not
available for cocaine abuse; studies of lithium blockade of the
cocaine high (Resnick, et al., 1977; Cronson and Flemenbaum,
1978) have not supported the initial optimism with which this
treatment was recommended. Although there is some reason to be-
lieve that alpha-methylparatyrosine might reduce stimulant self-
administration (pickens, et al., 1968), this drug probably is not
safe enough for wide clinical use. Therefore, it seems especially
important to develop psychological techniques for treating cocaine
abuse. But we are unable to find any controlled research assessing
the efficacy of psychological interventions for this problem.
The behavior of drug ingestion, like other behaviors, appears to
occur more or less often depending upon the events which regularly
follow it. The frequency of the behavior is controlled by the
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consequences of the behavior (Skinner, 1954). An agreement be-
tween a patient and therapist to change drug abuse behavior by
having the therapist deliver certain consequences, or “contingen-
cies” upon drug use is termed “contingency contracting”. The
usefulness of contingency management procedures has been demon-
strated for a variety of behavior settings and circumstances, for
example, abstinence from smoking (Elliott, and Tighe, 1968;
Winett, 1973), drug use (Liebson et al., 1973, 1978; Baldridge et
1974; Stitzer et al., 1977, 1979a, 1979b; Yen, 1974; Hall et
al., 1977: Bigelow et at., 1976, 1980) and alcohol use (Miller,-
1974, 1975; Cohen et al., 1971; Griffiths, 1978; Bigelow et al. ,
1975; Hunt and Azain, 1973). These numerous controlled reports
have been done in hospitalized research subjects, or in small
numbers of patients using, for example, ABA designs. Boudin (1972)
and Boudin et al. (1977) also report application of these tech-
niques to a general population of drug users in a substance abuse
clinic.
The present pilot study examined the hypotheses that cocaine
abusers, despite the reinforcing properties of the drug, could be
drawn into treatment and that outpatient contingency contracting
could be useful in securing abstinence.
METHODS
We established cocaine clinics in Denver and Aspen. Patients were
recruited through news media, professional referrals and educa-
tional presentations. Persons over the age of 18 with a DSM III
(American Psychiatric Association, 1980) diagnosis of cocaine
abuse were eligible for admission. We excluded individuals who
consistently were psychotic or who had a previous history of
schizophrenia, manic-depressive illness, or chronic organic brain
syndrome.
All patients were offered standard clinical treatment and the ad-
ditional option of using contingency contracts as an adjunct to
therapy. Standard treatment was: 1) brief hospitalization if
indicated; 2) psychological, and, as indicated, medical evaluation;
3) weekly individual psychotherapy; 4) family and couples therapy
as is standard in our clinics; 5) urine collection and analysis;
6) education and consultation; 7) interagency referral; and 8)
after care/follow up. Contingency contracts included two basic
elements: 1) agreement to participate in a urine monitoring
program, and 2) attachment of an aversive contingency to either a
cocaine-positive urine report or a failure to produce a scheduled
urine sample. Aversive contingencies were derived from patients’
own statements of the adverse consequence which they expected to
result from continued cocaine use. In order to make that adverse
effect a more potent deterrent to drug use, we used the contract
to “reschedule” (Kelleher, Goldberg, 1976) the adverse effect to
occur at the very next use of cocaine.
The following case report illustrates our method.
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Case
A 33-year-old married white male Certified Public Accountant (CPA)
injected 3-5g of cocaine daily for 18 months. He had spent about
$100,000 on cocaine. His wife threatened divorce if he didn’t ab-
stain, and when he entered treatment she was planning to leave
him. His independent business was failing because of the patient’s
inability to concentrate, poor memory, mood fluctuations, and
binges with failure to produce promised work, and because of sig-
nificant debts and embezzelment of company funds. The patient
anticipated losing his house, land, and business. His mood was
extremely &pressed; affect was blunted. His paranoid thinking
persisted beyond each cocaine intoxication. He expressed feelings
of guilt, remorse and suicidal ideation. In sum, he stated that
the risks of continued cocaine use included career, financial,
family, and personal loss.
Although these risks and impairments were obvious to the patient,
he still was ambivalent about giving up the drug because he “loved
it” and “needed it”. He had made several attempts to abstain in
order to avoid impending loss, but each time he had resumed using
the drug within two weeks.
He now was convinced that he had to abstain and that he needed
help to do so. He was sure that continued cocaine use would lead
to eventual revocation of his CPA certification. We suggested
that he write a letter to the State Board of Accountancy, ex-
plaining in the letter that he had been abusing cocaine, that he
had entered a stringent outpatient program, but that he had failed
to abstain (jeopardizing his professional performance), and that
he therefore was surrendering his certification. He deposited
this letter with us. In a written contract he directed us to col-
lect frequent, random, observed urine samples for six months; the
contract also directed us to mail the letter in the event of a
cocaine-positive urinalysis or a failure to appear for a scheduled
urine sample.
During a six-month period of abstinence the patient was engaged in
regular individual psychotherapy and intermittent couples psycho-
therapy. He and his wife have negotiated terms for continuing
their relationship and for relocating the family and business.
Work productivity increased and the bulk of past-due debts were
paid, thus avoiding foreclosure on his properties. Psychological-
ly, the patient reports that symptoms of depression and paranoia
are “much relieved”. He states that he finds no loss associated
with discontinued use of cocaine but recognizes numerous beneficial
Changes. At the end of his six-month contract, the patient elected
to utilize a contract for another six months to ensure “separation”
from the drug. It appears that the reinforcement associated with
an abstinent life may be exerting more control over his behavior
than the reinforcement of cocaine self-administration.
Some patients believed that continued use would lead to arrests
or other legal actions; they have written and deposited with us
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letters informing the District Attorney or Drug Enforcement Admin-
istration of their drug use. Others have determined that jobs
were at stake and have written and deposited with us letters in-
forming their employers of cocaine use. Still other patients
felt that continued use would lead to loss of income or loss of
property; these patients directed us to transfer a large sum of
money or a deed for property (deposited with us) to charities in
case of resumed drug use. Each punishment was individually de-
termined, based on the patient’s assessment of those adverse con-
sequences, unique to him or her, associated with continued use.
Each contract was written for a specified period of several
months and directed us to apply the adverse contingency if both
halves of any divided urine sample (a protection against labora-
tory error) were cocaine-positive, or if the patient failed to
appear for a scheduled urine test.
RESULTS
Our cocaine clinics admitted 67 patients in 12 months. The aver-
age age of the patients was 28.8 (R=19-42) years. Seventy-five
percent of the patient population was male. Marital status in-
cluded 42 percent single, 22 percent married, 27 percent divorced,
and 9 percent separated. Most patients were employed (72 percent),
and the mean educational level was 14.2 years. The group included
two Blacks, one Chicano, and 64 non-Hispanic Whites. In general,
this sample appeared to be more educated, more Anglo-White, and
more affluent than our program’s population of opioid users.
Our patients refer to cocaine with such comments as “I love it”,
“giving it up would be like losing my best friend”, “it grabs me
by the balls, and won’t let go”, and “it is the most compelling
experience I have ever had”. Such statements suggest the rein-
forcing ability of the drug, which drives continued self-admin-
istration despite the clear adverse effects reported by the pa-
tients, including: endangering of successful professional prac-
tices, auto accidents during intoxication, significant personal
losses, expenditures for the drug up to $180,000 in six months,
loss of business and property because of drug expenses, legal
involvement, major psychological dysfunction (depression, delu-
sions, hallucinations, and organic confusion), and physical ef-
fects including nasal and sinus problems, headaches, tremors,
and seizures. Thus, this pilot project demonstrates that seriously
dysfunctional patients will enter outpatient specialty clinics for
the treatment of cocaine abuse, despite the very attractive qual-
ities of this drug.
Thirty-two of these 67 patients entered contingency contracts with
seriously punishing consequences, agreeing that the threat of a
potent, immediate punishment would help to counter the drug’s re-
inforcing effects, which compel repeated self-administration.
Although 52 percent of our 67 patients refused contracts, Figure
1 illustrates that the percentage of patients signing contracts
has increased from 18.2 percent of our first 22 patients to 76.2
percent of our last 21 patients.
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FIGURE I
PERCENTAGE OF PATIENTS SIGNING CONTRACTS
(by consecutive admissions)
Of the 32 patients with contracts, 31 have continued to produce
cocaine-free urines, have appeared regularly for urinalysis, have
regularly participated in psychotherapy sessions, and have not
used cocaine. The 32nd patient did use cocaine, voluntarily told
his employer of his drug use (this was the contingency), and im-
mediately entered a residential treatment program. After dis-
charge from the program, that patient signed another contingency
contract with us and now remains abstinent in treatment. The pro-
found reduction in cocaine use among this group of daily or almost-
daily users suggests a powerful therapeutic effect associated with
the contingency contracting procedure.
Patients who chose to use a contract could designate 1) whether to
include drugs in addition to cocaine and 2) the duration of the
contract period. The mode was three months; however, many of
those who originally opted for three months requested extensions
of an additional three months.
to remain abstinent for a year.
Several patients have contracted
The duration of the contract and
abstinence is typically three to six months.
No one in the contract group left treatment prior to a mutual de-
cision to terminate. Approximately 81 percent of the 32 patients
who signed contracts remained in treatment and abstinent for three
or more months. (See Figure 2.) Although there was only one
“failure,” two patients signed one- and two-month contracts, and
three patients moved for reasons of employment. Of the patients
who used contingency contracts as an adjunct to their treatment,
five have been discharged by mutual agreement. One of these five
patients returned to treatment because he had resumed cocaine use
three months following discharge. Follow-up contacts indicate
that the other four discharged patients remain abstinent for up
to six months after treatment.
Thirty-five patients refused contracts. Twenty-nine of them
dropped out of treatment within five visits most of these within
one or two visits. Only 8.6 percent of the non-contract patients
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remained in treatment and abstinent for four weeks. Of the pa-
tients who continued in treatment without a contract, the longest.
duration of abstinence was four weeks and the longest duration in
treatment was two months.
FIGURE 2
PERCENTAGE OF PATIENTS
REMAINING IN TREATMENT AND ABSTINENT
DISCUSSION
The first goal of this pilot project was to determine whether an
outpatient specialty clinic could attract severely dysfunctional
cocaine abusers. The project clearly succeeded in this effort.
Our second goal was to make a preliminary, open-design assessment
of the apparent efficacy and safety of contingency contracting to
secure abstinence in these patients. It appears from these re-
sults that among a group of daily or almost-daily cocaine users
entering a specialty clinic, over 75 percent may agree to a pro-
perly presented contingency contract which provides severely
punishing, individualized consequences for further cocaine use.
Moreover, it appears that nearly all of those entering such a
contract will abstain for a lengthy period of time while they
engage in therapy aimed at promoting long-term abstinence. Our
results further indicate that those who do not enter such a con-
tract may have a much less favorable prognosis.
The clinical problem as we see it with these patients is to
avoid early relapses which frequently result in termination from
treatment; with the contracts, patients abstained and remained
in treatment long enough for them to redevelop rewarding cocaine-
incompatible behaviors which could then sustain choices for con-
tinued abstinence. We assisted patients in redeveloping cocaine-
incompatible behaviors through counselling to increase contacts
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with non-using friends, elimination of paraphernalia and drug
stashes, termination of relationships with dealers, changing phone
numbers or addresses (as needed) to stop drug-related calls and
visits, counselling with spouses, and psychotherapy as needed
around related problem areas in the patient's life.
Of course in this uncontrolled pilot project, self-selection may
have affected outcome. Conceivably, patients who were more moti-
vated to abstain also were more willing to sign the contingency
contracts, resulting in more favorable outcomes among those who
entered the contracts. Omly a controlled study with random as-
signment to contract vs. non-contract treatment groups can defi-
nitely settle this point. But there is an indication that self-
selection is not the main factor determining the different out-
comes in our clinic. We may assume that there were about equal
proportions of well- and poorly-motivated patients in the first
one-third, second one-third, and third one-third (Figure 1) of
our admissions. Many more of our later patients, however, signed
contracts, presumably because of our increasing skill at pre-
senting the contracts. If motivation level had been the important
determiner of outcome, outcome probably would have been similar
in the three subgroups. But in fact, signing the contract seems
to have been the important determiner; almost all signers ab-
stained, and outcome in the three subgroups varied with each
group's proportion of signers.
Despite the drastic nature of the contingency contracts, the risk/
benefit ratio seems to be favorable; only one of the patients has
undergone loss or embarrassment as a result of entering a contract,
and the medical and psychological health of patients has improved
considerably with sustained abstinence. However, controlled re-
search still is needed to demonstrate definitively that the bene-
fits do outweigh the risks in this drastic treatment, which does
put patients at risk of loss or embarrassment.
References will be furnished upon request.
ACKNOWLEDEMENT
Supported in part by grants DA-07043 and DA-02386 from the
National Institute on Drug Abuse, U.S. Public Health Service
AUTHORS
Antoinette L. Anker, Ph.D.
Thomas J. Crowley, M.D.
Addiction Research and Treatment Service
Department of Psychiatry
University of Colorado School of Medicine
Denver, Colorado 80262
Send reprint requests to Dr. Crowley
459
A Comparison of Urine Collection
Schedules with Different Predic-
tability in a Methadone Clinic
Carol-A. Atkinson, Ph.D., and Thomas J. Crowley, M.D.
Urinalysis data are the most valid indicators of patients’ actual
drug use and as such can provide useful information to the clin-
ician. Marks et al. (1969) and Nightingale et al. (1972) have
suggested, that these data can also encourage client’s abstinence
from illicit drug use and symbolize the clinician’s concern about
the client’s progress. Such data can also provide an important
measure of treatment program efficacy. To achieve maximum validity
observed urine specimens would have to be collected from every
patient daily. That was actually done at many clinics in the early
1970’s when methadone maintenance was a relatively new treatment
for opiate abuse, but the cost in staff time and laboratory fees
was enormous, and most clinics have gone to less rigorous, less
costly procedures.
Goldstein and Brown pointed out in 1970 that random urine collec-
tion schedules provide the most reasonable alternative to daily
collection. Because these schedules are unpredictable, they mini-
mize the possibility that the patient who continues to abuse drugs
will be able to avoid detection. Random schedules also allow the
clinic staff to decide on the level of certainty of detecting illi-
cit drug use they are willing to accept and set the schedule inter-
val accordingly.
Harford and Kleber presented a dramatic example of the comparative
efficacy of fixed and random urinalysis schedules in 1978, when
they published a retrospective study of the effects of a switch
from a fixed interval schedule to a random interval schedule. They
examined urine data collected in a clinic in New Haven, Connecticut,
from January 1970 to July 1975, and compared the percentage of
morphine positives detected each month for 11 months before the
change to a random schedule and for 56 months after. In the first
month after the change in schedules the percentage of morphine
positives detected rose from 2.4% to 6.8% of all urines analyzed.
In the following 55 months the rates dropped dramatically. In only
three of those months did the rates equal or exceed the lowest rates
detected on the fixed interval schedule. They assumed the rate of
opiate use was reduced by increasing the probability of detection
Supported in part by Grants DA-07043 and DA-02386 from NIDA USPHS.
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and the application of clinical sanctions such as revocation of
take-home medication privileges and the threat of termination from
treatment. Unfortunately, there are two serious weaknesses in the
Harford and Kleber study. Their hypothesis that the random sched-
ule accounted for the steep increase in the percentage of morphine-
positive urines detected does not explain the high rates which were
detected on the fixed-interval schedule six months before the
schedule change. Secondly, there was no concurrent control group
available for comparison of the efficacy of the two schedules.
We have shown that supply interdiction can produce a long-lasting
decrease in percentage of detected opiates comparable to the de-
crease presented by Harford and Kleber (Atkinson, 1981). Without
a control group, causal factors other than the schedule and clin-
ical sanctions cannot be ruled out. It was because of these weak-
nesses that we undertook two prospective studies of a urine sched-
ule change using a control group.
The urine-collection schedule in use at our clinic in Denver was a
variation of a random schedule which included “safe periods,”
periods when the probability of detection of illicit drug use was
close to zero. Clients were randomly assigned to one of five
urine groups at admission. The groups were randomly assigned each
week to give specimens on one weekday. For example, clients in
group 1 night be assigned to give on Tuesday, groups 2 and 3 on
Monday, group 4 on Thursday, and group 5 on Wednesday. Specimens
were collected only once each week from every client, so after a
client had given a specimen, he/she was safe from detection until
the following week. It seemed likely that the “safe period” would
allow clients to use illicit drugs without detection and cause us
to underestimate actual drug use among our patients. We decided,
therefore, to change all methadone patients to individually ran-
domized schedules in a stepwise procedure which would both ease the
administrative difficulties of the change and allow us to monitor
the effects of the change.
METHOD
Eligibility for methadone treatment is determined by federal cri-
teria, and no one who was in treatment and required to come to the
clinic daily was excluded from the study. Two samples were drawn
from among these patients. Clients in one sample were assigned to
a new random-schedule group. Clients in the other sample remained
on their usual urine schedules and served as a control group. The
random schedules had a maximum interval of 11 days and an average
of 7 days. Schedules were individualized and specimens were col-
lected seven days per week. Data were gathered for three months
before the end of the three-month post-change period were dropped.
The final sample sizes were 15 clients in the regular-schedule con-
trol group and 18 in the random-schedule group.
Urine specimens from this clinic are analyzed at the Colorado De-
partment of Health laboratory. They are routinely screened for
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opiates, amphetamine, barbiturates, and cocaine using a combined
EMIT (Enzyme Multiple Immunoassay Technique, The CIVA Co.) and
thin-layer chromatography procedure developed, at the laboratory
(Wislocki, et al. , 1974) and revised in 1979. Turn-around time
for urine specimens averages three days.
RESULTS
An average of 225 patients are in treatment at our clinic each
month; of these approximately 152 receive methadone. The average
dose is 35 mg. Most clients are in the 20 to 35 age range and 66
percent are males. Approximately 42 percent are Anglo, 23 percent
Black, and 32 percent Hispanic. Patients in the random-schedule
group had an average age of 32; 22 percent were Black, 33 percent
Anglo, and 44 percent were Hispanic. There were eleven males and
seven females. The average number of years since first opiate
addiction was 9.9, with a range of 2 to 29 years. The average age
of the regular schedule control group was 30; 20 percent were
Black, 46 percent Anglo, and 33 percent were Hispanic. There were
seven males and eight females in this group. The average number of
years since first opiate addiction was 9.8, with a range of 2 to 23
years.
It was anticipated that there would be no difference between groups
in frequency of opiate-positive urines before the implementation of
the random schedules and that there would be an increase in the
number of detected opiates in the random-schedule group after the
change. The results are shown in Figure 1.
FIGURE 1
Number of opiate urines detected from two groups of clients
before and after October 3lst, when the random-schedule
group was placed on individually randomized schedules.
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There was a consistent, but non-significant, difference between
groups before the change in schedules with somewhat more opiates
detected in specimens from the random-schedule group. The in-
crease noted by Harford and Kleber (1978) in the number of opiates
detected with the random schedule failed to occur in our sample.
The percentage of clients responsible for opiate urines is shown
in Figure 2. Again it can be seen that the random schedule failed
to detect opiate use differentially.
FIGURE 2
Percentage of clients responsible for opiate-positive urines
before and after October 31st, when the random-schedule group
was placed on individually randomized schedules.
In a second study beginning in December 1979, clients admitted to
the clinic, who qualified for methadone treatment by federal cri-
teria were alternately assigned to the random-schedule group or
one of the regular treatment groups. Since all new patients are
required to come to the clinic daily, there were no exclusions. A
total of 121 clients were admitted, of whom 59 were assigned to
the randon-schedule and 62 to the regular-schedule urine groups.
Again schedules were individually randomized for each client in
the random group and those patients were at risk to give specimens
seven days per week. The regular-schedule group continued, as
before, to have predictable “safe periods” following urine col-
lection. The two groups were comparable in age, average number of
years since first opiate addiction, sex, and ethnic composition.
The number of specimens containing illicit opiates detected from
clients on the random and regular schedules from time of admission
are shown in Figure 3. Contrary to our expectation, more opiates
were detected on the regular schedule in seven of the ten months.
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FIGURE 3
Number of opiate-positive urine specimens collected from
patients admitted to methadone treatment, January through
October, 1980. Clients in the random-schedule group were
placed on individually randomized schedules at admission.
Clients in the regular-schedule group were placed on semi-
random schedules with known “safe periods.”
DISCUSSION
The basic assumptions underlying the urine studies cited here is
that drug abusers attempt to conceal their drug use in or&r to
avoid clinical sanctions, and minimizing predictability of urine
collection schedules &creases their ability to avoid detection.
It was assumed that patients in the Harford and Kleber study had
been avoiding detection by abstaining from drugs for 36 to 48
hours before giving a urine specimen, or employing some other
method to avoid detection when the schedule was predictable.
When the random schedule was instituted they were no longer able
to predict when they would have to give a specimen, and the number
of opiate-positive urines detected increased. The number then
dropped as the contingencies were enforced, either because pa-
tients quit using opiates to avoid the sanctions, or because those
who did not were dismissed from treatment, or both. Another pos-
sibility, as mentioned above, was that the change in the number of
detected opiates was the result of factors not considered in their
study.
Based on the above assumptions we assume that the change to a ran-
&m schedule at our clinic did not affect the number of dirty
urines detected in our clinic because the contingencies were not
strong enough to alter patients’ behavior; neither the rewards for
abstinence, e. g., verbal reinforcement from the counselor and
take-home privileges after four months of abstinence and six months
of treatment, nor the punishment, delay of take-home privileges,
were effective. That is, the number of detected opiates did not
change with the institution of a schedule without “safe periods”
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because the patients were not bothering to avoid detection in the
first place.
The only tangible reinforcement for abstinence in most methadone
clinics is the take-home methadone dose. Typically this rein-
forcement is not available until the patient has been abstinent
for months. The patient finds him/herself in a position of choosing
between the immediate reinforcement of using an opiate and the long
delayed take-home medication privilege. It is not surprising that
many habitual drug abusers choose the immediate reinforcement.
Clinical sanctions such as reduction of dose and discharge from
treatment may have a stronger effect than the take-home privilege
reinforcement, but many programs are unable to effectively use
these sanctions because of census/funding problems, or treatment
philosophy. A comparison of the efficacy of sanctions and rein-
forcements in methadone treatment is an interesting possibility for
future research.
Havassy and Hall (1981) suggested that urinalysis is ineffective
in reducing opiate abuse among methadone patients. They seem to
view urinalysis as a treatment rather than a treatment tool. We
believe that urinalysis is a vitally important tool which must be
used therapeutically with immediate rewards and sanctions contin-
gent upon the results of the analyses.
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Depression in Pregnant Drug-
Dependent Women
Dianne O’Malley Regan, R.N., M.S.W., Betty Leifer, M.A.,
Theresa Matteucci, B.S., and Loretta P. Finnegan, M.D.
Family Center is a multidisciplinary program which provides com-
prehensive medical and psychosocial services to pregnant drug-
abusing women. Outpatient prenatal care for these high-risk
patients is provided, and intensive social and/or psychiatric
services are provided for these women on an individual, family,
or group basis. Our present patient population is 65 percent
black, 35 percent white; their average age is 28.8 years; and
90 percent of the clients receive welfare and/or medical assist-
ance.
It was clinically observed that our clients, particularly heroin
addicts, appeared to be depressed on admission for detoxification
from opiates and other drugs such as barbiturates and diazepam.
Clients transferred from other methadone programs also demon-
strated signs and symptoms of depression.
Data were collected in order to be able to evaluate levels of
depression existing among pregnant drug-dependent females ad-
mitted to our program during 1979 and 1980. The 13-item Beck
Depression Inventory (Beck et al., 1974) as well as the Profile
of Mood States (POMS), which measures depression, tension, anger,
vigor, fatigue, and confusion, were utilized. A violence ques-
tionnaire is also routinely administered to Family Center clients
in order to measure the presence of possible sexual or physical
abuse in the clients" lives. Clients are also routinely evalu-
ated on admission by our program psychiatrist.
SYMPTOMS OF DEPRESSION
De ressive symptomatology includes: 1) a change in mood, in-
volving feelings of sadness, apathy, and/or loneliness; 2) a
negative self-concept with feelings of guilt, self-blame, or
reproach; 3) a loss of interestin usual activities, including
sex, and a general loss of energy; 4) problems with sleeping
and/or eating (an increase or decrease in weight may occur);
5) poor concentration; 6) psychomotor retardation or agitation
(Rosenfield, 1980).
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METHODOLOGY
The Beck and POMS questionnairs were self-administered by all
pregnant women admitted to our program during 1979 and 1980.
A comparison group of pregnant women, presumably drug-free, who
were enrolled as patients in the prenatal clinic of Thomas
Jefferson University Hospital in 1981, were used as controls.
The Family Center researcher obtained volunteers, explaining the
interest in studying the mental attitudes of pregnant women.
Anonymity and confidentiality were guaranteed, and written per-
mission was obtained. The Beck Depression Inventory and the
Profile of Mood States (McNair, et al., 1971), as well as a
questionnaire on violence, were self-administered.
The purpose of this paper is to present information on the pre-
valence of depression among drug-abusing women and to evaluate
the hypothesis that this patient population has a higher rate of
depression than that found among the general population and metha-
done-maintained males. In addition, a number of other variables
with respect to the presence or absence of depressive symptoma-
tology were evaluated. The negative effects of depression on
parenting and as a factor in continued illicit drug use are
discussed, as are differentials with respect to marital status.
RESULTS
Of 84 multiparous women admitted to the Family Center Program in
1979 and 1980, 75 percent reported varying levels of depression
as measured by the Beck Depression Inventory. The average Beck
score was 9.8 with a standard deviation of 6.6. Using the fol-
lowing scores, patients were divfded into four depression-level
groups: 0-4 = none or little; 5-7 = mild; 8-15 = moderate;
16+ = severe. The results were as follows: 19 percent of the
women had mild depression; 37 percent were moderately depressed;
and 19 percent were severely depressed.
Because of the high correlation observed between Beck and POMS
scores (Oehlberg et al., 1980), analysis of depression was focused
on the results of Beck scores rather than multiple scoring systems.
An analysis of the women was done to see if current
placement of children with relatives or in foster care was a
factor. There was a significantly* higher incidence of moderate
or severe depression among' the drug-busing women whose children
were in placement as compared to women whose children lived with
them. Placement of children appears to be a factor in depression
and/or may be one factor which contributed to the necessity for
placing the child. It is difficult, however, to ascertain whether
child placement is an antecedent or consequential variable.
*An Analysis of Variance was performed on the Beck scores resul-
ting in F = 8.8 at df = 82 and p. < .O1.
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No significant differences were found in depression levels in our
population when they were differentiated according to race or
marital status. This lack of difference is surprising in light
of present knowledge about the prevalence of depression in various
marital-status groups, especially the well-documented findings
of "marital protection" as found in Gove (1977).
CONTROLS VERSUS FAMILY CENTER CLIENTS
As previously stated, the current investigation includes the
gathering of information about depression from a control group
of 26 pregnant women with similar socioeconomic status and who
reported no current drug use.
Results‘of a comparison between the control and drug-abusing
groups do indeed provide us with evidence of depression differ-
entials. While 50 percent of the controls exhibited Beck scores
of 5 or more, 75 percent of the Family Center patients reported
feelings of depression resulting in Beck scores of 5 or more.
As reported in the previous section, the average Beck score for
the Family Center patients was 9.8 (SD=6.6). The average Beck
score of the control group was 6.3 (SD=5.6). Performing an
analysis of variance on the scores resulted in a significant
difference with p < .05 (F = 5.72).
It must also be kept in mind that the control group consists of
volunteers. The fact that they have volunteered to provide us
with information on their emotional well-being may indeed be a
bias, the direction of which can not be ascertained.
DISCUSSION
Depression in Drug-Abusing Populations
The 56-percent moderate and severe depression rate found in Family
Center Program clients is consistent with the depression rate in
a study done by Dorus and Senay (1980) on 432 male and female sub-
stance abusers. This study found that on admission 46 percent
of the subjects reported moderate or high levels of depression
on the Beck while female subjects were significantly more (57
percent) depressed than male subjects as measured by the Beck
and Hamilton scales. It was also shown that education level was
inversely proportional to Beck-Scale depression levels; i.e., the
subgroup with the largest percentage of high depression scores
(26 percent) was the least educated. Also, a larger proportion
of moderate and high depression scores were found among the
younger clients (56 percent) (Dorus and Senay, 1980). Addi-
tionally, the group of subjects who had the least occupational
skills were the most depressed. Dorus and Senay found that there
was an apparent improvement in levels of depression in all groups
eight months after admission, but "substantial numbers of sub-
jects remained clinically depressed throughout the study" (Dorus
and Senay, 1980).
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The high rates of depression found in the Family Center clients
and in the Dorus and Senay study of substance abusers were also
found in a study of 106 methadone-maintained men in a New Haven
drug-treatment program (Weissman et al., 1976). The authors
found that about one-third of the men were moderately to severely
depressed as assessed on standard rating scales for depression.
The authors felt the subjects were clinically depressed and not
suffering from withdrawal since they were already stabilized on
methadone prior to the interviews.
The high rates of depression found among drug users, particularly
in opiate-dependent populations, may represent the "drug effect"
since "chronic opioid use results in increased feelings of dysphoria
and depression" (Dorus and Senay, 1980). However, our study in-
dicates that loss of children by placement may be a contributing
factor in our female substance-abusing population at Family Cen-
ter Program. The 2:1 sex ratio (female to male) of depression
in drug abusers is consistent with the sex ratio of depression
found in the population at large in the United States and is
"fairly consistent over time" (Weissman and Klerman, 1977).
Other countries report a similar preponderance of female depres-
sion "with the exception of a number of developing countries such
as India, Iran, New Guinea, and Rhodesia" (Weissman and Klerman,
1977). These exceptions may be due to the decreased availability
of medical care in third-world countries.
Theories of Female Depression
There are multiple theories extant which attempt to explain the
higher prevalence of depression in women which range from the
belief that the rates are a reporting artifact to a belief that
female endocrinology is a factor in depression.
The preponderance of women among depressed patients
is a real finding rather than an artifact of reporting
(Weissman and Klerman, 1977).
Post-partum depressive changes do frequently occur, and
there is overwhelming evidence that the longer post-par-
tum period (up to 6 months) carries an excess risk for
more serious psychiatric disorders (Weissman and Klerman,
1977).
Married women have higher rates of depression than mar-
ried men (Gove, 1977).
Reporting artifacts include the evidence that women
obtain medical care more frequently than males and
therefore are more likely to be diagnosed.
In addition, the marital differentials could be due to
a selection process in which depressed/ill females are
more likely to marry under the classical sex-role circum-
stance in which the male is the caretaker. Depressed or
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mentally ill males, not able to assume the "head of
household" role, would then marry less frequently.
Married females exhibit less evidence of mental ill-
ness than single (never married) females (Gove, 1977).
A psychosociological explanation for the increased pre-
valence of depression in women is that the disadvantaged
status of women "makes it difficult for them to achieve
mastery by direct action and self assertion...These
inequities lead to legal and economic helplessness,
dependency on others, chronically low self-esteem,
low aspirations, and ultimately, clinical depression."
(Weissman and Klerman, 1977).
The presence of high levels of depression in pregnant, addicted
women may be multiply determined by biosocial psychological fac-
tors. Addicted women have low levels of self-esteem, high levels
of anxiety, as well as depression and fewer social supports than
control groups of non-addicted women and addicted men (Reed,
1977). Addicted women show a greater adherence to traditional
sex-role ideology than non-addicted women. They share with ad-
dicted men traditional ex ectations
feelings of dependency toward men but also expressed the alter-
labor. Reed et al. (1977) found that addicted women expressed
for sex-based divisions of
native view that women are strong, while men are weak. Addicted
women are therefore in a bind, since they are dependent upon the
males, whom they mistrust. The drug subculture is male-dominated
and, in many cases, the women are abused by their spouses or
partners who may also be drug-dependent. Addicted women are
also more responsible for their children than male addicts are,
which can increase their levels of stress. Another factor which
may account for the depression levels of our client population
is their high level of unemployment. Employment outside the
home seems to have a positive effect on depressed women and helps
them to feel more able to cope with the stresses of daily life.
It should also be noted that there is a high degree of association
between low educational levels and unemployment. For the most
part, the Family Center patients are not high-school graduates.
Depression and Parenting
In a 1955 retrospective analysis of clinic records from a child-
guidance clinic, there was evidence of maternal depression in
one-third of the mothers (Fabian and Donohue, 1956). The authors
speculated that the children had been vulnerable to the effects
of maternal depression at a-critical juncture in their lives and
were evidencing dysfunctional behavior as a response to their
mothers' depression.
The high rates of depression found in pregnant women admitted to'
our program compounds the difficulty in attaching to an infant
who is being treated in the intensive care nursery for neonatal
abstinence syndrome (NAS) secondary to maternal drug use. In
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addition to the guilt the women feel regarding drug use, some
of the women have children in placement and may be in mourning
for these children. Due to unresolved mourning, the women may
experience difficulty in attaching to a new baby. The attachment
process is further complicated by the long course of therapy
necessitated by treatment for neonatal abstinence syndrome. A
child who is ill from the effects of prescribed methadone or
illicit maternal drug use is a subtle or overt rebuke to the
mother's sense of herself as a good person. The distressed
mothers report: "I know the baby is sick because of what I
took and I feel so guilty about it."
Depression, as well as drug-related dysphoria, may cause irrit-
ability in the mother in addition to anger toward her infant, a
feeling most women have difficulty in acknowledging. Continued
maternal depression over time can also have a devastating effect
on the mother-child interaction unless there is intervention or
dilution of this too intense or too distant relationship by other
interested family members or a surrogate parent. Neglect or abuse
may also occur in the context of drug use and depression.
In summary, the presence of depression in pregnant drug-abusing
women is a significant problem and needs to be addressed as early
as possible in the pregnancy so that maternal depression may not
distort the quality of attachment in the neonatal period and the
long-term parent/child relationship.
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LAAM Instead of Take-Home
Methadone
Richard B. Resnick, M.D., Arnold M. Washton, Ph.D., John
Garwood, M.D., and Joseph Perzel, Psy.D.
INTRODUCTION
A public health problem of major concern about methadone mainten-
ance treatment is widespread diversion of take-home methadone doses.
LAAM (levo-alpha acetylmethadol) is a long-acting opioid that of-
fers a viable alternative to daily methadone ingestion for many
patients (Klett 1978, Ling et al. 1976, Resnick et al. 1976). Sup-
ervised administration of LAAM three times per week in the clinic
allows maintenance of the opioid-dependent patient without take-
home doses.
One approach to curtailing methadone diversion might be to restrict
or eliminate take-home methadone and offer LAAM as the only altern-
ative for patients who desire reduced clinic visits. We now re-
port a clinical trial which tested the feasibility of conducting a
maintenance treatment program where patients had the choice of
either LAAM requiring three clinic visits per week or daily metha-
done requiring six clinic visits per week.
METHODS
During the eight-month trial period patients admitted for mainten-
ance treatment were given the choice of: (.a) attending the clinic
three days per week for LAAM; or, (b) attending six days per week
for methadone with one take-home dose. As contrasted with our
clinic policy before this eight-month trial and usual policy at
other clinics in this geographical area, no additional take-home
methadone doses were available during the study period. Patients
had the option of switching between maintenance on LAAM and metha-
done.
RESULTS
No patient declined admission to the program during the study per-
iod, despite the restrictions on take-home methadone. Choice of
LAAM or methadone for the 19 patients admitted during the study
period is shown in Table 1.
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TABLE 7
PATIENTS' CHOICE OF LAAM OR METHADONE
Initial Drug Choice
LAAM Methadone
N = 1 0 N=9
Continued initial drug choice 5 5
Switched to other drug 4 3
Dropped out 1 1
Patients were almost equally divided in terms of choice of LAAM or
methadone treatment. Patients who switched from methadone to LAAM
cited conflict between working schedules and daily clinic visits
as the major reason for the switch. Three of the four patients who
switched from LAAM to methadone did so after receiving only two
LAAM doses. When supplemental methadone was made available on al-
ternate days during LAAM induction, all patients choosing LAAM com-
pleted induction.
CONCLUSIONS
A. Cur findings demonstrate the feasibility of conducting a main-
tenance treatment program using LAAM or restricted take-home meth-
adone to curtail methadone diversion.
B. Acceptability of LAAM can be maximized by making supplemental
methadone available on alternate days to prevent abstinence symp-
tans during the initial LAAM induction period.
C. Further testing of the present strategy for reducing methadone
diversion appears warranted and may have implications for formu-
lating program policies.
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Methadone-Induced Endorphin
Dysfunction in Addicts
Mark S. Gold, M.D., A. Carter Pottash, M.D. Irl Extein, M.D.,
David Martin, and Herbert D. Kleber, M.D.
INTRODUCTION
A number of reproducible neuroendocrine responses are influenced
by the administration of exogenous opiates, endogenous opioids,
and opiate antagonists (eg., Naloxone),and these have been used to
understand and assess the endorphin system in the brain. Neuro-
endocrine functions are influenced by the administration of exo-
genous opiates, endogenous opioids, and opiate antagonists (Nal-
trexone) (1,2,3). The acute infusion of the exogenous opiate,
mathadone, has been demonstrated to produce a decrease in plasma
cortisol levels in man(4). Corticotropin(ACTH) and B-lipotropin/
B-endorphin are formed from a larger precursor protein which has
been called pro-ACTH/endorphin (5,6). ACTH and B-LPH/B-endorphin
are located and stored in the same cells and secretory granules
within the pituitary and may be inhibited by opiate administration.
These and other data (2,3,4,7) suggest that chronic opiate recep-
tor stimulation by exogenous self-administered opiates may, through
a feedback mechanism, cause a decrease in the release and possibly
the synthesis and available stores of pro-ACTH/endorphin and there-
fore decrease ACTH and cortisol response to a provocative stimulus
(3).
Chronic exogenous opiate administration might be responsible for
both the acute and protracted opiate withdrawal syndrome (8,9) by
producing a prolonged decrease in the availability of endorphins
or functional integrity of the B-Endorphin system originating from
a cell group near the arcuate nucleus of the hypothalamus which
sends long axons to midbrain/locus coeruleus and limbic structures
(10). However, the hypothesis that opiate administration may de-
crease endorphins in brain has been difficult to test. We have
recently administered the provocative test substance Naltrexone,
orally, to assess endorphin reserve and reported that chronic meth-
adone may have anti-endorphin effects (3). This preliminary find-
ing was limited by the fact that Naltrexone is administered orally,
it is not available in medical centers as a test substance, and is
a less profound stimulus of endorphin, ACTH or Cortisol release
than the short-acting intravenous Naloxone. In addition, we did
not test both heroin and methadone addicts to determine whether
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the reported lack of response was related to methadone or opiate
addiction.
We have recent Naloxone-endorphin reserve data from methadone and
heroin addicts which support and extend our previous findings on
diminished activity. The subjects were 5 male methadone addicts
who had been addicted to > 40 mg of methadone for 1-8 years, 5
male opiate addicts who had been addicted to heroin for > 6 months,
and 5 normal, age-matched male opiate-naive volunteers. The ad-
dicts had their chronic methadone abruptly discontinued and cloni-
dine suppression of withdrawal signs and symptoms as reported pre-
viously (9). All subjects were opiate and clonidine-free and at
least 16 days after their last opiate dose for the naloxone test.
All subjects were NPO past midnight and were at rest in bed for
the placement of an indwelling venous catheter at 800 h. Small
samples of blood were taken for the measurement of plasma cortisol
in duplicate by radioimmunoassay (3) through the catheter at -30,
0, 15, 30, 45, 60, 75, 105, and 135 minutes after 20 mg of Nalo-
xone was administered intravenously at 930 h.
In our group of 5 methadone addicts Naloxone caused a small and
insignificant (paired t test, t=1.64,NS) increase in plasma
cortisol levels from a baseline of 19.3 ± 2.5 ug/dl to a peak of
23.1 ± 1.9 ug/dl at 45 minutes after Naloxone administration.
Mean cortisol was 3.7 ± 2.3 ug/dl for the group of methadone
addicts. In normal controls Naloxone produced the expected rapid
and significant increase in cortisol from pretreatment baseline
of 15.1 ± 6.0 ug/dl to a peak of 24.8 ± 6.7 at + 45 minutes
(paired t test, t = 4.64 p < 0.01). M e a n cortisol for the
normal controls was 9.7 ± 2.1 ug/dl. The two groups had
significantly (t=3.9, p < 0.01) different cortisol responses to
Naloxone. Mean cortisol for heroin addicts was 7.9 ± 1.8 ug/dl.
cortisol response to Naloxone for heroin addicts was not signifi-
cantly different than normal controls. Methadone addicts had a
reduced response when compared to heroin addicts (t=2.88, p < 0.05).
For our group of lofexidine patients reported in this volume,
there was no significant increase in cortisol demonstrated with a
mean cortisol at 45 minutes after naloxone (20 mg) of 5.1 ug/dl.
While these data rely on the measurement of cortisol, they are not
likely to relate to adrenal factors since they are in agreement
with previous studies in the literature which have demonstrated
decreased ACTH in opiate addicts (7) and suggested that chronic
exogenous opiate administration might cause an endorphin system
inbalance (3,8,9,11,12,13,14). However, to further evaluate this
endorphin hypothesis and the possibility of opiate-induced adrenal
dysfunction, we administered 20 mg Naloxone to recently detoxified
methadone addicts as described above. Methadone had a markedly
impaired ACTH response to naloxone suggesting that chronic exoge-
nous opiate administration had led to an impaired functional
reserve of endorphin precursor. ACTH response to naloxone (20 mg)
was rapid and significant for normal opiate-naive controls from
baseline levels of 15.4 ± 11.1 to a peak of 59.0 ± 28.2 pg/ml at
+ 45 minutes. The recently detoxified methadone addicts (n=8) did
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not demonstrate an ACTH response to naloxone. Baseline levels of
26.2 ± 20.2 ware not significantly different than peak levels of
29.3 ± 21.3 pg/ml at + 45 minutes from the naloxone infusion. Our
data are also consistent with animal data which have shown reduced
brain B-endorphin immunoactivity in rats addicted to morphine for
3 months or longer (15) and decreased B-endorphin immunoactivity
and Naltrexone test response in chronic male opiate addicts (3).
Additional larger studies of methadone addicts are necessary to
confirm these data and to expand the biological measurements
(before and after Naloxone) to endorphin and B-lipotrophin. If
these data are confirmed, studies are also necessary to cause an
endorphin system dysfunction and to determine whether methadone
has more serious antiendorphin effects than other opiates.
We have previously suggested (8,9,11) that opiate withdrawal my
result from a sudden lack of exogenous opiates and an inadequate
functional endorphin reserve. The effects of opiates on catechol-
amine neurons have been reported elsewhere (19-23) but have tended
to show that opiates can decrease NE activity and turnover (22,24,
25). Studies of the brain's major noradrenergic nucleus, nucleus
locus coeruleus (LC), have clearly demonstrated that the prototype
opiate, morphine, causes a marked reduction in the normal LC
neuronal firing rate (25). These LC neurons are known to respond
to a painful stimulus with an increased firing rate and this pain-
induced effect can be blocked by morphine (25). These data demon-
strated an important opiate-NE interaction and suggested the possi-
bility that some of the effects of opiates might be mediated by
opiate-induced decreases in LC activity and NE release (25,26).
The discovery of specific opiate receptors in the brain (27,30),
the data by Pert, et al (28) and Simon (29) demonstrating very
dense opiate receptor a accumulations in the LC and the use of
naloxone reversal in electrophysiological studies as means of
identifying effects which could be attributable to opiate-receptor
stimulation (22,27,31) allowed LC-endorphin, LC-enkephalin and
LC-opiate interactions to be expanded and more clearly understood.
Investigators using single neuronal recording techniques and
microiontophoresis reported that endogenous opiates and exogenous
opiates decreased LC firing rates and that this effect was specifi-
cally reversed by the opiate antagonist naloxone (22,32). These
data suggested that the specific opiate receptors on the LC which
might normally utilize endorphins as a natural neurotransmitter
inhibit LC firing rate and modulate ascending NE activity (22,32).
These data suggested that this LC-opiate interaction was not tonic;
that is, endorphins do not tonically inhibit LC activity but rather
endorphins are released in response to neural or environmental
events. These data suggested to us that a critical endorphin-LC
connection might exist and be related to some opiate effects and
possibly play a critical role in opiate withdrawal (8,11,12,13,14).
Chronic exogenous opiate administration would tonically inhibit
the LC and compromise endorphin biosynthesis or functional integrity
(8,11,12,13). Acute opiate abstinence might be due to a rebound
NE hyperactivity and protracted abstinence due to slow endorphin
recovery and incomplete functional inhibition of spontaneous or
environmentally produced LC hyperactivity (8). In summary, we
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have investigated the opiate-withdrawal syndrome from the clinical
point of view. Neural events associated with opiate withdrawal
produced behavioral and phenomenological events in man and non-
human primates which could be reproduced by phamacological or
electrical activation of noradrenergic neuronal system. A NE
hyperactivity hypothesis was proposed for opiate-withdrawal-re-
lated and naturally occurring panic states. This hypothesis was
tested in non-human primates and in man during methadone, heroin
and other opiate withdrawal. These data supported the NE hypthe-
sis on the basis of Clonidine and Lofexidine's efficacy and the
neuropharmacology of these medications. The data supporting an
endorphin-LC connection were preliminarily studied using a nalo-
xone ("endorphin reserve") test paradigm These provocative stud-
ies demonstrated impaired cortisol and ACTH responses consistent
with an impaired B-Endorphin-ACTH precursor reserve. These data
support an important role for endorphin-system dysfunction in
acute and protracted abstinence syndrome. Further studies of vari-
ous anti-NE medications in withdrawal as well as studies of chronic
high-dose methadone addiction and endorphin study are necessary.
The effect of endorphin capacity and recovery on outcome measures
need careful consideration.
The specific opiate antagonists Naltrexone and Naloxone have been
reported to cause a marked increase in plasma ACTH and cortisol
levels in normal man (2,3), and this response may be a measure of
endophin function in vivo (3). These impaired Naloxone response
data reported here for recently detoxified addicts suggest that
chronic methadone administration decreases the synthesis, storage,
and quantity of available pro-ACTH/endorphin and endorphin/endoge-
nous opiate reserve. The data reported here and recent demonstra-
tion of an endorphin pathway to the locus coeruleus (10) support
the hypothesis that opiate withdrawal results from the failure of
endogenous opioid systems to compensate for the loss of exogenous
opiate-induced inhibition (8). These data also suggest that pro-
longed abstinence, post-detoxification depression and other affect-
ive symptoms which contribute to relapse may result from a prolonged
endorphin derangement (33). These data reporting significant re-
sponse differences for heroin and methadone addicts may explain
the increased withdrawal severity and poor detoxification/outcome
studies for methadone. Whether these findings relate only to the
potency of methadone vs. heroin or the natural history of heroin
addiction ("always in and out of withdrawal") having a sparing
effect on endorphin systems remains to be determined.
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Characteristics of 68 Chronic Phen-
cyclidine Abusers Who Sought
Treatment
Richard A. Rawson, Ph.D., Forest S. Tennant, Jr., M.D.,
Dr. P.H., and Michael A. McCann, M.A.
ABSTRACT
An analysis of 68 phencyclidine (PCP) users who sought treatment
reveals that chronic compulsive, daily use occurs and that
intravenous use is relatively common. Twenty-five (36.8%)
subjects considered themselves to be addicted to PCP and 19
(27.9%) desired medication to assist withdrawal. Unwanted
behaviors under the influence of PCP were common and primarily
related to memory loss, or acts which resulted from loss of
impulse control.
INTRODUCTION
Compulsive daily use of phencyclidine (PCP) recently has been
recognized as a significant clinical problem, but little is
known about the characteristics of chronic dependence in humans
(1). Behavioral studies with rats and mice suggest amphetamine-
like properties; however, PCP appears to have a calming effect
with guinea pigs and depressant effects on monkeys (2,3).
Subjective effects reported by human beings under the influence
of PCP include thought disturbances, heightened sensitivity to
stimuli, stimulation, tranquilization, mood elevation and
irritability. (4,5). Attention lapses and perceptual distor-
tions often occur under its influence although relatively few
users report hallucinations (5,6). PCP is generally considered
nonaddicting; however, monkeys will self-administer and appear
to develop a post-withdrawal syndrome (3). In this study 68
chronic PCP abusers who sought treatment were surveyed to deter-
mine major subjective effects of the drug in humans.
METHODS
Subjects were 68 PCP users who lived in Los Angeles County and
who sought treatment specifically for PCP in the years 1979 and
1980. At the time of admission all subjects completed a PCP
drug questionnaire which included demographic information, drug
use data, type of treatment desired, pharmacologic effects, and
unwanted behavior. Subjects were not clinically intoxicated at
483
the time of admission although almost all subjects admitted to
previous use of marijuana, alcohol, and a small number had
occasionally used amphetamines, sedatives, and other non-
opiate drugs. None, however, considered these other drugs to
be a problem which required treatment.
RESULTS
There were 37 (54.4%) males and 31 (45.6%) females (Table One).
Ages ranged from 14 to 38 years with a mean of 19.2. Use of
PCP ranged from 1 to 13 years with a mean of 3.0 years. A
total of 42 (61.8%) used PCP daily, and 14 (20.6%) injected
PCP intravenously. Twenty-five (36.8%) considered them-
selves addicted to PCP. Psychologic counseling was a desired
treatment for the majority of subjects (55; 80.9%), although
19 (27.9%) desired medication to withdraw, and 15 (22.1%)
desired a substitute maintenance drug (Table Two).
The most commonly reported pharmacologic effectsof PCP were
decreased appetite, confused thoughts, loss of memory, "speedy"
feeling, euphoria, and insomnia (Table Three). When PCP use
was discontinued, the most common symptoms reported were PCP
craving, increased appetite, increased need for sleep, de-
pression, and laziness (Table Four). Unwanted behaviors
tile under the influence of PCP were reported to be common
and included events related to memory loss (e.g., lost money,
got lost, etc.) violence (e.g., fights, hurt self or someone
else, etc.), or loss of inhibitions (e.g., unwanted sex act,
suicide, drug taking, etc.) (Table Five).
DISCUSSION
This study provides self-reported information on characteristics
of PCP abusers who desired treatment. Data collected from
these subjects could not be collaborated with body-fluid analy-
sis in all cases since most subjects had ceased PCP use just
prior to appearing for treatment. Data collected from these
subjects, therefore, do not necessarily apply to all PCP users.
Long term, chronic dependence was present in many of these sub-
jects since the mean length of usage was 3.0 years. The
majority (42; 61.8%) used PCP daily, and 25 (36.8%) felt they
were addicted. Nineteen (27.9%) desired medication to
withdraw. These reports, therefore, suggest that physical
dependence may occur in humans. Some animal studies indicate
that a withdrawal syndrome may occur after chronic PCP adminis-
tratian (3).
Subjects reported numerous behaviors which have been described
in other studies. Memory loss appeared to be particularly pre-
valent since subjects frequently became lost or misplaced money.
Other unwanted behaviors under the influence of PCP were
related to violence and loss of inhibitions which resulted in
fights, suicide attempts, sex acts, and crime.
484
PCP has often been considered to be a compound which is primarily
hallucinogenic or sedating in humans (1,2). The major effects
reported by these subjects, however, were amphetamine-like. A
majority stated the drug decreased appetite, increased strength,
and produced a "speedy" feeling. When PCP was stopped a post-
amphetamine type of syndrome was apparent with the most
commonly described symptoms being PCP craving, increased
appetite, need for sleep, and depression. Although PCP is
known to have various effects on the neurotransmitters, dopa-
mine and norepinephrine, its chronic use in humans is
apparently perceived to be more amphetamine-like than hallu-
cinogenic or sedative (7).
TABLE ONE
DEMOGRAPHIC AND DRUG-USE CHARACTERISTICS
Age Range (Yrs.)
Mean Age (Yrs.)
Males
Females
white
Non-White
Mean Education (Yrs.)
Range of PCP Use (Yrs.)
Mean PCP Use (Yrs.)
Number of Daily Users
Number Who Feel Addicted
Number Who Use Other Drugs
N = 68
14 to 38
19.2
31 (57%)
23 (43%)
10 (19%)
44 (81%)
9.7
1 to 13
3.0
42 (61.8%)
25 (36.8%)
63 (92.6%)
TABLE TWO
DESIRED TREATMENTS*
N = 68
TREATMENT DESIRED
Psychologic Counseling 55 (80.9%)
Residential program 7 (10.3%)
Withdrawal Medication 19 (27.9%)
Substitute Drug for PCP 15 (22.1%)
* Some subjects desired more than one treatment.
TABLE THREE
SELF-REPORTED PHARMACOLOGIC EFFECTS OF PCP
N = 68
EFFECTS
Decreased Appetite 42 (61.8%)
Confused Thoughts 41 (60.3%)
Loss of Memory 40 (58.8%)
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Increased Strength
Feel Speedy
Euphoria
Drowsiness
Bad Trips
Insomnia
Depression
Dizziness
Increased Anger
Increased Anxiety
Increased Violence
Increased Sex Drive
Visual Hallucinations
Paranoia
Ringing in Ears
Headaches
Decreased Sex Drive
Fatigue
Auditory Mallucinations
Feel Hot
Decreased strength
Vomiting
Feeling of Detachment
Increased Appetite
Decreased Anxiety
39 (57.4%)
38 (55.9%)
37 (54.4%)
35 (51.5%)
30 (44.1%)
28 (41.2%)
24 (35.3%
23 (33.8%)
23 (33.8%)
23 (33.8%)
22 (32.4%)
20 (29.4%)
19 (27.9%)
18 (26.5%)
16 (23.5%)
15 (22.1%)
14 (20.6%)
14 (20.6%)
14 (20.6%)
13 (19.1%)
12 (17.6%)
9 (13.2%)
9 (13.2%)
5 ( 7.4%)
5 ( 7.4%)
TABLE FOUR
SELF-REPORTED SYMPTOMS WHEN CHRONIC PCP USE IS DISCONTINUED
N = 68
EXPERIENCES
Craving for PCP
Increased Need for Sleep
Poor Memory
Depression
Laziness
Increased Appetite
confused Thoughts
Flashbacks
Irritable
Feeling Weak
Increased Anxiety
Headaches
Insomnia
None
Recurring Tastes
Panic
Decreased Appetite
Decreased Need for Sleep
Feeling Speedy
Feeling Hot
Ringing in Ears
35 (51.5%)
33 (48.5%)
31 (45.6%)
30 (44.1%)
30 (44.1%)
26 (38.2%)
24 (35.3%)
22 (32.4%)
21 (30.9%)
21 (30.9%)
15 (22.1%)
11 (16.2%)
10 (14.7%)
10 (14.7%)
9 (13.2%)
8 (11.8%)
6 ( 8.8%)
3 ( 4.4%)
1 ( 1.5%)
1 ( 1.5%)
1 ( 1.5%)
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TABLE FIVE
SELF-REPORTED UNWANTED BEHAVIORS UNDER THE INFLUENCE OF PCP
N = 68
BEHAVIOR
Lost Money 33 (48.5%)
Got Lost 27 (39.7%)
Took Drugs 24 (35.3%)
Got Into Fight 21 (30.9%)
Hurt Yourself 18 (26.5%)
Hurt Someone Else 16 (23.5%)
Unwanted Sexual Encounter 13 (19.1%)
Attempted Suicide 9 (13.2%)
Committed Crime 8 (11.8%)
Had Car Accident 7 (10.3%)
REFERENCES
1.
2.
3.
4.
5.
6.
7.
Burns, RS, Lerner SE, Corrado R, et al: Phencyclidine;
States of Acute Intoxication and Fatalities. West J Med,
123: 345-349, 1975.
Chen G, Ensor CR, Russell D, et al: The Pharmacology of
1-(1-Phenylcyclohexyl) Piperidine HCC. J Pharmacol Exp
Ther, 127:241-250, 1959.
Balster RL, Chait LD: The Behavioral Effects of Phencyclidine
in Animals. In: Peterson RC, Stillman RC, eds. Phencycli-
dine (PCP) Abuse: An Appraisal. National Institute on Drug
Abuse: Research Monograph Series, 1978.
Luby ED, Cohen BD, Rosenbaum G, et al: Study of a New
Schizophrenomimetic Drug-Sernyl. Arch Neurol Psychiatr, 81:
363-369, 1959.
Siegel RK; Phencyclidine and Ketamine Intoxications: A Study
of Four Populations of Recreational Users. In: Peterson RC,
Stillman RC, eds. Phencyclidine (PCP) Abuse: An Appraisal.
National Institute on Drug Abuse: Research Monograph Series,
1978.
Munch JC: Phencyclidine: Pharmacology and Toxicology.
Bulletin on Narcotics, 26:131-133, 1974.
Leonard BE, Tonge SR: The Effects of Some Hallucinogenic
Drugs Upon the Metabolism of Noradrenaline. Life Sci, 8:
815-825, 1969.
AUTHORS
Richard A. Rawson, Ph.D. Community Health Projects, Inc.
Forest S. Tennant, Jr., M.D., Dr.P.H. 336½ South Glendora Avenue
Michael J. McCann, M.A. West Covina, California 91790
487
Effect of Chronic Heroin Exposure
on Pregnant Rats and Their
Offspring
Ian S. Zagon and Patricia J. McLaughlin
INTRODUCTION
In the last 15 to 20 years a dramatic increase in the use of nar-
cotic drugs has occurred, particularly among young women. Of the
more than 500,000 persons estimated to be using heroin regularly
in the United States in 1976, 150,000 were female of childbearing
age (NIDA 1979). Heroin readily crosses the placenta and enters
the fetal circulation and has been detected in the milk of lactat-
ing humans (Perlmutter 1974). As a consequence of maternal narcotic
consumption, the fetus and neonate are known to become passively
addicted. Although a great deal of attention has focused on the
neonatal withdrawal syndrome, as well as on intrauterine growth.
retardation (Perlmutter 1974; Cobrinick et al. 1959; Zelson et al.
1971; Naeye et al. 1973; Vargas et al. 1975), concern for the long-
term sequelae associated with perinatal narcotic exposure has only
recently been expressed (NIDA 1979; Beschner and Brotman 1977;
Blinick et al. 1976; Wilson 1975; Wilson et al. 1975, 1979).
In order to more clearly elucidate the short- and long-term effects.
of perinatal heroin exposure on the developing organism, and to
begin to ascertain the risks involved with human drug addiction, the
present laboratory study was undertaken. In this investigation,
we have explored the effects of various dosages of heroin, admin-
istered either subcutaneously or intraperitoneally, on pregnant
rats and their offspring.
METHODS
Male (250-300 g) and primiparous female (180-200 g) Sprague-Dawley
rats (Charles River Laboratories, Wilmington, MA) and their off-
spring were utilized in this study and all rats were housed under
controlled conditions (Zagon and McLaughlin 1977, 1978), with water
and Purina Laboratory Chow available ad libitum. Adult animals were
quarantined 5 days prior to the beginning of experimentation.
Females were randomly divided into groups of 5-10 animals (5 rats/
cage) and each group received either dally intraperitoneal (i.p.)
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injections of 3, 5, 7, 10, or 20 mg/kg heroin (diacetylmorphine,
National Institute on Drug Abuse) or daily subcutaneous (s.c.)
injections of 1, 2.5, 5, or 10 mg/kg heroin; equivalent volumes of
saline were administered either by the i.p. or s.c. route to two
different groups of control rats. Females were weighed every 3
days and dosage adjustments made. Heroin was prepared weekly by
dissolution of the powder into sterile water.
Five days after the beginning of injection, females were mated
(one male to one female) and the presence of sperm in vaginal
smears indicated day 1 of gestation. On the 18th day of gestation,
females were placed in separate solid-bottomed cages to deliver their
offspring. Drug injections continued daily throughout gestation
and lactation until postnatal day 21 (weaning).
Litter size was maintained at eight pups per mother with an equal
distribution of males and females. Offspring were weighed at birth
and on postnatal days 6, 10, and 21. Gestation time, litter size,
and infant mortality were recorded. Pups found dead within 2 hr of
birth were considered stillborn.
For each route of administration, gestation time and litter size
were analyzed with the Mann-Whitney U test (Winer 1971), whereas
the number of stillborn pups, mortality in the first 3 days, and
body weights of preweaning offspring were evaluated using a one-
way analysis of variance. Subsequent comparisons between dosages
and their respective controls were made using the Newman-Keuls
procedure (Siegel 1956).
RESULTS
Subcutaneous Drug Administration
Mortalities were not noted in the s.c. heroin groups prior to mating;
however, two rats in the 2.5-mg/kg group and three rats in the 10-
mg/kg group died during gestation (TABLE 1). Two rats each in the
2.5- and 5-mg/kg groups and 1 animal in the 10-mg/kg group did not
have sperm-positive smears. Female rats receiving dosages of 2.5
mg/kg and 10 mg/kg tended to have longer gestation times than con-
trols, but only rats in the 2.5-mg/kg group were significant in this
regard. Litter size in the 5- and 10-mg/kg groups were somewhat
smaller than that of controls, but these differences were not Stat-
istically reliable. In comparison to control values, the number of
stillborn rats and the number of pups that had died by 3 dsys were
significantly increased in the 2.5; 5; and 10-mg/kg groups.
The effects of maternal s.c. injections of heroin on the body growth
of rat offspring are presented in TABLE 2. Mean birthweight of all
groups of heroin-subjected pups was significantly reduced from
control values, with reductions of 14-24% being noted. On day 6,
all offspring subjected to heroin were subnormal in body weight,
and on day 10 rats in the 2.5; 5; and 10-mg/kg groups were lower in
body weight than controls. At weaning, all groups of heroin-exposed
pups weighed 11% to 36% less than control animals.
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TABLE I
Effects of subcutaneous Heroin Administration of Pregnant Rats and Their Offspring
Dosage (mg/kg)
Control 1.0 2.5 5.0 10.0
Number of females rated 8 5 8 8 8
Number of females delivered 8 5 4 6 4
Length of gestation (days) 21.75 21.00 23.75† 22.33 23.50
X ± S.E. ±0.25 +0.41 ±0.95 ±0.72 ±0.87
Litter size, X ± S.E. 12.50 12.25 13.50 10.66 10.50
±0.68 ±0.47 ±1.55 ±1.89 ±0.64
Mean number Of stillborns/ 0 0 0.75** 1.0** 0.75**
litter
Mean mortality at 3 days 0 0 3.50** 1.33** 0.75**
Significantly different from controls at p<0.01 (**) using analysis of variance.
Significantly different from controls at p<0.02 (†) using Mann-Whitney U test.
TABLE 2
The Effects of Subcutaneously Administered Heroin to Maternal Rats on the
Body Growth of Their Offspring
Age Dosage (mg/kg)
(days) Control 1.0 2.5 5.0 1 0 . 0
0 7.409±0.14 6.41±0.10** 5.97±0.10** 6.02±0.10* 5.71±0.10**
6 13.78±0.14 12.44±0.28** 12.74±0.07* 12.70±0.16* 11.44±0.16**
10 24.74±0.12 24.28±0.24 19.01±0.59** 21.97±0.20** 20.90±0.29**
21 40.00±0.66 43.45±0.99** 36.49±1.22** 41.35±0.87** 31.24±1.38**
Mean body weights (g) + S.E. for 8-16 rats per group. Significantly different
from controls at p<0.0.05 (*) and p<0.01 (**) using analysis of variance.
Intraperitoneal Drug Administration
No mortalities were recorded in the i.p. heroin groups prior to
mating, but two female rats each in the 5-, 7-; 10-, and 20-mg/kg
groups died during gestation (TABLE 3). The length of gestation
of heroin-treated and control females was similar; however, one rat
each in the 7 and 10 mg/kg groups apparently resorbed their litters
and did not deliver. Litter size was abnormally small for all
heroin-treated groups, with reductions of 15-27% being recorded.
In a manner similar to the observations noted for rats born of s.c.-
injected mother, the number of stillborns and infant mortality by
3 days was generally increased in all i.p.-heroin litters.
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TABLE 3
Effects of Intraperitoneal Heroin Administration on Pregnant Rats and Their Offspring
Dosage (mg/kg)
Control 3.0 5.0 7.0 10.0 20.0
Number of females mated 0 4 10 8 0 10
Number of females delivered 0 4 8 4 5 0
Length of gestation (days) 21.66 21.50 21.72 22.50 22.00 22.37
X ± S.E. ±0.23 +0.28 ±0.24 +0.29 ±0.32 ±0.62
Litter size, X ± S.E. 12.64 10.75† 9.64† 10.75† 9.20† 9.87†
±0.33 ±1.65 ±0.60 ±0.48 ±1.16 ±0.74
Mean number stillborns/ 0 0.75** 1.18** 0.50** 0.60** 1.25**
litter
Mean mortality at 3 days 0.12 1.25** 0.90** 0.50 2.40** 3.50**
Significantly different from controls at p<0.01 (**) using analysis of variance.
Significantly different from controls at p<0.02 (†) using the Mann-Whitney U test.
Newborn pups of mothers given i.p. injections of heroin were sub-
normal in body weight, with reductions of 16% to 27% being recorded
(TABLE 4). Growth retardation was evident in all 6- and 10-day-
old offspring subjected to heroin, with heroin-exposed pups weighing
56% to 88% of control levels. At weaning, rats in the 3-mg/kg
group were comparable to controls in body weight, but animals in
all of the other heroin-exposed groups had reductions in mean
body weights of 15% to 24%.
TABLE 4
The Effects of Intraperitoneally Administered Heroin to Maternal Pats on the
Body Growth of Their Offspring
Age Dosage (mg/kg)
(days)
Control 3.0 5.0 7.0 10.0 20.0
0 6.91 5.81** 5.03** 5.25** 5.53** 5.45**
±0.10 ±0.25 ±0.11 ±0.19 ±0.10 ±0.11
6 13.77 12.13** 9.15** 11.11** 8.68** 9.46**
±0.21 ±0.37 ±0.17 ±0.13 ±0.39 ±0.22
10 24.94 14.98** 16.35** 15.11** 13.87** 14.60**
±0.39 ±0.79 ±0.22 ±0.30 ±0.32 ±0.49
21 49.28 40.95 41.67** 38.09** 37.56** 37.45**
±0.64 ±1.3.1 ±1.08 ±0.98 ±1.19 ±1.59
Mean body weights (g) ± S.E. for 8-16 rats per group. Significantly different
from controls at p<0.05 (*) and p<0.01 (**) using analysis of variance.
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DISCUSSION
Although the dosages of heroin used in this study were well below
the LD50 level of 100 mg/kg for the s.c. route in rats (Way et al.
1960), and no mortalities were recorded in either the s.c. or i.p.
heroin groups prior to mating, a number of heroin-injected rats
died during gestation. These results are similar to those by
Buchenauer et al. (1974) and Zagon and McLaughlin (1977, 1978)
showing an adverse effect of another opiate, methadone, during
gestation. At this time it is not known whether drug disposition
and susceptibility are altered during gestation, but it does appear
that exposure to narcotics during pregnancy has a profound influence
on maternal viability.
The present data indicate that chronic heroin exposure of female
rats prior to and during pregnancy has little effect on the estrous
cycle, fertility, or length of gestation, although some increase in
gestation time was noted in animals of the 2.5-mg/kg-s.c. group.
These data parallel those of clinical studies in which the fecundity
of heroin addicts has been reported to be unaffected (Blinick 1971).
The effects of heroin on litter size were dependenton the route of
administration. All groups of females receiving heroin by i.p.
injection had markedly smaller litters than controls, whereas
only the 5- and 10-mg/kg groups receiving heroin s.c. showed some
tendency to have fewer pups than controls. The reasons underlying
the discrepancy between the s.c. and i.p. routes in terms of litter
size is unclear; however, differences in drug metabolism and/or the
possibility of intrauterine placement of the i.p. injections could
account for these results. Maternal heroin consumption did result
in an increase in the number of stillborn pups in groups from both
routes of drug administration, as well as an abnormal increase in
infant mortality within the first 3 days. This increase in infant
mortality nay well have been the result of narcotic withdrawal,
even though these pups were still receiving heroin by way of the
maternal milk. These findings of infant mortality are consonant
with reports of human addiction wherein up to 71% of the Infants
delivered by addicts demonstrate some objective evidence of with-
drawal, and, if left untreated, these infants will eventually begin
to convulse and some may die (Perlmutter 1974).
One of the most consistent facts of in utero heroin exposure found
in this study was a reduction in birthweight. A dose-response
relationship was not found in this regard, but birthweights of all
groups of pups subjected to heroin were abnormally reduced in body
weight. Not only does heroin appear to be related to in utero
growth retardation, but body weight gain during the preweaning
period was also reduced. At weaning (day 21), decreases in body
weight were evident in all but the 3-mg/kg-i.p. group and, with both
routes of heroin administration, a dose-response effect could be
observed. These results are consistent with clinical findings in
which low birthweights have been reported for neonates of heroin-
addicted mothers, with these babies being small for gestational
age rather than premature (Perlmutter 1974; Naeye et al. 1973;
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Reddy et al. 1971; Kandall et al. 1976). In addition, our data
in regard to deficits in body weight gain can be correlated with
the results of Wilson and colleagues (1975, 1979), which have shown
that heroin-exposed children from 3 to 6 years have alterations in
growth. These children were often found to be lighter in weight
and shorter in stature than controls and to have head circum-
ference measurements considerably below those of controls.
In conclusion, these observations reveal that maternal exposure to
heroin can be detrimental to growth of the fetus and neonate.
Furthermore, our results can be correlated with those seen in clinical
situations. The question as to what other short- and long-term
developmental, and possibly neurobiological, abnormalities may be
occurring in heroin-exposed offspring needs investigation.
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Direct Relationship of Brain Con-
centration of Methadone with
Analgesia in Chronic Morphine-
Implanted and Acute Naloxone-
Treated Rats
Shean-jang Liu, Ph.D., and Richard I. H. Wang, M.D., Ph.D.
Roth chronic morphine pretreatment and acute naloxone treatment
have been shown to decrease or block methadone analgesia. We
have shown that the analgesic effect of methadone is directly
related to the brain concentration of methadone. The present
study was initiated to investigate the effect of morphine and
naloxone pretreatment on the brain concentration of methadone
and the possible mechanism of effect involved. Rats rendered
tolerant to morphine analgesia, by s.c. implantation of 2 pellets
containing 75 mg of morphine base each for 3 days, showed cross-
tolerance to methadone analgesia with or without subsequent
removal of the morphine pellet. The brain concentration of 14C-
methadone at 1 and 2 hr after administration of 14C-methadone was
markedly decreased (ranging from 25-58 percent of control values)
by morphine implantation without pellet removal. In contrast,
the urinary volume as well as urinary excretion of 14C-methadone
and total 14C were markedly increased by this pretreatment.
Essentially the same results were obtained in morphine-implanted
rats in whom the pellets were removed 6 hr before the experiments
were performed. This increased urinary excretion of 14C-methadone
and total 14C was apparently due to cross-tolerance to methadone-
induced antidiuresis in morphine-implanted rats. Naloxone (0.6,
1.8 and 5.4 mg/kg, i.p.) given 20 min before administration of
14C-methadone (5 mg/kg, s.c.) antagonized methadone-induced anti-
diuresis and caused a dose-related increase in urinary volume and
urinary excretion of 14C-methadone and total 14C. The same nal-
oxone treatment caused a dose-related decrease (49-64 percent of
controls) in the brain concentration of 14C-methadone. When nal-
oxone (5.4 mg/kg, i.p.) was given 30 min after administration of
14C-methadone (5 mg/kg, s.c.), it also decreased the brain con-
centration of 14C-methadone but caused no significant effect on
urinary volume and urinary excretion of 14C-methadone. When nal-
oxone was given 20 min before administration of a low dose of
methadone (1 mg/kg, s.c.), which produced no analgesia or anti-
diuresis, it exerted no significant effect on either brain con-
centration or urinary excretion of methadone. These results
indicate that the observed decreases in brain concentration of
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and acute naloxone-methadone in chronic morphine-implanted
treated rats were not due to direct effects of morphine and
naloxone on the biotransformation of methadone. Rather the
results suggest that the cross-tolerance to antidiuresis seen
in morphine-implanted rats and the naloxone-induced antidiuresis
seen in naloxone-treated rats could be partly responsible for
the rapid excretion of methadone and the decrease in brain con-
centration of methadone. This decrease in the brain concentra-
tion of methadone could, in turn, cause the observed blockade
or decrease in methadone analgesia in the morphine-implanted
and naloxone-treated rats.
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Psychological and Physiological
Reponse to Hydromorphone: An
Opponent Process View of
Addiction
Joseph W. Ternes and Charles P. O’Brien
INTRODUCTION
Drug Addiction, especially dependence upon narcotic drugs such as
heroin, is frequently cited to demonstrate the temporal dynamics
of affect in the opponent-process model (Solomon & Corbit, 1974).
Typically, the narcotic drug is described as the affect-arousing
stimulus. The euphoria which the narcotic induces is described
as the A state, the primary affective reaction, and the narcotic
abstinence syndrome is described as the B state, the opponent-
affective reaction. Each administration of the drug elicits an
a process and indirectly engages an opponent, the b process.
The intensity of the A state is determined by the algebraic
summation of these underlying processes. Redosing produces an
increase or "growth" in the b process. As the b process grows
in strength, the B state becomes more aversive and of longer
duration. Tolerance is seen as a natural result of the growth
of the b process. This mans that as the b process becomes more
intense, a larger dose of drug is needed to achieve the same
amount of positive affect.
According to an opponent-process analysis of drug addiction,
withdrawal agony motivates the addict to seek ways of relieving
the pain.
discarded.
Various coping procedures may be engaged in and then
Eventually redosing occurs and abstinence symptoms
are relieved. This selectively reinforces the drug-seeking
operants at the expense of other less effective responses.
Thus the addict learns to relieve his withdrawal symptoms by
using the drug to return to normal. But redosing indirectly
elicits the b process which eventually leads to withdrawal
symptoms, and so forth.
Stimuli which comprise drug preparation and self-injection
rituals naturally become associated with the drug (the UCS)
through the process of Pavlovian conditioning. They my be
thought of as conditioned stimuli (CSs) which are specifically
paired with the A state and which come to elicit a conditioned
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response (CR) which is similar to the a process. Since eli-
citing the a process always engages the b process, it seem
reasonable to predict that a conditioned a process will also
engage the b process. When the conditioned a process decays,
a B state will result. Therefore, a conditioned opiate state
(either delay of withdrawal symptom or relief of symptoms)
should be followed by increased opiate hunger. This is one way
the opponent-process theory accounts for "conditioned with-
drawal."
Other stimuli which occur earlier in the chain of events pre-
ceding redosing, such as the copping corner, the pusher, and
bags of heroin, are encountered near the onset of withdrawal,
the B state. As such they may be thought of as CSs which
predict the end of the drug effect. These stimuli are speci-
fically paired with the B state and therefore may acquire the
power to e1icit a CR which is hedonically opposite to the A
state. This is anotherway in which the opponent-process
theory accounts for "conditioned withdrawal." Whether these
CS's prolong or induce further growth of the b process is un-
known. However, it is known that presentation of a drug-re-
lated stimulus such as a syringe may elicit withdrawal signs
in both methadone-maintenance and detoxified addicts
(Ternes et al 1979). The opponent-process model predicts that
"conditioned withdrawal" and, by implication, relapse to opiate
addiction, is influenced by Pavlovian conditioned responses to
environmental stimuli as well as by the nonassociative re-
sponses of the nervous system which counteract strong affective
states.
Procedure
Although anecedotal accounts and clinical knowledge of the
phenomenolgy of addiction appear to fit the opponent-process
model, an empirical demonstration of these features would be
important. Since the model describes the temporal dynamics
of affect, one obviously would want to monitor the hedonic
quality of emotional states which are associated with both the
presentation and withdrawal of an opiate drug (the affect-
arousing stimulus). Psychological variables which we used
to infer affect were derived from the subjective ratings of
our subjects. Since we were studying human subjects, we ob-
tained self-reports in response to a short series of questions
about their subjective experience of high and withdrawal.
Since "high" and "withdrawal" are emotional states, we also
measured several psychophysiological variables. Due to space
limitations, we will only present data for two measures, sub-
jective ratings and skin temperature. Thus we intended to
characterize the opiate-induced A and B states of addicts in
terms of their psychological and psychophysiological correlates.
An experiment was performed in the following manner: Four de-
toxified heroin addicts who were abstinent from opiates for
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at least 24 hours prior to the experiment were exposed to four
experimental conditions, two unsignalled drug administrations;
hydromorphone infusion and saline infusion, and two signalled
drug administrations, hydromorphone self-injection and saline
self-injection. Each session lasted 60 minutes and consisted
of a baseline period of at least 20 minutes followed by either
an infusion or a self-injection and at least 20 minutes of
monitoring post-administration.
Results
The purpose of the unsignalled hydromorphone infusion session
was to demonstrate the A state which is produced by a potent
opiate. In this instance we equate the post drug infusion
period with the A state. Figure 1 shows a psychophysiological
measure, skin temperature. When the drug was infused, skin
temperatures increased (figure 1a). Figure 2 shows two psy-
chological measures, the subject's self-reports of high and
withdrawal. The subjects reported feeling "high" and relief
of withdrawal symptom following the hydromorphone infusion
(figure 2a). These data suggest that autonomic variables
track the onset and the presence of the drug. The psychologi-
cal measures also track the phenomenon and indicate the posi-
tive hedonic quality of the drug-elicited A state.
Figures 1b and 2b show the saline-infusion condition. Since
our subjects were in withdrawal while they were undergoing
detoxification (twenty four hours after their final dose of
methadone), the saline-infusion condition provided an example
of the B state. It demonstrates what happens when opiates are
not present in the addicts' system. The psychophysiological
and subjective measures both suggest a withdrawal state
characterized by low skin temperatures and subjective reports
of withdrawal. We feel these physiological patterns and nega-
tive affects generally characterize opiate withdrawal, the B
state.
Figures 1c and 2c show the hydromorphone self-injection condi-
tion. When the subjects began to self-inject, skin temperature
decreased. We interpret these physiological changes as
representing an anticipatory response, a CR in anticipation
of the drug effects. (This type of CR has been suggested as
the mechanism of tolerance by Siegel's (1975) Pavlovian con-
ditioning theory of tolerance.) After the injection the sub-
jects' skin temperature increased, and they reported feeling
"high" and no withdrawal.
The saline self-injection was designed to be a test trial for
Pavlovian conditioning which may have accompanied previous
drug use in the natural environment. The psychophysiological
data for the group did not seem to be typical of either opiate
or opiate-withdrawal effects. Skin temperature was depressed
during the injection and then increased following the injection
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SKIN TEMPERATURE
Figure 1
A HYDROMORPHONE INFUSION C HYDROMORPHONE SELF-INJECTION
SALINE INFUSION SALINE SELF-INJECTION
Figure 2
SUBJECTIVE RATING
but did not attain its previous baseline (figure 1d). The
subjective ratings indicated that no report of withdrawal
symptoms occurred until approximately 15 minutes after the
saline injection (figure 2d).
DISCUSSION
The unsignalled infusion data demonstrate two opiate-elicited
states. The "high" state occurs in the presence of the opiate.
This is an A state in opponent-process terms. The "withdrawal"
state occurs in the absence of the opiate. This is a B state.
We also appear to have physiological evidence for two different
CRs which could be responsible for "conditioned withdrawal":
the anticipatory CR (for example, the pre-injection response
to the injection ritual, figures 1c an 1d); and the placebo
CR (for example, the post-injection temperature increase
following saline injection, figure 1d). Both Siegel's con-
ditioned-tolerance theory and Solomon's opponent process
theory can account for the withdrawal symptoms, albeit in quite
different ways.
The conditioning theory focuses on the expected drug positive
effects which the CS predicts. Given this positive expectancy,
the injection CSs elicit a compensatory CR which tends to miti-
gate the drug effects. However, this compensatory CR may be
misinterpreted as narcotic withdrawal if it is unopposed by the
opiate. This is similar to Wikler's counter adaptive CR theory
of relapse to opiates. Essentially this position suggests that
conditioning is at first an adaptive process which acts in the
interest of preserving the homestatic balance of the organism.
Therefore the large physiological reactions which some drugs
cause are counteracted by CBs which change in the opposite
direction. However, after several repetitions of the drug,
the CR becomes quite strong and overshoots the adaptive level.
This could be "counteradaptive." In the instance of opiate
addiction, the adaptive CR produces tolerance, but presentation
of the CS in the absence of the US (for example, a placebo in-
jection) may precipitate withdrawal symptoms.
An opponent-process analysis can account for the withdrawal
symptoms following the saline injection in two different ways:
in the first case, the injection procedure may serve as a CS
which is associated with the B state (withdrawal) which, usu-
ally precedes opiate injection and therefore results in a
CB which resembles B., the withdrawal state. In the second
case, the injection procedure may serve as a CS which is
associated with the A state ("high") which immediately follows
an opiate injection. Therefore it results in a CB which re-
sembles the A state. However, when the conditioned a-process
decays, the B state (withdrawal symptoms) should follow. The
data are consistent with this latter version.
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SUMMARY
This paper has described the affective and psychophysiological
correlates of addictive states in detoxified opiate addicts.
These data tend to fit the opponent-process model of the tem-
poral dynamics of affect. Two types of autonomic conditioned
drug reactions were also demonstrated: an anticipatory CR
which is oppositeto the expected drug effects and a placebo CR
which is similar to the drug effect. However, both of these.
brief autonomic CRs tend to be followed by an increase in
negative affect and drug hunger. Although "conditioned with-
drawal" can be predicted with both the opponent process and
the Pavlovian conditioning theories, the present data are
more compatible with opponent-process theory.
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Postulated Origin of Narcotic
Antagonist Activity in Novel N-
Methyl benzomorphans
Gail Hashimoto, Stanley Burt, and Gilda Loew
Addition of a 3-alkanone (-CH2CH2C=OR) side chain to position 9ß
of metazocine results in compounds which demonstrate potent
narcotic antagonism when the R group reaches a crucial length.
For example, an analog with R = n-C3H7 is a potent pure agonist,
while one with R = n-C5H11 is a potent agonist and antagonist.
Similar behavior is observed for the pair of analogs R = phenyl,
R = CH2-phenyl.
In order to understand the origin of antagonist activity with
chain lengthening, energy-conformational studies were performed
for these two pairs of analogs using both an empirical energy and
a semiempirical quantum mechanical method (PCILO).
For all four analogs, two types of low-energy conformers were
found, one involving internal H-bonding interactions between the
carbonyl group and the protonated amine nitrogen, and the other
corresponding to an extended chain conformer of the -CH2CH2COR
group. Since they are common to all analogs, -both of these con-
formations are plausible candidates for interaction at the
receptor site leading to agonist activity.
Significantly, however, an additional low-energy conformation was
found for the longer-chain analogs of each pair (i.e., R = C5H11
and R = CH2 ) which was not present in the shorter-chain analogs.
In this conformation the R group was directly above the protonated
amine group and would interfere with its contact with an anionic.
site thought to be a postulated requirement for agonism.
This conformer, then, could represent an antagonist mode of bind-
ing to the receptor which is accessible only as R is lengthened to
five or more carbon atoms and could account for the onset of
antagonist activity 'in these longer-chain analogs.
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Naltrexone and Psychotherapy
Nannette Stone-Washton, M.S., Richard B. Resnick, M.D.,
and Arnold M. Washton, Ph.D.
We previously reported a preliminary controlled study in detox-
ified opiate addicts comparing the efficacy of naltrexone combin-
ed with psychotherapy as opposed to naltrexone treatment alone.
Our findings suggested that the combined treatment yielded better
clinical outcome than naltrexone alone, but our conclusions were
limited by methodological problem and incomplete follow-up data.
The present study is an extension of our earlier work with the
following modifications and improvements: (a) only detoxified
heroin addicts were included in the subject sample, and patients
detoxified from long-term methadone maintenance were excluded;
(b) there was greater consistency among therapists with regard to
theoretical orientation and techniques; (c) stronger efforts
were made to obtain the necessary follow-up information; and
(d) the duration of the study was extended to 18 months.
METHODS
The subjects were 22 recently detoxified heroin addicts who took
at least on dose of naltrexone, and stated willingness to accept
random assignment to either of the two treatment conditions. All
were at least 18 years of age, and had at least one year addiction
history, no serious medical or psychiatric illness, and no recent
methadone-maintenance treatment.
After signing an informed consent, each volunteer was randomly
assigned to either naltrexone and psychotherapy (Hi Intervention)
treatment or naltrexone alone (Lo Intervention) treatment. The
Hi-Intervention treatment consisted of naltrexone maintenance
requiring three clinic visits per week and assignment to an
experienced psychodynamically oriented therapist who provided a
minimun of one individual therapy session per week and additional
sessions including group or family therapy, as indicated. The
therapist maintained a high level of availability for crises and
other problems that arose between scheduled sessions, and emphasis
was placed on developing a strong therapeutic alliance with the
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patient. The Lo-Intervention treatment consisted of naltrexone
maintenance requiring three clinic visits per week and assignment
to a case manager who provided crisis intervention and concrete
services only. The case manager did not attempt to engage the
patient in a therapeutic alliance or to encourage discussions of
personal problems. No attempts were made to reach out to Lo-
Intervention patients who missed clinic visits. Subjects in
both groups were given access to the usual medical services of
the clinic.
RESULTS
Pre-treatment demographic and drug&history variables, such as
gender, ethnicity, employment, and percent of time drug-free
since first becoming addicted, were similar for the two treatment
groups. Table 1 shows that Hi-Intervention subjects stayed in
TABLE 1
Mean Time on Naltrexone Treatment (Weeks)
H I LO
All subjects 18.8 wks 6.0 wks
Subjects currently opiate-free 30 wks 8.5 wks
Subjects currently opiate-dependent 3.0 wks 7.0 wks
naltrexone treatment significantly longer than Lo-Intervention
subjects. Within the Hi-Intervention group, subjects were more
likely to be opiate-free at a 6- to 18-month follow-up than Lo-
Intervention subjects (59% vs. 20%). Additionally, if re-addicted
at follow-up, Hi-Intervention subjects were more likely to be
in methadone-maintenance treatment, whereas Lo-Intervention sub-
jects were likely not to be in treatment and using heroin.
TABLE 2
Follow-up status at 6-18 months
Hi (N=12)
N (%)
Lo (N=10)
N (%)
Opiate free or in MMTP 10 (84%) 4 (40%)
On Heroin 1 (8%) 5 (50%)
unknown 1 (8%) 1 (10%)
Only 8% of Hi-Intervention subjects were using heroin at follow-
up as compared with 50% of Lo-Intervention subjects. Within the
Hi-Intervention group, subjects who were opiate-free at follow-
up had a longer history of psychotherapy treatment before the
study (1.6 years) than subjects who were re-addicted (0.7 years).
However, treatment outcome was unrelated to the length of previous
methadone-maintenance treatment.
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DISCUSSION
Consistent with our earlier study1 the combination of naltrexone
and psychotherapy fostered better retention in treatment and
greater likelihood of opiate abstinence than naltrexone alone.
Five of the seven Hi-Intervention patients who are opiate-free
at 6-18 months after starting naltrexone experienced at least
one short relapse to heroin use: However, their engagement in
psychotherapy appeared to help minimize the duration and potent-
ially damaging effects of these relapses. Perhaps treatment
outcome is better measured by the cummulative time in opiate-free
status rather than status at an arbitrarily designated point in
time. This is consistent with the fact that cycles of relapse
and recovery are to be expected during the treatment process.
Transient episodes of relapse during continued involvement in
psychotherapy may be viewed as part of a continuing growth
process rather than as treatment failures.
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inhibition of field stimulated rat vas deferens, 173-174
Etorphine
bioassays of, 215-222
stereospecific binding, inhibition by, 90
Fentanyl
bioassays of, 215-222
FK 33824
bioassays of, 215-222
Flurazepam (NIH 9829, MCV 4223)
dependence studies in monkeys, 370
mouse analgesia, 370
self-administration in the baboon, 190
Hallucinogens
use by American Indians, 39
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Heroin
effect of chronic exposure on pregnant rats and their
offspring, 488-494
LAAM vs methadone in withdrawal
propoxyphene vs methadone maintenance treatment, 246-252
self-administration in primates, effects of buprenorphine
and methadone on, 67-73
an opponent process analysis of, 497-503
detoxificxation with naltrexone and psychotherapy,
505-507
2,3,5,6,11,11b-Hexahydro-11,11b-dimethyl-11H-pyrido[3',2':
4,5]pyrrolo[3,2- g] indolizine dihydrochloride (NIH 8835,
UM 973)
biological evaluation for dependence liability, 337
mouse analgesia, 393
self-administration in monkeys, 393
1-[(2 6 11S)-(±)-1-(1,2,3,4,5,6-Hexahydro-8-hydroxy-3,6,
11-trimethyl-2,6-methano-3-benzazocin-11-yl)]-6-methyl-3-
hepatanone methanesulfonate (NIH 9625A, MCV 4176)
biological evaluation for dependence liability, 335
dependence studies in monkeys, 358-359
mouse analgesia, 358
dl-1-[(2 6 11S)-1-(1,2,3,4,5,6-Hexahydro-8-hydroxy-3,6,
11-trimethyl-2,6-methano-3-benzazocin-11-yl)]-3-octanone
methanesulfonate (NIH 9624, MCV 4175, UM 1258)
biological evaluation for dependence liability, 335
depression of smooth muscle twitch, 423
displacement of stereospecific 3H-etorphine binding,
423
mouse analgesia, 423
1,2,3,4,10,14b-Hexahydro-2-methyldibenzo{c,t}pyrazino{1,2a}
(mianserin, UM 1243)
dependence studies in monkeys, 416
depression of smooth muscle twitch, 416
displacement of stereospecific 3H-etorphine, binding,
416
mouse analgesia, 416
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(NIH 9894, MCV 4247, UM 1276)
(+)-2-n-Hexyl-5-( m-hydroxyphenyl)morphan hydrochloride
biological evaluation for dependence liability, 336
dependence studies in monkeys, 443
depression of smooth muscle twitch, 443
displacement of stereospecific 3H-etorphine binding,
443
mouse analgesia, 378, 443
N-2-Hexylnorketobemidone hydrobromide (NIH 9741, UM 1221)
biological evaluation for dependence liability, 336
depression of smooth muscle twitch, 409
displacement of stereospecific 3H-etorphine binding,
409
mouse analgesia, 409
Hydromorphone
See Dilaudid
effects on pupil diameter, in humans, 303
effects on respiration, in humans, 304
effects on skin temperature, in humans, 305
physiological and subjective effects in post addict
volunteers, 301-308
psychological and physiological response produced in
detoxified heroin addicts, an opponent process view
of addiction, 497-503
self-administration in primates, effects of buprenorphine
on, 67-73
(±)-2'-Hydroxy-5,9 dimethyl-2-(3,3-dimethylallyl)-6,7-
benzomorphan (pentazocine, NIH 7958, MCV 4268, UM 381)
biological evaluation for dependence liability, 335
dependence studies in monkeys, 380
mouse analgesia, 379
(±)-9-Hydroxy-4,7-dimethyl-C-homobenzomorphan hydrobromide
(NIH 9612, MCV 4167, UM 1267)
biological evaluation for dependence liability, 335
dependence studies in rats, 353
depression of smooth muscle twitch, 435
displacement of stereospecific 3H-etorphine binding,
435
mouse analgesia, 353, 435
521
(+)-9-Hydroxy-4,7-dimethyl-C-homobenzomorphan hydrobromide
(NIH 9613, MCV 4168, UM 1268)
biological evaluation for dependence, liability, 335
dependence studies in rats, 335
depression of smooth muscle twitch, 436
displacement of stereospecific 3H-etorphine binding,
436
mouse analgesia, 354-355, 436
(-)-9-Hydroxy-4,7-dimethyl-C-homobenzomorphan hydrobromide
(NIH 9614, MCV 4169, UM 1269)
biological evaluation for dependence liability, 335
dependence studies in rats, 356-357
depression of smooth muscle twitch, 437-438
displacement of stereospecific 3H-etorphine binding,
mouse analgesia, 356, 437
self-administration in monkeys, 438
4-Hydroxy-N-methylmorphinan
analgesic activity, mouse hot plate assay, 87
antagonist activity, 89
inhibition of etorphine stereospecific binding, 90
(-)-4-Hydroxy-N-methylmorphinan hydrochloride (NIH 9677,
UM 1201)
biological evaluation for dependence liability, 337,
dependence studies in monkeys, 405
displacement of stereospecific 3H-etorphine binding,
405
mouse analgesia, 404
d-3-Hydroxy-N-methylmorphinan tartrate (dextrorphan, NIH
4591, UM 106, UM 1262)
dependence studies in monkeys, 427
displacement of stereospecific 3H-etorphine binding,
427
4-Hydroxy-N-methylmorphinan-6-one
analgesic activity, mouse hot plate assay, 87
inhibition of etorphine stereospecific binding, 90
(-)-4-Hydroxy-N-methylmorphinan-6-one hydrobromide (NIH
9674, UM 1200)
biological evaluation for dependence liability, 334
dependence studies in monkeys, 404
displacement of stereospecific 3H-etorphine binding,
404
mouse analgesia, 404
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5-Hydroxypentylnorketobemidone hydrobromide (NIH 9789,
UM 1237)
depression of smooth muscle twitch, 414
displacement of stereospecific 3H-etorphine binding,
414
mouse analgesia, 414
(-)-5-(m-Hydroxyphenyl)-2-methylmorphan hydrochloride (NIH
8508A, MCV 4231, UM 809)
biological evaluation for dependence liability, 336
dependence studies in monkeys, 373
mouse analgesia, 373
(+)-5-(m-Hydroxyphenyl)-2-methylmorphan hydrochloride (NIH
8509A, MCV 4232, UM 810)
biological evaluation for dependence liability, 336
dependence studies in monkeys, 374
mouse analgesia, 374
(-)-5-(m-Hydroxyphenyl)-2- n-pentylmorphan hydrochloride
(NIH 9886, MCV 4233)
biological evaluation for dependence liability, 336
dependence studies in monkeys, 374-375
mouse analgesia, 374
(-)-5-(m-Hydroxyphenyl)-2- n-propylmorphan hydrochloride
(NIH 9884, MCV 4241, UM 1273)
biological evaluation for dependence liability, 336
dependence studies in monkeys, 440
depression of smooth muscle twitch, 440
displacement of stereospecific 3H-etorphine binding,
440
mouse analgesia, 377, 440
Hypothalamic-pituitary-Luteinizing hormone (LH) axis
interaction between endogenous opioids and ethanol,
265-271
Inhalants
use by American Indians, 39
Ketamine (UM 1263)
dependence studies in monkeys, 427-428
displacement of phencyclidine binding in rat brain,
179
Ketobemidone
antagonism of ß-endorphin effects in the rat vas deferns,
175-176
523
Ketocyclazocine
antagonism of ß-endorphin effects in the rat vas deferens,
175-176
effects in etonitazene dependent monkeys, 206
LAAM
See l Acetylmethadol
Lefetamine
cross self-administration with buprenorphine in rhesus
monkeys, 211
Leu-enkephalin
bioassays of, 215-222
Levallorphan
displacement of 3H-etorphine binding, 385
Levomethorphan
analgesic activity, mouse hot plate assay, 87
Levonantradol (NIH 9596, MCV 4161, UM 1265)
biological evaluation for dependence liability, 337
dependence studies in monkeys, 429-431
mouse analgesia, 429
self-administration in monkeys, 429-430
Levorphanol
analgesic activity, mouse hot plate assay, 87
displacement of 3H-etorphine binding, 90, 385
mouse analgesia, 341, 382
Lofexidine
blockade of acute opiate withdrawal signs, 264-268
use in outpatient opiate detoxification, 261-263
Luteinizing Hormone (LH)
interaction between endogenous opioids and ethanol,
265-271
naloxone and ethanol interactions on serum levels of,
166,167
Ly97435
agonist and antagonist measures, 115
inhibition of naloxone stereospecific binding, 116
Ly97436
agonist and antagonist measures, 115
inhibition of naloxone stereospecific binding, 116
5 2 4
Ly150720
affinity for opiate receptors, 116, 120, 124
antagonist measure in mice 120, 122
antagonist measure in rats, 115, 120, 122
mouse locomotor activity, 120, 122
mouse writhing test, agonist measure, 115, 119, 121
rat tail heat, agonist measure, 115, 119, 121
respiratory depressant measure in rats, 120, 123
suppression of spontaneous withdrawal in morphine
dependent rats, 120, 123
Marihuana
developmental epidemiological studies of 21-33
use by American Indians, 38
Mazindol
evaluation for international control, 82
MCV 4102 (NIH 9342, UM 1124)
See (-)m-[2-(Cyclopropylmethyl)-1,2,3,4,4a,5,6,7,8,8a-
decahydro-4a-isoquinolyl]phenol succinic acid salt
MCV 4145 (NIH 9540, UM 1169)
See trans-3-(1,2-Dimethyl-4-propyl-4-piperidinyl)phenol
hydrobromide
MCV 4155 (clonidine, NIH 9549, UM 1151)
See 2-(2,6-Dichloroanilino)-2-imidazoline hydrochloride
MCV 4157 (NIH 9576A, UM 1242)
See (-)-cis-(Octahydro-2-methyl-1H-2-pyrindin-4a-yl)
phenol, (Z)-2-butenedioic acid salt
MCV 4158 (phencyclidine, NIH 9580, NIH 9580A, UM 1264)
See 1-(Phenylcyclohexyl)piperidine hydrochloride
MCV 4161 (levonantradol, NIH 9596, UM 1265)
See (-)-trans-5,6,6aß,7,8,9,10 Octahydro-1-acetoxy-
9ß-hydroxy-6ß-methyl-3-(5-phenyl-2-pentyloxy)phenan-
thridine hydrochloride
MCV 4167 (NIH 9612, UM 1267)
See (±)-9-Hydroxy-4,7-dimethyl-C-homobenzomorphan
hydrobromide
MCV 4168 (NIH 9613, UM 1268)
See (+)-9-Hydroxy-4,7-dimethyl-C-homobenzomorphan
hydrobromide
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MCV 4169 (NIH 9614, UM 1269)
See (-)-9-Hydroxy-4,7-dimethyl-C-homobenzomorphan
Hydrobromide
MCV 4170 (NIH 9618)
See cis-3-(Octahydro-1ß,2-dimethyl-4aH-2-pyrindin-4a-
yl)phenol, (Z)-2-butenedioic acid salt
MCV 4172 (NIH 9616)
See cis-3-Octahydro-1 2-dimethyl-4H-2-pyrindin-4a-yl)
phenol, (Z)-2-butenedioic acid salt
MCV 4173 (NIH 9617)
See cis-2-(1,2-Dimethyl-4-propyl-4-piperidinyl)phenol
(Z)-2-butenedioic acid salt
MCV 4175 (NIH 9624, UM 1258)
See dl-1-[(2 6 11S)-1-(1,2,3,4,5,6-Hexahydro-8-hydroxy-
3,6,11-trimethyl-2,6-methano-3-benzazocin-11-yl)]-3-
octanone methanesulfonate
MCV 4176 (NIH 9625A)
See 1-[(2 6 11S)-(±)-1-(1,2,3,4,5,6-Hexahydro-8-hydroxy-
3,6,11-trimethyl-2,6-methano-3-benzazocin-11-yl)]-6-
methyl-3-hepatanone methanesulfonate
MCV 4187 (NIH 9724, UM 1212)
See L-Tyrosyl-D-alanylglycyl-L-N allyl-phenylalanine
amide acetate
MCV 4190 (NIH 9650, UM 1198)
See N-4-Methylpentylnorketobemidone hydrobromide
MCV 4192 (zopemirac, NIH 9730, UM 1217)
See Sodium 5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrole-
2-acetate
MCV 4195 (NIH 9735, UM 1223)
See N-Cyclopropylmethyl-7,8-dihydronormorphinone
MCV 4196 (NIH 9736, UM 1224)
See N-Cyclobutylmethyl-3-hydroxy-6-methylene-8ß-methyl-
morphinan
MCV 4197 (NIH 9737, UM 1225)
See 17-Cyclopropylmethyl-7,7-dimethyl-3-methoxy-4,5
epoxymorphinan-6-one
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MCV 4199 (NIH 9738, UM 1226)
See Nitronaltrexone
MCV 4201 (NIH 9342, UM 1124)
See (-)-m-[2-(Cyclopropylmethyl)-1,2,3,4,4a,5,6,7,8,8a
decahydro-4aß-isoquinolyl]phenol succinic acid salt
MCV 4206 (NIH 8834A, UM 972)
See (-)-13ß-Amino-5,6,7,8,9,10,11,12-octahydro-5 -methyl-
5,11-methanobenzocyclodecen-3-ol hydrobromide
MCV 4208 (NIH 9787)
See 17-Cyclopropylmethyl-6,7-didehydro-4,5 -epoxy-6-
fluoro-3-acetoxymorphinan
MCV 4210 (NIH 9791, UM 1238)
See N-Methyl-L-tyrosyl-D-serylglycyl-N-methyl-L-
phenylalanyl-D-serinamide monoacetate
MCV 4212 (NIH 9804, UM 1245)
See (-)-(1R,5R,9R,2"S)-(5,9-Dimethyl-2'-hydroxy-2-(2-
methyltetrahydrofurfuryl)-6,7-benzomorphan) L-tartrate
MCV 4213 (NIH 9805, UM 1246)
See (-)-(1R,5R,9R)-5,9-Dimethyl-2'-hydroxy-2-(2-
methoxyisobutyl)-6,7,benzomorphan
MCV 4217 (NIH 9809)
(-)-(1R,5R,9R,2"S)-5,9-Dimethyl-2'-hydroxy-2-(2-
methoxypropyl)-6,7-benzomorphan hydrobromide
MCV 4218 (NIH 9810)
See 2,3-Dihydro-2-methyl-3-[2-(dimethylamino)-propyl]-
3-phenyl-1H-indol-1-carboxaldehyde methanesulfonate
MCV 4219 (NIH 9821, UM 1252)
See Oripavine hydrochloride
MCV 4220 (NIH 9824, UM 1253)
See (-)-trans-3-(Octahydro-2-methyl-4a(2H)-isoquinoline)
phenol hydrobromide
See also (-)-trans-[(2-Methyl)-1,2,3,4,4a,5,6,7,8,8a
decahydro-4aß-isoquinolyl]phenol hydrobromide
MCV 4221 (NIH 9825, UM 1254)
See (+)-trans-3-(Octahydro-2-methyl-4a(2H)-isoquinoline)
phenol hydrobromide
See also (+)-trans-[2-(Methyl)-1,2,3,4,4a,5,6,7,8,8a
decahydro-4aß-isoquinolyl]phenol hydrobromide
527
MCV 4222 (Oxazepam, NIH 9826)
See 7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-
benzodiazepin-2-one
MCV 4223 (flurazepam, NIH 9829)
See 7-Chloro-1-[2-(diethylamino)ethyl]-5-(O-fluoro-
phenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one
dihydrochloride
MCV 4225 (NIH 9839, UM 1259)
See (-)-trans-3-(Octahydro-2-methyl-1H-2-pyrindin-4a-
yl) phenol, (Z)-2-butanedioate
MCV 4226 (NIH 9840, UM 1260)
See (+)-trans-3-(Octahydro-2-methyl-1H-2-pyrindin-4a-
yl)phenol, (Z)-2-butanedioate
MCV 4227 (NIH 9832, UM 1261)
See N-(6,14-Endoetheno-7,8-dihydromorphine-7 -carbonyl)-
L-leucine ethyl ester hydrochloride
MCV 4288 (nabilone, NIH 9872, UM 1266)
See dl-trans-3-(1-1-Dimethylheptyl)-6,6aß,7,8,1O,1Oa
hexahydro-1-hydroxy-6,6-dimethyl-9Hdibenzo[b,d]pyran-
9-one
MCV 4229 (NIH 9873)
See 3-(2-Ethyl-4,6-dimethyl-2-morpholinyl)phenol
MCV 4230 (NIH 9874, UM 1322)
See 17-Cyclopropylmethyl-4,5 -epoxy-6,6-difluoro-3-
acetoxymorphinan
MCV 4231 (NIH 8508A, UM 809)
See (-)-5-(m-Hydroxyphenyl)-2-methylmorphan hydrochloride
MCV 4232 (NIH 8509A, UM 810)
See (+)-5-(m-Hydroxyphenyl)-2-methylmorphan hydrochloride
MCV 4233 (NIH 9886)
See (-)-5-(m-Hydroxyphenyl)-2-n-pentylmorphan hydrochloride
MCV 4235 (NIH 9895)
See (+)-4-Allyl-1-methyl-1O-hydroxy-2,3,4,5,6,7-hexahydro-
1,6-methano-1H-4-benzazonine
MCV 4236 (NIH 9896)
See (-)-4-Allyl-1-methyl-1O-hydroxy-2,3,4,5,6,7-hexahydro-
1,6-methano-1H-4-benzazonine
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MCV 4237 (NIH 9899)
See (+)-1-Methyl-4-cyclopropylmethyl-10-hydroxy-2,3,
4,5,6,7-hexahydro-1,6-methano-1H-4-benzazonine
MCV 4238 (NIH 9900)
See (-)-1-Methyl-4-cyclopropylmethyl-10-hydroxy-2,3,
4,5,6,7-hexahydro-1,6-methano-1H-4-benzazonine
MCV 4241 (NIH 9884, UM 1273)
MCV 4242 (NIH 9885, UM 1274
MCV 4247 (NIH 9894, UM 1276)
See (-)-5-(m-Hydroxyphenyl)-2- n-propylmorphan hydro-
chloride
See (-)-2-n-Butyl-5-( m-hydroxyphenyl)morphan hydro-
chloride
See (+)-2-n-Hexyl-5-( m-hydroxyphenyl)morphan hydro-
choloride
MCV 4249 (NIH 9898, UM 1280)
MCV 4250 (NIH 9901, UM 1277)
See 1,12 -Dimethyl-4-allyl-10-hydroxy-2,3,4,5,6,7-
hexahydro-1,6-methano-1H-4-benzazonine
See (±)-1-Methyl-4-cyclopropylmethyl-10-hydroxy-2,3,
4,5,6,7-hexahydro-1,6-methano-1H-4-benzazonine
MCV 4251 (NIH 9902, UM 1281)
See 1,12 -Dimethyl-4-cyclopropylmethyl-1O-hydroxy-2,3,
4,5,6,7-hexahydro-1,6-methano-1H-4-benzazonine
MCV 4268 (pentazocine, NIH 7958, UM 381)
MCV 4287 (NIH 9961, UM 1324)
See (±)-2'-Hydroxy-5,9 -dimethyl-2-(3,3-dimethylallyl)-
6,7-benzomorphan
See 1-(Methyl-2-phenylethyl)-4-(N-propranilido)piperidine
hydrochloride
Medazepam
self-injection in the baboon, 190
Melanotropin-release-inhibiting factor (MIF)
effects of MIF and cycle (Leu-Gly) analog on tolerance
to buprenorphine in the rat, 134-140
529
Meperidine
effects in etonitazene dependent monkeys, 205
mouse analgesia, 341, 382
mouse writhing and rat tail heat, 115
Metazocine
inhibition of phencyclidine binding in rat brain, 180
(-)-Metazocine
mouse analgesia, 341, 382
Methadone
baciofen in methadone withdrawal in humans, 269-275
blockade of acute withdrawal signs by lofexidine in
humans, 264-268
comparison of urine collection schedule with different
predictability in a clinic, 460-465
contingent reinforcement of benzodiazepine-free urines
from methadone maintenance patients, 282-287
correlation of brain levels with analgesia in chronic
morphine and acute naloxone-treated rats, 495-496
effects in etonitazene dependent monkeys, 205
effects of pretreatment on self-regulated opioid
detoxification by humans, 232-238
effect on cortisol levels in addicts, 476-482
effects on opiate self-administration in primates,
67-73
maintenance treatment narcotic dependence, comparison
with propoxyphene, 246-252 - 253-260
neonatal behavioral assessment, 318
outpatient detoxification procedures, 239-245
patient self-adjustment of maintenance dose, 327-330
urine monitoring of methadone maintenance patients,
276-281
versus LAAM in a maintenance treatment program, 473-475
vs LAAM in heroin withdrawal, 230-231
Met-enkephaline
bioassays of, 215-222
3-Methoxy-N-methylmorphinan-6-one
analgesic activity, mouse hot plate assay, 87
4-Methoxy-N-methylmorphinan
analgesic activity, mouse hot plate assay, 87
inhibition of etorphine stereospecific binding, 90
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4-Methoxy-N-methylmorphinan-6-one
analgesic activity, mouse hot plate assay, 87
inhibition of etorphine stereospecific binding, 90
4ß-(m-Methoxyphenyl)-1,3-dimethyl-4 -piperidinol propionate
hydrochloride (NIH 9541, UM 1170)
biological evaluation for dependence liability, 336
dependence studies in monkeys, 402
depression of smooth muscle twitch, 402
displacement of stereospecific 3H-etorphine binding, 402
mouse analgesia, 401
self-administration in monkeys, 401
N-Methylbenzomorphane
energy-conformational studies, narcotic antagonist
activity, 504
(+)-1-Methyl-4-cyclopropylmethyl-10-hydroxy-2,3,4,5,6,7-
hexahydro-1,6-methano-1H-4-benzazonine (NIH 9899, MCV 4237)
(-)-1-Methyl-4-cyclopropylmethyl-10-hydroxy-2,3,4,5,6,7-
hexahydro-1,6-methano-1H-4-benzazonine (NIH 9900, MCV 4238)
biological evaluation for dependence liability, 335
dependence studies in monkeys, 377
mouse analgesia, 377
(+)-1-Methyl-4-cyclopropylmethyl-10-hydroxy-2,3,4,5,6,7-
hexahydro-1,6-methano-1H-4-benzazonine (NIH 9901, MCV 4250,
UM 1277)
biological evaluation for dependence liability, 335
dependence studies in monkeys, 444
depression of smooth muscle twitch, 444
displacement of stereospecific 3H-etorphine binding, 444
mouse analgesia, 379, 444
(-)-trans-[(2-Methyl)-1,2,3,4,4a,5,6,7,8,8a -decahydro-4aß-
isoquinolyl]phenol hydrobromide (NIH 9824, MCV 4220, UM 1253)
biological evaluation for dependence liability, 337
mouse analgesia, 368
See also (-)-trans-3-(Octahydro-2-methyl-4a(2H)-
isoquinoline)phenol hydrobromide
(+)-trans-[2-(Methyl)-1,2,3,4,4a,5,6,7,8,8a -decahydro-
4aß-isoquinolyl]phenol hydrobromide (NIH 9825, MCV 4221,
UM 1254
biological evaluation for dependence liability, 337
mouse analgesia, 369
See also (+)-trans-3-(Octahydro-2-methyl-4a(2H)-isoquinoline)
phenol hydrobromie
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N-4-Methylpentylnorketobemidone hydrobromide (NIH 9650,
MCV 4190, UM 1198)
biological evaluation for dependence liability, 336
dependence studies in monkeys, 360
mouse analgesia, 360
1-(4-Methylphenyl)-3-azabicyclo [3.1.0] hexane (CL 220,
075; Bicifadine)
non-narcotic analgesic activity, 93-98
1-(-Methyl-2-phenylethyl)-4-(N-propranilido)piperidine
hydrochloride (China White, NIH 9961, MCV 4287, UM 1324)
biological evaluation for dependence liability, 337
dependence studies in monkeys, 380
depression of smooth muscle twitch, 449
displacement of stereospecific 3H-etorphine binding, 449
mouse analgesia, 380, 449
N-Methyl-4-(1-phenyl-1H-5-tetrazolyloxy)-morphinan-6-one
analgesic activity, mouse hot plate assay, 87
[D-Met2,Pro5]-enkephalinamide
bioassays of, 215-222
N-Methyl-L-tyrosyl-D-seryl-glycyl-N-methyl-L-phenylalanyl-
D-serinamide monacetate (NIH 9791, MCV 4210, UM 1238)
biological evaluation for dependence liability, 337
dependence studies in monkeys and rats, 365-366
depression of smooth muscle twitch, 415
displacement of stereospecific 3H-etorphine binding, 415
mouse analgesia, 365, 415
Mianserin (UM 1243)
See 1,2,3,4,10,14b-Hexahydro-2-methyldibenzo{c,t}
pyrazino{1,2a}azapine
Midazlom
self-injection in the baboon, 190
MIF
See melanotropin-release-inhibiting factor
Morphine
analgesic activity, 87, 89, 340-341, 382
antagonism of ß-endorphin effects, in the rat vas
deferens, 175, 176
bioassays of, 215-222
clinical analgesic study, comparison with sublingual
buprenorphine, 288-293
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Morphine
clonidine in withdrawal, 47
correlation of brain levels of methadone with analgesia
in chronic morphine-treated rats, 495-496
cross tolerance with ß-endorphin in the isolated
guinea pig ileum, 151-152
cross tolerance with normorphine in the isolated guinea
pig ileum, 151-152
effects in etonitazene-dependent monkeys, 205
effect of acute treatment on motor activity in the
rat, interaction with naloxone, 141, 143
effect of spinalization in tail-flick latency in mice,
60-61
inhibition of etorphine stereospecific binding, 90, 385
inhibition of field-stimulated rat vas deferens, 173, 174
inhibition of naloxone stereospecific binding, 116
interaction with (-)- -tetrahydrocannabinol in rats,
141-147
intracranial self-administration in the rat, 158-164
mouse writhing and rat tail heat, 115
operant behavior in the rat, interaction with (-)
tetrahydrocannabinol and naloxone, 144-145
release of endogenous opiates into CSF, 60-66
variation of analgesia in cancer patients with chronic
pain, 294-300
Nabilone (NIH 9872, MCV 4228, UM 1266)
biological evaluationfor dependence liability, 337
dependence studies in monkeys, 372, 432-435
mouse analgesia, 371, 432
self-administration in monkeys, 433
Nalbuphine
effects in etonitazene-dependent monkeys, 206
Nalorphine
antinociceptive and antagonist activities, 89, 115,
340-341, 383
displacement of 3H-etorphine binding, 385
effects in etonitazene-dependent monkeys, 205
agonistic-antagonistic activity in mouse analgesia tests,
340-341, 383
antagonism of ß-endorphin effects in the rat vas de-
ferens, 175, 176
Naloxone
correlation of brain levels of methadone with analgesia
in acute naloxone-treated rats, 495-496
533
Naloxone
displacement of 3H-etorphine binding, 385
effects in etonitazene-dependent monkeys, 205
effects of ethanol on naloxone-induced increases in
serum LH, 166-167
effect-of ethanol on stereospecific binding of, 166, 168
effect on cortisol levels in addicts, 476-482
effects on ethanol-induced depressions in serum LH
in rats, 166-167
effect on morphine-induced and THC-induced depression
of motor activity in the rat, 141, 143
inhibition of naloxone stereospecific binding, 116
stereospecific binding, inhibition of, 116
Naltrexone
antagonistic activity in mouse analgesia tests, 340,
383
combination with pyschotherapy in heroin detoxification,
505-507
displacement of 3H-etorphine binding, 385
Narcotics
etonitazene-dependent rhesus monkey as a model to
study agonist and antagonist activities of, 200-207
Narcotic antagonist
prediction of activity through study of energy confor-
mation of N-methylbenzomorphan, 504
Nathan B. Eddy Memorial Award
Committee on Problems of Drug Dependence, Past, Pre-
sent and Future, 3-9
introduction of award recipient, 1
Neonatal studies
behavioral assessment in newborns of women on methadone,
318
effects of perinatal addiction on pulmonary function
of the new born, 319-326
Nicotine
behavioral studies in dogs and monkeys, 57-59
studies of dependence in man, 49-51
NIDA addiction Research Center
progress report, Baltimore, MD, 45-52
progress report, Lexington, KY, 53-59
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NIH 4591 (dextrophan, UM 106, UM 1262)
NIH 7958 (pentazocine, MCV 4268, UM 381)
NIH 8439 (UM 747)
NIH 8508A (MCV 4231, UM 809)
NIH 8509A (MCV 4232, UM 810)
See d-3-Hydroxy-N-methylmorphinan tartrate
See (±)-2'-Hydroxy-5,9 -dimethyl-2-(3,3-dimethylallyl)-
6,7-benzomorphan
See (-)-5,9 -Diethyl-2'-hydroxy-2-methylenecyclopropyl-
methyl-6,7-benzomorphan hydrochloride
See (-)-5-(m-Hydroxyphenyl)-2-methylmorphan hydro-
chloride
See (+)-5-(m-Hydroxyphenyl)-2-methylmorphan hydro-
chloride
NIH 8805 (UM 952)
NIH 8833 (UM 961)
See Buprenorphine
See (-)-cis-2-(Dimethylamino- m-hydroxybenzyl)cyclohexanol
hydrochloride
NIH 8834 (NIH 8834A, MCV 4206, UM 972)
See (-)-13ß-Amino-5,6,7,8,9,10,11,12-octahydro-5
methyl-5,11-methanobenzocyclodecen-3-ol hydrobromide
NIH 8834A (NIH 8834, MCV 4206, UM 972)
NIH 8835 (UM 973)
NIH 8863 (UM 983)
NIH 9112 (UM 1076)
NIH 9256 (UM 1103)
See (-)-13ß-Amino-5,6,7,8,9,10,11,12-octahydro-5
methyl-5,11-methanobenzocyclodecen-3-ol hydrobromide
See 2,3,5,6,11,11b-Hexahydro-11,11b-dimethyl-1H-pyrido
[3',2':4,5]pyrrolo[3,2- g]indolizine dihydrochloride
See N-( -Pyridyl)-N-(1-ß-phenylethyl-4-piperidyl)-
ethylcarbamate hydrochloride
See (±)-3-Allyl-1,3-dimethyl-4-phenyl-4-propionoxy-
piperidine hydrochloride
See 2-Cyclopropylmethyl-9 -ethyl-2'-hydroxy-5-methyl-
6,7-benzomorphan
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NIH 9342 (MCV 4102, UM 1124)
See (-)-m-[2-(Cyclopropylmethyl)-1,2,3,4,4a,5,6,7,8,
8a -decahydro-4aß-isoquinolyl]phenol succinic acid
salt
NIH 9521 (UM 1160)
See 3- -(1,2ß,3ß,4-Tetramethyl-4-piperidinyl)phenol
hydrobromide
NIH 9540 (MCV 4145, UM 1169)
See trans-3-(1,2-Dimethyl-4-propyl-4-piperidinyl)phenol
hydrobromide
NIH 9541 (UM 1170)
See 4ß-(m-Methoxyphenyl)-1,3-dimethyl-4 -piperidinol
propionate hydrochloride
NIH 9549 (clonidine, MCV 4155, UM 1151)
See 2-(2,6-Dichloroanilino)-2-imidazoline hydrochloride
NIH 9576A (MCV 4157, UM 1242)
See (-)-cis-(Octahydro-2-methyl-1H-2-pyrindin-4a-yl)
phenol, (Z)-2-butenedioic acid salt
NIH 9580 (phencyclidine, NIH 9580A, MCV 4158, UM 1264)
See 1-(1-Phenylcyclohexyl)piperidine hydrochloride
NIH 9580A (phencyclidine, NIH 9580, MCV 4158, UM 1264)
See 1-(Phenylcyclohexyl)piperidine hydrochloride
NIH 9585 (UM 1218)
See N-Cyclohexylmethylnorketobemidone hydrobromide
NIH 9596 (levonantradol, MCV 4161, UM 1265)
See (-)trans -5,6,6aß,7,8,9,10a -Octahydro-1-acetoxy-
9ß-hydroxy-6ß-methyl-3-(5-phenyl-2-pentyloxy)-
phenanthridine hydrochloride
NIH 9612 (MCV 4167, UM 1267)
See (±)-9-Hydroxy-4,7-dimethyl-C-homobenzomorphan
hydrobromide
NIH 9613 (MCV 4168, UM 1268)
See (+)-9-Hydroxy-4,7-dimethyl-C-homobenzomorphan
hydrobromide
NIH 9614 (MCV 4169, UM 1269)
See (-)-9-Hydroxy-4,7-dimethyl-C-homobenzomorphan
hydrobromide
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NIH 9616 (MCV 4172)
NIH 9617 (MCV 4173)
NIH 9618 (MCV 4170)
NIH 9624 (MCV 4175, UM 1258)
NIH 9625A (MCV 4176)
NIH 9637 (UM 1195)
NIH 9650 (MCV 4290, UM 1198)
NIH 9674 (UM 1200)
NIH 9677 (UM 1201)
NIH 9724 (MCV 4187, UM 1212)
NIH 9730 (zopemirac, MCV 4192, UM 1217)
NIH 9735 (MCV 4195, UM 1223)
NIH 9736 (MCV 4196, UM 1224)
See cis-3-0ctahydro-1 ,2-dimethyl-4H-2-pyrindin-4a-
yl)phenol, (Z)-2-butenedioic acid salt
See cis-2-(1,2-Dimethyl-4-propyl-4-piperidinyl)phenol,
(Z)-2-butenedioic acid salt
See cis-3-(0ctahydro-1ß,2-dimethyl-4aH-2-pyrindin-4a-
yl)phenol, (Z)-2-butenedioic acid salt
See (±)-1-[(2a,6 ,11S)-1-(1,2,3,4,5,6-Hexahydro-8-
hydroxy-3,6,11-trimethyl-2,6-methano-3-benzazocin-11-
yl)]-3-octanone methanesulfonate
See 1-[(2 6 11S)-(±)-1-(1,2,3,4,5,6-Hexahydro-8-
hydroxy-3,6,11-trimethyl-2,6-methano-3-benzazocin-
11-yl)]-6-methyl-3-heptanone methanesulfonate
See s-N-sec-Butylnormorphine hydrochloride
See N-4-Methylpentylnorketobemidone hydrobromide
See (-)-4-Hydroxy-N-methylmorphinan-6-one hydrobromide
See (-)-4-Hydroxy-N-methylmorphinan hydrochloride
See L-Tyrosyl-D-alanylglycyl-L-N allyl-phenylalanine
amide acetate
See Sodium 5-(4-Chlorobenzoyl)-,4-dimethyl-1H-pyrrole-
2-acetate
See N-Cyclopropylmethyl-7,8-dihydronormorphinone
See N-Cyclobutylmethyl-3-hydroxy-6-methylene-8ß-methyl-
morphinan
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NIH 9737 (MCV 4197, UM 1225)
See 17-Cyclopropylmethyl-7,7-dimethyl-3-methoxy-4,5
epoxymorphinan-6-one
NIH 9738 (MCV 4199, UM 1226)
See 2-Nitronaltrexone
NIH 9741 (UM 1221)
See N-2-Hexylnorketobemidone hydrobromide
NIH 9787 (MCV 4208)
See 17-Cyclopropylmethyl-6,7-didehydro-4,5 -epoxy-6-
fluoro-3-acetoxymorphinan
NIH 9789 (UM 1237)
See 5-Hydroxypentylnorketobemidone hydrobromide
NIH 9791 (MCV 4210, UM 1238)
See N-Methyl-L-tyrosyl-D-serylglycyl-N-methyl-L-
phenylalanyl-D-serinamide monoacetate
NIH 9804 (MCV 4212, UM 1245)
See (-)-(1R,5R,9R,2"S)-(5,9-Dimethyl-2'-hydroxy-2-(2-
methyltetrahydrofurfuryl)-6,7-benzomorphan)-L-tartrate
NIH 9805 (MCV 4213, UM 1246)
See (-)-(1R,5R,9R)-5,9-Dimethyl-2'-hydroxy-2-(2-
methoxyisobutyl)-6,7,benzomorphan
NIH 9809 (MCV 4217)
See (-)-(1R,5R,9R,2"S)-5,9-Dimethyl-2'-hydroxy-2-(2-
methoxypropyl)-6,7-benzomorphan hydrobromide
NIH 9810 (MCV 4218)
See 2,3-Dihydro-2-methyl-3-[2-(dimethylamino)-propyl]-
3-phenyl-1H-indol-1-carboxaldehyde methanesulfonate
NIH 9821 (MCV 4219, UM 1252)
See Oripavine hydrochloride
NIH 9824 (MCV 4220, UM 1253)
See (-)-trans-3-(0ctahydro-2-methyl-4a(2H)-isoquinoline)
phenol hydrobromide
See also (-)-trans-[2-(Methyl)-1,2,3,4,4a,5,6,7,8,8a
decahydro-4aß-isoquinolyl]phenol hydrobromide
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NIH 9825 (MCV 4221, UM 1254)
NIH 9826 (oxazepam, MCV 4222)
NIH 9827
NIH 9829 (flurazepam, MCV 4223)
NIH 9832 (MCV 4227, UM 1261)
NIH 9839 (MCV 4225, UM 1259)
NIH 9840 (MCV 4226, UM 1260)
NIH 9872 (nabilone, MCV 4228, UM 1266)
NIH 9873 (MCV 4229)
NIH 9874 (MCV 4230, UM 1322)
NIH 9884 (MCV 4241, UM 1273)
NIH 9885 (MCV 4242, UM 1274)
See (+)-trans-3-(0ctahydro-2-methyl-4a(2H)-isoquinoline)
phenol hydrobromide
See also (+)-trans-[2-(Methyl)-1,2,3,4,4a,5,6,7,8,8a
decahydro-4aß-isoquinolyl]phenol hydrobromide
See 7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-
benzodiazepin-2-one
biological evaluation for dependence liability, 337
See 7-Chloro-1-(2-(diethylamino)ethyl]-5-(o-fluoro-
phenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one-
dihydrochloride
See N-(6,14-Endoetheno-7,8-dihydromorphine-7 -carbonyl)-
L-leucine ethyl ester hydrochloride
See (-)trans-3-(0ctahydro-2-methyl-1H-2-pyrindin-4a-
yl)phenol, (Z)-2-butanedioate
See (+)-trans-3-(0ctahydro-2-methyl-1H-2-pyrindin-4a-
yl)phenol, (Z)-2-butanedioate
See (±)-trans-3-(1-1-Dimethylheptyl)-6,6aß,7,8,10,
10a -hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo[b,
d]pyran-9-one
See 3-(2-Ethyl-4,6-dimethyl-2-morpholinyl)phenol
See 17-Cyclopropylmethyl-4,5 -epoxy-6,6-difluoro-3-
acetoxymorphinan
See (-)-5-(m-Hydroxyphenyl)-2-n-propylmorphan hydro-
chloride
See (-)-2-n-Butyl-5-(m-hydroxyphenyl)morphan hydro-
chloride
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NIH 9886 (MCV 4233)
NIH 9894 (MCV 4247, UM 1276)
NIH 9895 (MCV 4235)
NIH 9896 (MCV 4236)
NIH 9898 (MCV 4249, UM 1280)
NIH 9899 (MCV 4237)
NIH 9900 (MCV 4238)
NIH 9901 (MCV 4250, UM 1277)
NIH 9902 (MCV 4251, UM 1281)
NIH 9961 (MCV 4287, UM 1324)
See (-)-5-(m-Hydroxyphenyl)-2- n-pentylmorphan hydro-
chloride
See (+)-2-n-Hexyl-5-( m-hydroxyphenyl)morphan hydro-
chloride
See (+)-4-Allyl-1-methyl-10-hydroxy-2,3,4,5,6,7-
hexahydro-1,6-methano-1H-4-benzazonine
See (-)-4-Allyl-1-methyl-10-hydroxy-2,3,4,5,6,7-
hexahydro-1,6,methano-1H-4-benzazonine
See 1,12 -Dimethyl-4-allyl-10-hydroxy-2,3,4,5,6,7-
hexahydro-1,6-methano-1H-4-benzazonine
See (+)-1-Methyl-4-cyclopropylmethyl-10-hydroxy-2,3,4,
5,6,7-hexahydro-1,6-methano-1H-4-benzazonine
See (-)-1-Methyl-4-cyclopropylmethyl-10-hydroxy-2,3,
4,5,6,7-hexahydro-1,6-methano-1H-4-benzazonine
See (±)-1-Methyl-4-cyclopropylmethyl-10-hydroxy-2,3,4,
5,6,7-hexahydro-1,6-methano-1H-4-benzazonine
See 1,12 -Dimethyl-4-cyclopropylmethyl-10-hydroxy-2,3,
4,5,6,7-hexahydro-1,6-methano-1H-4-benzazonine
See 1-(Methyl-2-phenylethyl)-4-(N-propranilido)-
piperidine hydrochloride
2-Nitronaltrexone (NIH 9738, MCV 4199, UM 1226)
biological evaluation for dependence liability, 334
depression of smooth muscle twitch, 413
displacement of stereospecific 3H-etorphine binding, 413
mouse analgesia, 413
(-)-Nordihydrocodeinone
efficient synthesis of, 99-104
540
Normorphine
cross-tolerance with morphine in the isolated guinea-pig
ileum, 151-152
interactions with Ca++ on the guinea-pig ileum, 148-157
(-)-trans-5,6,6aß,7,8,9,1O -Octahydro-1-acetoxy-9ß-hydroxy-
6ß-methyl-3-(5-phenyl-2-pentyloxy)phenanthridine hydrochloride
(levonantradol, NIH 9596, MCV 4161, UM 1265)
biological evaluation for dependence liability, 337
dependence studies in monkeys, 429-431
mouse analgesia, 429
self-administration in monkeys, 429-430
cis-3-(Octahydro-1 ,2-dimethyl-4H-2-pyrindin-4a-yl)phenol,
(Z)-2-butenedioic acid salt (NIH 9616, MCV 4172)
biological evaluation for dependence liability, 337
dependence studies in monkeys, 358
mouse analgesia, 357
cis-3-(Octahydro-16,2-dimethyl-4aH-2-pyrindin-4a-yl)phenol,
(Z)-2-butenedioic acid salt (NIH 9618, MCV 4170)
biological evaluation for dependence liability, 337
mouse analgesia, 357
(-)-trans-3-(Octahydro-2-methyl-4a(2H)-isoquinoline)phenol
hydrobromide (NIH 9824, MCV 4220, UM 1253) (sponsor nomenclature)
biological evaluation for dependence liability, 337
dependence studies in monkeys, 421
depression of smooth muscle twitch, 421
displacement of stereospecific 3H-etorphine binding, 421
mouse analgesia, 421
See also (-)-trans-[2-(Methyl)-1,2,3,4,4a,5,6,7,8,8a
decahydro-4aß-isoquinolyl]phenol hydrobromide
(+)-trans-3-(Octahydro-2-methyl-4a(2H)-isoquinoline)phenol
hydrobromide (NIH 9825, MCV 4221, UM 1254) (sponsor-nomenclature)
biological evaluation for dependence liability, 337
dependence studies in monkeys, 423
depression of smooth muscle twitch, 422
displacement of stereospecific 3H-etorphine binding, 422
mouse analgesia, 422
See also (+)-trans-[2-(Methyl)-1,2,3,4,4a,5,6,7,8,8a
decahydro-4aß-isoquinolyl]phenol hydrobromide
(-)-cis-(Octahydro-2-methyl-1H-2-pyrindin-4a-yl)phenol,
(Z)-2-butenedioic acid salt (NIH 9576A, MCV 4157, UM 1242)
biological evaluation for dependence liability, 337
dependence studies in monkeys, 349-351
mouse analgesia, 349
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(+)-trans-3-(Octahydro-2-methyl-1H-2-pyrindin-4a-yl)phenol,
(Z)-2-butanedioate (NIH 9840, MCV 4226, UM 1260)
biological evaluation for dependence liability, 337
dependence studies in monkeys, 425
depression of smooth muscle twitch, 425
displacement of stereospecific 3H-etorphine binding, 425
mouse analgesia, 371, 425
(-)-trans-3-(Octahydro-2-methyl-1H-2-pyrindin-4a-yl)phenol,
(Z)-2-butanedioate (NIH 9839, MCV 4225, UM 1259)
biological evaluation for dependence liability, 337
dependence studies in monkeys, 424
depression of smooth muscle twitch, 424
displacement of stereospecific 3H-etorphine binding, 424
mouse analgesia, 370, 424
Opiates
use by American Indians, 39
Opiate dependence
effects of perinatal addiction on pulmonary function
in the new born, 319-326
propoxyphene maintenance treatment vs methadone, 246-
252, 253-260
Opiate detoxification
comparison of three outpatient methadone detoxification
procedures, 239-245
effects of methadone pretreatment in humans, 232-238
use of lofexidine, 261-263
Opiate receptors
evidence for a single opioid receptor type in the rat
vas deferens, 172-177
localization of the reward-relevant opiate receptor
in the rat, 158-164
phencyclidine sigma opiate receptor, autoradiographic
localization in rat brain, 178-183
selective tolerance to, 215-222
specific binding sites for SKF-10047, 55-56
Opium
a chronic opium eater: a drug metabolic case study,
53-55
Opium alkaloids
synthetic opium alkaloids and derivatives, 99-1O4
542
Opponent Process Analysis
psychological and physiological response of detoxified
heroin addicts to hydromorphone, 497-503
Oripavine hydrochloride (NIH 9821, MCV 4219, UM 1252)
dependence studies in monkeys, 368
depression of smooth muscle twitch, 420
displacement of stereospecific 3H-etorphine binding, 420
mouse analgesia, 368, 420
Oxazepam (NIH 9826, MCV 4222)
biological evaluation for dependence liability, 337
dependence studies in monkeys, 369
mouse analgesia, 369
Oxygenated morphinans
structure-activity relationship, 86-92
Oxymorphone
antagonism of ß-endorphin effects in the rat vas
deferens, 175, 176
inhibition of field-stimulated rat vas deferens, 173,174
PCE
See N-Ethyl-1-phencyclohexamine
oral self-administration, in monkeys, 74-81
PCP
See Phencyclidine
Pentazocine (NIH 7958, MCV 4268, UM 381)
agonist and antagonist measures, 89, 115
biological evaluation for dependence liability, 335
dependence studies in monkeys, 380
depression of smooth muscle twitch,
displacement of stereospecific 3H-etorphine binding, 385
inhibition of naloxone stereospecific binding, 116
inhibition of phencyclidine binding in rat brain, 180
mouse analgesia, 340-341, 379, 383
oral therapeutic index, 97
Pentobarbital
comparison with diazepam and chlordiazepoxide, in man,
48
self-injection in the baboon, 190
Peyote
use by American Indians, 39
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Phendimetrazine
evaluation for international control, '82
Phencyclidine (PCP, NIH 9580, MCV 4158, UM 1264)
autoradiographic localization of receptor in rat brain,
178-183
behavioral dependence in rhesus monkeys, 185-189
binding assay, 129, 130
biological evaluation for dependence liability, 337
characteristics of chronic abusers, 483-487
dependence studies in monkeys, 351-353, 428
discriminative stimulus assay in rats, 127, 130
effect of cycloalkyl ring size, 128
inhibition of sterospecific binding by various analogs
and opioids in rat brain, 179, 180
mouse analgesia, 351
mouse rotarod test, 129, 130
oral self-administration and tolerance to behavioral
effects in monkeys, 74-81
structure-activity relationship study, 126-133
evaluation for international control, 82
See also 1-(1-phenylcyclohexyl)piperldine
1-(Phenylcyclohexyl)piperidine hydrochloride (phencyclidine,
NIH 9580A, MCV 4158)
See also phencyclidine
biological evaluation for dependence liability, 337
dependence studies in monkeys, 351-353, 428
mouse analgesia, 351
5-Phenyl-2-methylmorphans
agonist and antagonist measures, 115
inhibition of naloxone stereospecific binding, 116
4-Phenylpiperidines
structural requirements for affinity and intrinsic
activity at the opiate receptor, 112-118
4 -Phenyl-2-pyrindines
structural requirements for affinity and intrinsic
activity at the opiate receptor, 112-118
cis-Phenylpyrindines
agonist and antagonist measures, 115
inhibition of naloxone sterospecific binding, 116
trans-Phenylpyrindines
agonist and antagonist measures, 115
inhibition of naloxone sterospecific binding, 116
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Prazepam
subjective effects, comparison with diazepam, 309-317
Pregnancy
depression in drug-dependent women, 466-472
Propoxyphene
maintenance treatment of narcotic dependence, comparison
with methadone, 246-252, 253-260
oral therapeutic index, 97
Psychotherapy
combination with naltrexone in heroin detoxification,
505-507
N-( -Pyridyl),N-(1-ß-phenylethyl-4-piperidyl)ethylcarbamate
hydrochloride (NIH 8863, UM 983)
biological evaluation for dependence liability, 336
mouse analgesia, 394
self-administration in monkeys, 394
Secobarbital
self-injection in the baboon, 190
Self-administration
buprenorphine and lefetamine in rhesus monkeys, 211
comparison of barbiturate and benzodiazepine in the
baboon, 190
comparison of buprenorphine and methadone in primates,
67-73
intracranial self-administration of morphine in the
rat, 158-164
SKF-10047
See N-Allylnormetazocine
Sodium-5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrole-2-acetate
(zomepirac, NIH 9730, MCV 4192, UM 1217)
biological evaluation for dependence liability, 337
dependence studies in monkeys and rats, 361
depression of smooth muscle twitch, 407
displacement of stereospecific 3H-etorphine binding, 407
mouse analgesia, 360, 406
self-administration in monkeys, 407
Substance abuse,
susceptibility among American Indians, 34-44
545
Sufentanyl
bioassays of, 215-222
TCP
See 1-1-(2-Thienyl)cyclohexylpiperidine
9-Tetrahydrocannabinol (UM 1270)
dependence studies in monkeys, 439
effect of acute treatment on motor activity, in the
rat, interaction with naloxone, 141, 143
interactions with morphine, in rats, 141-147
operant behavior in the rat, interaction with morphine
and naloxone, 144, 145
self-administration in monkeys, 439
3- -(1,2ß,3ß,4-Tetramethyl-4-piperidinyl)phenol hydrobromide
(NIH 9521, UM 1160)
biological evaluation for dependence liability, 336
mouse analgesia, 398
self-administration in monkeys, 398-399
1-1-(2-Thienyl)cyclohexylpiperidine (TCP)
oral self-administration, in monkeys, 74-81
Tobacco
studies of dependence in man, 49-51
Tolerance
oral self-administration of phencyclidine and tolerance
to PCP's behavioral effects 74-81
selective tolerance to particular types of opiate
receptors, 215-222
L-Tyrosyl-D-alanylglycyl-L-N- -allyl-phenylalanine amide
acetate (NIH 9724, MCV 4187, UM 1212)
biological evaluation for dependence liability, 335
dependence studies in monkeys, 406
depression of smooth muscle twitch, 406
displacement of stereospecific 3H-etorphine binding, 405
mouse analgesia, 359-360, 405
UM 106 (dextrophan, NIH 4591, UM 1262)
See d-3-Hydroxy-N-methylmorphinan tartrate
UM 381 (pentazocine, NIH 7958, MCV 4268)
See (±)-2'-Hydroxy-5,9 -dimethyl-2-(3,3-dimethylallyl)-
6,7-benzomorphan
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UM 747 (NIH 8439)
See (-)-5,9 -Diethyl-2'-hydroxy-2-methylenecyclopropyl-
methyl-6,7-benzomorphan hydrochloride
UM 809 (NIH 8508A, MCV 4231)
See (-)-5-(m-Hydroxyphenyl)-2-methylmorphan hydrochloride
UM 810 (NIH 8509A, MCV 4232)
See (+)-5-(m-Hydroxyphenyl)-2-methylmorphan hydrochloride
UM 952 (NIH 8805)
See Buprenorphine
UM 961 (NIH 8833)
See (-)-cis-2-(Dimethylamino-m-hydroxybenzyl)cyclohexanol
hydrochloride
UM 972 (NIH 8834A, MCV 4206)
See (-)-13ß-Amino-5,6,7,8,9,10,11,12-octahvdro-5 -methyl-
5,11-methanobenzocyclodecen-3-ol hydrobromide
UM 973 (NIH 8835)
See 2,3,5,6,11,11b-Hexahydro-11,11b-dimethyl-1H-pyrido
[3',2':4,5]pyrrolo[3,2- g ]indolizine dihydrochloride
UM 983 (NIH 8863)
See N-( -Pyridyl),N-(1-ß-phenylethyl-4-piperidyl)-
ethylcarbamate hydrochloride
UM 1076 (NIH 9112)
See dl-3-Allyl-1,3-dimethyl-4-phenyl-4-propionoxy-
piperidine hydrochloride
UM 1103 (NIH 9256)
See 2-Cyclopropylmethyl-9 -ethyl-2'-hydroxy-5-methyl-
6,7-benzomorphan
UM 1124 (NIH 9342, MCV 4201)
See (-)-m-[2-(Cyclopropylmethyl)-1,2,3,4,4a,5,6,7,8,
8a -decahydro-4aß-isoquinolyl]phenol succinic acid
salt
UM 1151 (clonidine, NIH 9549, MCV 4155)
See 2-(2,6-Dichloroanilino)-2-imidazoline hydrochloride
UM 1160 (NIH 9521)
See 3 -(1,2ß,3ß,4-Tetramethyl-4-piperidinyl)phenol
hydrobromide
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UM 1169 (NIH 9540, MCV 4145)
See trans-3-(1,2-Dimethyl-4-propyl-4-piperidinyl)phenol
hydrobromide
UM 1170 (NIH 9541)
See 4ß-(m-Methoxyphenyl)-1,3-dimethyl-4 -piperidinol
propionate hydrochloride
UM 1195 (NIH 9637)
See s-N-sec-Butylnormorphine hydrochloride
UM 1198 (NIH 9650, MCV 4190)
See N-4-Methylpentylnorketobemidone hydrobromide
UM 1200 (NIH 9674)
See (-)-4-Hydroxy-N-methylmorphinan-6-one hydrobromide
UM 1201 (NIH 9677)
See (-)-4-Hydroxy-N-methylmorphinan hydrochloride
UM 1212 (NIH 9724, MCV 4187)
See L-Tyrosyl-D-alanylglycyl-L-N- -allyl-phenylalanine
amide acetate
UM 1217 (zomepirac, NIH 9730, MCV 4192)
See Sodium 5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrole-
2-acetate
UM 1218 (NIH 9585)
See N-Cyclohexylmethylnorketobemidone hydrobromide
UM 1221 (NIH 9741)
See N-2-Hexylnorketobemidone hydrobromide
UM 1223 (NIH 9735, MCV 4195)
See N-Cyclopropylmethyl-7,8-dihydronormorphinone
UM 1224 (NIH 9736, MCV 4196)
See N-Cyclobutylmethyl-3-hydroxy-6-methylene-8ß-methyl-
morphinan
UM 1225 (NIH 9737, MCV 4197)
See 17-Cyclopropylmethyl-7,7-dimethyl-3-methoxy-4,5
epoxymorphinan-6-one
UM 1226 (NIH 9738, MCV 4199)
See 2-Nitronaltrexone
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UM 1237 (NIH 9789)
See 5-Hydroxypentylnorketobemidone hydrobromide
UM 1238 (NIH 9791, MCV 4210)
See N-Methyl-L-tyrosyl-D-serylglycyl-N-methyl-L-
phenylalanyl-D-serinamide monoacetate
UM 1242 (NIH 9576A, MCV 4157)
See (-)-cis-(Octahydro-2-methyl-1H-2-pyrindin-4a-yl)
phenol, (Z)-2-butenedioic acid salt
UM 1243
See 1,2,3,4,10,14b-Hexahydro-2-methyldibenzo{c,t}
pyrazino{1,2a}azapine(mianserin)
UM 1245 (NIH 9804, MCV 4212)
See (-)-(1R,5R,9R,2"S)-(5,9-Dimethyl-2'-hydroxy-2-(2-
methyltetrahydrofurfuryl)-6,7-benzomorphan L-tartrate
UM 1246 (NIH 9805, MCV 4213)
See (-)-(1R,5R,9R)-5,9-Dimethyl-2'-hydroxy-2-(2-
methoxyisobutyl)-6,7,benzomorphan
UM 1252 (NIH 9821, MCV 4219)
See Oripavine hydrochloride
UM 1253 (NIH 9824, MCV 4220)
See (-)-trans-3-(Octahydro-2-methyl-4a(2H)-isoquinoline)
phenol hydrobromide
See also (-)-trans-[(2-Methyl)-1,2,3,4,4a,5,6,7,8,8a
decahydro-4aß-isoquinolyl]phenol hydrobromide
UM 1254 (NIH 9825, MCV 4221)
See (+)-trans-3-(Octahydro-2-methyl-4a(2H)-isoquinoline)
phenol hydrobromide
See also (+)-trans-[2-(Methyl)-1,2,3,4,4a,5,6,7,8,8a
decahydro-4aß-isoquinolyl]phenol hydrobromide
UM 1258 (NIH 9624, MCV 4175)
See dl-1-[(2 6 11S)-1-(1,2,3,4,5,6-Hexahydro-8-hydroxy-
3,6,11-trimethyl-2,6-methano-3-benrazocin-11-yl)]-3-
octanone methanesulfonate
UM 1259 (NIH 9839, MCV 4225)
See (-)-trans-3-(Octahydro-2-methyl-1H-2-pyrindin-4a-
yl)phenol, (Z)-2-butanedioate
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UM 1260 (NIH 9840, MCV 4226)
See (+)-trans-3-(Octahydro-2-methyl-1H-2-pyrindin-4a-
yl)phenol, (Z)-2-butanedioate
UM 1261 (NIH 9832, MCV 4227)
See N-(6,14-Endoetheno-7,8-dihydromorphine-7 -carbonyl)-
L-leucine ethyl ester hydrochloride
UM 1262 (dextrorphan, NIH 4591, UM 106)
See d-3-Hydroxy-N-methyl-morphinan tartrate
UM 1263 (ketamine)
See dl-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone
hydrochloride
UM 1264 (phencyclidine, NIH 9580, MCV 4158)
See 1-(1-Phenylcyclohexyl)piperidine hydrochloride
UM 1265 (levonantradol, NIH 9596, MCV 4161)
See (-)-trans-5,6,6aß,7,8,9,10a -Octahydro-1-acetoxy-
9ß-hydroxy-6ß-methyl-3-(5-phenyl-2-pentyloxy)phenan-
thridine hydrochloride
UM 1266 (nabilone, NIH 9872, MCV 4228)
See dl-trans-3-(1-1-Dimethylheptyl)-6,6aß,7,8,10,10a
hexahdroxy-1-hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-
9-one
UM 1267 (NIH 9612, MCV 4167)
See (±)-9-Hydroxy-4,7-dimethyl-C-homobenzomorphan
hydrabromide
UM 1268 (NIH 9613, MCV 4168)
See (+)-9-Hydroxy-4,7-dimethyl-C-homobenzomorphan
hydrobromide
UM 1269 (NIH 9614, MCV 4169)
See (-)-9-Hydroxy-4,7-dimethyl-C-homobenzomorphan
hydrobromide
UM 1270
See -Tetrahydrocannabinol
UM 1273 (NIH 9884, MCV 4241)
See (-)-5-(m-Hydroxyphenyl)-2- n-propylmorphan hydro-
chloride
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UM 1274 (NIH 9885, MCV 4242)
See (-)-2-n-Butyl-5-(m-hydroxyphenyl)morphan hydro-
chloride
UM 1276 (NIH 9894, MCV 4247)
See (+)-2-n-Hexyl-5-(m-hydroxyphenyl)morphan hydro-
chloride
UM 1277 (NIH 9901, MCV 4250)
See (±)-1-Methyl-4-cyclopropylmethyl-10-hydroxy-2,3,4,
5,6,7-hexahydro-1,6-methano-1H-4-benzazonine
UM 1280 (NIH 9898, MCV 4249)
See 1,12 -Dimethyl-4-allyl-10-hydroxy-2,3,4,5,6,7-
hexahydro-1,6-methano-1H-4-benzazonine
UM 1281 (NIH 9902, MCV 4251)
See 1,12 -Dimethyl-4-cyclopropylmethyl-10-hydroxy-2,3,
4,5,6,7-hexahydro-1,6-methanol-1H-4-benzazonine
UM 1322 (NIH 9874, MCV 4230)
See 17-Cyclopropylmethyl-4,5 -epoxy-6,6-difluoro-3-
acetoxymorphinan
UM 1324 (NIH 9961, MCV 4287)
See 1-(Methyl-2-phenylethyl)-4-(N-propranilido)piperidine
hydrochloride
Withdrawal
clonidine in morphine withdrawal, 47
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Zomepirac (NIH 9730, MCV 4192, UM 1217)
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